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Abstract 
 
The SKP1-Cullin1-F-box (SCF) E3 ligases promote the ubiquitination and proteasome-
mediated degradation of regulatory proteins. Subunits of the SCF complex have shown 
oncogenic activity, including the F-box protein S-phase Kinase-associated Protein 2 
(SKP2).  The SCF
SKP2
 E3 ligase targets several cell cycle negative regulators, e.g. p27, 
enabling replicative immortality. The only marketed drug that targets the ubiquitin-
proteasome system is Bortezomib (Velcade; Millenium Pharmaceuticals) (15),
 
which is 
used to treat multiple myeloma, but has numerous side effects, as the result of targeting 
a proteasome involved in the regulation of multiple proteins. Targeting an F-box protein 
is an attractive solution because the F-box protein defines E3 ligase selectivity and each 
E3 ligase regulates fewer proteins. To date, no small molecule targeting an F-box 
protein has entered clinical trials. A recently reported compound, (((3-(2,2-
dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutyl)amino)methyl)-N,N-dimethylaniline 
(16a), has shown evidence to suggest it inhibits the SCF
SKP2
 ligase. The synthesis of 
16a (diastereoisomeric mixture) was completed at Newcastle University and growth 
inhibitory activity was confirmed in HeLa cells using a sulforhodamine B assay.  
 
 
 
Both enantiomers of N,N-dimethyl-4-(((4-phenyl-3-(tetrahydro-2H-pyran-4-
yl)butyl)amino)methyl)aniline (68a) were synthesised, in one of the first documented 
enantioselective syntheses of a molecule of this chemotype, and demonstrated similar 
growth inhibitory activity in HeLa cells to each other and to the racemate, suggesting 
the compounds have a non-specific mechanism of action. 
 
  
ID HeLa GI50 (µM) 
68a 27 ± 4 
(S)-68a 33 ± 4 
(R)-68a 29 ± 2 
vi 
 
Murine double minute 2 (MDM2) and its structurally related homologue MDMX 
(MDM4) negatively regulate the protein level and transcriptional activity of the tumour 
suppressor p53. Overexpression of MDM2 and MDMX has been observed in multiple 
human cancers and is associated with cell immortality.  
 
Co-crystallisation of the p53-MDM2 and p53-MDMX complexes showed that three p53 
residues (F19, W23 and L26) are critical to the formation of these dimers and small-
molecule inhibitors function by competitively blocking the p53-binding sites on MDM2 
or MDMX. Several small-molecule MDM2 inhibitors have entered clinical trials; 
however, no small-molecule MDMX inhibitor has reached the same stage. A recently 
discovered series of 2,4-disubstituted thiazoles have shown modest potency against 
MDM2 and MDMX. In silico modelling suggested the compounds interacted with the 
p53-binding domains in both proteins and extensive SAR studies around 4-(2-((4-
fluorobenzyl)amino)thiazol-4-yl)benzene-1,2-diol (59a) were conducted. This series 
was extended to include benzenoid and pyrrole-based compounds, including 2’-(4-
chlorophenoxy)-3’-((4-fluorophenyl)amino)-[1,1’-biphenyl]-4-ol (138c) and 2-(4-
chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3-carboxylic acid 
(220c). All three chemotypes demonstrated low micromolar activity against MDMX 
and MDM2 by ELISA.  
 
 
 
ID MDMX IC50 (µM) MDM2 IC50 (µM) 
59a 24.7 12.1 
138c 19.0 23.2 
220c 14.6 11.2 
 
Current efforts are focussing on potentiating MDMX potency in each of the above 
chemotypes and trialling various co-crystallisation conditions so as to understand the 
molecules’ binding mechanism and guide rational drug design. 
vii 
 
Abbreviations 
Table i: Amino acids 
 
Full Name 3-Letter Code 1-Letter Code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
 
Table ii: Elements and Groups 
 
Element or Group Definition 
H Hydrogen 
C Carbon 
O Oxygen 
N Nitrogen 
P Phosphorus 
S Sulfur 
B Boron 
viii 
 
F Fluorine 
Cl Chlorine 
Br Bromine 
Al Aluminium 
Li Lithium 
Na Sodium 
K Potassium 
Mg Magnesium 
Si Silicon 
Ti Titanium 
Fe Iron 
Ni Nickel 
Cu Copper 
Zn Zinc 
Ru Ruthenium 
Ag Silver 
Pd Palladium 
Ce Cerium 
Mn Manganese 
Tb Terbium 
Me Methyl (CH3) 
Et Ethyl (CH2CH3) 
Pr n-Propyl (CH2CH2CH3) 
i
Pr iso-Propyl (CH(CH3)2) 
t
Bu tert-Butyl (C(CH3)3) 
Hex n-Hexyl (CH2CH2CH2CH2CH2CH3) 
Cy Cyclo 
Ph Phenyl (C6H5) 
Bn Benzyl (CH2Ph) 
TMS Trimethylsilyl (Si(CH3)3) 
TIPS Triisopropylsilyl (Si(CH)3(CH3)6) 
TBS tert-Butyldimethylsilyl (SiC(CH3)3(CH3)2) 
Ac Acetyl 
Alk Alkyl 
ix 
 
Ar Aryl 
 
Table iii: Units of Measurement 
 
Symbol Definition 
h Hour 
min Minute 
s Second 
m Metre 
mm Millimetre (10
-3
 m) 
µm Micrometre (10
-6
 m) 
nm Nanometre (10
-9
 m) 
Å Angstrom (10
-10
 m) 
L Litre 
mL Millilitre (10
-3
 L) 
µL Microlitre (10
-6
 L) 
nL Nanolitre (10
-9
 L) 
Hz Hertz 
MHz Megahertz (10
3
 Hz) 
M Molar (mol L
-1
) 
mM Millimolar (10
-3
 M) 
µM Micromolar (10
-6
 M) 
nM Nanomolar (10
-9
 M) 
mP Millipolarisation unit 
o
C Degrees Celsius 
Bar Bar 
Atm Atmosphere 
Ki Dissociation constant 
g Grams 
mg Milligrams (10
-3
 g) 
Mol Moles 
Da Daltons (g mol
-1
) 
% Percent 
 
x 
 
Table iv: Miscellaneous 
 
A AML Acute Myeloid Leukaemia 
 ATP Adenosine triphosphate 
 ABCG2 ATP-binding cassette subfamily G member 2 
 ADME Absorption, distribution, metabolism, excretion 
 Akt Protein kinase B 
 AR Androgen receptor 
 ARF Alternate reading frame 
 aq Aqueous 
B Bcl B-cell lymphoma 
 Bax Bcl-2-associated X 
 BRCA BReast CAncer (gene or protein) 
 Β-TrCP Beta-transducin repeat-containing protein 
 BAD Bcl-2-associated death 
 BuLi Butyllithium 
 Boc2O Di-tert-butyldicarbonate 
 B2(Pin)2 Bis(pinacolato)diboron 
 Boc tert-Butoxycarbonyl 
 BSA Bovine serum albumin 
C CAM Cell-to-cell adhesion molecule 
 CRC Colorectal cancer 
 CML Chronic myelogenous leukaemia 
 CTCL Cutaneous T-cell lymphoma 
 CCR5 C-C chemokine receptor type 5 
 CAD Computer-aided design 
 Cul Cullin 
 Cks1 Cyclin kinase subunit 1 
 CDK Cyclin-dependent kinase 
 CSC Cancer stem cell 
 CYP450 Cytochrome P450 
 c Calculated 
 CSA Camphor sulfonic acid 
 COOT Crystallographic Object-Oriented Toolkit 
xi 
 
 CCP4 Collaborative Computational Project 4 
 CO2 Carbon dioxide 
D d Doublet 
 DNA Deoxyribonucleic acid 
 DHFR Dihydrofolate reductase 
 DCM Dichloromethane 
 DMF N,N-Dimethylformamide 
 DMSO Dimethylsulfoxide 
 DMAP N,N-Dimethylaminopyridine 
 DIPA Diisopropylamine 
 DIBAL-H Diisobutylaluminium hydride 
 DTP Developmental therapeutics program 
 DePPICT Design of protein-protein interaction inhibitors for cancer 
therapy 
 DMP Dess-Martin periodinane 
 de Diastereoisomeric excess 
 dr Diastereoisomeric ratio 
 DMC Dimethylcarbonate 
 dppf 1,1’-Bis(diphenylphosphino)ferrocene 
 dtbpf 1,1’-Bis(di-tert-butylphosphino)ferrocene 
 DoM Directed-ortho-metallation 
 DHP Dihydropyran 
 DSF Differential scanning fluorimetry 
 DTT Dithiothreitol 
 DAD Diode array detector 
E EGFR Epidermal growth factor receptor 
 EtOAc Ethyl acetate 
 Et2O Diethyl ether 
 EtOH Ethanol 
 EC Effective concentration 
 Emax Maximum effective concentration 
 ELISA Enzyme-linked immunosorbent assay 
 ee Enantiomeric excess 
 Equiv. Equivalent 
xii 
 
F FDA Food and Drugs Administration 
 FBxW7 F-box/WD repeat-containing protein 7 
 FP Fluorescence polarisation 
 FRET Fluorescence resonance energy transfer 
 FPLC Flash performance liquid chromatography 
 FTIR Fourier transform infrared 
G GIST Gastrointestinal stromal tumour 
 G1/2 Growth phase 1 or 2 (cell cycle) 
 GI Growth inhibition 
 GST Glutathione S-transferase 
H HPV Human papilloma virus 
 HCC Hepatocellular carcinoma 
 HDAC Histone deacetylase 
 HTS High-throughput screening 
 h Humanised 
 HIV Human immunodeficiency virus 
 H-bond Hydrogen bond 
 HAUSP Herpes virus-associated ubiquitin-specific protease 
 HPLC High performance liquid chromatography 
 HTRF Homogeneous time-resolved fluorescence 
 HWE Horner-Wadsworth-Emmons 
 HMPA Hexamethylphosphoramide 
 HMDS Hexamethyldisilazide 
 HD Halogen dance 
 HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
 HRP Horseradish peroxidase 
 HRMS High resolution mass spectrometry 
I IND Investigational new drug 
 IC Inhibitory concentration 
 IR Infrared or ionising radiation 
 IPTG Isopropyl-β-D-thiogalactoside 
 IV Intravenous 
L LTT Ligand-targeted therapy 
 LD Lethal dose 
xiii 
 
 LRR Leucine-rich repeat 
 LC-MS Liquid chromatography mass spectrometry 
 LDA Lithium diisopropylamide 
 LE Ligand efficiency 
 LipE Lipophilic efficiency 
 LB Lysogeny broth 
M m Multiplet 
 MBC Metastatic breast cancer 
 MM Multiple myeloma 
 MTC Medullary thyroid carcinoma 
 MeOH Methanol 
 MeCN Acetonitrile 
 MDM2/X Murine double minute 2/X 
 mTOR Mammalian target of rapamycin 
 MoAB Monoclonal antibody 
 MEF Mouse embryonic fibroblast 
 Ms Mesyl/methanesulfonyl 
 MCL-1 Myeloid cell leukaemia 1 
 MDR Multidrug resistance 
 MTS 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium 
 mRNA Messenger ribonucleic acid 
 mCPBA meta-Chloroperbenzoic acid 
 MW Microwave 
 m meta 
 mHBS Modified HEPES buffer solution 
 MWCO Molecular weight cut-off 
N NSCLC Non-small cell lung cancer 
 NMR Nuclear magnetic resonance 
 NDA New drug application 
 NAE Need8 activating enzyme 
 NF Nuclear factor 
 NCI National Cancer Institute 
 NIH National Institute of Health 
xiv 
 
 ND Not determined 
 NA Not active 
 NBS N-bromosuccinimide 
 NoLS Nuclear localisation signal 
 NICR Northern Institute for Cancer Research 
O o Ortho 
 o/n Overnight 
P p Protein/phosphorylated 
 p Para 
 P Partition coefficient 
 PDGF Platelet-derived growth factor 
 PPI Protein-protein interaction 
 PI3K Phosphatidylinositol-3-kinase 
 PTEN Phosphatase and tensin homologue 
 PDB Protein Data Bank 
 pTSA para-Toluenesulfonic acid 
 PBS Phosphate-buffered saline 
 PMA Phosphomolybdic acid 
 PMB para-Methoxybenzyl 
 pRB Retinoblastoma protein 
Q qPCR Quantitative polymerase chain reaction 
R RNA Ribonucleic acid 
 RGD Arginine-glycine-aspartate 
 RING Really interesting new gene 
 RoC Regulator of Cullins 
 RBX RING-box protein 
 RT Room temperature 
 Rac or ± Racemic 
 RLU Relative luminescence units 
 RPM Revolutions per minute 
 RCF Relative centrifugal force 
S s Singlet 
 SKP S-phase kinase-associated protein 
 SCF SKP1-cullin-F-box 
xv 
 
 SAR Structure-activity relationship 
 STAT3 Signal transducer and activator of transcription 3 
 SRB Sulforhodamine B 
 SNAr Nucleophilic aromatic substitution 
 SDS-PAGE Sodium dodecylsulfate polyacrylamide gel electrophoresis 
 SOB Super-optimal broth 
T TK Tyrosine kinase 
 THF Tetrahydrofuran 
 THP Tetrahydropyran 
 TFE 2,2,2-Trifluoroethanol 
 tPSA Topological polar surface area 
 Tf Trifluoromethanesulfonyl 
 TAD Transactivation domain 
 TR Time-resolved 
 TFA Trifluoroacetic acid 
 TCA Trichloroacetic acid 
 Temp. Temperature 
 TBAF Tetra-n-butylammonium fluoride 
 TMEDA N,N,N’,N’-Tetramethylethylenediamine 
 Tm Melting temperature 
 TBS-Tween Tris-buffered saline Tween 
 TB Terrific broth 
 TLC Thin layer chromatography 
U UV Ultraviolet 
 Ub Ubiquitin 
 UPS Ubiquitin-proteasome system 
V VEGF Vascular endothelial growth factor 
 VEGFR Vascular endothelial growth factor receptor 
 VLS Virtual ligand screening 
W WT Wild-type 
 WST Water-soluble tetrazolium salt 
 
  
xvi 
 
Contents 
 
Declaration ii 
Acknowledgements  iii 
Abstract v 
Abbreviations vii 
Chapter One: Introduction 1 
 1.1 Characteristics of Cancer 1 
 1.2 Causes of Cancer 3 
 1.3 Treatments for Cancer 4 
 1.3.1 Chemotherapy 5 
 1.3.2 Targeted Therapy 7 
 1.3.2.1 Antibody-targeted Therapy 8 
 1.3.2.2 Ligand-targeted Therapy  9 
 1.3.2.3 Targeted Therapy with Small Molecules  11 
 1.3.2.4 Protein-Protein Interaction Inhibitors  12 
 1.4 The Drug Development Process 13 
 1.4.1 SKP2 Hit Identification Criteria 16 
Chapter Two: Project SKP2 18 
 2.1 The SCF E3 Ubiquitin Ligases  18 
 2.2 SCF E3 Ubiquitin Ligases as Anticancer Targets  20 
 2.2.1 Targeting the F-Box Protein SKP2 for Cancer Therapy 22 
 2.3 (((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-
phenylbutyl)amino)methyl)-N,N-dimethylaniline: An SCF
SKP2
 Ligase 
Inhibitor 
27 
 2.4 Aims of the SKP2 Project 30 
 2.5 Competitor Compounds Targeting the SCF
SKP2 
E3 Ligase Pathway 32 
 2.5.1 Inhibitors of the SKP2-Cks1-p27 Trimer  32 
 2.5.2 Inhibitors of the SKP2-SKP1 Interaction  37 
 2.5.3 Inhibitors of the SKP2-Cks1 Interaction  42 
 2.5.4 Salinomycin as an Inhibitor of STAT3  45 
Chapter Three: Project MDMX 49 
 3.1 The p53 Tumour Suppressor 49 
 3.2 MDM2 49 
xvii 
 
 3.3 MDMX 51 
 3.4 Aims of the MDMX Project 55 
 3.5 Literature Compounds with Moderate MDMX Inhibitory Activity 60 
 3.5.1 SJ-172550 61 
 3.5.2 Imidazole-based MDMX Inhibitors  64 
 3.5.3 Diaryl- and Triaryl-Pyrroles as MDM2 and Dual MDM2/MDMX 
Inhibitors  
69 
 3.5.4 Pyrrolidone Inhibitors of MDM2 and MDMX 74 
 3.6 Potent Dual MDM2 and MDMX Inhibitors 77 
 3.6.1 Indolyl-Hydantoin MDM2 and MDMX Dual Inhibitors  77 
 3.6.2 Stapled α-Helical Peptides as Potent Dual Inhibitors of MDM2 and 
MDMX 
79 
Chapter Four: SKP2 Results and Discussion 83 
 4.1 Synthesis of 16a, 68a and their Derivatives 83 
 4.2 Improving the Aqueous Solubility of 16a 86 
 4.3 Inhibition Data for 16a, 68a and their Derivatives  91 
 4.4 Synthesis of Novel Pyran-4-ones   94 
 4.4.1 Formation from Mesityl Oxide  94 
 4.4.2 Formation of 1-Hydroxy-5-methylhex-4-en-3-one (85) 96 
 4.4.3 Formation of Dihydropyran-4-ones by Cycloaddition 98 
 4.5 Finding the Minimum Pharmacophore of 16a 99 
 4.6 Synthesis of the Enantiomers of 68a 101 
 4.7 Conclusion 107 
Chapter Five: MDMX Results and Discussion 108 
 5.1 The 1,3-Disubstituted Benzenoid MDMX Inhibitors 108 
 5.2 The Disubstituted Pyridyl MDMX Inhibitors 115 
 5.3 The 1,2,3-Trisubstituted Benzenoid MDMX Inhibitors 119 
 5.3.1 Investigating the Binding Mode of the 1,2,3-Trisubstituted 
Benzenoid Series 
124 
 5.3.1.1 Interchanging the Hydroxy and Fluoro Groups of 138c 130 
 5.3.2 Optimising the Drug-like Properties of 138c 137 
 5.3.2.1 Synthesis of 3-Hydroxyheterocycles 183a and 183b 138 
 5.3.2.2 Formation of Triazole 185 and Carboxylic Acid 187 148 
 5.3.2.3 Replacing the 4-Chlorophenoxy Ring with a 6-Chloroindol-3-yl 152 
xviii 
 
Ring 
 5.3.2.4 Replacing the 4-Chlorophenoxy Ring with a 6-Chloroindol-3-yl 
Ring by the SNAr Reaction 
158 
 5.3.3 Addition of Water-Solubilising Groups to the Benzenoid Scaffold 165 
 5.3.3.1 Homologation of the Carboxy Group of 226 168 
 5.3.3.2 Carboxylic Acid Regioisomers of 226 174 
 5.4 The 2,4-Disubstituted Thiazole MDMX Inhibitors 177 
 5.5 The 1,2,3,5-Tetrasubstituted Pyrrole MDMX Inhibitors 184 
 5.5.1 Synthesis of 220c and Regioisomer 220g 186 
 5.6 Conclusion  188 
Chapter Six: MDMX and MDM2 Structural Biology 189 
 6.1 Protein Crystallography of Benzenoid and Thiazole-based Inhibitors of 
MDMX and MDM2 
189 
 6.1.1 Expression and Purification of MDMX and MDM2  193 
 6.1.2 Crystallisation Trials of MDMX and MDM2 Constructs 1-3 with 
Benzenoid and Thiazole-based Inhibitors 
198 
 6.1.3 Crystal Formation and Data Collection 201 
 6.2 Measuring the Potency of Benzenoid, Thiazole- and Pyrrole-based 
MDMX Inhibitors by Homogeneous Time-Resolved Fluorescence 
202 
 6.3 Analysing MDMX Stabilisation by Benzenoid, Thiazole- and Pyrrole-
based Inhibitors using Fluorescence-based Thermal Shift 
209 
 6.4 Conclusion 215 
Chapter Seven: Experimental 216 
 7.1 Computer Software 216 
 7.2 SKP2 Sulforhodamine B Assay 216 
 7.3 MDMX-p53 and MDM2-p53 Enzyme-linked Immunosorbent Assay 217 
 7.4 Expression of Recombinant GST-MDMX and GST-MDM2 in E. coli 219 
 7.5 Purification of Recombinant GST-MDMX and GST-MDM2 220 
 7.6 Protein Preparation for Crystallography 220 
 7.7 GST-MDMX
22-111
 Homogeneous Time-resolved Fluorescence Assay 221 
 7.8 MDMX Thermal Shift (Differential Scanning Fluorimetry) Assay 222 
 7.9 General Biology Procedures and Materials Used 223 
 7.9.1 MDMX and MDM2 protein constructs used 223 
 7.9.2 Culture media protein buffer and stock solutions used 224 
xix 
 
 7.9.3 Polyacrylamide Gel Electrophoresis 225 
 7.10 Chemicals and solvents 225 
 7.11 Chemistry Analytical Techniques 226 
 7.11.1 Chromatography 228 
 7.12 General Procedures 229 
 7.12.1 SKP2 229 
 7.12.2 MDMX 272 
Chapter Eight: Bibliography 372 
 
  
1 
 
Chapter One: Introduction 
 
1.1 Characteristics of Cancer 
 
Cancer is the leading cause of death worldwide, responsible for over 7.6 million deaths 
(13% of all deaths) in 2008, with the death toll expected to reach more than 11 million 
by 2030.
1
 The disease stems from changes to the genome within a cell. Mutations in the 
DNA sequence lead to the production of oncogenes with a dominant gain in function 
and tumour-suppressor genes with a loss of function.
2
 This produces cells with defects 
in the regulatory circuits controlling cell proliferation and homeostasis. Most, if not all, 
cancer cell genotypes are the manifestation of six cellular alterations thought to be 
essential for malignant growth, termed the ‘Hallmarks of Cancer’ (Figure 1).3, 4 Each 
capability and its functional significance are explained below: 
 
 
 
 
Figure 1: The hallmarks of cancer
4
 
 
 
 
2 
 
1. Sustaining proliferative signalling 
Cells require mitogenic growth signals before they can move from a dormant state into 
an active proliferative state. However, many oncogenes act by mimicking the action of 
these growth signals, so the dependence of cancer cells on exogenous growth 
stimulation is lower than that of normal cells.
4
  
 
2. Evading growth suppressors 
Within a normal tissue, soluble growth inhibitors and immobilised inhibitors embedded 
in the extracellular matrix and on the surface of nearby cells work to maintain cellular 
quiescence and tissue homeostasis. Anti-proliferative signals are channelled through the 
retinoblastoma protein (pRb), p107 and p130. In cancer cells the pRb pathway is 
disrupted, causing uncontrolled cell division that is insensitive to growth suppressors.
4, 5
  
 
3. Resisting cell death 
One of the most significant natural defences against tumour development is 
programmed cell death (apoptosis)
4, 5
 and acquired resistance to apoptosis is being 
supported by ever increasing evidence as a hallmark of most, if not all, cancers.
4, 5, 6
 
Once triggered, apoptosis occurs in a precisely choreographed sequence of steps, in 
which the cell membrane degrades, the cytoplasmic and nuclear skeletons break down, 
the cytosol is extruded, the chromosomes degrade and the nucleus fragments.
7
 The p53 
tumour-suppressor protein facilitates apoptosis by upregulating the expression of the 
pro-apoptotic Bcl-2 protein Bax. Mutation of the p53 gene, which produces the 
functionally inactive p53 protein, is seen in almost 50% of human cancers.
8, 9, 10
 
 
4. Enabling replicative immortality 
Many mammalian cells can only undergo a limited number of divisions before entering 
senescence.
11
 Disabling the pRb and p53 proteins enable the cells to continue 
multiplying for a finite number of doublings until they enter a second senescence state 
termed ‘crisis’, characterised by mass cell death and the occasional emergence of a cell 
(1 in 10
7
) which has limitless replicative potential, a process termed immortalisation.
12
 
Most tumour cell types grown in culture appear immortalised, indicating that limitless 
replicative potential is a phenotype which is acquired in vivo and is essential for the 
development of the cancer cells’ malignant growth.11 
 
 
3 
 
5. Inducing angiogenesis 
All cells require oxygen and nutrients to function and survive. Once a new tissue is 
formed, the formation of new blood vessels (angiogenesis) is carefully coordinated.
3, 4
 
Despite the need for blood vessels to provide nutrients, proliferating cells have no 
intrinsic ability to induce blood vessel growth. To progress to larger sizes, neoplasias 
must develop angiogenic capability and the experimental evidence highlighting the 
significance of sustained angiogenesis in tumours is profound.
13, 14, 15
 
 
6. Activating invasion and metastasis 
All types of cells possess proteins which bind the cells to their surroundings, including 
the cell-to-cell adhesion molecules (CAMs).
3
 These proteins are altered in cells 
possessing invasive or metastatic capabilities. The most widely studied is E-cadherin, a 
CAM expressed ubiquitously in epithelial cells. The function of this protein is disrupted 
in the majority of epithelial cancers, meaning primary tumours can spawn cells capable 
of invading adjacent tissues and travelling to distant sites.
16
 Invasive tumours are the 
cause of 90% of human cancer deaths.
17
 If E-cadherin is forcibly expressed in cultured 
cancer cells, this impairs their invasive and metastatic phenotypes, whereas interference 
of E-cadherin enhances both phenotypes, meaning the functional elimination of E-
cadherin is a key step in the acquisition of metastasis.
18
  
 
1.2 Causes of Cancer 
 
There are over 200 types of cancer, all with their own triggers which cause sufficient 
damage to a cell’s genome to make it cancerous, but the most significant causes of 
cancer are summarised below: 
 
1. Carcinogens: Cancer-causing chemicals, e.g. tobacco smoke, which has been 
shown to be a major cause of lung cancer.
1, 19, 20, 21
  
 
2. Age: When cells divide they must precisely replicate their genetic sequence in 
the new cell being made. In approximately one in 10
7
 base pair replications, an 
error will occur, which is normally corrected by DNA-repairing enzymes.
22
 If 
this fails to happen, the replicative error will be passed on to the daughter cell. 
Multiple replicative errors produce oncogenes, but this process takes a long 
time, which explains why most cancers are more common in older people. 
4 
 
3. Genetic predisposition: Some people are born with genetic mutations that 
increase their chances of developing a particular cancer, e.g. women born with 
mutations in the BRCA1 or BRCA2 genes are statistically more likely to develop 
breast cancer.
23
 
 
4. Lifestyle choices: Obesity, smoking, excessive alcohol and the consumption of 
certain foods, e.g. red and processed meat, have all been linked to an increased 
risk of cancer.
24
 
 
5. Radiation: UV radiation from the sun has been shown to increase the risk of 
developing a melanoma and nuclear radiation has been linked to a rise in several 
cancer types, e.g. leukaemia.
25
 
 
6. Viral and bacterial infections: Viruses can cause the genetic damage to a cell 
that lead to it becoming malignant, e.g. human papilloma virus (HPV) has been 
shown to increase the risk of cervical cancer.
26
 Helicobacter pylori has been 
linked to the onset of several cancers, e.g. stomach cancer.
27
 
 
1.3 Treatments for Cancer 
 
Various forms of oncological treatments exist, the most fundamental of which is to 
surgically remove the tumour and an area of healthy tissue surrounding it to prevent a 
recurrence at that site. If removal of the entire tumour is impossible, as much of it will 
be removed as possible so as to alleviate any pain, airway obstruction or bleeding. 
While this treatment can be effective for treating benign or pre-metastatic tumours, 
those which have spread beyond the primary tumour site cannot often be targeted. 
 
Radiation therapy uses high-energy X-rays, proton or neutron beams to damage the 
DNA of cancer cells to elicit single- or double-strand breaks, causing the cell either to 
die or senesce. Radiation can be applied externally, using a beam of radiation, or 
internally where a source of radioactivity is implanted in the body near the tumour site. 
However, radiation therapy is considered a ‘local’ form of treatment and so cannot be 
used to effectively treat metastatic tumours. It can also cause DNA damage to the 
surrounding healthy cells, potentially leading to relapse in the long term. 
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1.3.1 Chemotherapy 
 
Chemotherapy is one of the most widely used forms of cancer therapy. Various classes 
of chemotherapeutic agents have been used, a short summary of which is given below: 
 
1. Mustard agents: One of the first groups of chemicals found to have anticancer 
activity and examples include mechlorethamine (1) and cyclophosphoramide 
(2). The drugs are alkylating agents and bind covalently to purine bases in DNA 
and cross-link strands which induce apoptosis.
28, 29
 
 
 
 
2. Antimetabolites: Chemicals which inhibit the action of a metabolite responsible 
for normal cell function. Examples include purine analogues, e.g. 6-thioguanine 
(3),
30
 pyrimidine analogues, e.g. 5-fluorouracil (5-FU) (4)
31
 and antifolates, e.g. 
methotrexate (5), a competitive inhibitor of dihydrofolate reductase (DHFR), an 
enzyme essential for purine biosynthesis.
29
  
 
 
 
3. Vinca alkaloids: Naturally occurring chemicals produced in the common 
periwinkle plant (Vinca rosea). Examples include vincristine (6) and vinblastine 
(7) and they function as antimitotic agents.
32
 They inhibit microtubule 
polymerisation, which is a fundamental process in the metaphase of mitosis, and 
induce cell cycle arrest.
33, 34
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4. Taxanes and camptothecins: Plant-derived antimitotic agents, like the vinca 
alkaloids. Taxanes promote the formation of irregularly structured microtubule 
bundles that cannot form the mitotic spindles required to separate the 
chromosomes during the anaphase of mitosis, promoting cell cycle arrest. 
Camptothecin (8) and its analogues inhibit Type I topoisomerases, which are 
critical for the unwinding of DNA from the histones during prophase.
34
  
 
 
 
5. Platinum-containing drugs: Examples include cis-platin (9) and carboplatin 
(10) and they function by forming intrastrand cross-links by binding covalently 
to two neighbouring guanines. This causes a significant bending in the DNA 
helix, sufficient to inhibit DNA synthesis and induce apoptosis.
35, 36, 37
 
 
 
  
Cytotoxic chemotherapy has shown potent activity against a range of cancer types and 
the ability to affect tumours in multiple sites of the body gives it an advantage over 
surgery and radiation therapy. However, all the agents listed suffer from the onset of 
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resistance which reduces their efficacy. Many have poor selectivity towards cancer cells 
and therefore produce adverse reactions in patients, commonly including nausea, 
vomiting, fatigue and alopecia, but some side effects can be severe, e.g. peripheral 
neuropathy, cardiotoxicity and bone marrow toxicity, which can lead some patients to 
abstain from taking their medication. To reduce the side effects, drugs are now being 
developed which are tailored to patients’ individual circumstances.  
 
1.3.2 Targeted Therapy 
 
Targeted therapy refers to a new generation of cancer drugs designed to alter the 
biological function of a specific protein which has been shown to play a fundamental 
role in the growth or progression of the tumour.  These drugs have enhanced selectivity 
towards tumour cells and therefore promise reduced patient toxicity compared with 
cytotoxics. However, the compounds are less versatile because they are only effective in 
cancers which depend upon the protein or pathway being targeted. Most solid tumours, 
which comprise 90% of human cancers, are the manifestation of multiple genetic 
mutations and so a drug which targets a single cellular pathway may not have a strong 
efficacious effect.
38
 Similar to chemotherapy, the impact of targeted therapies on 
tumours is reduced by the build-up of resistance. The design of drugs capable of 
targeting multiple pathways, as well as combination therapy in which several drugs with 
different modes of action are used to combat the same tumour, can overcome these 
problems and various forms of targeted therapy exist (Figure 2).  
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Figure 2: Different types of targeted therapy; adapted from
38
 
 
1.3.2.1 Antibody-targeted Therapy 
 
Monoclonal antibodies (MoAbs) (i.e. antibodies which recognise only one type of 
antigen and are produced by identical immune cells) are well tolerated and effective 
against a range of human malignancies. Anticancer agents can be conjugated to MoAbs, 
improving their selectivity and the versatility of those unable to be administered alone.
38
 
The agents which can be attached include small-molecule drugs and toxins. The high 
tolerance for antibodies is due to the often simple conversion of non-human antibodies, 
e.g. murine antibody, to human or humanised formats not recognised as foreign by the 
immune system. However, this mode of therapy does have drawbacks; success of 
treatment critically depends on the choice of antigen to target. The antigen must be 
present on most, if not all of the cancer cells to ensure selectivity and prevent a 
subpopulation of antigen-negative cells from developing. Antigens which shed from the 
cell membrane and travel in the blood stream are not optimal targets, as higher doses of 
the antibody will be required to clear the circulating antigen before it reaches the cancer 
cells. Penetrance of solid tumours is also a problem due to various barriers, e.g. the 
vascular epithelium, and the fact solid tumours are often heterogeneous means that 
targeting them completely is difficult.
38
 Despite this, several antibodies have been 
approved for anticancer therapy (Table 1). 
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Table 1: Therapeutic antibodies approved by the US FDA for cancer treatment
38
 
 
Monoclonal 
Antibody 
Target Indication Product Year Corporate 
Sponsor 
 
Trastuzumab 
(Herceptin) 
 
 
HER2/neu 
 
Metastatic 
breast cancer 
 
Humanised 
 
1998 
 
Genentech 
Gemtuzumab-
ozogamicin 
(Mylotarg) 
 
CD33 AML Humanised 2000 Wyeth 
Laboratories 
Bevacizumab 
(Avastin) 
VEGF Metastatic 
CRC; 
NSCLC 
Humanised 2004 Genentech 
AML, acute myeloid leukaemia; CRC, colorectal cancer; NSCLC, non-small cell lung cancer; VEGF, 
vascular endothelial growth factor 
 
Herceptin is a genetically engineered MoAb that inhibits proliferation of cells 
overexpressing the HER2 oncoprotein, which is seen in 25-30% of breast cancers and 
has been associated with aggressive cell growth.
38
 Humanisation of Herceptin reduces 
the immunogenicity seen when using murine MoAb therapy. Avastin targets the VEGF 
signal protein, which plays a key role in establishing angiogenesis. This makes Avastin 
a versatile medication, as VEGF inhibition has been shown to be an effective treatment 
for solid tumours, various leukaemias and haematological cancers.  
 
1.3.2.2 Ligand-targeted Therapy  
 
Ligand-targeted therapy (LTT) involves the conjugation of an anticancer drug to a 
molecule capable of recognising an antigen or receptor expressed uniquely or 
overexpressed on cancer cells relative to healthy cells. This allows for the selective 
delivery of higher concentrations of a drug to cancer cells that otherwise would cause 
unwanted toxicity to the patient.
38, 39
 This makes LTT similar to antibody-targeted 
therapy, but whereas antibodies can be used as anticancer agents in their own right, LTT 
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encompasses all molecules that can act as carriers of cytotoxic drugs, e.g. liposomes and 
nano-particles (Table 2).
39
 One reason for the onset of resistance in chemotherapy is the 
use of suboptimal doses of a drug to combat the tumour, due to the risk of toxicity at 
higher concentrations. LTT allows for high concentrations to be administered in a safer 
manner to the patient, thereby reducing the chances of resistance build-up and early 
relapse.
38, 39
  
 
The success of this treatment is dependent on the choice of antigen to target, similar to 
antibody-targeted therapy. The antigen must have a high density on the target cell and 
the cancer cells cannot have too high a heterogeneity in their antigens, as this could 
affect the selectivity of the carrier.
38
 Antigens which shed from the cell and circulate in 
the bloodstream also do not make optimal targets. Compared with antibodies, non-
antibody carriers are often readily available, inexpensive to manufacture and simple to 
store and handle.
39
 However, they can have worse selectivity profiles; the RGD 
(arginine-glycine-aspartate) and transferrin ligands have been shown to bind to non-
target tissues.
38, 39, 40
 Folate, which has also been used as a carrier, is found naturally in 
body fluids and the natural folate competes with the targeted therapy for the antigen. 
Antibodies have an advantage over other carriers in that they can have cytotoxic 
properties themselves, allowing for a potential synergy with the bound 
chemotherapeutic, as the tumour cell can be targeted via two different mechanisms. 
 
Table 2: Non-antibody carriers used in LTT
39
 
 
Ligand Target Indication 
RGD 
 
Cellular adhesion molecules Solid tumours 
Folate Folate receptor Cancer cells overexpressing 
the folate receptor 
 
Transferrin Transferrin receptor Cancer cells overexpressing 
the transferrin receptor 
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1.3.2.3 Targeted Therapy with Small Molecules  
 
This modern form of chemotherapy provides molecular level-based anticancer medicine 
with greater selectivity for cancer cells over normal cells, significantly reducing the 
frequency and severity of side effects that patients experience. Hit compounds (i.e. 
molecules which demonstrate activity against a pre-determined target) are identified in a 
molecular screen and the structures are meticulously altered to enhance and improve the 
pharmacological properties and selectivity profile to produce a drug candidate (Table 
3). 
 
Table 3: Small-molecule targeted cancer therapies
38, 41
 
 
Drug Target Indication Year of FDA 
Approval 
Corporate Sponsor 
Imatinib 
(Glivec)42 
Bcr-Abl, c-Kit, 
PDGF receptor, 
ARG kinase 
CML, 
GIST 
2001 Novartis 
Gefitinib 
(Iressa)43 
EGFR TK NSCLC 2003 AstraZeneca 
Erlotinib 
(Tarceva)44 
EGFR TK NSCLC 2005 Genentech 
Lapatinib 
(Tyverb)45 
ErbB1 (EGFR) and 
ErbB2 TK 
MBC 2007 GlaxoSmithKline 
Bortezomib 
(Velcade)46 
26S proteasome MM 2003 Millennium 
Pharmaceuticals 
Sorafenib 
(Nexavar)47 
b-Raf and c-Raf 
kinase 
HCC 2007 Bayer AG 
Vandetanib 
(Caprelsa)48 
VEGFR MTC 2011 AstraZeneca 
Vorinostat 
(Zolinza)49, 50 
HDACs CTCL 2006 Merck 
PDGF, platelet-derived growth factor; CML, chronic myelogenous leukaemia; GIST, gastrointestinal 
stromal tumour; EGFR, epidermal growth factor receptor; TK, tyrosine kinase; NSCLC, non-small cell 
lung cancer; MBC, metastatic breast cancer; MM, multiple myeloma; HCC, hepatocellular carcinoma; 
VEGFR, vascular endothelial growth factor receptor; MTC, medullary thyroid carcinoma; HDAC, 
histone deacetylase; CTCL, cutaneous T-cell lymphoma 
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The advantage of small-molecule targeted therapies having significantly reduced side 
effects than previous chemotherapies is also a limitation in that the drugs can only be 
used to treat cancers possessing a specific overexpressed or amplified protein. Imatinib 
has shown dramatic results in CML patients, but clinical trials on related protein targets 
in different cancers showed greatly reduced efficacy, highlighting the importance of 
target expression over pathway activation.
38
 Gefitinib treatment has shown noticeable 
tumour regression in only 10-30% of NSCLC patients, despite the near universal 
presence of EGFR kinase. This can be explained by the presence of transporter proteins, 
e.g. ABCG2, which remove foreign agents from the cell and have high affinities for 
tyrosine kinase receptor inhibitors such as Gefitinib.
38, 43
 Variable expression levels and 
polymorphisms of these transporters amongst different cultures and races can influence 
the responses observed in individual patients. Targeted therapies are also not immune to 
the occurrence of side effects. Uncommon but serious side effects of Gefitinib treatment 
include interstitial lung disease and skin toxicity.
38
 
 
1.3.2.4 Protein-Protein Interaction Inhibitors  
 
Protein-protein interactions (PPIs) play a crucial role in many cellular processes and 
inhibition of these interactions is an important method for investigating the cell-
signalling pathways critical to cellular function.
51
 This makes PPI inhibitors desirable 
agents for anticancer therapy. Combinatorial chemistry, high-throughput screening 
(HTS) and structure-based rational design methodologies have all produced promising 
small-molecule inhibitors of PPIs. One example is the cis-imidazoline-based Nutlin 
family, which were optimised to selectively inhibit the hMDM2-p53 interaction. Nutlin-
3a (11) inhibits this PPI with an IC50 of 90 nM and activates the p53 pathway, 
promoting cell cycle arrest, apoptosis and reducing tumour cell proliferation in vivo.
52
 A 
close analogue, RG7112 (12), has now been advanced to clinical development, with 
evidence suggesting the compound activates p53 signalling in human tumour 
xenografts.
53
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Currently, the only marketed PPI inhibitor is Maraviroc (Celsentri; Pfizer) (13), an 
antiretroviral modulator of the CCR5 receptor, found on the surface of white blood 
cells. This receptor has high binding affinity for several HIV strains and is important for 
entry of the virus into the cell. Maraviroc has been shown to significantly reduce the 
levels of HIV RNA found in human cells.
51, 54
  
 
 
 
To efficiently bind to a protein’s surface, a small molecule must cover an area of 800-
1100 Å
2
 whilst complimenting sufficiently the often poorly defined hydrophobic and 
hydrophilic domains of a flat or near-flat surface. Consequently, many of the potential 
PPI inhibitors entering clinical trials are larger and more lipophilic than the currently 
marketed binding inhibitors of a protein with a relatively smaller substrate, e.g. ATP.
51
  
 
1.4 The Drug Development Process 
 
The full drug development process, starting from the identification and validation of a 
target, e.g. a protein, to the approval and marketing of a drug, takes 10-15 years and 
costs $800 million to $1 billion. It can be split into four main stages: 
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 1. Pre-drug discovery  
 2. Drug discovery  
 3. Drug trials  
 
 
4. Drug approval  
The following tables outline the various sub-stages associated with each of the four 
main steps in the drug development process, to explain what was done prior to these 
projects commencing, what the aims of these project were, and what will be done 
following discovery of a drug candidate (Tables 4-7). 
 
Table 4: Objectives in the pre-drug discovery process 
Task Description 
Disease 
Identification 
Identify the target disease and the underlying cause of the condition (i.e. 
which genes are altered and how, the proteins they encode, how those 
proteins function and how they affect the patient). 
Target 
Identification 
Decide which biochemical pathway or receptor is to be targeted and 
develop a hypothesis for the mechanism of treatment (e.g. to inhibit a PPI 
crucial to cell transformation). 
Target 
Validation 
Use in vitro and animal-based studies to confirm the chosen target is 
critical to the onset of the disease and can be affected by the use of a drug 
or gene-silencing.  
Hit 
Identification 
Employ combinatorial chemistry, HTS or computer-aided design (CAD) 
with 3D modelling software to identify compounds or pharmacophores 
which appear crucial for activity against the chosen target, then evaluate 
the feasibility of producing the compound and further derivatives. 
Hit 
Validation 
Fully characterise the hit compounds’ chemical structures and confirm the 
biological activity observed in the initial screen. The latter may involve 
isolated protein assays with dose-response studies, NMR evaluation or co-
crystallisation of the hit compound with the target.  
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Table 5: Objectives in the drug discovery process 
Task Description 
Hit-to-Lead 
 
Structurally optimise hit compounds to optimise their pharmacological 
properties, e.g. potency and selectivity for the target. Structural analogues 
are screened against the target and the data suggests further changes which 
can be made. Compounds demonstrating significant activity against the 
target are called ‘leads’. 
Lead 
Optimisation 
Novel compounds demonstrating high potency are optimised to produce a 
drug candidate. Compounds will be screened across various cell lines to see 
if potency and selectivity are maintained. Potential routes of formulation, 
administration and metabolism are considered.  
 
Table 6: Objectives in the drug trials process 
Task Description 
Pre-Clinical 
Trials 
Conduct in vitro and in vivo studies to determine if a drug candidate is safe 
to trial in humans. Evaluate the acute and sustained toxicity in non-human 
animals (often one rodent, one non-rodent). Dose at increasingly high levels 
to induce toxicity and determine a lethal dose (LD). Dose at levels which 
give a therapeutic value over short and long periods to analyse long-term 
use toxicity. Assess how a drug may be absorbed, distributed, metabolised 
and excreted in animals (ADME properties).  
IND 
Application 
Investigational New Drug (IND) application submitted to the Food and 
Drugs Administration (FDA) to allow human exposure to a drug candidate. 
Phase I 
Clinical 
Trials 
Evaluates the pharmacokinetic (ADME) properties of a drug in 20-80 
healthy volunteers over a one-year period, costing $100,000-$1 million. 
Conduct single-dose, dose-escalation and short-term repeated dose studies 
to determine any side effects with increased dosing and initial evidence of 
drug efficacy.  
Phase II 
Clinical 
Trials 
Assess a drug’s effectiveness at treating a particular condition or disease 
and side effect profile in 100-300 volunteers over a two-year period, costing 
$10-100 million. Compare findings to those of rival compounds or 
placebos. 
Phase III 
Clinical 
Trials 
Confirm the effectiveness and safety of a drug within a large population, 
involving 1000-3000 volunteers over a 3-4-year period in multiple sites 
(nationally and internationally) and costing $10-500 million. Compare 
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findings to those of rival compounds or placebos, at various doses and 
trialling various routes of administration.   
 
Table 7: Objectives in the drug approval process 
Task Description 
NDA New Drug Application (NDA) submitted to the FDA for approval to market 
a drug. Supply sufficient evidence that the drug is safe and effective, that 
the benefits outweigh the risks, that the proposed labelling is appropriate 
and that manufacturing methods and controls maintain the drug’s identity, 
strength, quality and purity. 
Phase IV 
Clinical 
Trials 
After gaining approval to market a drug, further studies are done to evaluate 
a drug’s benefits and side effects when used more widely over greater time 
periods. 
 
1.4.1 SKP2 Hit Identification Criteria  
 
The Lipinski Rules of Five
55, 56
 describe the criteria to maximise the oral activity of a 
candidate drug by successfully balancing aqueous solubility with cell-permeability in 
vivo: 
  Molecular mass ≤ 500 g/mol  
  clogP ≤ 5  
  Number of H-bond donors ≤ 5  
  Number of H-bond acceptors ≤ 10  
 
There are many properties to consider for a lead compound before classifying it as such 
and different drug discovery programs prioritise different properties to optimise, 
depending on the drug’s mode of action and administration. In this project, the priority 
characteristics to optimise were molecular mass, calculated partition coefficient (clogP), 
potency, solubility and topological polar surface area (tPSA). The significances of these 
properties are described below.  
 
1. Potency 
A measurement of drug activity expressed as the concentration of drug required to elicit 
a pharmacological response of pre-defined intensity. The response intensifies with 
increasing concentrations of the drug until a point is reached at which higher doses do 
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not affect the response; this is the maximal effective/inhibitory concentration (Emax). 
The drug concentration at which the response is 50% Emax is the half-maximal 
effective/inhibitory concentration (EC50 or IC50) and potency refers to this value. Drugs 
with higher potency require lower quantities to achieve a therapeutic outcome, which 
often correlates with reduced side effects.
57
 
 
2. Partition coefficient (P) 
A measurement of drug lipophilicity, defined as the ratio of concentrations of a drug 
between two immiscible solvents at equilibrium. The two solvents are often deionised 
water and octan-1-ol. High lipophilicity correlates with extensive metabolism high 
clearance and reduced target selectivity.  
 
3. Aqueous solubility  
A drug must have sufficient solubility to dissolve in blood plasma and the desired 
solubility range for a particular drug depends on its potency and cell permeability. Low 
aqueous solubility correlates with poor absorption and a delayed therapeutic effect.
58
 
 
4. Molecular mass 
Most marketed drugs have a molecular mass below 500 g/mol. Larger molecules diffuse 
slower through cell membranes resulting in a delayed therapeutic response. 
 
5. Topological polar surface area (tPSA) 
Quantifies the polarity of a drug (measured in Å
2
) by calculating the sum of all polar 
atom surfaces (usually oxygens, nitrogens and their attached hydrogens) and predicts a 
drug’s transport properties. High polarity correlates with accelerated clearance and a 
poor pharmacological response. 
 
In the case of the projects described herein, the criteria defining a suitable PPI inhibitor 
lead compound designed for intravenous (IV) administration are as follows: 
 
  Potency: ≤ 100 nM  
  Selectivity: ≥ 100-fold  
  LogP: ≤ 5  
  Solubility: ≥ 50 µM  
  Molecular mass: ≤ 500 g/mol  
  tPSA: 75-100 Å2  
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Chapter Two: Project SKP2 
 
2.1 The SCF E3 Ubiquitin Ligases  
 
The SKP1-Cullin1-F-box (SCF) E3 ligases are the largest family of E3 ubiquitin ligases 
and regulate many cellular processes by promoting the ubiquitination of regulatory 
proteins, e.g. cell cycle regulators and transcription factors, targeting them for 
proteasome-mediated degradation or otherwise affecting their function/activity.
59
  
 
Ubiquitination of a substrate is a multi-step process (Figure 3). Ubiquitin-activating 
enzyme E1 coordinates to ubiquitin through use of ATP and transfers it to ubiquitin-
conjugating enzyme E2. The SCF ligase E3 recognises and coordinates to the protein 
substrate and catalyses ubiquitin transfer from E2 to the protein. Ubiquitin is conjugated 
to a protein by an isopeptide link formed between the carboxy group of the C-terminal 
glycine residue of ubiquitin and the ɛ-amino group of a lysine residue within the 
substrate. This process can be repeated to assemble polyubiquitin chains by conjugating 
the carboxy group of the C-terminal glycine residue of the new ubiquitin molecule to 
the ɛ-amino group of one of seven internal lysines within the preceding ubiquitin. The 
fate of the ubiquitinated substrate depends on the type of isopeptide linkage formed; 
K48-linked polyubiquitination targets the substrate for proteasome-mediated 
degradation, but K63-linked or monoubiquitination alters the protein’s function and its 
interactions with other proteins etc.
60
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Figure 3: Protein ubiquitination pathway (Ub, ubiquitin); adapted from
60
  
 
The SCF E3 ligases are multi-subunit complexes consisting of adaptor proteins, cullins, 
RING finger proteins and F-box (receptor) proteins (Figure 4). Crystal structures of 
SCF complexes reveal the cullins are scaffold proteins, which bind the adaptor and F-
box proteins at its N-terminus and the RING finger proteins at its C-terminus.
59
 Seven 
cullins are known in the human genome (Cul-1, -2, -3, -4A, -4B, -5 and -7) and all are 
involved in the coordination of different F-box proteins. The RING finger proteins 
coordinate to E2 enzymes and facilitate ubiquitin transfer to the substrate. Two RING 
finger proteins are known in the human genome, RBX1 (RoC1) and RBX2 (RoC2), 
both of which have been shown to be functionally non-redundant in mouse-knockout 
studies.
59, 61
 SKP1 is an adaptor protein found in several SCF complexes and links the 
cullin with the F-box protein.
59
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Figure 4: The SCF
SKP2
 E3 Ligase; adapted from
62
. Ubiquitin (Ub) is transferred from an E2 enzyme to a 
substrate that is bound to SKP2. The substrate must be phosphorylated before SKP2 can bind to it (P = 
phosphate). Once ubiquitinated, the substrate is degraded by the 26S proteasome with the release of 
ubiquitin. Substrates of SKP2 include p21, p27, p57, p103, TOB1, FOXO1 and c-Myc 
 
F-box proteins are the substrate-recognising subunits that determine the selectivity of an 
SCF complex. One F-box protein can recognise multiple substrates, some of which have 
opposite biological functions, e.g. cell cycle suppressors and promoters. Whether a 
particular substrate will be targeted or not depends on the cell’s internal environment, 
highlighting the significance of SCF complexes in determining the life and death of a 
cell. In the human genome there are 69 F-box proteins,
63
 each of which binds to the 
adaptor protein via its F-box domain, and are classed into one of three categories 
depending on the nature of the binding domain that links them to the substrate.
59
 Those 
which have WD40 domains (i.e. domains consisting of a 40-amino acid motif ending in 
a tryptophan-aspartic acid dipeptide) are called FBXWs, those with domains consisting 
of leucine-rich repeats are called FBXLs and those which have other diverse domains 
are called FBXOs. To date, three F-box proteins have been well studied: Fbxw7,
64
 β-
TrCP
65
 and SKP2.
59, 65, 66
  
 
2.2 SCF E3 Ubiquitin Ligases as Anticancer Targets  
 
Several subunits of the SCF complex have demonstrated oncogenic activity; of the 
seven cullin scaffold proteins, Cul-1 is overexpressed in 40% of lung cancers and Cul-
4A is overexpressed in breast cancer, HCC and mesotheliomas. Cul-4A overexpression 
is associated with cell cycle progression in breast cancer cells resulting in poor 
prognosis and Cul-4A knockdown by siRNA causes accumulation of cell cycle 
suppressors p21 and p27, inducing G1 cell cycle arrest.
59
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SCF-mediated ubiquitination must be activated by the coordination of a ubiquitin-like 
protein, Nedd8 activating enzyme (NAE), to the cullins of the SCF ligase; a process 
termed neddylation. This forms an isopeptide bond between the C-terminal glycine 
residue of Nedd8 and the ε-amino group of a conserved cullin lysine residue.  Inhibitors 
of neddylation, e.g. MLN4924 (14), induce many SCF substrates, including p27, which 
can promote cell cycle arrest and cell death (Figure 5). This evidence suggests the 
significance of targeting Nedd8 as a form of cancer treatment.
67
 
 
 
 
The accessory protein cyclin kinase subunit 1 (Cks1) is essential for efficient SKP2-
mediated degradation of p27, as evidenced by the slow proliferation of p27 in Cks1-
knockout mice. Cks1 levels have been shown to correlate positively with those of SKP2 
and inversely with those of p27. As a result, Cks1 overexpression has been linked with 
tumour aggressiveness and a poor prognosis in several cancers including colorectal 
carcinoma.
68
  
 
RBX1 is overexpressed in several human tumours including lung cancer. Knockdown 
of RBX1 by siRNA triggers a DNA damage response and subsequent G2/M cell cycle 
arrest, senescence and apoptosis. RBX2 is also overexpressed in several human cancers 
giving a poor prognosis. The RING finger proteins exert E3 ubiquitin ligase activity and 
promote the degradation of multiple cell cycle regulators including p27 and c-Jun.
61
 
RBX2 siRNA silencing induces cancer cell apoptosis and sensitisation to 
chemotherapeutics and radiation. This evidence suggests the significance of the RING 
finger proteins as anticancer targets.
59
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Figure 5: Targeting the SCF E3 ligases to trigger multiple cancer cell killing mechanisms
59
  
 
2.2.1 Targeting the F-Box Protein SKP2 for Cancer Therapy  
 
The SCF
SKP2
 E3 ligase recognises and targets several cell cycle negative regulators, e.g. 
p21, p27, p57 and p130.
69
 Oncogenic SKP2 increases ubiquitination of these proteins 
and enables replicative immortality.
63
 Reduced p27 levels are common in many human 
cancers, being associated with an aggressive phenotype and poor prognosis.
70, 71
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multiple myeloma (MM), clinical studies show patients with low p27 expression have a 
shorter survival period compared to those with high p27 expression on high-dose 
chemotherapy.
72
 SKP2 is overexpressed in several human cancers, giving a poor 
prognosis in gastric, colon, prostate and breast cancers. Xenografts of breast cancer cells 
with high SKP2 levels in mice grow faster than xenografts expressing low SKP2 levels. 
In mouse knock-out models, disruption of SKP2 alone does not induce cellular 
senescence, but SKP2-null environments or siRNA silencing of SKP2 does induce 
senescence and inhibits cell growth in melanoma, oral cancer, glioblastoma and lung 
cancer. SKP2-null mice are still viable and do not show an increased incidence of 
cancer. This evidence suggests that pharmacological inhibitors of SKP2 activity would 
be of therapeutic value for cancer therapy.
73
 Several protein regulators of SKP2 have 
been discovered, many of which are down-regulated or inactivated in cancer cells 
(Figure 6). Their mechanisms of action on the activity of SKP2 are discussed below: 
 
1. PI3K/Akt  
Phosphatidylinositol-3-kinases (PI3Ks) regulate many cellular functions including cell 
growth, proliferation, differentiation and signal transduction. Akt is an important 
regulator of cell growth and survival, which is able to inhibit or promote apoptosis 
through the regulation of several signaling pathways including Bcl-2-Associated-Death 
(BAD), caspase-9 and mTOR. Studies in which the PI3K/Akt pathway has been 
disrupted report reduced SKP2 protein expression, coupled with increased p27 levels.
62
  
 
2. PTEN 
Phosphatase and tensin homolog (PTEN) is a tumour suppressor protein which 
functions as a negative regulator of the PI3K/Akt pathway and is frequently inactivated 
in several human cancers, e.g. prostate cancer. PI3K/Akt signaling is up-regulated by 
30-50% in prostate cancer cells, often due to PTEN inactivation, but restoration of 
PTEN activity inhibits the growth of PTEN-null prostate cancer xenografts in mice.
62
 
PTEN regulates the oncogenic activity of SKP2 in prostate cancer cells. DU145 cells 
with down-regulated PTEN function showed a PTEN/Akt-dependent regulation of 
SKP2 activity, with an inverse correlation observed between PTEN levels and SKP2 
expression.
62
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3. Androgen and AR 
The androgen receptor (AR) is a ligand-activated transcription factor which, upon 
binding to androgen, undergoes phosphorylation and relocates to the nucleus where it 
interacts with DNA, initiating gene transcription and subsequently promoting cell 
growth. The AR has been implicated in all stages of prostate carcinogenesis including 
initiation, proliferation and treatment resistance, partly through regulation of SKP2 by 
inhibiting its degradation.
62
 SKP2 in turn serves as an effector of the AR by promoting 
cell proliferation independent of AR activity. Androgen expression has been shown to 
promote G1 cell cycle arrest in prostate cancer cells through reduction of SKP2 
expression and induction of p27 in an AR-dependent manner.
62
  
 
 
Figure 6: The cross-communication between the PI3K/Akt, PTEN and AR pathways and their combined 
regulation of SKP2 activity.
62 
 
4. MYCN  
MYCN is a member of the MYC family of transcription factors and is frequently 
amplified in human neuroblastomas.
74, 75
 Half of neuroblastomas are considered high 
risk (survival rates under 40%) and all instances with amplified MYCN fall into this 
25 
 
category, being associated with rapid disease progression and metastasis.
74, 76
 SKP2 
levels are higher in neuroblastomas where MYCN is amplified than when it is not. In 
one study, SKP2 expression was 2- to 9.5-fold higher in MYCN-amplified cancer cells 
than in cells showing no MYCN amplification and this SKP2 activation was 
independent of mitogenic signalling.
76
 This evidence shows that MYCN is another 
important regulator of SKP2 activity in neuroblastomas.  
 
Currently, the only marketed drug that targets the ubiquitin-proteasome system (UPS) is 
bortezomib (Velcade; Millenium Pharmaceuticals) (15),
46
 which is used to treat 
multiple myeloma (MM).
 
Myeloma cells are up to 1000-fold more susceptible to 
apoptosis in the presence of 15 than normal cells in vitro, due to the inhibition of 
nuclear factor-κB (NF-κB), a transcription factor crucial to the pathogenesis of many 
inflammatory and neoplastic diseases.
46, 77
  
 
 
 
The boronic acid group in 15 interacts irreversibly with and inhibits the action of the 
26S proteasome (Figure 7), which is responsible for the degradation of multiple pre-
ubiquitinated targets, including p27.
46
 In normal cells, NF-κB, which exists as a dimer 
of p50 and p65, is bound to an inhibitory protein, IκB, which keeps it inactive. In cancer 
cells, the 26S proteasome activates NF-κB by catalysing the destruction of IκB and the 
generation of p50 from its inactive precursor p105. NF-κB then enters the nucleus 
where it helps the cancer cells to survive and proliferate. Inhibition of the 26S 
proteasome keeps NF-κB inactivated by IκB and blocks cell proliferation.  
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Figure 7: The mechanism of action of 15. By inhibiting the 26S proteasome (red cross), and therefore the 
activation of NF-κB (orange crosses), 15 suppresses the growth of myeloma cells; adapted from46  
 
Bortezomib has numerous side effects, including peripheral neuropathy, as the result of 
targeting a proteasome involved in the regulation of many proteins with diverse cellular 
functions.
46
 Targeting the F-box protein of an SCF E3 ligase is an attractive therapeutic 
approach, as the F-box protein defines E3 ligase selectivity and each E3 ligase has 
fewer target proteins than the 26S proteasome. This means that targeting a specific E3 
ligase pathway would have reduced patient toxicity.  
 
To date, no small molecule targeting an F-box protein has entered clinical trials. 
78
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2.3 (((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-
phenylbutyl)amino)methyl)-N,N-dimethylaniline: An SCF
SKP2
 Ligase 
Inhibitor 
 
(((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutyl)amino)methyl)-N,N-
dimethylaniline (16a) was identified as an inhibitor of HeLa cell growth in an in vitro 
reconstituted system containing the cyclin E, CDK2, SKP2, SKP1, Cul-1, RBX1 and 
cellular extract from vehicle-treated HeLa cells (Figure 8).
78
 This system could 
ubiquitinate 
35
S-labelled in vitro-transcribed and -translated p27 and was adapted to a 
high-throughput format to screen compound libraries. The screen analysed labelled p27 
levels (Lanes 1 and 4) and levels of its polyubiquitinated form (Lane 2). In the presence 
of 30 µM 16a (Lane 3), ubiquitination was inhibited. Addition of excess 
SKP2/SKP1/Cul-1/RBX1 (SCF
SKP2
 complex) restored ubiquitination both in the 
absence of 16a (Lane 5) and in its presence (Lane 6). 
 
 
 
 
 
Figure 8: The in vitro reconstituted system used to identify HeLa cell growth inhibitors
78
 (Cpd A = 16a; 
Roc 1 = RBX1) 
 
In a subsequent experiment (Figure 9), HeLa cells were arrested in the S-phase and 
exposed to either a vehicle, 30 µM 16a or 10 µM proteasome inhibitor MG132 (17) for 
16 h, then treated with cycloheximide to inhibit protein biosynthesis. Compounds 16a 
and 17 extended the half-life of p27 and phosphorylated p27 compared with vehicle-
treated cells.  
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Figure 9: Western blots reveal 16a (Cpd A) and 17 (MG132) extend the half-life of p27 and 
phosphorylated p27. β-Actin serves as a loading control.78 
 
In WT mouse embryonic fibroblast (MEF) cells, 5 µM 16a increased p21, p27 and p57 
levels. In p27
-/-
 cells, it increased p21 and p57 levels and in SKP2
-/-
 cells it had no effect 
on these proteins’ levels (Figure 10).78 This evidence suggests 16a inhibits the action of 
SKP2, as the only cells in which 16a had no detectable effect were those in which the 
SKP2 had been removed.  
 
 
 
 
 
 
 
 
 
 
Figure 10: WT, P27
-/-
 and SKP2
-/-
 MEF cells exposed to 5 µM 16a (Cpd A) for 24 h before Western blot 
analysis
78
  
 
WT MEFs showed a dose-dependent reduction in viability upon treatment with 16a 
(Figure 11). SKP2
-/-
 and p27
-/-
 cells showed greater resistance to the increasing doses of 
16a, with only a small drop in viability recorded compared to vehicle-treated cells.  
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Figure 11 WT, P27
-/-
 and SKP2
-/-
 MEF cells treated with a vehicle or increasing concentrations of 16a 
(Cpd A) for 24 h before assessment of cell viability using a WST-1 assay.
78
  
 
RPMI 8226 myeloma cells treated with 16a or bortezomib (15) showed increased levels 
of p21, p27 and p57 but 15-treated cells also showed increased levels of β-catenin (an 
SCF
β-TrCP
 substrate) and c-Jun (an SCF
Fbxw7
 substrate). All MM cell lines treated with 
16a showed a dose-dependent fall in viability, with IC50 values ranging from 4.2 ± 0.2 
µM for U266 cells to 13.2 ± 1.4 µM for NCI-H929 cells.
78
 RPMI 8226 cells treated 
with 16a underwent cell cycle arrest at the G0/G1 phases, showing a dose-dependent rise 
in apoptosis, as measured by a correlational rise in positive staining by annexin V.
78
  
 
Melphalan (18)-resistant RPMI 8226 and U266 cells showed sensitivity towards 16a 
with similar IC50 values to their non-melphalan-resistant analogues. Doxorubicin (19)-
resistant RPMI 8226 and MM1.S cells also displayed sensitivity towards 16a, 
demonstrating that 16a could be used to treat myelomas which have become resistant to 
currently used medication (Table 8). 
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Table 8: Comparison of IC50 values obtained with various MM cell lines and their drug-resistant 
counterparts upon treatment with 16a
a 
 
Parental Cell Line 16a IC50 (µM) Drug-Resistant Cell Line 16a IC50 (µM) 
RPMI 8226 8.0 ± 1.1 RPMI 8226/LR5 
RPMI 8226/Dox40 
6.3 ± 1.0 
8.5 ± 0.9 
U266 4.2 ± 0.2 RPMI 8226/LR6 4.3 ± 0.8 
MM1.S 5.4 ± 0.4 MM1.RL 5.4 ± 0.7 
ANBL-6 10.0 ± 0.4 ANBL-6/B7R 8.0 ± 0.3 
(a) Cells were cultured with 16a for 72 h and cell viability determined using a WST-1 assay. Data 
represent average IC50 plus or minus SD from triplicate assays. 
 
Compound 16a demonstrated enhanced activity against RPMI 8226 cells when 
combined with bortezomib (15), possibly due to the combined inhibition of protein 
ubiquitination and of the degradation of proteins which have been ubiquitinated.
78
 This 
suggests that 15 and 16a could be used synergistically to enhance the accumulation of 
SCF
SKP2
 substrates. 
 
2.4 Aims of the SKP2 Project 
 
The aim of this project was to design and synthesise a novel, potent antitumour agent 
targeting the SKP2 pathway, using 16a for structure-activity studies. The compound 
was synthesised using the route described by McKenna (Scheme 1),
79
 and its growth-
inhibitory activity in vitro was confirmed in HeLa cells using a sulfohodamine B (SRB) 
assay. Its structure was modified to optimise potency, measured by the half-maximal 
inhibitory concentration of HeLa cell growth (GI50), and other pharmacokinetic 
properties including clogP and tPSA.   
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Scheme 1: Literature synthesis of 16a;
79
 (i) CH2O, Amberlyst-15; (ii) (MeO)2(O)PCH2CO2Me, NaH, 
THF; (iii) H2, Pd/C, EtOAc; (iv) 
i
Pr2NH, n-BuLi, THF, BnBr;  (v) DIBAL-H, DCM; (vi) MsCl, 
i
Pr2NEt, 
DCM; (vii) NaCN, DMF, 100 
o
C; (viii) LiAlH4, THF; (ix) 4-(N,N-dimethylamino)benzaldehyde, MgSO4, 
DCM; NaBH4, MeOH 
 
Compound 16a had a suitable molecular mass for a drug candidate (394 g/mol) but had 
a high clogP (5.8) and low tPSA (24.5 Å
2
) and potency in myeloma cells. It also had 
two chiral centres, although it was unknown whether one diastereoisomer was 
responsible for the observed activity in myeloma and HeLa cells. Determining the 
significance of the two stereogenic centres in 16a was another aim of this project. The 
proposed structural modifications to 16a for SAR studies are displayed below (Figure 
12). 
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Figure 12: Proposed structural modifications to 16a 
 
2.5 Competitor Compounds Targeting the SCF
SKP2 
E3 Ligase Pathway 
2.5.1 Inhibitors of the SKP2-Cks1-p27 Trimer  
 
Wu et al. recently described the identification of several selective inhibitors of the PPI 
between p27 and the SKP2-Cks1 complex.
80
 In silico interrogation of the published 
SKP2-Cks1-p27 crystal structure identified a p27 binding pocket formed at the SKP2-
Cks1 interface (Figure 13). This pocket was flanked by amino acids SKP2-R294, 
SKP2-Y346, Cks1-R44 and Cks1-Q52, which were shown to be essential for p27 
binding and ubiquitination, interacting with p27-pT187 and p27-E185. 
 
 
A)                                                                      B) 
Figure 13: A) Crystal structure of SKP2 (orange), Cks1 (green) and phosphorylated p27 (purple); B) In 
silico binding pocket (blue) identified upon removal of p27. Images created using ICM-PocketFinder 
(Molsoft, La Jolla, CA, USA); adapted from
80
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Virtual ligand screening (VLS) of 315,000 diverse compounds identified 202 hit 
molecules, of which 96 were selected, based on their calculated binding scores and 
Lipinski properties. In vitro ubiquitination assays of these 96 compounds identified 29, 
30, 31 and 32 as modest inhibitors of p27 ubiquitination with good selectivity for non-
SKP2-p27 interfaces (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: The initial hit compounds identified by in vitro screening for selective SKP2-p27 inhibitors. 
Active groups, thought to be responsible for the observed activity, are shown in the red boxes.
80
 
 
In silico modelling of 29 in the p27 binding domain predicted electrostatic interactions 
with Cks1-Q52 and/or hydrogen bonding to Cks1-R44 or SKP2-R344 (Figure 15a). In 
silico modelling of 30 predicted cation-π interactions with SKP2-R294 and/or hydrogen 
bonding to Cks1-R44 (Figure 15b).  
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A)                                                                   B) 
Figure 15: A) Predicted lowest energy conformation of 29 in the p27 binding domain of the SKP2 
(orange)-Cks1 (green) interface. Key residues thought to be involved in binding are highlighted. 
Electrostatic interactions and hydrogen bonds are shown as dotted lines; B) Predicted lowest energy 
conformation of 30 in the p27 binding domain of the SKP2 (orange)-Cks1 (green) interface. Images 
created using ICM-PocketFinder (Molsoft, La Jolla, CA, USA); adapted from
80
 
 
Compounds 31 and 32 were thought to have similar binding modes to 29 and 30 
respectively and this hypothesis was supported when in vitro screening of analogues 
lacking the chemical moieties thought to be responsible for these interactions (shown in 
red boxes) exhibited no inhibition of p27 ubiquitination with WT SKP2 and Cks1 
(Figure 16). 
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Figure 16: Ubiquitination assays treated either with a vehicle (0.1 % DMSO), 50 µM each inhibitor (29 
(C1), 30 (C2), 31 (C16) or 32 (C20)) or 50 µM analogous unmatched compound (UM) lacking proposed 
active groups (shown in red boxes in Figure 14)
80
 
 
The significance of the interaction between Cks1-Q52 and the carboxy groups of 29 and 
31 was confirmed when these compounds showed activity against WT SKP2 and WT 
Cks1 but lacked activity with WT SKP2 and Q52L-Cks1 mutants. The fact that Cks1-
Q52 was significant for the binding of p27 inidicated that compounds 29 and 31 could 
be potent inhibitors of the SKP2-p27-cks1 trimer. 
 
To assess the ability of each compound to inhibit p27 ubiquitination in cells, the 
metastatic melanoma cell line 501 MeI was treated with either a vehicle (0.1% DMSO) 
or a 10 µM solution of each inhibitor. Levels of p27 were elevated in the presence of 
these compounds, compared with the vehicle, in a dose-dependent manner (Figure 17). 
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Figure 17: Protein induction assay, immunoblotting for steady-state levels of SKP2 substrates (p27, p21, 
p130 and Cdt), SKP2, SKP1, Cul1 and Nedd8 in 501 MeI cells, with loading normalised to α-tubulin. 
Cells treated either with a vehicle (0.1% DMSO), 10 µM each inhibitor (29 (C1), 30 (C2), 31 (C16) or 32 
(C20)), 10 µM MG-132 (17) (MG) or 400 nM MLN-4924 (14) (MLN). Unt, untreated cells
80
 
 
In 501 MeI cells treated with a vehicle (0.1% DMSO) or 10 µM each inhibitor and 
subsequently exposed to cycloheximide, cells treated with the vehicle reported a p27 
half-life of 1 h but cells treated with one of the SKP2 ligase inhibitors gave p27 half-
lives ranging from 3 to > 5 h. Protein levels of SKP2 and SKP1 remained constant, 
showing that these inhibitors function by increasing the half-lives of SKP2 substrates, 
without affecting levels of the SCF complex.
80
  
 
These compounds represent some of the first small-molecule inhibitors of SKP2-
mediated p27 degradation, which have been shown to function specifically by inhibiting 
formation of the SKP2-Cks1-p27 trimer. The identified compounds have been shown to 
induce p27 levels, both in in vitro and in vivo experiments, establishing a proof of 
principle for the selective targeting of SCF
SKP2
 as a novel treatment for a variety of 
cancers. 
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2.5.2 Inhibitors of the SKP2-SKP1 Interaction  
 
A series of chromone-based small molecules were identified, by high-throughput in 
silico screening
81
 and subsequent SAR analysis, to suppress activity of the SCF
SKP2
 E3 
ligase and trigger p53-independent cellular senescence and apoptosis.
82
 Using 
HiPCDock software, over 120,000 compounds were screened, of which 25 were 
predicted to bind with SKP2. One of these compounds (26a) was subsequently shown to 
bind to SKP2 in vivo and inhibit the SKP2-SKP1 interaction, thus attenuating E3 ligase 
activity. 
 
 
 
Structural analysis of the SCF
SKP2
 complex (Figure 18)
83
 had revealed the SKP2 protein 
interacts directly with SKP1 via its F-box domain. Along the SKP2-SKP1 interface, 
several residues were shown to contribute significantly to this binding interaction and 
were termed hot-spot residues. The authors concluded from their hot spot analysis that 
19 SKP2 residues made direct contact with SKP1, forming two distinct pocket-like 
regions.
82
 Pocket 1 was located at the N-terminus of SKP2, within the F-box motif, and 
included residues W97, F109, E116, K119 and W127. Pocket 2 was close to the SKP2 
C-terminus, formed by the leucine-rich repeat (LRR) region and several residues from 
the F-box.  
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Figure 18: Quaternary structure of the SCF
SKP2
 complex, with the SKP2, SKP1, Cul-1 and RBX-1 
proteins coloured in magenta, blue, green and red respectively. Labels A-E represent the 5 α-helices 
which make up a repeat unit in the cullin protein and three such repeats exist; adapted from
83
 
 
Modelling of 33a in these binding regions of SKP2 indicated efficient binding in pocket 
1 (Figure 19). The benzothiazole ring was predicted to make polar contacts and 
aromatic stacking interactions with W97. The chromone moiety was extended through a 
pocket, formed by residues D98 and W127, and was predicted to make hydrogen bonds 
or hydrophobic/aromatic interactions with these amino acids. The ethyl group extended 
into the region where SKP1 normally bound, therefore inhibiting the interaction with 
SKP2 and its natural substrate. Finally, the piperidine ring was shown to interact closely 
with D98 and W127 and so was also essential for binding.
82
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Figure 19: Predicted docking of 33a in pocket 1 of the SKP2 protein. Yellow dashed lines represent 
hydrogen bonds between 33a and the protein. Residues in green form hydrogen 
bonds/hydrophobic/aromatic stacking interactions with compound 33a.
82
  
 
In agreement with modelling predictions, analogues of 33a in which the benzothiazole 
was replaced by a smaller thiazole ring (33n and 33o) lost all binding affinity (Table 9) 
but the isosteric benzimidazole (33j) retained activity. Removal of the ethyl group (33b) 
abolished potency, in agreement with the hypothesis that the ethyl group was projecting 
into the SKP1-binding region and was thus preventing SKP1 from binding. Attempts to 
insert groups at the 2-position of the chromone scaffold were detrimental to potency 
(33k, 33l and 33m). The 4-chromone scaffold could be replaced by a 2-chromone and 
retain affinity (33f), which was predicted to be due to the molecule adopting a different 
binding conformation. In support of this theory, the ethyl group was no longer essential 
for activity in the 2-chromone series, as it was shown by modelling that the piperidine 
ring was occupying the space thought to be where the ethyl group binds in the 4-
chromone series. In the 4-chromone series, the piperidine ring was found to be essential, 
with ring-opened and substituted ring systems abrogating potency (33e, 33g, 33h and 
33i). The model had predicted that the piperidine ring occupied a channel formed by 
residues D98 and W127, and was also in close proximity to R126, therefore substituted 
derivatives would not be tolerated. Site-directed mutagenesis revealed that 33a could 
not inhibit binding between SKP2 W97A or D98A mutants with SKP1, highlighting the 
importance of these two residues in binding to 33a. 
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Table 9: SAR studies of compound 26 and its derivatives
82
 
 
ID R1 R2 R3 R4 Activity 
33a Benzothiazole Et H -N(CH2)5 ACTIVE 
33b Benzothiazole H H -N(CH2)5 Inactive 
33c Benzothiazole H Me -N(CH2)6 Inactive 
33d Benzothiazole H Me -N(CH2)4 Inactive 
33e Benzothiazole H Me 4-N-Me-
piperazine 
Inactive 
33f See above for structure ACTIVE 
33g Benzothiazole H Me 2-Me-
piperidine 
Inactive 
33h Benzothiazole Et H 4-Olamine-
piperazine 
Inactive 
33i Benzothiazole Et H -NEt2 Inactive 
33j Benzimidazole Et H -N(CH2)5 ACTIVE 
33k Benzothiazole Et CO2Et -N(CH2)5 Inactive 
33l Benzothiazole n-Pr Me 4-N-Me-
piperazine 
Inactive 
33m Benzothiazole Et Me -N(CH2)5 Inactive 
33n 4-Me-thiazole Et H -N(CH2)4 Inactive 
33o 4-Me-thiazole Et H 3-Piperidin-
3-ylpyridine 
Inactive 
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In vitro binding assays revealed 5 µM 33a could completely inhibit the SKP2-SKP1 
interaction and a similar observation was made in vivo, with 33a impeding this 
interaction in a dose-dependent manner (Figure 20a). In vivo p27 ubiquitination assays 
revealed 33a inhibited SKP2-mediated p27 ubiquitination and induced p27 and p21 
expression in prostate cancer cells (Figure 20b). 
 
 
 
 
 
 
 
 
 
 
A)                                                                   B) 
Figure 20: A) In vivo SKP2-SKP1 binding assay with or without #25 (33a) in PC3 cells; B) Treatment of 
PC3 cells with either a vehicle or 26 for 24 h before harvesting by immunoblotting assay
82
 
 
Compound 33a inhibited SKP2-mediated ubiquitination of known SKP2 substrates, 
including p27, p21 and Akt, however it showed no inhibiting effects on ubiquitination 
mediated by other SCF E3 ligases, including Fbw-7 and β-TrCP. Consequently, levels 
of c-Jun, MCL-1 (both Fbw-7 substrates), Snail and IκBα (both β-TrCP substrates) were 
unaffected upon treatment with 33a. Compound 33a was also shown to significantly 
reduce cell viability in PC3 cells, in contrast to normal prostate PNT1A cells, where cell 
viability was only slightly affected (Figure 21).  
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Figure 21: Prostate cancer PC3 and LNCaP cells and normal prostate PNT1A cells were treated with 
various doses of #25 (33a) before analysis by cell survival assay
82
 
 
Compound 33a caused cell-cycle arrest at the G2/M phase of the cell cycle, an effect 
that was attenuated in SKP2-silenced cells. The evidence from these studies conclude 
that 33a can suppress cell viability of prostate cancer cells by inhibiting SKP2-mediated 
ubiquitination of cell cycle regulators, including p27, without affecting levels of other 
E3 ligase substrates and with only limited cytotoxicity in healthy prostate cells.  
 
2.5.3 Inhibitors of the SKP2-Cks1 Interaction  
 
The cyclin-dependent kinase regulatory subunit 1 (Cks1) is an adaptor protein required 
for p27 ubiquitination by SCF
SKP2
. In order for p27 to be recognised and targeted for 
ubiquitination, it must first be phosphorylated at T187, either by CDK2/cyclin E or 
CDK2/cyclin A. Cks1 binds the CDK/cyclin complex, phosphorylated p27 and SKP2 
proteins together (Figure 22), therefore disruption of the interaction between SKP2 and 
Csk1 should prevent p27 ubiquitination and induce p27 expression. 
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Figure 22: Schematic of the SCF
SKP2
-dependent ubiquitination of p27 in vitro
84
 
 
In an AlphaScreen assay of 3,125 compounds supplied by the National Cancer Institute 
(NCI) and the National Institutes of Health (NIH) Developmental Therapeutics Program 
(DTP), 45 were identified as potential inhibitors of the SKP2-Cks1 interaction. Further 
testing of these hits in an in vitro p27 ubiquitination assay revealed 12 compounds with 
the ability to inhibit p27 ubiquitination. Two of these compounds (34 and 35) were 
investigated further, as they were among the most potent inhibitors of p27 
ubiquitination but were also structurally related.
84
 The authors did stress that, while both 
compounds are known to possess antitumour activity, their mechanism of action 
remains elusive.
85
 
 
 
 
SAR analysis on 34 revealed that oxidation to the quinone (36) retained activity but 
monomethylation of either of the hydroxy groups (37 and 38) was detrimental to 
potency (Table 10). However, screening the lone quinol (39) or quinone fragment (40) 
also gave no activity in the SKP2-Cks1 AlphaScreen assay, implying that it was due to 
the compound’s specific structure rather than the quinol or quinone warhead that was 
responsible for the observed inhibitory activity.
84
  
 
Ubiquitin 
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Table 10: SAR analysis of SKP2-Cks1 Inhibitors
84
 
 
ID Structure SKP2-Cks1 IC50 
(µM) 
p27 Ubiquitination IC50 
(µM) 
 
34 
 
 
36 ± 6 
 
30 
 
35 
 
 
76 ± 7 
 
80 
 
36 
 
 
71 ± 4 
 
15 
 
37 
 
 
1090 ± 189 
 
> 300 
 
38 
 
 
8311 ± 1458 
 
> 300 
 
39 
 
 
434 ± 40 
 
> 300 
 
40 
 
 
626 ± 66 
 
> 300 
 
Compounds 34 and 35 gave GI50 values of 12.8 and 18.5 µM respectively in leukaemia 
K562 cells and, in the NCI 60 cell lines, returned average GI50 values of 1.25 and 7.97 
µM respectively. While the authors did concede this wide-ranging activity may be due 
to inhibition of tyrosine kinases, the evidence provided in these aforementioned assays 
suggests the compounds may also be involved in preventing p27 ubiquitination via 
inhibition of the SKP2-Cks1 interaction. 
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2.5.4 Salinomycin as an Inhibitor of STAT3  
 
Salinomycin (41) is isolated from Streptomyces albus and has been widely used as an 
agricultural antibiotic. Koo et al. described the cytotoxic properties of 41; this 
compound selectively targets cancer stem cells (CSCs) in breast, colorectal, lung and 
gastric cancer, as well as osteosarcoma and leukaemia.
86
 CSCs are a subpopulation of 
cancer cells possessing genetic alterations which confer drug resistance and disease 
relapse.  
 
 
 
Compound 41 induced growth inhibition in human ovarian adrenocarcinoma OVCAR-8 
cells, as well as the multidrug-resistant NCI/ADR-RES and DXR cell lines (Figure 
23a). The latter two cell lines had previously demonstrated resistance to a range of 
chemotherapeutic agents, including doxorubicin (Figure 23b), and were shown to have 
higher levels of multidrug resistance protein 1 (MDR-1) than the non-drug-resistant 
OVCAR-8 cells.  
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A)                                                                           B)                                    
Figure 23: A) Treatment of OVCAR-8, NCI/ADR and DXR cell lines with various concentrations of 41 
over 72 h and monitoring of cell growth inhibition by MTS assay. Data are average values of triplicate 
measurements, with error bars representing standard deviations. *P <0.05, **P < 0.005 and ***P < 
0.0005; B) Treatment of OVCAR-8, NCI/ADR and DXR cell lines with various concentrations of 
doxorubicin over 72 h and monitoring of cell growth inhibition by MTS assay. Data are average values of 
triplicate measurements, with error bars representing standard deviations. *P <0.05, **P < 0.005 and 
***P < 0.0005
86
 
 
Compound 41’s mechanism of action involves the downregulation of SKP2 and it was 
observed that levels of p27 conversely accumulated on treatment with 41 in all three cell 
lines (Figure 24a). SKP2 degradation was enhanced in cells transfected with si-SKP2 
and treated with 41, but any 41-induced cell cycle arrest was attenuated in si-p27 cells. 
In DXR cells, quantitative PCR (qPCR) revealed the levels of SKP2 mRNA reduced by 
43% following treatment with 41, compared with control cells (Figure 24b). In the 
presence of MG132 (17), 41-induced SKP2 downregulation was impeded, suggesting 
41 reduces SKP2 levels via a proteasomal pathway. 
  
Doxorubicin Salinomycin 
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A)                                                                           B) 
Figure 24: A) Cells treated with or without 4 µM 41 for 24 h before immunoblot analysis; B) DXR cells 
treated with or without 4 µM 41 for 24 h before determination of SKP2 mRNA by qPCR. ***P < 
0.0005
86
 
 
The mechanism of action of 41 is currently unclear, but it has been shown to inhibit the 
activity of signal transducer and activator of transcription 3 (STAT3), and with it, 
decrease levels of known STAT3-target genes, including SKP2. STAT3 is a 
transcription activator protein which mediates the expression of several genes involved 
in cell growth and apoptosis. Known STAT3-specific inhibitors, e.g. S3I-201 (42)
87
, 
reduced DXR cell viability in a dose- and time-dependent manner similar to that seen 
upon treatment with 41 (Figure 25). Compound 42 also reduced the levels of SKP2 and 
increased levels of p27. Activation of STAT3, using DXR cells transfected with 
constitutively active STAT3 (CA-STAT3), attenuated SKP2-downregulation and p27-
upregulation mediated by 41, further establishing 41 as a novel of inhibitor of STAT3 
for cancer therapy. 
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Figure 25: Treatment of DXR cells with increasing concentration of 42 for 24 h and cell viability was 
measured using MTS assay. Data are average values of triplicate measurements, with error bars 
representing standard deviations. *P <0.05, **P < 0.005 and ***P < 0.0005
86
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Chapter Three: Project MDMX 
 
3.1 The p53 Tumour Suppressor 
 
Murine double minute X (MDMX), also known as MDM4, interacts with and inhibits 
the activity of the p53 protein, a tumour suppressor which maintains genomic stability 
and protects against malignant transformations by inducing cell cycle arrest, apoptosis 
and senescence in response to cellular stress.
10, 88, 89
 The p53 protein is activated in 
response to oncogenic transformations, extrinsic stress and viral infections and in most 
cancers the p53 pathway is disrupted.
90, 91
 In approximately 50% of cancers the p53 
gene is mutated and in the remaining tumours the genes which regulate the p53 pathway 
are mutated.
91
 The latter scenario may include deletion or inactivation of the p53 
positive regulator Alternate Reading Frame (ARF) or overexpression of the p53 
negative regulators MDM2 and MDMX.
92
  
 
3.2 MDM2 
 
MDM2 is a member of the RING E3 ubiquitin ligase family and promotes proteasome-
mediated degradation of p53.
92
 MDM2 acts as a molecular scaffold to position p53 and 
ubiquitin-carrying E2 enzymes in sufficiently close proximity to enable ubiquitin 
transfer to p53, where it is subsequently degraded.
92
 Overexpression of MDM2 inhibits 
p53-mediated cell cycle arrest and apoptosis and in 30% of human osteogenic sarcomas 
and soft tissue sarcomas, MDM2 is overexpressed by gene amplification.
10, 89
 
Hyperactivation due to silencing of ARF expression also leads to p53 inactivation and 
MDM2 has been an attractive anticancer target for over 20 years.
10
 
 
Binding between the MDM2 and p53 N-termini has been explored by X-ray 
crystallography.
93, 94, 95
 Amino acids 15-29 of p53 are a highly conserved region known 
as Box I or the p53 Transactivation Domain (TAD). Binding between MDM2 and p53 
is largely hydrophobic; p53-F19 and p53-W23 are positioned face-to-face on the same 
side of the α-helix and, like p53-L26, point towards a cleft on the surface of MDM2. 
These three amino acids become surrounded by the following MDM2 residues: L54, 
L57, I61, M62, Y67, V75, F86, F91, V93, I99, Y100 and I103. Additionally, 
intermolecular hydrogen bonds between the following amino acids stabilise the 
50 
 
interaction: p53-F19 with MDM2-Q72, p53-W23 with MDM2-L54 and p53-N29 with 
MDM2-Y100. In total, 13 residues in the MDM2-p53 binding domain are critically 
important for a strong interaction between the two proteins but p53 residues F19, L22, 
W23 and L26 appear fundamental to this binding mechanism (Figure 26).
93
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: X-ray crystal structure of MDM2 (magenta) bound to p53 (blue). The p53 residues F19, L22, 
W23 and L26 are highlighted (green). Image created using COOT with CCP4mg plug-in (resolution, 2.6 
Å; PDB: 1YCR)
95
 
 
cis-Imidazoline Nutlin-2 (43) dissociates the p53-MDM2 complex by competitively 
blocking the p53-binding sites on MDM2 crucial for a successful interaction (Figure 
27).
89
 Small molecules disrupting this complex can reactivate p53, stimulating in vivo 
tumour regression. Nutlin-3a (11) and RG7112 (12) sensitise tumour cells to 
chemotherapy and inhibit the growth of human tumour xenografts in nude mice.
4, 52, 53, 
96
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A)                                                                 B) 
Figure 27: A) X-ray structure of Nutlin-2 (green) bound to MDM2 (coral); B) Same image zoomed in. 
The MDM2 surface has been made partially transparent. The p53 residues F19, W23 and L26 are overlaid 
(magenta). Images created using COOT with CCP4mg plug-in (resolution, 2.3 Å; PDB: 1RV1).
52
 
 
3.3 MDMX 
 
MDMX is a negative regulator of p53 with high homology to MDM2, especially in the 
p53-binding domain.
10, 88, 89, 97, 98
 MDMX overexpression has been discovered in a 
variety of tumour cell lines, most notably 80% of adult pre-B lymphoblastic leukaemia, 
60-65% of retinoblastomas, 50% of hepatocellular carcinomas, 50% of head and neck 
cancers, 25% of bladder cancers, 20% of breast, lung and colon cancers and 14% of 
melanomas.
10, 89, 92, 99
  
 
Genetic studies show that MDM2 and MDMX perform non-redundant functions to keep 
p53 inactivated during embryogenesis and later development.
92
 MDMX-knockout mice 
die in utero despite the presence of MDM2.
10, 90
 Overexpression of MDM2 and MDMX 
is mutually exclusive in cancer cells, suggesting that transformation of just one of these 
W23 
L26 
F19 
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proteins is sufficient to inactivate p53 and initiate carcinogenesis.
89
 MDMX knockdown 
leads to p53-dependent growth arrest and apoptosis in breast carcinoma and 
retinoblastoma cell lines, which suggests that, in the absence of changes to other p53 
regulatory proteins, MDMX-dependent inhibition of p53 is essential for 
tumourigenesis.
92
 Despite high structural homology between MDM2 and MDMX, most 
small-molecule inhibitors of the p53-MDM2 interaction fail to strongly inhibit p53-
MDMX binding.
89
 Nutlins cannot induce apoptosis in cancer cells with increased 
MDMX levels, showing a 40-fold weaker equilibrium binding constant (Ki) for MDMX 
than for MDM2.
89, 91
  
 
MDMX and MDM2 are negative regulators of p53 activity but MDMX does not have 
intrinsic E3 ligase activity and does not promote p53 degradation.
10
 Instead, MDMX 
binds to MDM2 via their C-terminal RING domains, forming a heterodimer with 
enhanced E3 ligase activity relative to monomeric or homodimeric MDM2.
10
 
Quantitative analysis of normal human fibroblasts and mammary epithelial cells 
suggests endogenous MDMX levels are approximately 10-20% of those of MDM2.
92
 
The high binding affinity of the MDM2 RING domain for that of MDMX suggests most 
MDMX exists as a heterodimer with MDM2 in normal cells. Immunoprecipitation of 
MCF-7 breast cancer cells (MDMX overexpressed) indicate that the MDM2:MDMX 
heterodimer is the predominant complex. No MDMX homodimers have been 
observed.
92
 
 
MDM2 requires only ubiquitin and E1 or E2 enzymes to catalyse p53 ubiquitination in 
vitro.
92
 However, MDM2-mediated inhibition of p53 is inadequate in the absence of 
MDMX as evidenced by the embryonic lethality or postnatal induction of cell cycle 
arrest and apoptosis in mice.
92
 When MDMX is absent, higher concentrations of MDM2 
are required to maximise the formation of homodimers to elicit an equivalent effect. The 
data conclude that, while MDM2 can successfully ubiquitinate and degrade p53, the 
presence of MDMX and the formation of heterodimers augments E3 ligase activity and 
reduces the concentration of MDM2 required for efficient p53-degradation.
92
  
 
Mice which overexpressed MDMX developed tumours earlier than a control group of 
mice which did not express MDMX.
99
 Out of 75 mice overexpressing MDMX, twenty 
(27%) developed tumours during an 18-month observation period, four of which had 
more than one type of tumour. MDMX levels were higher in the cancer tissues relative 
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to the normal tissues, suggesting that overexpression of MDMX contributes to a tumour 
phenotype.
99
 The mice which overexpressed MDMX showed reduced MDMX levels in 
spleen samples following exposure to ionising radiation (IR). This is essential to induce 
MDM2 self-degradation and MDM2-mediated degradation of MDMX to elicit a p53 
DNA damage response (Figure 28). However, p53 levels were less stabilised in these 
spleen samples compared with those of WT mice, suggesting that MDMX 
overexpression diminished the p53 response following IR. High MDMX levels could 
therefore affect the efficacy of radiotherapy in cancer patients.
99
  
 
 
 
Figure 28: The roles of MDM2 and MDMX in mediating the p53 response; (a) In unstressed cell, p53 
levels are kept low (MDM2-mediated degradation) and inactive (MDMX-mediated TAD domain 
blocking). (b) Initial stress response: MDM2 stops targeting p53 and degrades itself and MDMX. (c) 
Maximum p53 activation initiates DNA repair/cell-cycle arrest and increases MDM2 levels (green 
arrow), enhancing MDMX degradation. (d) Stress response complete: MDM2 targets p53 again, MDMX 
levels rise and p53 levels fall. The cell can now re-enter the cell cycle (grey arrow). In this diagram, p53 
stability is represented as a blue circle and its activity as a green star. MDM2 and MDMX are represented 
as red and orange ovals respectively.
93
 
  
Studies of the deubiquitinating enzyme Herpes Virus-Associated Ubiquitin-Specific 
Protease (HAUSP) explain how MDM2 switches from ubiquitinating p53 in unstressed 
cells to targeting itself and MDMX following DNA damage.
93
 HAUSP interacts with 
and stabilises MDM2, MDMX and p53. When cells are unstressed, the Death Domain-
Associated Protein (Daxx) associates with MDM2 and HAUSP forming a trimer, which 
reduces the autoubiquitination of MDM2, allowing it to target p53. DNA damage 
disrupts the trimer resulting in increased MDM2 degradation and subsequent p53 
stabilisation.  
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Ten of the thirteen residues in the MDM2-p53 binding domain which are critically 
important for a strong interaction are conserved in MDMX. Additionally, MDM2 and 
MDMX possess a flexible ‘lid’, composed of residues 16-24 in both proteins. This 
region regulates binding between either proteins with p53 but it does not share a 
conserved homology.
92, 93
 This suggests the p53-MDM2 and p53-MDMX interfaces 
have subtle but distinctive differences. MDMX possesses a P95-S96-P97 motif at the 
end of the α-helical domain in the p53 binding site, which is absent in MDM2.92 It has 
been proposed that the proline residues shift the α-helical section of MDMX, relative to 
MDM2, and make the p53-binding site in MDMX shallower and less accessible to 
small molecules.
92
 The shallower binding site of MDMX and the contrasting amino acid 
sequence which makes up residues 16-24 could explain why MDM2 inhibitors do not 
have the same efficacy against MDMX.
10, 92
 However, the p53 residues F19, W23 and 
L26 appear fundamental to the interaction with MDM2 and MDMX and it is these 
residues which MDMX inhibitors will be designed to mimic (Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: X-ray structure of MDMX (yellow) bound to p53 (purple). The p53 residues F19, W23 and 
L26 are highlighted (green). Image created using COOT with CCP4mg plug-in (resolution, 1.9 Å; PDB: 
3DAB).
100
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3.4 Aims of the MDMX Project 
 
The aim of this research project was to design and synthesise a novel inhibitor of the 
MDMX-p53 interaction. A series of 2-amino-4-substituted thiazoles with modest 
activity against MDMX and MDM2, including 44a, were identified in a screen of 
several hundred compounds. The molecule was structurally altered with the aim of 
improving potency against MDMX and achieving selectivity over MDM2. An EU-
funded Framework Program 6 initiative set up between various institutions, including 
Newcastle University and Siena Biotech, termed DePPICT (Design of Protein-Protein 
Interaction Inhibitors for Cancer Therapy), financed the program.  
 
 
 
 
The compound had moderate ligand efficiency (LE) (MDM2, 0.31; MDMX, 0.29) and a 
low molecular weight (377.3 Da), making it a suitable hit compound. The catechol ring, 
2-aminothiazole scaffold and 4-fluorobenzyl substituent were all modified to construct 
SARs (Figure 30). 
 
 
Figure 30: Structural modifications made to the 2-aminothiazole scaffold 
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As well as potency against MDMX (IC50 < 10 nM) a suitable drug candidate needed to 
have high LE and lipophilic efficiency (LipE). LE is a parameter which measures 
compound potency relative to molecular mass and is calculated by dividing the pIC50 by 
the number of non-hydrogen atoms in the compound. LipE measures compound 
potency relative to lipophilicity and is calculated by subtracting the clogP or clogD7.4 
value from the pIC50. In this project, a drug candidate needed to have a LE value of at 
least 0.30 and a LipE value of at least 5.0. 
 
The catechol moiety, 2-aminothiazole ring and benzyl methylene group were all 
potential sites of metabolism. Catechols are often glucuronidated in vivo to produce 
polar compounds which are easily excreted (Scheme 2). They can also be oxidised by 
cytochrome P450 (CYP450) enzymes to give ortho-quinones which are highly 
electrophilic Michael acceptors with potential genotoxicity. Two-amino thiazoles have 
demonstrated hepatotoxicity in vivo in previous drug discovery projects due to oxidation 
of the heterocycle to a thiourea.
112, 113
 Benzyl methylene carbons are a well-
characterised area of CYP450-mediated oxidation to give hemi-aminals, which can 
fragment to give aldehydes. 
 
 
 
Scheme 2: Potential metabolic pathways for 44a, including glucuronidation (A) and CYP450-mediated 
oxidation to give an ortho-quinone (B), thiourea (C) and aldehyde (D) 
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Desirable lead compounds produced in this project had to therefore possess suitable 
metabolic resistance and not produce potentially toxic metabolites. Preliminary work 
conducted at Newcastle University (E. Bulatov, MPhil 2009-10) investigated whether 
the catechol ring could be substituted for more metabolically stable groups and retain 
activity (Table 11).
114
 The significance of the halogen substituent for improving target 
activity was also investigated (Table 12).
114
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Table 11: ELISA inhibition data for thiazoles 44a-44j
114
 (conducted by Dr Yan Zhao at the NICR) 
 
 
ID R MDMX IC50 
(µM)
a 
MDM2 IC50 
(µM)
b 
Ratio (MDMX : 
MDM2) 
 
44a  
 
24.7 
 
12.1 
 
0.49 
 
44b 
 
 
650 ± 150 
 
260 ± 35 
 
0.40 
 
44c 
 
 
64 ± 7 
 
17 ± 5 
 
0.27 
 
44d 
 
 
351 ± 19 
 
93 ± 24 
 
0.26 
 
44e 
 
 
919 ± 81 
 
468 ± 175 
 
0.51 
 
44f 
 
 
200 ± 3 
 
115 ± 28 
 
0.58 
 
44g 
 
 
909 ± 62 
 
859 ± 273 
 
0.94 
 
44h 
 
 
677 
 
38 
 
0.06 
 
44i 
 
 
200 ± 40 
 
110 ± 30 
 
0.55 
 
44j 
 
 
5.7 ± 1 
 
11 ± 2 
 
1.93 
(a) n = 2; (b) n = 3 
 
Elimination of the 3-hydroxy substituent (44c) had little effect on MDM2 and MDMX 
affinity, but elimination of the 3- and 4-hydroxy groups (44b) abolished potency against 
both targets. The fact that methylation of the 4-hydroxy group also abrogated activity 
against both proteins (44d) suggested the hydroxy group was functioning as a hydrogen 
bond donor but not an acceptor. Pyridyl rings (44f and 44g) were equally inactive to the 
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benzene ring with no 4-hydroxy group present. Replacement of the 4-hydroxy group 
with isosteric hydrogen bond donors (44h and 44i) reduced activity against both 
proteins, but substitution for a trifluoromethylsulfonamide (44j) afforded a 4-fold 
increase in MDMX-activity 44a. The fact that the methylsulfonamide (44i) was less 
active than 44j suggested substituent size and acidity were the key determinants of 
activity.  
 
Table 12: ELISA inhibition data for thiazoles 44c and 44j-44q
114
 (conducted by Dr Yan Zhao at the 
NICR) 
 
 
ID R X MDMX IC50 
(µM)
a
 
MDM2 IC50 
(µM)
b 
Ratio (MDMX : 
MDM2) 
 
44c  
 
4-F 
 
64 ± 7 
 
17 ± 5 
 
0.49 
 
44k 
 
 
H 
 
150 ± 20 
 
77 ± 22 
 
0.51 
 
44l 
 
 
4-Cl 
 
32 ± 9 
 
5.6 ± 1.3 
 
0.18 
 
44m 
 
 
4-Br 
 
20 ± 5 
 
6.9 ± 1.2 
 
0.35 
 
44n 
 
 
3-Cl 
 
270 ± 91 
 
36 ± 3 
 
0.13 
 
44o 
 
 
3-Br 
 
192 ± 9 
 
44 ± 5 
 
0.23 
 
44j 
 
 
4-F 
 
5.75 ± 1 
 
11 ± 2 
 
1.93 
 
44p 
 
 
4-Cl 
 
17 ± 4 
 
6.2 ± 2 
 
0.36 
 
44q 
 
 
4-Br 
 
6.0 ± 1 
 
5.5 ± 4 
 
0.92 
(a) n = 2; (b) n = 3 
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para-Halogenated rings (44a, 44l, 44m, 44j, 44p and 44q) improved potency against 
both proteins compared to the unsubstituted ring (44k). The difference in activity 
between different halogens was small, suggesting their electronics were more important 
than their steric bulk. para-Substituted rings were more active against both proteins than 
their meta-substituted derivatives (44l vs. 44n and 44m vs. 44o) but it was clear that the 
substituent at the para-position of the 4-aryl group was more significant for determining 
potency than the halogen.  
 
3.5 Literature Compounds with Moderate MDMX Inhibitory Activity 
 
There are three strategies to inhibit the oncogenic activity of MDMX, the first of which 
is to reduce MDMX levels to increase p53 activity. Down-regulation of MDMX mRNA 
has been shown to activate p53 and induce cell cycle arrest in vitro. However, 
improvements to the delivery of RNA-interfering agents to solid tumours must be made 
before this is considered a viable treatment option.
92
 A second approach is to target the 
proteins involved in the transcription and translation of MDMX. The transcription 
factors c-Ets-1 and Elk-1 have been described as key regulators of these processes
101
 but 
they are general transcriptional co-activators and any attempt to deregulate their activity 
would likely have off-target effects.
92
  
 
A third approach is to target the MDMX protein, either by enhancing MDMX 
proteolysis pathways or inhibiting those which prevent MDMX degradation. Targeting 
the MDMX-HAUSP interaction could be an effective cancer therapy
92, 93
 but proving 
this method results in potent antitumour activity is difficult, as HAUSP has multiple 
substrates, so any observed therapeutic benefit may not originate from inhibition of 
MDMX.
92
 Targeting the interaction between MDMX and MDM2 is another potential 
therapeutic strategy. The two proteins are linked via their RING domains but the RING-
RING interaction would be difficult to drug because crystal structures reveal it lacks a 
defined catalytic site or any hydrophobic pocket into which a small molecule could 
bind.
92, 102
 Small-molecule inhibition of the p53-MDMX interaction is an attractive 
approach to cancer therapy. MDMX is a negative p53 regulator so disrupting this 
interaction should restore p53-mediated cell cycle arrest and apoptosis.
92
 The subtle 
structural differences between MDM2 and MDMX necessitate the design of small 
molecules that specifically target the MDMX-p53 interaction, as potent inhibitors of the 
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MDM2-p53 interaction show comparatively reduced efficacy.
89, 91
The following 
sections review literature attempts to disrupt the MDMX-p53 interaction. 
 
3.5.1 SJ-172550 
 
High-throughput screening of more than 200,000 compounds at the St. Jude Research 
Hospital, TN, US, with the aim of finding novel small-molecule inhibitors of the 
MDMX-p53 interaction, identified over 1,000 active compounds. Dose-response assays 
on all compounds in MDMX, hMDMX and hMDM2, and Weri-1 cell-based assays 
(MDMX amplified), identified SJ-172550 (45), as the first small-molecule MDMX 
inhibitor.
91
 
 
 
 
 
 
 
 
 
Compound 45 was found to bind reversibly with MDMX to inhibit p53 binding, with an 
IC50 of 4.3 µM against WT p53 in in vitro assays. Isobologram experiments in which 45 
and Nutlin-3a (11) were incubated with Weri-1 retinoblastoma cells indicated an 
additive inhibitory effect on cell growth. In a separate experiment, Weri-1 and RB355 
retinoblastoma cell lines and ML-1 leukaemia cells (WT p53) were exposed to 20 µM 
45 for 20 h before analysis by immunofluorescence (Figure 31a). Cells exposed to 45 
demonstrated modest accumulation of p53 compared with vehicle-treated cells, though 
not to the same extent as cells exposed to 11 or ionising radiation (IR). Apoptosis was 
induced in 45-treated cells in a p53-dependent manner (Figure 31b) 
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A)                                                                  B) 
Figure 31: A) p53 induction on exposure of Weri-1, RB355 and ML-1 cells to DMSO (control), 5 µM 
Nutlin-3a (11), 20 µM SJ-172550 (45) or IR. B) caspase-3-mediated apoptosis in Weri-1, RB355 and 
ML-1 cells exposed to DMSO (control), 5 µM Nutlin-3a (11), 20 µM SJ-172550 (45) or IR.
91
 
 
A reduction in potency was observed for 45 against several MDMX mutants (Table 
13). Some mutants (e.g. H54F) were predicted to displace 45 without affecting peptide 
binding while other mutations (e.g. M53L) were predicted to make the p53 binding 
domain of MDMX more structurally similar to that of MDM2, therefore reducing 45 
potency without affecting that of 11. Compound 45 is the first small molecule to inhibit 
the MDMX-p53 interaction and establish a proof of principle that this effect can induce 
apoptosis in cancer cell lines.  
 
Table 13: IC50 values obtained for binding of WT p53, Nutlin-3a (11) and SJ-172550 (45) to several 
MDMX mutants
91
 
 
Inhibitor MDMX Mutation 
 WT M53L H54F Q58D M61F Y66I Q71K QUAD
 
p53 peptide (µM) 1.4 2.3 1.4 1.3 2.4 15.7 12.4 38.9 
11 (µM) 29.5 12.8 69.1 43.4 >400 22.3 ND ND 
45 (µM) 4.3 14.7 12.7 8.3 9.6 7.0 ND ND 
WT, wild-type; QUAD, quadruple mutant (P95H, S96R, P97K and R103Y); ND, not determined  
 
Published data on the mechanism of action of 45 has shown that MDMX can exist in 
various conformations, which differ in affinity for p53 and small molecules.
103
 
Compound 45 binds covalently to MDMX-C76 and it is possible that non-reducing 
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conditions cause a conformational shift in the MDMX protein which exposes C76.
103
 
Nucleophilic attack of the cysteine thiol on the β-carbon of the ene-amide functionality 
in 45 was predicted to be major binding mechanism and saturation of this group to give 
46 reduced MDMX inhibitory activity 30-fold (Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: FP assay measuring MDMX-p53 inhibition by 45 (IC50, 3 µM) and 46 (IC50 > 100 µM).
103
 
mP, milli-polarisation units 
 
Compound 45 showed 10-fold reduced activity against a C77V MDM2 mutant 
compared with inhibition of WT MDM2, suggesting that 45 is not a competitive 
inhibitor of MDMX but instead causes a conformational change that reduces p53 
affinity.
103
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3.5.2 Imidazole-based MDMX Inhibitors  
 
Several published imidazole-based MDM2 inhibitors have demonstrated moderate 
MDMX inhibitory activity (Table 14).
104
 The published data explained how the 
significant structural differences between the two proteins prevented a dual inhibitory 
effect being observed and this data could therefore be used to develop a potent MDMX 
inhibitor.  
 
 
 
Table 14: MDM2 and MDMX inhibitory activity of imidazole-based compounds
104
 
 
 MDM2 MDMX 
 
 
IC50 (µM) Ki (nM) IC50 (µM) Ki (µM) 
47 3.40 ND ND ND 
48 0.90 ND ND ND 
49 0.20 ND ND ND 
50 1.71 916 44.5 36 
51 0.19 109 19.7 11 
52 0.03 ND 19.0 ND 
ND, not determined 
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Molecular modelling revealed that positioning a planar aromatic ring within Van der 
Waals proximity to the MDM2-V93 side chain gave appropriate substitution vectors for 
accessing the p53-F19, p53-W23 and p53-L26 binding pockets of MDM2. These 
vectors would stem from three consecutive atoms on the core aromatic ring (Figure 33).  
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Molecular scaffold model in which a 5-membered aromatic core (beige), positioned near 
MDM2-V93 (yellow), directs three branching substituents into the key p53-binding pockets of MDM2. 
The side chains of p53-F19, p53-W23 and p53-L26 are overlaid (green)
104
 
 
In early compounds, a p-chlorobenzyl ring was used to access the p53-W23 pocket. The 
significance of the chloro group was observed from peptide-based MDM2 inhibitors, in 
which a chloro-substituted aromatic ring enhanced binding potency by filling the p53-
W23 pocket more than the unsubstituted ring.
104, 105
 Additional benzylic substituents 
were attached either side of the p-chlorobenzyl ring on an imidazole scaffold and 
docking studies indicated a tight fit in the MDM2 protein. TR-FRET analysis of 47 gave 
an IC50 of 3.4 µM (cf. Table 12) and modelling this compound in the MDM2 domain 
suggested that potency could be enhanced by exploiting the hydrogen bond between the 
NH of p53-W23 and the backbone carbonyl of MDM2-L54. The p-chlorobenzyl ring 
was substituted for a 6-chloroindole (Figure 34).
104, 105
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Figure 34: Binding model of 47 (beige) in the p53 binding domain of MDM2. The side chains of p53-
F19, p53-W23 and p53-L26 are overlaid (green)
104
 
 
Modelling also suggested that a phenyl ring bound directly to the imidazole scaffold 
would better occupy the p53-F19 pocket than one bound via a methylene linker. 
Analysis of the p53-L26 pocket revealed it was of predominantly hydrophobic character 
so it was decided to replace the 4-methoxy group. Compounds 48 and 49 were 
synthesised and were found to be 4- and 17-fold more potent than 47 respectively by 
TR-FRET analysis. The isobutyl substituent in 48 mimiced exactly the p53-L26 side 
chain but the 4-chlorobenzyl group in 49 gave better occupancy of the pocket.  
 
Introducing hydrophilic groups at the 2-position of the 6-chloroindole ring was 
predicted to point into solvent. Compounds 50, 51 and 52 were synthesised and the 
latter improved MDM2 inhibition to 30 nM by TR-FRET analysis. Compound 52 also 
demonstrated micromolar inhibition of growth in SJSA-1 cells (MDM2 amplified). The 
crystal structure of 52 with MDM2 confirmed the morpholine chain does not interact 
with any MDM2 residue but instead folds onto the imidazole ring (Figure 35).
104
 The 
amide carbonyl of 52 forms water-mediated hydrogen bonds with MDM2 residues K51, 
F55 and Q59. In addition, the chlorobenzyl moiety makes an aromatic stacking 
interaction with MDM2-H96. This interaction is what gives these molecules selectivity 
for MDM2 over MDMX; the latter has a proline residue in place of the histidine and all 
compounds in this series were much less active against MDMX.
104
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Figure 35: Crystal structure of 52 (green) in the p53 binding domain of MDM2. The side chains of 
residues which interact with 52 are shown (beige). Hydrogen bonds are shown as pink dots (resolution, 
1.9 Å; PDB code: 4DIJ)
104
 
 
Analysis by Popowicz of compound 51 interacting with MDMX confirmed the 6-
chloroindole occupies the p53-W23 pocket, with the indole NH forming a hydrogen 
bond with the carbonyl of MDMX-M53 (Figure 36).
106
 However, the plane of the 5-
chloroindole ring is shifted 0.63 Å more towards the p53-L26 pocket compared with the 
p53-W23 substituent. The 4-chlorobenzyl ring of 51 occupies the p53-L26 pocket and 
the phenyl ring fills the p53-F19 pocket, but the plane of this ring is almost 
perpendicular to that of the p53-F19 ring.
106
 Other known interactions include a 
hydrogen bond (3.29 Å) between the amide carbonyl of 51 and the MDMX-H54 Nδ 
atom. The dimethylamino side-chain folds over the p53-F19 pocket and shields the 
hydrophobic region, made up of MDMX residues M61 and Y66, from solvent.
106
 
  
68 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Crystal structure of 51 (green) in the p53 binding domain of MDMX (yellow). The p53 
binding subpockets F19, W23 and L26 are highlighted. Image modified using CCP4mg (resolution, 1.5 
Å; PDB code: 3LBJ)
106
 
 
Compound 51 binds to MDMX by an induced fit. To accommodate the chloro ligand on 
the indole ring the MDMX-L56 side-chain retracts by 0.81 Å. Other residues forced to 
move include MDMX-M53 (0.71 Å), MDMX-L98 (0.69 Å) and MDMX-L102 (1.14 
Å). The structural differences between the 51-MDMX and the p53-MDMX complexes 
are energetically unfavourable and explain the reduced potency of 51 against MDMX 
compared with MDM2.
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p53-L26 
p53-W23 
p53-F19 
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3.5.3 Diaryl- and Triaryl-Pyrroles as MDM2 and Dual MDM2/MDMX 
Inhibitors  
 
Developed at Newcastle University, a screen of 800 compounds obtained from the 
Cancer Research UK screening collection, using a MDM2-p53 ELISA assay, identified 
pyrrole 53a as a moderately active MDM2-p53 inhibitor.
107
 Compound 53a 
demonstrated dose-dependent inhibition of MDM2 and induction of p53 by Western 
blotting. A screen of 96 structurally similar compounds under similar conditions 
identified pyrroles 53b-53l, with MDM2 inhibition all < 10 µM (Table 15).  
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Table 15: SARs for pyrrole barbiturates 53a-53l against MDM2
107
 
 
 
ID R
1
 R
2
 R
3
 R
4
 MDM2 IC50 
(µM) 
53a 
 
Me H H 12.3 ± 1.5 
53b 4-ClPh Me H H 0.72 ± 0.10 
53c 4-ClPh Me H Ph 3.30 ± 0.70 
53d 4-ClPh Ph H H 0.12 ± 0.02 
53e 4-ClPh Ph H Ph 0.23 ± 0.04 
53f 4-ClPh Ph H 3-ClPh 0.16 ± 0.02 
53g 4-ClPh Ph 3,4-diMePh Ph 0.26 ± 0.04 
53h 4-ClPh Ph Me Me Insoluble 
53i 4-BrPh Me Ph Ph 0.20 ± 0.02 
53j 4-MePh Me H Ph 8.40 ± 0.90 
53k 4-MePh Me H H 4.70 ± 0.20 
53l 4-EtO2CPh Ph H H 0.70 ± 0.02 
 
Compounds with an aromatic ring at R
1
 that was para-substituted by chloro (53b-53g), 
bromo (53i) or ethoxylcarbonyl (53l) were the most potent. Pyrroles with 2,5-diphenyl 
substituents (53d-53e) were 5-10-fold more active than the analogous 2,5-dimethyl 
pyrroles (53b-53c) and any substitution on the barbiturate ring reduced activity.  
 
Compound 52d was the most potent pyrrole identified and was selected for further SAR 
analysis (Table 16). The N-4-aryl substituent significantly affected potency, with active 
compounds possessing only electron-withdrawing groups at this position, including 
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chloro, bromo, cyano and nitro. Substitution on the barbiturate ring was met with a loss 
in potency or had no effect on potency, however thiobarbiturates generally had superior 
activity than the corresponding oxobarbiturates. Pyrrole 53d also demonstrated low 
micromolar activity against MDMX. N-alkylation of the barbiturate ring had a more 
detrimental effect on MDMX activity than for MDM2 and alkylation also reduced the 
aqueous solubility of these compounds.
107
 
 
Table 16: SARs for pyrroles 53d and 53m-53z against MDM2 and MDMX
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ID R
1
 R
2
 X Y MDM2 IC50 
(µM)
a 
MDMX IC50 
(µM)
a 
53d H H Cl S 0.12 ± 0.02 4.2 ± 1.2 
53m H H Cl O 0.30 ± 0.03 ND 
53n H H Br O 0.18 ± 0.07 ND 
53o H H OMe O 1.9 ± 0.3 13 ± 7 
53p H H t-Bu O 1.9 ± 0.3 ND 
53q H H CN O 4.7 ± 1.9 7.0 ± 3.0 
53r H H CN S 0.20 ± 0.07
d 
0.90 ± 0.42 
53s H H NO2 O 0.15 ± 0.06 0.68 ± 0.18 
53t H H NO2 S 0.17 ± 0.09
d 
0.63 ± 0.12 
53u Et Et Cl S 0.30 ± 0.12
c 
ND 
53v Et Et Br O 0.89 ± 0.04 74%
b 
53w Et Et Br S 0.26 ± 0.05 ND 
53x Me H Cl S 0.11 ± 0.02
d 
28 ± 23 
53y Me H Br O 0.34 ± 0.08 35 ± 20 
53z Me H Br S 0.073 ± 0.002 ND 
(a) n = 3; (b) % inhibition at 50 µM; (c) n = 6; (d) n = 4; ND, not determined 
 
A series of 2-alkyl-1,5-diarylpyrroles were designed to further probe the SAR for 
MDM2 and MDMX inhibition (Table 17). All attempts to replace the 2-aryl group with 
an alkyl group caused a large drop in potency against MDM2 and an even more 
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substantial reduction in MDMX potency, which was independent of the position of the 
barbiturate ring.
107
 
 
Table 17: SARs for pyrroles 54a-54g against MDM2 and MDMX
107
 
 
 
ID Regioisomer R X Y MDM2 
IC50 (µM)
a 
MDMX 
IC50 (µM)
b 
54a Mixture Me Cl O > 1 ND 
54b 4 t-Bu Br S 0.76 ± 0.27
c 
963 
54c 4 t-Bu Cl S 1.1 ± 0.7
c 
1684 
54d 3 CyPr Cl S 1.6 ± 1.7 3486 
54e 3 CyPr Br S 1.6 ± 1.6 3428 
54f 4 CyPr Cl S 2.1 ± 2.7 4916 
54g 4 CyPr Br S 2.2 ± 2.7 5322 
(a) n = 3; (b) n = 1; (c) n = 4; ND, not determined 
 
Binding modes for selected pyrroles were generated by superpositioning the pyrrole on 
top of the imidazole-based inhibitors 50 and 51 in the crystal structures
106
 of these 
compound with MDM2 (pdb: 3LBK) and MDMX (pdb: 3LBJ) respectively, and 
removing the original ligand (Figure 37).
107
 For 53d, the N-4-chlorophenyl ring 
occupies the p53-W23 pocket in MDM2 and MDMX, overlaying with the 6-
chloroindole ring of 50 and 51. The 5-phenyl ring of 53d occupies the p53-F19 pocket, 
overlaying well with the 1-phenyl ring of 50 and 51, and the 2-phenyl ring of 53d 
accommodates the p53-L26 pocket. The barbiturate ring projects into solvent, 
suggesting this group functions as a hydrophilic cap.
107
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A)                                                       B) 
Figure 37: A) Modelled binding of 53d (green) overlaid with 50 (magenta) in MDM2 (blue) (pdb: 
3LBK); B) Modelled binding of 53d (green) overlaid with 51 (purple) in MDMX (pink) (pdb: 3LBJ). 
Hotspot p53 residues F19, W23 and L26 are highlighted. Image created using COOT with CCP4mg plug-
in.
107
 
 
When pyrrole 54c was modelled in MDM2 and MDMX, the tert-butyl group was 
placed in the p53-F19 pocket in both proteins, with the 5-phenyl ring projecting into the 
p53-L26 pocket. In this series the 5-phenyl ring no longer made a well-defined 
interaction with the p53-L26 pocket. This would explain the loss of activity observed 
against MDM2 and MDMX for the 2-alkylpyrrole series. 
 
Cell-based assay data suggested the pyrroles were non-specific MDM2 and MDMX 
binders.
107
 Compounds 53d, 53r, 53t and 53x were equally growth inhibitory in SJSA-1 
osteosarcoma cells (MDM2 amplified, WT p53) and SN40R2 cells (MDM2 amplified, 
mutant p53), suggesting a non-specific mechanism of action (Table 18). Nutlin-3a (11) 
only possessed activity in the SJSA-1 cells. The pyrroles were also equipotent in MRK-
NU-1 breast cancer cells (MDMX amplified, WT p53), despite large potency 
differences against MDM2 and MDMX in the ELISA. 
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Table 18: Growth inhibitory activity for pyrroles 53d, 53r, 53t and 53x in SJSA-1, SN40R2 and MRK-
NU-1 cell lines
107 
 
 GI50 (µM)
a 
ID SJSA-1 SN40R2
b 
MRK-NU-1 
53d 2.3 ± 0.2 2.8 ± 0.6 2.3 ± 0.3 
53r 5.1 ± 0.9 5.9 ± 0.3 6.1 ± 0.7 
53t 4.7 ± 1.0 5.2 ± 0.4 4.9 ± 0.6 
53x 5.5 ± 0.6 6.3 ± 0.4 7.0 ± 1.0 
(a) n = 3; (b) p53-null 
 
Compound 53d induced p53 in SJSA-1 cells at 5 µM by Western blotting but not in 
A2780/CP70 ovarian carcinoma cells (mutant p53). These results demonstrated a p53-
dependent response to 53d in cells, however the growth inhibitory data in Table 16 
suggested this was not the only effect the pyrroles had in cells.
107
  
 
3.5.4 Pyrrolidone Inhibitors of MDM2 and MDMX 
 
Several pyrrolidone-based MDM2 inhibitors synthesised at the School of Pharmacy, 
Shanghai were found to possess moderate MDMX affinity.
108
 Structure-based screening 
of the Specs molecular database and fluorescence polarisation (FP) analysis identified 
nine hit compounds with MDM2 inhibitory activity below 100 µM, six of which shared 
a pyrrolidone scaffold. The most potent compounds (55a and 56) had IC50 values below 
1 µM. 
 
 
 
Modelling studies of 55a and 56 with MDM2 revealed primarily hydrophobic 
interactions, with the N-, 5- and 4- substituents occupying the p53-F19, p53-W23 and 
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p53-L26 binding pockets respectively (Figure 38). The compounds also formed a 
hydrogen bond with MDM2-G16 via the acetophenone carbonyl oxygen. 
 
 
 
 
 
 
 
A)                                                                         B) 
Figure 38: A) Binding mode of 55a (purple) and B) 56 (yellow) in MDM2. Hydrogen bonds are shown 
as green dotted lines. The p53 binding pockets F19, W23 and L26 are highlighted, as is the key hydrogen 
bond-forming residue MDM2-G16
108
 
 
The aqueous solubility of 55a was superior to that of 56 and therefore the former was 
selected for hit optimisation against MDM2. Several of the most active compounds 
identified from SAR analysis against MDM2 were also screened against MDMX (Table 
19). The nature of the 3-substituent significantly affected potency, with compounds 55d 
and 55i exhibiting more potent MDMX inhibition than Nutlin-3a, but the structurally 
similar compound 55c was 15-fold less active.  
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Table 19: SARs of selected pyrrolidones against MDM2 and MDMX
108
 
 
 
ID R X MDM2 Ki 
(µM)
a
 
MDMX Ki 
(µM)
a
 
55a OH Me 0.78 Not tested 
55b OH Br 0.29 NA 
55c OEt Br 0.69 38.91 
55d O
i
Pr Br 0.26 2.68 
55e O(CH2)4Me Br 0.34 NA 
55f O(CH2)3Me Br 0.47 NA 
55g OCyHex Br 0.49 17.93 
55h OBn Br 2.07 NA 
55i O(CH2)2OMe Br 1.34 2.11 
55j O(CH2)2Me Br 6.97 9.32 
55k NH2 Br 0.048 NA 
55l
b NH(R)-1-
phenylethyl 
Br 0.15 NA 
Nutlin-3a (11) - - 0.23 5.86 
(a) FP assay; (b) Specifically the R,R-diastereomer; the R,S-diastereomer was inactive against MDM2 and 
not tested against MDMX; NA, not active  
 
Compound 55d gave dose-dependent increases in MDMX, p21 and p53 levels in MCF-
7 breast cancer cells after 24 h, although it had no effect on the activity of 
phosphorylation-p53 (p-p53) (Figure 39). From this research, several novel 
pyrrolidone-based inhibitors were identified as potent MDM2 inhibitors with activity in 
MDMX-overexpressing cell lines that was superior to that of Nutlin-3a.  
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Figure 39: Dose-dependent induction of p53, p21 and MDMX in MCF-7 cells by 55d after 24 h detected 
by Western blotting
108
 
 
3.6 Potent Dual MDM2 and MDMX Inhibitors 
3.6.1 Indolyl-Hydantoin MDM2 and MDMX Dual Inhibitors  
 
High-throughput screening at the Roche Research Centre, NJ, US, identified several 
indolyl-hydantoin compounds with potent dual inhibitory activity of MDM2 and 
MDMX (Table 20).
109
  
 
Table 20: TR-FRET inhibition data for 57, 58 and Nutlin-3a against MDM2 and MDMX
109
 
 
Inhibitor MDM2-p53 IC50 (µM) MDMX-p53 IC50 (µM) 
57 0.033 0.041 
58 0.017 0.024 
Nutlin-3a (11) 0.019 9 
55d 
µM 
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Co-crystallisation of 57 with MDMX revealed a structure composed of two molecules 
of 57 and two molecules of MDMX, arranged as a pair of dimers (Figure 40).
109
 For 
each molecule of 57, the indolyl-hydantoin moiety occupies the p53-F19 pocket of one 
MDMX protein, while the difluorophenyl ring occupies the p53-W23 pocket of the 
second. Extensive aromatic π-stacking between the two indolyl-hydantoin scaffolds 
stabilises the complex, extending to include both MDMX-Y63 side chains, forming a 
four-level π-sandwich.  
 
 
 
 
 
 
 
 
 
Figure 40: Crystal structure of two molecules of 57 (cyan and green) in the p53 binding domain of two 
MDMX proteins. One protein is shown in surface rendition (carbon, white; oxygen, red; nitrogen, blue; 
sulfur, yellow), the other as a stick figure (same colour scheme except carbons are cyan). In the cyan-
coloured 57, the indolyl-hydantoin moiety is occupying the p53-F19 pocket of the stick-figure MDMX, 
while the difluorophenyl ring is occupying the p53-W23 pocket of the surface-rendition protein. The 
green-coloured 57 binds in the reverse mode (resolution, 1.8 Å; PDB code: 3U15)
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Co-crystallisation of 57 with MDM2 revealed the analogous homodimeric structure 
(resolution, 2.8 Å, PDB code: 3VBG).
109
 Compound 57 demonstrated potent MDM2 
and MDMX inhibition in vitro but had poor aqueous solubility. Addition of hydrophilic 
groups to the methylene carbon yielded 58, which was more active than 57 against both 
targets and had enhanced aqueous solubility.
109
 Compound 58 penetrated MCF-7 breast 
cancer cells and stabilised p53, increased levels of its transcription targets p21 and 
MDM2, and induced apoptosis. Immunoprecipitation of p53 or MDMX from 58-treated 
MCF-7 cells confirmed these observations were the result of inhibition of the p53-
MDMX and -MDM2 interactions. When the cells were treated with Nutlin-3a, a lower 
apoptotic response resulted.
109
  
 
The indolyl-hydantoins therefore represent the first small-molecule dual inhibitors of 
the MDM2- and MDMX-p53 interactions, demonstrating nanomolar activity against 
79 
 
both proteins in vitro and inducing apoptosis in various cell lines overexpressing either 
protein or both. These compounds exhibit high potency without any substituent 
occupying the p53-L26 pocket of the protein target, which may explain why the 
compounds are similarly active against both proteins, as it is in this p53-binding pocket 
that the structures of MDM2 and MDMX are most diverse. However, the unorthodox 
binding mode of the compounds complicates SARs and limits the development of these 
compounds as a lead series. 
 
3.6.2 Stapled α-Helical Peptides as Potent Dual Inhibitors of MDM2 
and MDMX 
 
Stapled peptide 59 is a selective dual inhibitor of MDM2 and MDMX with nanomolar 
potency against both targets and can activate p53-mediated tumour suppression in 
multiple MDM2- and MDMX-overexpressing cancer xenografts.
110
  
 
 
 
 
 
 
 
Peptide 59 was created at Hoffman-La Roche by modification of the natural p53 peptide 
to make it stable to administration by IV and bind with greater affinity than the natural 
peptide.
110
 Taking influence from the recently reported sequence enhancements 
described for linear phage display peptide (pDI) Ac-L
17
TFEHYWAQLTS
28
-NH2,
90, 98
 
59 was formed by the inclusion of an 11-carbon linker between two α-methylated 
alanine residues. Peptide 59 possessed high binding affinity for MDM2 and MDMX, 
with Ki inhibition values of 0.9 and 6.8 nM respectively, which was more potent than 
competitor peptides, e.g. SAH-p53-8,
111
 and for Nutlin-3a (Table 21). The negative 
control ATSP-7342, in which the Phe
19
 residue was mutated to Ala
19
 was comparatively 
inactive against both targets.  
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Table 21: SARs of various stapled and non-stapled peptides against MDM2 and MDMX with Nutlin-3a 
as a reference
110
 
 
 Residue Sequence
a  
ATSP# 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Ki 
(MDM2) 
(nM) 
Ki 
(MDMX) 
(nM) 
1800 Q S Q Q T F R8b N L W R L L S5b Q N  25.9 105.7 
3648    L T F E H Y W A Q L T S   14.6 47.4 
3900    L T F R8b H Y W A Q L S5b S   1.0 18.3 
4641    L T F R8b A Y W A Q L S5b S   4.9 34.3 
6935    L T F R8b E Y W A Q L S5b S   1.2 8.0 
7041    L T F R8b E Y W A Q Cba S5b S A A 0.9 6.8 
7342    L T A R8b E Y W A Q Cba S5b S A A 536 > 1000 
Nutlin-
3a 
                 52.3 > 1000 
(a) Each sequence begins with an acetyl group (Ac-) and ends with an amino group (-NH2); (b) R8 and S5 
are the linker residues. ATSP-3648 is not a stapled peptide 
 
Peptide 59 had greater potency and aqueous solubility compared to prototype peptides 
such as ATSP-3900, mainly due to replacing His
21
 in 3900 with Glu
21
 in 59. 
Modification of Leu
26
 to the unnatural Cba amino acid and adding the Ala
29
-Ala
30
 C-
terminus further augmented binding affinity against both proteins.  
 
Conformational studies of 59 indicated it was approximately 70% α-helical in solution 
at pH 7.0. The greater α-helical nature of 59 compared to earlier peptides, e.g. 3900, has 
been used to explain the improved cell penetration efficiency and the corresponding 
increase in potency of 59 against MDM2 and MDMX. The crystal structure of 59 bound 
to humanised zebrafish MDMX (15-106, L46V/V95L) confirmed the Phe
19
 and Trp
23
 
side-chains occupied the expected sub-pockets in MDMX, with the Cba residue 
interacting in the Leu
26
 sub-pocket (Figure 41).
110
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Figure 41: X-ray structure of peptide 59 (brown) interacting with humanised zebrafish MDMX (blue). 
Residues which make interactions with the protein, including the staple olefin, are highlighted in green 
and orange respectively (resolution, 1.7 Å; PDB code: 4N5T).
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Compound 59-Y22 makes multiple Van der Waals contacts with MDMX-Q66, -R67, -
Q68, -H69, -V89 and -K90, as well as water-mediated hydrogen bonds with Nε of 
MDMX-K90 and Nδ1 of MDMX-H69. The staple is also well accommodated in the 
MDMX protein and forms multiple Van der Waals contacts with MDMX-K47, -M50, -
H51, -G54, -Q55 and -M58.  
 
Peptide 59 was shown to reduce the levels of MDM2-p53 and MDMX-p53 in MCF-7 
cells at 10 µM, in comparison to a DMSO control, following analysis by Western 
blotting after 4 h incubation. Peptide 59 induced p53 in a dose-dependent manner in 
MCF-7 and SJSA-1 cell lines, as well as p53 target genes, including p21 and MDM2, 
that was comparable to that observed with Nutlin-3a in SJSA-1 cells and superior to that 
seen in MCF-7 cells. Induction of p53 was only observed in cell lines which expressed 
WT p53; treatment of MDA-MB-435 and SW480 cell lines (p53 mutants) with 59 
resulted in no induction of p53 target genes and no reduction in cell viability, as 
measured by MTT assay (Figure 42). 
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A)                                                                                    B) 
Figure 42: A) Treatment with varying concentrations of 59 causes dose-dependent induction of MDM2 
in MCF-7 and SJSA-1 cell lines but not in p53 mutant MDA-MB-435 or SW480 cell lines. Cells were 
incubated with 2.5, 5.0 or 10.0 µM 59 or 10.0 µM Nutlin-3a (N3) for 24 h before measuring MDM2 
mRNA levels by qPCR, expressed as fold increase. B) Treatment with 59 causes a fall in viability of 
SJSA-1, MCF-7, HCT-116 and RKO cell lines, but has no effect on the viability of p53 mutant MDA-
MB-435 or SW480 cell lines.
110
 
 
Peptide 59 could be readily formulated for IV administration and a plasma 
pharmacokinetic profile was compiled in mouse, rat and cynomolgus monkey. Exposure 
to 59 increased in a dose-dependent manner in all species, with durable plasma half-
lives of 1.5, 2.1 and 18.3 h in mouse, rat and monkey respectively and suitably low 
clearance.
110
 The data indicated the potential to achieve efficacious exposure levels of 
59 at therapeutic doses in man, highlighting the ongoing success of stapled peptides in 
the design of potent dual MDM2 and MDMX inhibitors.  
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Chapter Four: SKP2 Results and Discussion 
 
4.1 Synthesis of 16a, 68a and their Derivatives 
 
Owing to the high cost of 2,2-dimethyldihydro-2H-pyran-4(3H)-one (21), the des-
dimethyl derivative N,N-dimethyl-4-(((4-phenyl-3-(tetrahydro-2H-pyran-4-
yl)butyl)amino)methyl)aniline (68a) was synthesised first. Horner-Wadsworth-Emmons 
(HWE) olefination of pyranone 60 with trimethyl phosphonoacetate gave ester 61 in 
excellent yield. Hydrogenation of alkene 61 was examined under a range of conditions, 
starting with the  literature approach, using hydrogen over Pd/C in ethyl acetate,
79
 which 
gave ester 62 in 70% yield. Hydrogenation was also accomplished using a ‘H-cube’ 
hydrogenation reactor. However, for larger scale reactions, multiple hydrogenations 
were necessary because the catalyst cartridges could support no more than 300 mg 
samples. Transfer hydrogenation using ammonium formate and Pd/C proceeded to 
completion at 90 
o
C in half the time required to achieve full conversion using the H-
cube and ester 62 was also isolated in superior yield. 
 
Deprotonation of 62 with LDA followed by addition of benzyl bromide gave 63. 
Reduction of the ester to give 64 was initially attempted using DIBAL-H, as described 
in the literature synthesis,
79
 but no product could be isolated. Subsequent reductions 
using lithium aluminium hydride gave 64 in quantitative yield. Treatment of 64 with 
methanesulfonyl chloride gave mesylate 65 in high yield. Mesylation was found to be 
more high-yielding than tosylation, achieving full conversion more rapidly and with 
lower equivalents of the sulfonyl chloride required. Nitrile 66 was obtained upon 
heating 65 with sodium cyanide in DMF.  
 
Reduction of nitrile 66 was achieved in good yield using lithium aluminium hydride to 
give amine 67. This transformation was also achieved by hydrogenation using the H-
cube with a Raney nickel catalyst. The nitrile was hydrogenated cleanly and the amine 
was isolated with no need for purification, giving this method an advantage over 
reduction with lithium aluminium hydride. However, similar problems with scale-up to 
those encountered when hydrogenating ester 61, and the need for longer reaction times 
and specialised conditions, meant that reduction with lithium aluminium hydride was 
the preferred method. 
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Reductive amination of 67 with 4-(N,N-dimethylamino)benzaldehyde, followed by 
addition of sodium borohydride, gave pyran 68a. This synthetic route was repeated for 
the formation of 16a, using a commercially available sample of pyranone 21. 
Compound 16a was synthesised in overall yields of up to 58% over eight steps (Scheme 
3). The diastereoisomeric ratio was 5:2 by 
1
H NMR analysis, which is in agreement 
with the 3:1 ratio reported in the published synthesis.
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Scheme 3: (i) (MeO)2(O)PCH2CO2Me, NaH, THF, 0 
o
C-RT, 20 h; (ii) NH4HCO2, 10% Pd/C, MeOH, 0-
90 
o
C, 90 min; (iii) 
i
Pr2NH, n-BuLi, THF, -78 
o
C, 1 h; BnBr, THF, 30 
o
C, o/n; (iv) LiAlH4, THF, 0 
o
C, 2 
h; (v) MsCl, 
i
Pr2NEt, DCM, RT, 2 h; (vi) NaCN, DMF, 100 
o
C, 7 h; (vii) LiAlH4, THF, 0 
o
C, 3 h; (viii) 4-
(N,N-dimethylamino)benzaldehyde, MgSO4, DCM, RT, 4 h; NaBH4, MeOH, RT, 1 h 
 
To explore initial structure-activity relationships (SARs), amines 28 and 67 were 
reacted with various benzaldehyde derivatives under analogous conditions to those 
shown in Scheme 3. The corresponding analogues in the gem- and des-dimethylpyran 
series were synthesised to compare cellular activities. To synthesise regioisomer 16c (cf. 
Table 23), the required aldehyde 70 needed to be synthesised. Oxidation of alcohol 69 
using manganese(IV) oxide gave a complex mixture of products. However, oxidation 
using Dess-Martin periodinane (DMP) gave 70 in 54% yield. Subsequent reductive 
amination of amine 28 gave 16c (Scheme 4). 
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Scheme 4: (i) DMP, DCM, RT, 1 h; (ii) 28, MgSO4, DCM, RT, 4 h; NaBH4, MeOH, RT, 1 h 
 
Amines 28 and 67 were also reacted with acyl chlorides and sulfonyl chlorides, giving 
high yields of the corresponding amides and sulfonamides (Scheme 5).  
 
 
 
Scheme 5: (i) Appropriate acyl or sulfonyl chloride, Et3N or 
i
Pr2NEt, DCM, RT, 1-2 h 
 
To synthesise sulfonamide 16j, the required sulfonyl chloride 73 was not available 
commercially. Treating bis(trimethylsilyl)sulfate with N,N-dimethylaniline (71) gave 
sulfonic acid 72, which was converted to 73 using phosphorus(V) chloride (Scheme 6).  
 
 
 
Scheme 6: (i) (SiMe3)2SO4, 170 
o
C, 1 h; (ii) PCl5, DCM, 0 
o
C-RT, 20 h 
 
The secondary amines of 16a and 68e were methylated by means of Eschweiler-Clarke 
reactions using formic acid and formaldehyde, to give 74a and 74b, respectively 
(Scheme 7).  
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Scheme 7: (i) 37% aq. H2CO, 95% aq. HCO2H, EtOH, 40 
o
C, 90 min 
 
To synthesise azide 68i, reductive amination of 4-nitrobenzaldehyde with amine 67 
gave 68g, which was hydrogenated to aniline 68h. Oxidation of 68h with sodium nitrite 
in HCl, followed by addition of sodium azide at 0 
o
C, generated 68i (Scheme 8).  
 
 
 
Scheme 8: (i) 4-Nitrobenzaldehyde, MgSO4, DCM, RT, 4 h; NaBH4, MeOH, RT, 1 h; (ii) H2, Raney Ni, 
MeOH, RT/1 atm, 3 h; (iii) NaNO2, 5 M HCl, 0 
o
C, 40 min, dark; NaN3, 0 
o
C-RT, 2.5 h, dark 
 
4.2 Improving the Aqueous Solubility of 16a 
 
Several of the compounds synthesised so far were relatively lipophilic [clogP values 
ranged from 3.0 (68k) to 7.1 (16d), cf. Tables 23 and 24]. In an effort to reduce 
lipophilicity but retain cellular activity, the tetrahydropyran ring of 16a was replaced 
with a morpholino group (80). The synthetic route to 80 was shorter than the synthesis 
of 16a, potentially allowing for the rapid synthesis of analogues (Scheme 9). 
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Scheme 9: Retrosynthetic analysis of morpholine 80 
 
Reductive amination of 4-(N,N-dimethylamino)benzaldehyde with β-alanine ethyl ester 
hydrochloride (75) in DMF and acetic acid gave amine 76. Work-up of the crude 
reaction mixture was difficult due to the high aqueous solubility of 76, meaning that 
multiple extractions were needed to recover the product. Protection of the amino group 
was accomplished using di-tert-butyl dicarbonate (Boc2O) (Scheme 10). 
 
 
 
 
Scheme 10: (i) 4-(N,N-Dimethylamino)benzaldehyde, NaB(OAc)3H, AcOH, DMF, RT, 4 h; (ii) Boc2O, 
DCM, 0 
o
C-RT, 1 h 
 
It was found that 77 could be synthesised from 75 without needing to isolate 76. 
Addition of 4-(N,N-dimethylamino)benzaldehyde to neutralised 75 in THF gave 76 
upon addition of sodium borohydride in methanol. Removal of the solvent followed by 
addition of Boc2O gave 77.  While the yield of 77 was poorer (21%) than that achieved 
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by the procedure in Scheme 10 (77%), the less laborious work-up and purification 
meant it was the preferred procedure for the formation of this intermediate.  
 
Weinreb amide 78 was isolated in 61% yield following reaction of N,O-
dimethylhydroxylamine hydrochloride with 77 in the presence of 
i
PrMgCl (Scheme 11). 
Conversion was poor when the reaction was conducted at 0 
o
C due to competing side 
reactions. Reducing the temperature to -20 
o
C minimised these side reactions and 
increasing the equivalents of N,O-dimethylhydroxylamine and 
i
PrMgCl accelerated the 
reaction to give 78 within 1 h in almost quantitative yield. Treatment of 78 with 
BnMgCl at 0 
o
C gave a 1:2 mixture of ketone 79 and carbamate 81 by LC-MS. The 
latter was presumably formed by deprotonation and fragmentation of 78 to give 81 and 
acrylamide 82, which were not isolated (Scheme 11). 
 
 
 
Scheme 11: Conversion of 77 to 78 and competing nucleophilic addition (blue arrow) to give 79 and 
elimination (red arrow) to give 81 and 82; (i) HN(OMe)Me.HCl, 
i
PrMgCl, THF, -20 °C, 1 h 
 
No reaction was observed at -78 
o
C, whilst allowing the reaction mixture to warm 
slowly to room temperature gave a 1:1 mixture of 79 and 81. Imamoto had previously 
described the use of CeCl3 for accomplishing the addition of organometallic compounds 
to Weinreb amides with acidic α-protons.115 Transmetallation of BnMgCl with CeCl3, 
followed by addition of 78, resulted in no reaction, but when CeCl3 was mixed with 78 
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followed by addition of BnMgCl, full conversion was achieved within 30 min at 0 
o
C, 
with no observed formation of 81 (Scheme 12). 
 
 
 
Scheme 12: (i) CeCl3, THF, RT, 1 h; BnMgCl, THF, 0 
o
C, 30 min 
 
Attempts to react ketone 79 with morpholine proved unsuccessful, showing poor 
conversion by LC-MS (Table 22). The steric bulk of the benzyl and carbamate groups 
presumably hindered access to the ketone carbonyl group. The relatively low 
nucleophilicity of morpholine compared to other secondary amines also reduced the rate 
of reaction. 
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Table 22: Conditions applied to the reductive amination of 79 with morpholine
a
 
 
Attempt Reducing 
Agent 
Solvent Temp. 
(
o
C) 
Additional 
Reagents 
Results 
1 NaB(OAc)3H DMF 25-90 AcOH
c 
No 
product 
2 NaBH4 DCM, 
MeOH
b 
25 MgSO4
d 
No 
product 
3 NaB(OAc)3H 
 
THF 25 Ti(O
i
Pr)4
e 
No 
product 
4
f NaB(OAc)3H PhMe 140 AcOH
c
 No 
product 
(a) 79 (100-180 mg, 1.0 equiv.), morpholine (1.0-5.0 equiv.) and reducing agent (1.2-2.0 equiv.) at 0.5-
1.0 M; (b) DCM removed before addition of MeOH and NaBH4; (c) 1% (v/v); (d) Anhydrous, excess; (e) 
1.5 equiv.; (f) Dean-Stark set-up 
 
Reduction of amide 78 with lithium aluminium hydride gave aldehyde 84. Employing 
Katritzky’s protocol for the synthesis of tertiary amines,116, 117 carbamate 83 was 
obtained by reaction of 84 with morpholine in the presence of 1H-benzotriazole, 
followed by addition of BnMgCl. Removal of the Boc group with TFA proceeded 
quantitatively at room temperature to give 80 in 15% overall yield over five steps 
(Scheme 13).  
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Scheme 13: (i) LiAlH4, THF, 0 
o
C, 1 h; (ii) morpholine, 1H-benzotriazole, 3 Å MS, DCM, RT, 3 h; 
BnMgCl, THF, 0 
o
C, 1 h; (iii) TFA, DCM, RT, 1 h 
 
4.3 Inhibition Data for 16a, 68a and their Derivatives  
 
Compounds 16a and 68a were assessed for their ability to inhibit cell growth in a 
sulforhodamine B (SRB) assay using HeLa cervical cancer cells (Figure 43). Both 
compounds demonstrated growth-inhibitory activity, with 16a giving a GI50 of 16 ± 1 
µM and 68a giving a GI50 of 27 ± 4 µM. Compound 16a was the more potent, bringing 
cell density below that of the pre-treatment level. All derivatives were analysed for cell 
growth-inhibitory activity in the SRB assay (Tables 23 and 24). The procedure for the 
SRB assay is described in Chapter 7.2. 
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Figure 43: Inhibition of HeLa cell growth by 16a and 68a in a SRB assay (conducted by  Laura Evans at 
the NICR) 
 
Table 23: HeLa SRB assay for inhibitors 16a-16j (conducted by Laura Evans at the NICR) 
 
 
ID
a 
 
X Y Z HeLa GI50 (µM)
b 
16a
c CH2 CH 4-NMe2 16 ± 1
 
16b CH2 CH H 17 ± 3 
16c CH2 CH 3-NMe2 18 ± 2 
16d CH2 CH 4-
i
Pr 5.8 ± 1.1 
16e CH2 CH 4-Cl 11 ± 4 
16f CH2 CH 4-CN 36 ± 2 
16g CH2 CH 4-OMe 29 ± 7 
16h CH2 N 4-NMe2 40 ± 3 
16i CO CH 4-NMe2 53 ± 7 
16j SO2 CH 4-NMe2 35 ± 2 
(a) Diastereoisomers (dr, 5:2); (b)
 
n = 3; (c)
 
Compound tested as the free base. Dihydrochloride salt was 
similarly active at 13 ± 0 µM 
 
All compounds in the gem-dimethylpyran series (16a-16j) were active against HeLa cell 
growth with 16d, possessing a 4-isopropyl substituent, displaying superior potency to 
68a 
16a 
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16a. Unsubstituted analogue 16b and regioisomer 16c had similar potency to 16a, 
suggesting that the dimethylamino group was not essential for cellular activity. 
Replacing the 4-NMe2 group with a cyano (16f) or a methoxy substituent (16g) afforded 
a 2-fold loss in activity in each case. Introduction of a pyridyl ring (16h), as well as 
substituting an amide (16i) or sulfonamide (16j) for the methylene group of 16a, 
reduced HeLa cell growth inhibition. However, none of these structural changes had a 
significant effect on activity, although interestingly, the most active compounds were 
also the most lipophilic [clogP 7.1 (16d); 6.4 (16e); clogP values for 16a-16c and 16f-
16j were in the range 4.9-5.8], possibly due to improved cell penetration. Methylation 
of the secondary amine (74a) did not significantly affect potency, giving a GI50 value of 
31 ± 3 µM, suggesting the amine NH was not involved in binding to the protein. 
 
Table 24: HeLa SRB assay for pyrans 68a-68m and morpholine 80 (conducted by Laura Evans at the 
NICR) 
 
 
ID
a 
 
X Y Z HeLa GI50 (µM)
b 
68a CH CH2 4-NMe2 27 ± 4 
68b CH CH2 4-N(CH2)4 8 ± 1 
68c CH CH2 4-CF3 16 ± 1 
68d CH CH2 4-SMe 17 ± 1 
68e CH CH2 4-Cl 18 ± 1 
68f CH CH2 4-F 45 ± 1 
68g CH CH2 4-NO2 47 ± 5 
68h CH CH2 4-NH2 > 100 
68i CH CH2 4-N3 17 ± 2 
68j CH CH2 4-N(Me)CH2CH2OH 33 ± 2 
68k CH CH2 4-SO2Me > 100 
68l CH CO 4-Cl 37 ± 3 
68m CH SO2 4-Cl 30 ± 1 
80 N CH2 4-NMe2 40 ± 5 
(a) Racemates; (b) n = 3 
 
In the des-dimethyl series (68a-68m), 4-pyrrolidinyl (68b), 4-trifluoromethyl (68c), 4-
methylthio (68d) and 4-chloro (68e) ligands improved HeLa cell growth-inhibitory 
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activity relative to 68a. Comparison between 68a and 68e with the gem-dimethyl 
analogues (16a and 16e) showed that the latter had marginally superior growth-
inhibitory activity. Reducing 4-nitro (68g) to 4-amino (68h) or oxidising methylthio to 
methylsulfone (68k) abolished potency. These compounds were also the least lipophilic 
[clogP 3.4 (68h) and 3.0 (68k), as opposed to clogP 4.1-5.5 for the remaining 
compounds] supporting the hypothesis that compound activity depended on cell 
permeability. Replacing the methylene linker with an amide or sulfonamide and 
retaining the 4-chloro substituent (68l and 68m, respectively) gave compounds of 
similar potency to 68a. Compound 80 was 2-fold less active than 16a, but had reduced 
lipophilicity [clogP 4.1 (80) and 5.8 (16a)] and the carbamate precursor 83 was 
similarly potent to 16a, giving a GI50 of 20 ± 4 µM. Methylation of the secondary amine 
(74b) did not significantly affect potency, giving a GI50 value of 23 ± 2 µM. 
 
4.4 Synthesis of Novel Pyran-4-ones  
 
The high cost of pyranone 21 and the lack of commercially available 2,2-disubstituted 
pyranone analogues necessitated the development of a general procedure for the 
synthesis of pyranones for SAR studies. 
 
4.4.1 Formation from Mesityl Oxide (20) 
 
Following the published methodology,
79
 refluxing mesityl oxide (20) in aqueous 
formaldehyde failed to form β-hydroxyenone 85, giving no observable reaction by LC-
MS, even after prolonged heating (Scheme 14). Subsequently, no cyclisation to 
pyranone 21 was observed upon addition of Amberlyst-15 resin to the crude material. 
 
 
Scheme 14: (i) 37% aq. H2CO, 165 
o
C, 2 h; (ii) Amberlyst-15, CHCl3, RT
79
 
 
Using conditions described by Colonge,
118
 20 was successfully reacted with ethyl 
formate in the presence of sodium hydride to give 1,3-dicarbonyl 86 (Scheme 15). 
Cyclisation in the presence of mercury(II) sulfate and sulfuric acid gave 
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dihydropyranone 87 in 39% yield (
1
H NMR analysis) after heating for several days, but 
the product was difficult to purify. 
 
 
Scheme 15: (i) HCO2Et, NaH, Et2O, 0-10 
o
C, 24 h; (ii) HgSO4, 10% aq. H2SO4, 100 
o
C, 48 h  
 
The low yield in the cyclisation could be due to an unfavourable equilibrium so that full 
conversion of 86 could not be achieved. The low yield and the use of a toxic mercuric 
salt made this synthesis of 21 less attractive. It was found that cyclisation could be 
achieved using pTSA in place of mercury(II) sulfate,
119
 but full conversion could still 
not be achieved. Alternative synthetic methods for a general synthesis of 21 and other 
2,2-disubstituted pyranone derivatives were therefore investigated. 
 
Deprotonation of 20 using LDA followed by addition of trioxane gave no reaction by 
LC-MS, even after warming to room temperature. However, it was shown that LDA did 
deprotonate 20, as 
1
H NMR analysis of the product from a D2O-quenched reaction 
proved the incorporation of one atom of deuterium (Scheme 16). 
 
 
 
 
Scheme 16: (i) 
i
Pr2NH, n-BuLi, Et2O, -78 
o
C, 24 h; (ii) (H2CO)3, Et2O, -78-33 
o
C, 24 h; (iii) D2O, Et2O, -
78 
o
C-RT 
 
Using the procedure described by Yamamoto, trioxane was added neat to aluminium 
complex 90, which was prepared in situ from trimethylaluminium (89) and 2,6-
diphenylphenol (Scheme 17).
120
 The high oxophilicity of aluminium(III) causes the 
trioxane to fragment into individual formaldehyde molecules and the Lewis acidity of 
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the aluminium centre potentiates the electrophilicity of formaldehyde by withdrawing 
electron density from the carbonyl carbon.
120
 However, addition of the enolate of 20 to 
aluminium complex 91 at -78 
o
C resulted in no reaction (
1
H NMR analysis), even after 
warming to room temperature.  
 
 
 
Scheme 17: (i) 2,6-Diphenylphenol (2.0 equiv.), DCM, RT, 1 h; (ii) (H2CO)3, DCM, 0 
o
C, 1 h 
 
4.4.2 Formation of 1-Hydroxy-5-methylhex-4-en-3-one (85) 
 
Starting from 3-hydroxypropionitrile (92), high-yielding silylation of the alcohol was 
followed by reaction with 2-methyl-1-propenylmagnesium bromide (Scheme 18).
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However, the desired enone 94 did not form under these conditions. 
 
 
 
Scheme 18: (i) TBSCl, imidazole, DCM, 0 
o
C-RT, 5 h; (ii) Me2CCHMgBr, THF, 0 
o
C, 2 h; NH4Cl, RT 
 
1
H NMR analysis of the crude material showed that tert-butyldimethylsilylalcohol 
(
t
BuMe2SiOH) was the predominant species present.  It was possible that the Grignard 
reagent behaved as a base and eliminated 
t
BuMe2SiOH, forming 2-methylpropene (95) 
and acrylonitrile (96) (Scheme 19). These low-boiling side products would have been 
lost during concentration of the crude material in vacuo, explaining the absence of their 
corresponding peaks in the 
1
H NMR spectrum. 
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Scheme 19: Proposed elimination of 2-methylpropene (95) and acrylonitrile (96) initiated by 2-methyl-1-
propenylmagnesium bromide 
 
To reduce the basicity of the organometallic reagent, 2-methyl-1-propenylmagnesium 
bromide was transmetallated to the corresponding organocopper reagent (Scheme 20). 
Upon addition of 93, no reaction occurred, as shown by 
1
H NMR analysis after stirring 
at room temperature for 24 h.  
 
 
 
Scheme 20: (i) CuCl, THF, 0 
o
C-RT, 1 h; (ii) 93, THF, RT, 24 h; NH4Cl, RT 
 
Following the procedure by Fry, nitrile 93 was coupled with 2-chloropropane in the 
presence of FeCl3 to give the isopropylnitrilium salt 97 with enhanced electrophilicity at 
the nitrile carbon (Scheme 21).
122
 Reaction of 97 with 2-methyl-1-propenylmagnesium 
bromide gave enone 94, as shown by 
1
H NMR analysis. However, the purification was 
difficult and the yield was low. A similar result was obtained upon reaction of 97 with 
the corresponding organocopper reagent (cf. Scheme 20). 
 
 
 
Scheme 21: (i) 2-Chloropropane, FeCl3, 0-50 
o
C, o/n; (ii) Me2CCHMgBr or Me2CCHCu, THF, 0 
o
C-RT, 
6-16 h; NH4Cl, RT 
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4.4.3 Formation of Dihydropyran-4-ones by Cycloaddition 
 
Huang and Rawal had synthesised 2,2-disubstituted dihydropyran-4-ones by reacting 
ketones with diene 98, with pyranone 87 reportedly being synthesised in 40% yield 
using acetone (Scheme 22).
123
 2-Butanol was found to be the optimal solvent for the 
cyclisation, as it resulted in negligible diene alcoholysis when compared to water or 
other simple alcohols.
123
 The solvent needed to be protic, as it formed a hydrogen bond 
with the carbonyl oxygen, enhancing the electrophilicity of the ketone. When this 
reaction was attempted under the described conditions, no observable quantities of 87 
could be isolated and diene 98 rapidly converted to enone 100 at room temperature (
1
H 
NMR analysis). 2-Butanol was subsequently used in catalytic amounts in acetone but 
this reaction was slower and diene 98 was still subject to alcoholysis. Replacing 2-
butanol with TFE (pKa 12.4) was expected to accelerate the reaction and reduce 
alcoholysis. However, replacing 2-butanol with TFE gave no obvious advantage, with 
most of 98 being alcoholysed at room temperature within 1 h (
1
H NMR analysis). Based 
on the possibility that conversion of 98 to 100 was mediated by adventitious water, 
acetone and 2-butanol were rigorously dried by distillation over calcium hydride. This 
reduced alcoholysis of 98, but no cyclisation product 99 was detected by 
1
H NMR 
analysis after 30 h at room temperature. Despite considerable efforts to repeat the claims 
of Huang and Rawal, no trace of pyranone 87 was obtained.  
 
 
 
Scheme 22: Me2CO, 2-BuOH, RT, 30 h; (ii) AcCl, Et2O, -78 
o
C
123
 
 
 
 
99 
 
4.5 Finding the Minimum Pharmacophore of 16a 
 
In the gem-dimethylpyran series, deletion of the dimethylamino group (cf. Table 23, 
16b) did not affect potency and indeed, substitution of the benzylamino substituent for a 
carbamate (101), synthesised by treatment of amine 28 with Boc2O (Scheme 23), 
produced a similarly active species (Table 25). 
 
 
 
Scheme 23: (i) Boc2O, DCM, 0 
o
C-RT, o/n 
 
Removal of the gem-dimethyl group had no significant impact on cellular potency (cf. 
Table 24, 68a and 68e) and deletion of the tetrahydropyran ring (109) also retained 
activity in HeLa cells (Table 25). Compound 109 was synthesised from ester 103, 
obtained via HWE olefination of benzaldehyde (102) with triethyl 2-
phosphonopropionate (Scheme 24). 
 
 
Scheme 24: (i) (EtO)2(O)PCH(Me)CO2Et, NaH, THF, 0-30 
o
C 48 h; (ii) NH4HCO2, 10% Pd/C, MeOH, 
0-90 
o
C, 90 min; (iii) LiAlH4, THF, 0 
o
C, 2 h; (iv) MeSO2Cl, 
i
Pr2NEt, DCM, RT, 2 h; (v) NaCN, DMF, 
100 
o
C, 7 h; (vi) H2, Raney Ni, 60 bar, 70 
o
C, 24 h; (vii) 4-chlorobenzaldehyde, MgSO4, DCM, RT, 4 h; 
NaBH4, MeOH, RT, 1 h 
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Further simplification to compound 111, synthesised by reductive amination of 4-
chlorobenzaldehyde with isopentylamine (110) (Scheme 25), abrogated activity in 
HeLa cells. Several intermediates (63, 66 and 67) in the synthesis of 68a were also 
evaluated and found to be inactive (Table 25). 
 
 
 
Scheme 25: (i) 4-Chlorobenzaldehyde, MgSO4, DCM, RT, 4 h; NaBH4, MeOH, RT, 1 h 
 
Table 25: HeLa SRB assay for fragment derivatives of 16a and 68e
a
 (conducted by Laura Evans at the 
NICR) 
 
ID
b 
Structure HeLa GI50 (µM)
c 
 
101 
 
 
35 ± 2 
 
 
67 
 
 
 
 
 
> 100 
 
 
66 
 
 
 
 
 
> 100 
 
63 
 
 
> 100 
 
109 
 
 
16 ± 1 
 
111 
 
 
> 100 
(a) Compound 16a HeLa GI50, 16 ± 1 µM and compound 68e HeLa GI50, 18 ± 1 µM; (b) Racemates or 
diastereoisomers (dr, 5:2); (c) n = 3 
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Substitution of the tetrahydropyran ring by a methyl group (109) retained activity but 
replacement of both the pyran and phenyl ring by methyl groups (111) abolished 
potency, suggesting that the phenyl ring was important for cell toxicity, although this 
modification was accompanied by a decrease in lipophilicity. The intermediates 63, 66 
and 67 possessed no growth-inhibitory activity, suggesting with reference to compounds 
67 and 111, that structure 109 is the minimum pharmacophore. 
 
4.6 Synthesis of the Enantiomers of 68a 
 
It was of interest to determine if 16a demonstrated stereoselectivity in HeLa cells, as 
this would provide evidence of a specific binding interaction with a receptor. The 
enantiomers of 68a were selected, as the racemate was similarly active to 16a in HeLa 
cells and the absence of the gem-dimethyl group meant that 68a had only one chiral 
centre. Separation of the enantiomers of 68a by chiral HPLC was unsuccessful, 
necessitating the development of an enantioselective route.  
 
 
 
Starting from pyranone 60, HWE olefination and transfer hydrogenation yielded ester 
62. Hydrolysis with lithium hydroxide provided carboxylic acid 112 and treatment with 
pivaloyl chloride and (R)- or (S)-4-benzyloxazolidin-2-one, gave oxazolidinones (R)-
113 and (S)-113, respectively (Scheme 26). 
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Scheme 26: (i) (MeO)2(O)PCH2CO2Me, NaH, THF, 0 
o
C-RT, 20 h; (ii) NH4HCO2, 10% Pd/C, MeOH, 0-
90 
o
C, 90 min; (iii) LiOH.H2O, 50% THF, H2O, 60 
o
C, 2 h; (iv) 
t
BuCOCl, Et3N, THF, 0 
o
C, 45 min; (R)- 
or (S)-4-benzyloxazolidin-2-one, LiCl, THF, RT, 16 h 
 
Using Evans’ methodology,124 enolate formation with LDA in the presence of HMPA 
prior to addition of benzyl bromide, gave (R,R)-114 and (S,S)-114 in > 98% de. 
Removal of the chiral auxiliary to give alcohols (R)-64 and (S)-64 proved surprisingly 
difficult. Reduction of (S,S)-114 with lithium borohydride failed to yield (S)-64, instead 
yielding amide (S,S)-115, as a result of borohydride attack on the endo-carbonyl group 
of the oxazolidin-2-one (Scheme 27). 
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Scheme 27: Competing borohydride attack on the exo (blue arrow) and endo carbonyls of (S,S)-114; (i) 
i
Pr2NH, n-BuLi, HMPA, THF, 0 to -78 
o
C, 1 h; BnBr, THF, -78 
o
C, 6 h; (ii) LiBH4 (2.0 M in THF), THF, 
40 
o
C, 1 h 
 
Palomo had described the use of sodium borohydride in water as a convenient method 
for the reduction of chiral auxiliaries to the corresponding alcohols.
125
 However, these 
conditions resulted in only partial conversion to (S,S)-115 when applied to (S,S)-114 
and none of the desired alcohol was formed. Kanomata had described the use of sodium 
methoxide in an excess of dimethyl carbonate (DMC) as a facile method for cleaving 
sterically demanding chiral auxiliaries to the corresponding methyl esters.
126
 Attack by 
methoxide on the endo-carbonyl would generate DMC as a by-product, but if DMC was 
already present in excess, the equilibrium would shift to minimise this reaction and 
form only the exo-product (Scheme 28).
126
 
 
 
 
 
104 
 
 
 
Scheme 28: (i) NaOMe, DMC, RT-50 
o
C
126
 
 
When these conditions were applied to (S,S)-114, amide (S,S)-115 was obtained as the 
sole product. Success was achieved by switching from lithium borohydride to either 
lithium aluminium hydride solution or triethylborohydride (superhydride) solution.
127
 
At -78 
o
C,
 
(S,S)-114 was converted to a mixture of (S)-64 and (S,S)-115 upon warming 
to room temperature. Lithium aluminium hydride gave a 1:1 ratio of the products whilst 
superhydride generated a 3:1 ratio of (S)-64 and (S,S)-115 by LC-MS. Removal of the 
auxiliaries using superhydride gave (R)-64 and (S)-64 in 41% yield. Mesylation, 
substitution with sodium cyanide, reduction with lithium aluminium hydride and 
reductive amination with 4-(N,N-dimethylamino)benzaldehyde gave enantiomer (R)-
68a or (S)-68a (Scheme 29). 
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A) 
 
 
B) 
Scheme 29: A) Synthesis of (S)-68a; B) synthesis of (R)-68a; (i) 
i
Pr2NH, n-BuLi, HMPA, THF, 0 to -78 
o
C, 1 h; BnBr, THF, -78 
o
C, 6 h; (ii) LiBEt3H, Et2O, -78 
o
C-RT, o/n; (iii) MsCl, 
i
Pr2NEt, DCM, RT, 2 h; 
(iv) NaCN, DMF, 100 
o
C, 7 h; (v) LiAlH4, THF, 0 
o
C, 3 h; (vi) 4-(N,N-dimethylamino)benzaldehyde, 
MgSO4, DCM, RT, 4 h; NaBH4, MeOH, RT, 1 h 
 
Chiral HPLC on intemediates (R)-67 and (S)-67 revealed both compounds were present 
in ≥ 99% ee (± 1%) when compared to a sample of the racemate (Figure 44). 
Enantiomers (R)-68a and (S)-68a were analysed by the HeLa cell-based SRB assay 
(Table 26). Both enantiomers and the racemate were equipotent in HeLa cells, 
suggesting a non-stereoselective mechanism of cellular toxicity. 
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A)  
 
B) 
 
C) 
Figure 44: Chiral HPLC results for A) (S)-67; B) (R)-67 and C) (±)-67 (conducted by Dr Karen Haggerty 
in the Medicinal Chemistry Laborotories) 
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Table 26: HeLa cell-based assay for compound 68a enantiomers
a
 (conducted by Laura Evans at the 
NICR) 
 
ID
 
HeLa GI50 (µM)
b 
(S)-68a 33 ± 4 
(R)-68a 29 ± 2 
(a) ±-68a HeLa GI50, 27 ± 4 µM; (b) n = 3 
 
4.7 Conclusion 
 
In conclusion, an efficient and versatile synthesis of the first-reported small-molecule 
inhibitor of the SCF
SKP2
 complex, 16a, was completed and growth-inhibitory activity 
was confirmed in HeLa cells using an SRB assay. Removal of the gem-dimethyl group 
from the pyran ring of 16a did not significantly affect potency in HeLa cells and 
modification of the 4-(N,N-dimethylamino)benzyl substituent also did not improve 
activity in either the gem- or des-dimethylpyran series. Replacing the pyran ring with a 
morpholino ring (80) reduced compound lipophilicity without seriously affecting 
activity but complete removal of the pyran ring (109) had a similar effect. There was a 
trend observed between lipophilicity and growth-inhibitory activity, with the most 
lipophilic compounds, 16d and 16e, being the most active and the least lipophilic 
compounds, 68h and 68k, being inactive. (R)- and (S)-68a were synthesised using an 
enantioselective route featuring Evans’ chiral auxiliaries. Both enantiomers and the 
racemate were equipotent in HeLa cells, suggesting that these cytotoxic compounds 
have a non-specific mechanism of action yet to be defined. 
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Chapter Five: MDMX Results and Discussion 
 
5.1 The 1,3-Disubstituted Benzenoid MDMX Inhibitors 
 
Docking of thiazole 44a in the MDMX binding site indicated that a substituent 
branching from the thiazole nitrogen atom could potentially make hydrophobic 
interactions within the p53-W23 subpocket (Figure 45).  
 
 
 
 
 
 
 
 
 
 
Figure 45: Model of thiazole 44a interacting with the p53-binding site of MDMX (coral). Compound 
colour scheme: carbon = green; hydrogen = grey, small; fluorine = grey, large; oxygen = red; nitrogen = 
blue; sulfur = yellow. The p53-W23 binding pocket is the area of white indicated by the arrow. Image 
created using COOT with CCP4mg plug-in.  
 
Substitution at the thiazole nitrogen would form a reactive thiazolium salt so the 
thiazole scaffold was replaced by a benzene ring, allowing for multiple derivatives to be 
rapidly synthesised for developing SARs (Scheme 30). 
 
 
 
Scheme 30: Scaffold-hop from a 2,4-disubstituted thiazole to a 1,3-disubstituted benzene ring 
p53-F19 
pocket 
p53-L26 
pocket 
p53-W23 
pocket 
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Initial target compounds were based on hit compounds synthesised in the thiazole 
series, to examine whether the SARs in the benzenoid series differed significantly. 
Starting from 3-aminobenzeneboronic acid (116), Suzuki coupling with 4-bromophenol 
in the presence of Pd(PPh3)4, gave aniline 117a in 26% yield after heating at 100 
o
C for 
22 h. Optimisation of the conditions found that Pd(dtbpf)Cl2 was a superior catalyst and 
gave a faster and cleaner conversion compared with Pd(PPh3)4 and Pd(dppf)Cl2 (Table 
27). Combined with microwave irradiation instead of conventional heating, full 
conversion could be achieved within 20 min at 120 
o
C. 
 
 
 
Table 27: Optimisation of temperature and catalyst in the Suzuki coupling between boronic acid 116 and 
4-bromophenol
a 
 
Catalyst
 
 
Temp. (
o
C) % Conversion
b 
Pd(PPh3)4 40 1.6 
Pd(PPh3)4 60 8.2 
Pd(PPh3)4 80 9.6 
Pd(PPh3)4 100 11.5 
Pd(PPh3)4 120 16.8 
Pd(PPh3)4 140 17.5 
Pd(dppf)Cl2 140 31.8 
Pd(dtbpf)Cl2 140 70.0 
(a) 116 (48 mg, 1.2 equiv.), 4-bromophenol (1.0 equiv.), catalyst (5.0 mol%), 2 M aq. Na2CO3 (2.0 
equiv.), 1,2-DME (3.2 mL); (b) After 5 min by LC-MS 
 
The optimised Suzuki coupling conditions were used to couple 116 with several aryl 
bromides in moderate to excellent yields. All reactions achieved full conversion of the 
aryl bromide within 20 min at 120 
o
C. Reductive amination of 4-fluorobenzaldehyde 
with 117a to 117d yielded the target compounds 118a to 118d respectively (Scheme 
31). 
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Scheme 31: (i) Aryl bromide, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 20 min; (ii) 4-
fluorobenzaldehyde, MgSO4, THF, RT, 4 h; NaBH4, MeOH, RT, 1 h 
 
For the synthesis of 117d, the desired aryl bromide (120) was not commercially 
available. Triflation of 4-bromoaniline (119) using triflic anhydride (Tf2O) with Hünig’s 
base gave 120 in high yield (Scheme 32). 
 
 
 
Scheme 32: (i) Tf2O, 
i
Pr2NEt, DCM, 0 
o
C-RT, 30 min; 2.5 M NaOH, MeOH (1:3), RT, 3 h 
 
The 1,4-disubstituted regioisomer 118e was obtained by Suzuki coupling of aryl 
bromide 120 with 4-aminobenzeneboronic acid pinacol ester under previously 
optimised conditions (cf. Scheme 31), followed by reductive amination of 4-
fluorobenzaldehyde with 117e (Scheme 33). 
 
 
 
Scheme 33: (i) 4-Aminobenzeneboronic acid pinacol ester, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, 
MW, 20 min; (ii) 4-fluorobenzaldehyde, MgSO4, THF, RT, 4 h; NaBH4, MeOH, RT, 1 h 
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Compounds 118a-118e were screened against MDMX and MDM2 using an enzyme-
linked immunosorbent assay (ELISA) (Table 28). 
 
Table 28: ELISA data for 1,3-disubstituted benzene derivatives 118a-118e (conducted by Dr Yan Zhao at 
the NICR) 
 
ID Structure MDMX 
IC50 
(µM)
a 
MDM2 
IC50 
(µM)
b
 
Ratio 
(MDMX: 
MDM2) 
LE
c 
LipE
c,d 
 
118a 
 
 
41.3 
 
48.3 
 
1.17 
 
0.27 
 
+ 1.70 
 
118b 
 
 
208 
 
71.0 
 
0.34 
 
0.23 
 
+ 0.99 
 
118c 
 
 
64.7 
 
35.0 
 
0.54 
 
0.25 
 
+ 2.15 
 
118d 
 
 
61.2 
 
49.8 
 
0.81 
 
0.20 
 
+ 0.73 
 
118e 
 
 
48.9 
 
59.9 
 
1.22 
 
0.20 
 
+ 0.87 
(a) n = 2; (b) n = 1; (c) With respect to MDMX; (d) LipE = pIC50 – clogD7.4 (clogD values from 
StarDrop) 
 
A benzenoid scaffold was tolerated, with compounds 118a, 118c, 118d and 118e 
showing modest activity against MDMX. All compounds demonstrated low selectivity 
for MDMX or MDM2 but the selectivity profiles were dependent on the molecular 
scaffold (cf. Table 20, 44a, 44c and 44j). Compound 44c showed 5-fold greater MDM2 
potency over MDMX but the corresponding benzenoid compound (118a) was 
equipotent against both proteins. With a p-hydroxy group, activity against MDMX or 
MDM2 was moderate, but a m-hydroxy group reduced MDMX potency 5-fold in the 
benzenoid series (118b). A 3,4-catechol restored potency (118c) suggesting the p-
hydroxy group was making a favourable interaction with the protein. Most of the 
corresponding benzenoid and thiazole compounds were similarly active against both 
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proteins (1.5 to 4-fold difference in activities). However, compound 44j was 10-fold 
more active against MDMX than the corresponding benzenoid compound 118d. When 
the 4-fluorobenzylamino substituent was para to the 4-N-sulfonamidobenzene ring 
(118e), affinity for MDMX and MDM2 was not affected relative to the 1,3-disubstituted 
derivative (118d). It is possible that the 4-fluorobenzylamino moiety was either not 
making any significant contact with the protein or the binding pocket was sufficiently 
large to accommodate either regioisomer.  
 
Future SARs were limited to 1,3-disubstituted benzenoid compounds due to the 
structural similarity of the 1,4-disubstituted compound to benzidine (121), a potent 
human bladder carcinogen. 
 
 
 
The SAR data in Table 28 highlighted the significance of a p-OH or p-NHSO2CF3 
group for potent inhibition of MDMX or MDM2, an observation previously made in the 
2,4-disubstituted thiazole series. However, phenols display metabolic instability in vivo 
(cf. Scheme 2) and the trifluoromethylsulfonamide significantly increased molecular 
weight and lipophilicity, necessitating alternative functionalities. Several alternative 
substituents had been tested in the thiazole series, facilitating comparisons with the 
benzenoid series (Table 29). Reductive amination of 4-fluorobenzaldehyde with aniline 
122 gave boronic ester 123. Compounds 118f-118h, 118j and 118k were synthesised 
via Suzuki coupling with 123 and the appropriate aryl bromide (Scheme 34). 
 
 
Scheme 34: (i) 4-Fluorobenzaldehyde, MgSO4, THF, RT, 4 h; NaBH4, MeOH, RT, 1 h; (ii) appropriate 
aryl bromide, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 20 min 
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Compound 118i was synthesised by reductive amination of 4-fluorobenzaldehyde with 
aniline hydrochloride 117f (Scheme 35). 
 
 
 
Scheme 35: (i) 4-Fluorobenzaldehyde, NaB(OAc)3H, DMF, AcOH, RT, 24 h 
 
Compounds 118l, 118m and 118o were synthesised by reductive amination of 4-
fluorobenzaldehyde with anilines 117g, 117h and 117i (Scheme 36). 
 
 
 
Scheme 36: (i) 4-Fluorobenzaldehyde, MgSO4, THF, RT, 4 h; NaBH4, MeOH, RT, 1 h 
 
For the synthesis of 118n, aryl bromide 125 was prepared from neutralised 4-
bromopyridine hydrochloride (124) by oxidising with mCPBA, followed by Suzuki 
coupling with 123 (Scheme 37). 
 
 
 
Scheme 37: (i) NaOH (aq.), RT, 20 min; mCPBA, Et2O, RT, 3 h; (ii) 123, Pd(dtbpf)Cl2, Na2CO3, 1,2-
DME, 120 
o
C, MW, 45 min 
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Table 29: ELISA data for 1,3-disubstituted benzene derivatives 118f-118o (conducted by Dr Yan Zhao at 
the NICR) 
 
 
ID R MDMX 
IC50 (µM)
a 
MDM2 IC50 
(µM)b 
Ratio (MDMX : 
MDM2) 
 
LE
c 
LipE
c,f 
118f 
 
13%
e 
913 - - - 
118g 
 
419 496 1.18 0.21 + 0.39 
118h 
 
688 205 0.30 0.20 0.14 
118i 
 
25%
e 
20%
d 
- - - 
118j 
 
1002 10%
d 
- 0.18 - 0.35 
118k 
 
197 588 2.98 0.20 + 0.69 
118l 
 
14%
e 
697 - - - 
118m 
 
41%
e 
29%
d 
- - - 
118n 
 
33%
d 
25%
d 
- - - 
118o 
 
1000 34%
d 
- 0.20 + 0.44 
(a) n = 2; (b) n = 1; (c) With respect to MDMX; (d) 200 µM; (e) 1 mM; (f) LipE = pIC50 – clogD7.4 
(clogD values from StarDrop) 
 
The presence of a p-hydroxy or p-trifluoromethylsulfonamido group (cf. Table 28, 
118a, 118c, 118d and 118e) was essential for activity against MDMX and MDM2. 
Removal of the hydroxy proton by methylation (118i) or replacing with an N-oxide 
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(118n) or unsubstituted phenyl ring (118l) or pyridyl ring (118m and 118o) abolished 
activity, supporting the hypothesis that the hydroxy group was interacting favourably 
with the protein. Replacing the trifluoromethylsulfonamido group with a 
methylsulfonamido substituent (118f) abolished target activity, as did replacing the 
hydroxy group with an isosteric amino group (118g), suggesting that a relatively acidic 
proton at the 4-position was needed for potency. All m-substituted derivatives (118h, 
118j and 118o) were equally or less active than the corresponding p-substituted 
compounds against MDMX. However, none of these compounds improved MDMX or 
MDM2 potency over 118a, 118c, 118d or 118e. 
 
5.2 The Disubstituted Pyridyl MDMX Inhibitors 
 
Pyridyl scaffolds were investigated, as they should also have allowed access to the p53-
W23 binding pocket of MDMX but would reduce lipophilicity without compromising 
molecular weight (Scheme 38).    
 
 
 
Scheme 38: Scaffold-hop from a benzene to a pyridyl scaffold 
 
Starting from pyridines 126a, 126b and 126c, Suzuki coupling with 4-
hydroxybenzeneboronic acid followed by reductive amination of 4-fluorobenzaldehyde 
gave 4- and 5-pyridyls 128a and 128b, but not 128c (Scheme 39).  
 
 
 
 
Scheme 39: (i) 4-Hydroxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 30-150 
min; (ii) 4-fluorobenzaldehyde, MgSO4, THF, RT, 4 h; NaBH4, MeOH, RT, 1 h 
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Difficulties with achieving full conversion and purification contributed to the poor 
yields obtained compared with the benzenoid series. Longer reaction times, increased 
equivalents of catalyst and boronic acid in the Suzuki couplings and increased 
equivalents of 4-fluorobenzaldehyde in the reductive aminations were necessary to 
achieve suitable conversion. The low reactivity of aminopyridines 127a, 127b and 127c 
relative to the corresponding anilines was due to conjugation of the amino nitrogen lone 
pair into a comparatively electron-deficient aromatic ring. The reactivity of pyridine 
127b was moderate, giving 61% yield of 128b, but the lower reactivity of pyridines 
127a and 127c meant only 12% yield of 128a was obtained. Aminopyridine 128c was 
not obtained under these conditions. 
 
Starting from pyridine 126c, coupling with 4-fluorobenzoyl chloride in the presence of 
pyridine gave amide 130. It was observed by LC-MS that some 130 reacted further with 
4-fluorobenzoyl chloride to form imide 129. Quenching the reaction with methanolic 
sodium hydroxide converted 129 to 130.  Suzuki coupling with 4-
hydroxybenzeneboronic acid, followed by reduction of the amide using lithium 
aluminium hydride gave 128c, with no reduction of the pyridyl ring observed (Scheme 
40). 
 
 
Scheme 40: (i) 4-Fluorobenzoyl chloride, pyridine, MeCN, RT, o/n; (ii) 2.5 M NaOH, MeOH (1:3), RT, 
15 min; (iii) 4-hydroxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 1 h; (iv) 
LiAlH4, THF, 0 
o
C-RT, 6 h 
 
Oxidation of 128b to pyridine-N-oxide 128d with mCPBA was unsuccessful due to 
problems with purifying the product from the 3-chlorobenzoic acid impurity (Scheme 
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41). The high aqueous solubility of 128d meant that the product could not be separated 
from the 3-chlorobenzoic acid into an organic and aqueous layer, despite numerous 
extractions of the aqueous layer. Compound 128d was synthesised via reductive 
amination of 4-fluorobenzaldehyde with aniline 126b to give 132. This compound was 
oxidised with mCPBA to give 133 and Suzuki coupling with 4-hydroxybenzeneboronic 
acid gave 128d with no deprotection of the N-oxido group observed (Scheme 41). 
Pyridyl compounds 128a, 128b, 128c and 128d were analysed by ELISA (Table 30). 
 
 
 
Scheme 41: (i) 4-Fluorobenzaldehyde, MgSO4, THF, RT, 4 h; NaBH4, MeOH, RT, 1 h; (ii) mCPBA, 
DCM, 0 
o
C-RT, 30 min; (iii) 4-hydroxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, 
MW, 1 h 
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Table 30: ELISA data for pyridyl derivatives 128a, 128b, 128c, 128d and 131(conducted by Dr Yan 
Zhao at the NICR) 
 
 
ID Scaffold / Structure MDMX 
IC50 
(µM)
a
 
MDM2 
IC50 
(µM)
b
 
Ratio 
(MDMX : 
MDM2) 
 
LE
c 
LipE
c,e 
128a 
 
574 303 0.53 0.20 
 
+ 1.17 
128b 
 
552 459 0.83 0.20 + 1.23 
128c 
 
17%
d 
128 - - - 
128d 
 
212 50.0 0.24 0.22 + 1.46 
131 
 
467 11%
d 
- 0.20 + 0.39 
(a) n = 2; (b) n = 1; (c) With respect to MDMX; (d) 200 µM; (e) LipE = pIC50 – clogD7.4 (clogD values 
from StarDrop) 
 
A large drop in MDMX and MDM2 activity was observed relative to the benzenoid 
scaffold (cf. Table 28, 118a), with compounds 128a and 128b being 13-14-fold less 
active against MDMX and 128c being so inactive that only a percentage inhibition 
value could be recorded. Compound 128d partially restored potency against MDMX 
and totally restored activity against MDM2 relative to 118a. The results showed that an 
electron-deficient scaffold was detrimental to MDMX and MDM2 potency. The 
increase in activity observed with 128d also showed that substitution at the 5-position of 
the scaffold was tolerated and could be investigated in future SAR studies. 
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5.3 The 1,2,3-Trisubstituted Benzenoid MDMX Inhibitors 
 
Published MDM2 inhibitors, e.g. RG7112,
53
 and MDMX inhibitors, e.g. Novartis-
101,
104
 used chloride-substituted aromatic rings to access the p53-W23 pocket. To see if 
such a group would be tolerated in the benzenoid series, trisubstituted benzene 
derivatives were designed (Figure 46). 
 
 
 
Figure 46: 1,2,3-Trisubstituted benzenoid derivatives with predicted binding mode in MDMX and 
MDM2 
 
The proposed synthesis of phenol 138a started with Ullman coupling of 2-bromo-6-
nitrophenol (134) with 1-chloro-4-iodobenzene to give biaryl ether 135a. Suzuki 
coupling with 4-hydroxybenzeneboronic acid would give 136a and reduction of the 
nitro group followed by reductive amination of 4-fluorobenzaldehyde would give 138a 
(Scheme 42).  
 
 
 
Scheme 42: Retrosynthesis of 138a  
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Buchwald had previously described conditions for the efficient formation of biaryl 
ethers where the aryl halide or phenol were flanked by o-substitutents.
128
 Heating 134 
and 1-chloro-4-iodobenzene at 80 
o
C in DMSO with tripotassium phosphate, CuI and 2-
picolonic acid gave 25-30% conversion to 135a after 24 h. Microwave irradiation at 140 
o
C and tripling the loading of CuI and 2-picolinic acid did not improve this result. The 
poor conversion was possibly due to inactivation of the phenol by the o-nitro 
substituent. The authors only cited phenols and aryl iodides flanked by o-methyl and o-
methoxy groups,
128
 therefore it is possible that the steric hinderance of the bromo and 
nitro groups further reduced the reactivity of 134.  
 
Starting from 3-bromo-2-fluoronitrobenzene (139), nucleophilic aromatic substitution 
with 4-chlorophenol in DMF gave 135a in excellent yield. Suzuki coupling with 4-
hydroxybenzeneboronic acid gave phenol 136a, with similar yields obtained compared 
to the 1,3-disubstituted benzenoid series. It was found that the success of this reaction 
depended on irradiation time and reaction concentration; irradiation for longer than 30 
min at 120 
o
C or having a concentration above 0.5 M resulted in significant de-
chlorination of the product. Iron-mediated reduction of the nitro group gave aniline 
137a at 50 
o
C. Subsequent nitro reductions found that the temperature could be reduced 
to 30 
o
C, with full conversion after 2 h. Attempts to reduce the nitro group using Pd/C 
or Ru/C resulted in significant de-chlorination. Reductive amination of 4-
fluorobenzaldehyde gave 138a in 34% yield (Scheme 43). Poor conversion of 137a was 
observed by LC-MS even with increased equivalents of 4-fluorobenzaldehyde. 
Refluxing at 70 
o
C overnight did not have any significant effect. This was possibly due 
to the steric hinderance of the 4-chlorophenoxy substituent hindering access to the 
aniline nitrogen. Hosseinzadeh had described the use of TFE in reductive aminations, 
giving substantially accelerated reactions compared with conventional solvents.
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Using TFE in place of THF gave full conversion to the imine without need for a drying 
agent and improved yields of the desired amines by at least two-fold. 
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Scheme 43: (i) 4-Chlorophenol, K2CO3, DMF, 120 
o
C, MW, 20 min; (ii) 4-hydroxybenzeneboronic acid 
or phenylboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, MW, 20 min; (iii) Fe, AcOH, 50 
o
C, MW, 1 h; 
(iv) 4-fluorobenzaldehyde, MgSO4, THF, RT, o/n; NaBH4, MeOH, RT, 1 h 
 
Compounds 138c, 138d, 138e and 138f were also synthesised from anilines 137a and 
137b. Buchwald coupling of the appropriate aryl bromide proceeded in moderate to 
high yields with Pd2dba3 and XPhos proving an effective catalyst (Scheme 44). 
 
 
 
Scheme 44: (i) 1-Bromo-4-fluorobenzene or 1-bromo-4-chlorobenzene or bromobenzene, Pd2dba3, 
XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h 
 
To determine whether a 4-chlorophenoxy substituent was of optimal length to access 
the p53-W23 binding pocket, compounds 138g and 138h were synthesised with a 4-
chlorobenzoxyl substituent. Starting from 134, coupling of 4-chlorobenzyl bromide in 
acetonitrile gave 135b in high yield. Suzuki coupling, nitro group reduction and either 
Buchwald coupling or reductive amination gave 138g or 138h respectively (Scheme 
45). Compounds 138a-138h were screened using an ELISA (Table 31). 
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Scheme 45: (i) 4-Chlorobenzyl bromide, K2CO3, MeCN, 80 
o
C, MW, 90 min; (ii) 4-
hydroxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, MW, 20 min; (iii) Fe, AcOH, 50 
o
C, 
MW, 1 h; (iv) 1-bromo-4-fluorobenzene, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h; (v) 4-
fluorobenzaldehyde, MgSO4, THF, RT, o/n; NaBH4, MeOH, RT, 1 h 
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Table 31: ELISA data for 1,2,3-trisubstituted benzene derivatives 138a-138h (conducted by Dr Yan Zhao 
at the NICR) 
 
ID Structure MDMX 
IC50 
(µM)
a 
MDM2 
IC50 
(µM)
b
 
Ratio 
(MDMX : 
MDM2) 
LE
c
 LipE
c,e 
 
138a 
 
 
79.0 
 
135 
 
1.71 
 
0.19 
 
- 0.30 
 
138b 
 
 
22%
d 
 
 
5%
d 
 
- 
 
- 
 
- 
 
138c 
 
 
19.0 
 
23.2 
 
1.22 
 
0.22 
 
- 1.51 
 
138d 
 
 
19%
d 
 
 
5%
d 
 
- 
 
- 
 
- 
 
138e 
 
 
28.9 
 
15.9 
 
0.55 
 
0.22 
 
- 1.72 
 
138f 
 
 
33.0 
 
81.0 
 
2.45 
 
0.21 
 
- 2.28 
 
 
138g 
 
 
 
41.0 
 
 
36.0 
 
 
0.88 
 
 
0.20 
 
 
- 1.93 
 
 
138h 
 
 
 
126 
 
 
37%
d
 
 
 
- 
 
 
0.17 
 
 
- 0.68 
(a) n = 2; (b) n = 1; (c) With respect to MDMX; (d) 200 µM; (e) LipE = pIC50 – clogD7.4 (clogD values 
from StarDrop) 
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Compound 138a had similar activity against MDMX to the corresponding analogue 
with no 4-chlorophenoxy ring (cf. Table 28, 118a), indicating that the 4-chlorophenoxy 
group was tolerated and could be optimised to improve potency. Compound 138c was 
the most active compound, with removal of the methylene linker in 138a improving 
MDMX potency 4-fold and MDM2 potency 6-fold. Having a methylene linker between 
the 4-chlorophenyl ring and the oxygen (138g) gave a 2-fold drop in MDMX activity 
relative to 138c. Compound 138h, with two methylene linkers, saw a cumulative fall in 
potency against both protein targets. This is possibly because the shorter compounds 
could accommodate the p53 binding domain of MDMX and MDM2 more efficiently. 
Removing the fluoro group (138e) or replacing it with a chloro group (138f) did not 
significantly affect MDMX activity, although 138f was 3-fold less active against 
MDM2 than 138c. Removal of the p-hydroxy group abolished potency against both 
proteins (138b and 138d).  
 
5.3.1 Investigating the Binding Mode of the 1,2,3-Trisubstituted 
Benzenoid Series 
 
The structural nature of the compounds synthesised thus far potentially enabled binding 
to MDMX in different orientations (Figure 47). 
 
 
 
Figure 47: Two possible binding orientations of the 1,2,3-trisubstituted benzenoid compounds in the p53 
binding domains of MDM2 and MDMX 
 
Modelling of thiazole 44a in the MDMX binding pocket had indicated that a sub-
pocket, present in the p53-F19 pocket, could be accessed by substitution at the 2-
position of the catechol ring (Figure 48). Since the binding orientation of the 
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compounds was ambiguous, substitution at the 2-position of the catechol ring and the 4-
fluorophenyl ring was investigated.  
 
 
 
 
 
 
 
 
 
 
 
Figure 48: Model of thiazole 44a interacting with the p53-binding site of MDMX (coral). Compound 
colour scheme: carbon = green; hydrogen = grey, small; fluorine = grey, large; oxygen = red; nitrogen = 
blue; sulfur = yellow. Image created using COOT with CCP4mg plug-in. 
 
Derivatives of 138c were synthesised possessing a 2-methyl or 2-chloro group on either 
the 4-fluorophenyl or 4-hydroxyphenyl ring. Methyl and chloro substituents were 
selected as these groups would not significantly affect the electron density of the ring to 
which they were attached. Using aniline 137a, compounds 138i and 138j were 
synthesised by Buchwald coupling of 2-bromo-5-fluorotoluene or 1-bromo-2-chloro-4-
fluorobenzene, respectively (Scheme 46).  
 
 
Scheme 46: (i) 2-Bromo-5-fluorotoluene or 1-bromo-2-chloro-4-fluorobenzene, Pd2dba3, XPhos, K2CO3, 
MeCN, 120 
o
C, MW, 3 h 
p53-F19 
Accessible 
pocket 
1 
2 3 
4 
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Initial attempts to synthesise 138k and 138l began with borylation of 135a using the 
conditions described by Imanishi.
130, 131
 When 135a was heated in 1,4-dioxane with 
bis(pinacolato)diboron (B2(pin)2) and (PPh3)2PdCl2 it was completely consumed. 
However, 
1
H NMR analysis revealed that approximately 50% of product 140 had 
coupled with 135a to give dimer 141. Despite attempts to optimise the yield of 140, 
significant dimerisation could not be avoided (Table 32). Using Pd(dppf)Cl2.DCM in 
place of (PPh3)2PdCl2 increased the levels of dimerisation. Increasing the equivalents of 
B2(pin)2 and reducing the reaction temperature both failed to reduce dimerisation so 
other synthetic routes were investigated.  
 
 
 
Table 32: Conditions applied to minimise dimerisation of 140
a 
 
Entry Catalyst B2(pin)2 
equiv. 
Temp. 
(
o
C)/time 
140:141 
ratio 
Results 
1 (PPh3)2PdCl2 
 
1.2 90, o/n 1:1 140 isolated in 29% 
yield (impure) 
2 Pd(dppf)Cl2. 
DCM 
1.2 90, o/n 1:5 No product isolated 
3 (PPh3)2PdCl2 2.0 80, 4 h 1:1 No product isolated 
4
b (PPh3)2PdCl2 2.0 90, 20 min 2:3 No product isolated 
(a)
 
140 (50 mg, 1.0 equiv.), catalyst (5.0 mol%), KOAc (2.0 equiv.) 1,4-dioxane (0.5 M); (b) Microwave 
irradiation instead of conventional heating 
 
Goodacre had described the successful borylation of 3-bromo-2-fluoronitrobenzene 
(139).
132
 Under the described conditions, boronate ester 142 was synthesised with just 
5-10% dimerisation (
1
H NMR analysis). Using (PPh3)2PdCl2 in place of 
Pd(dppf)Cl2.DCM eliminated dimerisation completely. However, reducing the quantity 
of B2(pin)2 from 1.5 to 1.2 equivalents increased dimerisation. 
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Nucleophilic aromatic substitution with 4-chlorophenol resulted in complete 
deborylation of the product (Scheme 47). 
 
 
 
Scheme 47: (i) 4-Chlorophenol, K2CO3, DMF, 120 
o
C, MW, 20 min 
 
Suzuki coupling of 142 with 4-bromo-3-methylphenol or 4-bromo-3-chlorophenol gave 
144a and 144b respectively (Scheme 49). Subsequent nucleophilic aromatic 
substitution found that increased equivalents of 4-chlorophenol were necessary to 
minimise competing dimerisation of the starting materials. Using 144b, four equivalents 
of 4-chlorophenol gave a mixture of 136e and dimer 145 (Scheme 48).  
 
 
 
Scheme 48: (i) 4-Chlorophenol (4 equiv.), K2CO3, DMF, 120 
o
C, MW, 40 min (136e:145 ratio = 5:1) 
 
Using six equivalents of 4-chlorophenol minimised formation of 145 and gave biaryl 
ethers 136d and 136e in 83 and 82% yield respectively. Iron-mediated reduction of the 
nitro groups at 30 
o
C gave anilines 137d and 137e and Buchwald coupling gave final 
compounds 138k and 138l (Scheme 49). Compounds 138i-138l and intermediates 
136d-136e and 137d-137e were analysed by ELISA (Table 33). 
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Scheme 49: (i) B2(pin)2, (PPh3)2PdCl2, KOAc, 1,4-dioxane, DMSO, 90 
o
C, 15 h; (ii) 4-bromo-3-
methylphenol or 4-bromo-3-chlorophenol, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, MW, 20 min; (iii) 4-
chlorophenol, K2CO3, DMF, 120 
o
C, MW, 30 min; (iv) Fe, AcOH, 30 
o
C, 2 h; (v) 1-bromo-4-
fluorobenzene, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h 
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Table 33: ELISA data for 1,2,3-trisubstituted benzene derivatives 138i-138l and their intermediates 
(conducted by Dr Yan Zhao at the NICR) 
 
 
ID R R’ MDMX 
IC50 
(µM)
a
 
MDM2 
IC50 
(µM)
a
 
Ratio 
(MDMX : 
MDM2) 
LE
b 
LipE
b,d 
 
138i 
 
H 
 
 
40.2 
 
137 
 
3.41 
 
0.20 
 
- 2.19 
 
138j 
 
H  
 
42%
c 
 
44%
c
 
 
- 
 
- 
 
- 
 
138k 
 
Me 
 
 
49.0 
 
43.0 
 
0.88 
 
0.20 
 
- 2.28 
 
138l 
 
Cl 
 
 
23.7 
 
52.9 
 
2.23 
 
0.21 
 
- 2.13 
136d Me NO2 43%
c
 51.5 - - - 
136e Cl NO2 54.5 20.1 0.37 0.23 - 1.24 
137d Me NH2 33%
c
 99.1 - - - 
137e Cl NH2 58.4 56.6 0.97 0.25 + 0.54 
(a) n = 1; (b) With respect to MDMX; (c) 200 µM; (d) LipE = pIC50 – clogD7.4 (clogD values from 
StarDrop) 
 
Methylation at the 2-position of the 4-fluorophenyl ring (138i) and 4-hydroxyphenyl 
ring (138k) reduced potency for MDMX 2-fold compared to the non-methylated 
analogue (cf. Table 31, 138c). Chlorination on the 4-fluorophenyl ring (138j) abolished 
activity against both proteins but the 2-chlorophenol derivative (138l) had similar 
activity to 138c. With no fluorophenyl substituent, intermediates with a 2-methylphenol 
ring (136d and 137d) were completely inactive against MDMX, but the corresponding 
2-chlorophenol compounds (136e and 137e) had modest MDMX activity. Coupling of 
the 4-fluorophenyl ring greatly increased the activity of the 2-methylphenol 
intermediate 137d and doubled the potency of the 2-chlorophenol compound 137e 
against MDMX. The data suggest that a 2-chloro ligand on the phenol ring was making 
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a favourable interaction, possibly in the binding domain highlighted in Figure 48, as 
intermediates with a 2-chlorophenol ring were active, whereas the corresponding 2-
methylphenol compounds were not. Attaching the 4-fluorophenyl ring improved 
binding affinity in both derivatives, generating similarly active compounds. This could 
be because the 4-fluorophenyl ring affected the binding orientation of the compounds, 
so that any substituent at the 2-position of the phenol ring no longer made a favourable 
interaction with the protein.  
 
5.3.1.1 Interchanging the Hydroxy and Fluoro Groups of 138c 
 
SAR studies had shown that the p-hydroxy group was important for binding potency 
against MDMX and MDM2. It was of interest to synthesise analogues with the fluoro 
and hydroxy groups of active compounds interchanged to investigate the binding 
orientation of the trisubstituted benzenoid compounds (Figure 49). If the compounds 
had one fixed binding orientation in the target protein, interchanging the position of 
these groups should abolish target potency.  
 
 
 
Figure 49: New targets to investigate the binding orientation of the trisubstituted benzenoid compounds 
with the fluoro and hydroxy substituents interchanged 
 
Starting from 135a, Suzuki coupling with 4-fluorobenzeneboronic acid and iron-
mediated nitro reduction gave aniline 137f as the precursor to compounds 138m-138p 
(Scheme 50). 
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Scheme 50: (i) 4-Fluorobenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 20 min; (ii) 
Fe, AcOH, 40 
o
C, 2 h 
 
The attempted synthesis of 138m and the synthesis of 138n proceeded via reduction of 
the corresponding amides. Trial amide couplings with 3-bromo-2-methylaniline (146) 
and methyl 4-methoxybenzoate resulted in no reaction following irradiation at 120 
o
C 
(LC-MS analysis). However, addition of 
i
PrMgCl.LiCl to this reaction at room 
temperature led to rapid conversion to amide 147a and these conditions were also 
effective with ethyl 4-hydroxybenzoate to give 147b. Suzuki coupling with 4-
fluorobenzeneboronic acid and reduction of the amide with lithium aluminium hydride 
gave 149a but not 149b (Scheme 51). Compound 147b was taken forward to the Suzuki 
coupling without purification to give 148b in 93% yield from 146. 
 
 
 
Scheme 51: (i) Methyl 4-methoxybenzoate or ethyl 4-hydroxybenzoate, 
i
PrMgCl.LiCl (5.0 equiv.), 1,2-
DME, RT, 30 min; (ii) 4-fluorobenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 20 
min; (iii) LiAlH4, THF, 0 
o
C-RT, 48 h 
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Attempts to demethylate 149a using boron tribromide failed to yield 149b due to rapid 
debenzylation of the product (Scheme 52). For this reason, target compounds 149b and 
138m were abandoned. 
 
 
 
Scheme 52: (i) BBr3, DCM, 0 
o
C-RT, o/n 
 
The amide coupling conditions in Scheme 51 were similarly effective for coupling ethyl 
4-hydroxybenzoate, ester 153 or methyl 4-methoxybenzoate with aniline 137f to give 
amides 151a, 151b or 151c, respectively (Scheme 53). 
 
 
 
Scheme 53: (i) Ethyl 4-hydroxybenzoate or 153 or methyl 4-methoxybenzoate, 
i
PrMgCl.LiCl, 1,2-DME, 
RT, 30 min 
 
Attempts to reduce the amide of 151b or 151c using lithium aluminium hydride failed 
to yield 138n or 138q, respectively, so these compounds were synthesised via reductive 
amination of the required aldehydes. Starting from methyl 4-aminobenzoate (152), 
sulfonylation with Tf2O gave ester 153. Reduction of the ester was accomplished using 
DIBAL-H to afford alcohol 154 and oxidation with DMP gave aldehyde 155 (Scheme 
54).  
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Scheme 54: (i) Tf2O, NEt3, DCM, RT, 90 min; 2.5 M aq. NaOH, MeOH (1:3), RT, 40 min; (ii) DIBAL-
H, PhMe, -78 
o
C-RT, o/n; (iii) DMP, DCM, RT, 2 h 
 
Reductive amination of either aldehyde 155 or 4-anisaldehyde with 137f in TFE gave 
target compounds 138n and 138q, respectively (Scheme 55). 
 
 
 
Scheme 55: (i) 155 or 4-anisaldehyde, TFE, 40 
o
C, o/n; NaBH4, TFE, RT, 1 h 
 
Attempted Buchwald coupling of 4-bromophenol or aryl bromide 120 with 137f to 
synthesise 138o and 138p, respectively gave no reaction after 3 h at 120 
o
C. Verkade 
had postulated that chelation of the phenoxide (or sulfonamide) anion to the palladium 
inhibited oxidative addition to the C-Br bond.
133
 Verkade had identified lithium 
hexamethyldisilazide (LiHMDS) as a suitable base when protic functional groups were 
present in the aryl halide, suggesting that migration of a trimethylsilyl group from the 
base to the anion would act as an in situ protecting group, preventing coordination to the 
palladium.
133
 However, attempts to couple 137f with 4-bromophenol under these 
conditions resulted in poor conversion and no product was isolated. Coupling of 137f 
with 4-bromoanisole isolated 138r and demethylation with boron tribromide gave 138o 
(Scheme 56). 
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Scheme 56: (i) 4-Bromoanisole, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h; (ii) BBr3, DCM, 0 
o
C-RT, 2 h 
 
To synthesise 138p, aniline 137f was coupled with 1-bromo-4-nitrobenzene. Using 
acetonitrile produced a mixture of by-products but switching to toluene
134, 135
 gave 138s 
in 87% yield. Reduction of the nitro group was accomplished with iron in glacial acetic 
acid and sulfonylation was achieved selectively on the terminal amino group of 138t 
using Tf2O to give 138p in 35% yield (Scheme 57). The steric bulk of the 4-
chlorophenoxy substituent blocked access to the secondary amino group of 138t. No 
base was required to achieve full conversion, possibly due to the secondary amino 
group acting as a base. Compounds 138n-138p and several intermediates were screened 
by ELISA against MDMX and MDM2 (Table 34). 
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Scheme 57: (i) 1-Bromo-4-nitrobenzene, Pd2dba3, XPhos, K2CO3, PhMe, 120 
o
C, 15 h; (ii) Fe, AcOH, 50 
o
C, o/n; (iii) Tf2O, DCM, 0 
o
C, 10 min 
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Table 34: ELISA data for 1,2,3-trisubstituted benzene derivatives 138n-138r, 138t, 148a, 148b, 149a 
and 151a-151c (conducted by Dr Yan Zhao at the NICR) 
 
 
ID R R’ MDMX 
IC50 
(µM)a 
MDM2 
IC50 
(µM)a 
Ratio 
(MDMX : 
MDM2) 
LEb LipEb,d 
 
138n  
 
 
5.23 
 
10.0 
 
1.91 
 
0.20 
 
+ 0.36 
 
138o 
 
 
 
19.2 
 
3.82 
 
0.20 
 
0.22 
 
- 1.51 
 
138p 
  
 
6.45 
 
10.5 
 
1.63 
 
0.20 
 
- 1.48 
 
138q 
 
 
 
34%c 
 
0%c 
 
- 
 
- 
 
- 
 
138r 
  
 
198 
 
1517 
 
7.66 
 
0.17 
 
- 3.09 
 
138t   
 
33.9 
 
96.2 
 
2.84 
 
0.21 
 
- 0.41 
 
148a 
 
Me 
 
 
1.1%c 
 
16%c 
 
- 
 
- 
 
- 
 
148b 
 
Me 
 
 
20%c 
 
25%c 
 
- 
 
- 
 
- 
 
149a 
 
Me  
 
0%c 
 
0%c 
 
- 
 
- 
 
- 
 
151a   
 
22.0 
 
69.8 
 
3.17 
 
0.21 
 
- 0.97 
 
151b  
 
 
107 
 
13.5 
 
0.13 
 
0.14 
 
- 2.10 
 
151c   
 
43%c 
 
21%c 
 
- 
 
- 
 
- 
(a) n = 1; (b) With respect to MDMX; (c) 200 µM; (d) LipE = pIC50 – clogD7.4 (clogD values from 
StarDrop) 
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Interchanging the fluoro and hydroxy (or trifluoromethylsulfonamido) substituents had 
no detrimental effect on activity against MDMX or MDM2, with 138n and 138p 
becoming the first trisubstituted benzenoid compounds with an IC50 below 10 µM 
against MDMX. There was a notable similarity in SARs between this series of 
compounds and those in which the fluoro and hydroxy groups were in opposite 
positions (cf. Table 31). A hydrogen bond donor was essential for activity; removing the 
methyl group from 138r afforded a 10-fold gain in activity against MDMX and a 400-
fold increase in MDM2 activity (138o). Compounds 138q, 148a, 149a and 151c were 
completely inactive against both proteins. The aniline (138t) was two-fold less active 
against MDMX than 138o and five-fold less potent than the sulfonylated derivative 
(138p). Compound 148b was inactive against both proteins despite the presence of a 
hydroxy group. The corresponding derivative with a 4-chlorophenoxy group (151a) did 
have activity against MDMX and MDM2, highlighting the significance of this 
substituent for potency.  
 
5.3.2 Optimising the Drug-like Properties of 138c 
 
Single digit micromolar MDMX inhibitors had now been identified with a key 
hydrogen bond donor on one side of a 4-chlorophenoxy substituent. Compound 138n 
had 4-fold greater potency against MDMX than 138c, possibly related to the increased 
lipophilicity of 138n (Table 35). This suggested that the increased activity of 138n was 
the result of increased hydrophobic interactions rather than the interaction of a 
functional group with the protein. A more detailed SAR around the hydroxyphenyl ring 
in 138c had also been compiled compared with the trifluoromethylsulfonamide in 138n. 
For these reasons, 138c was selected as the lead compound for further optimisation. 
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Table 35: Comparison of active compounds 138c and 138n 
 
ID Structure MW 
(g/mol) 
clogP
a 
clogD7.4
b 
MDMX 
IC50 
(µM)
c
 
MDM2 
IC50 
(µM)
c
 
LE
d 
138c 
 
405 7.5 6.2 19.0 23.2 0.223 
138n 
 
550 8.8 4.9 5.23 10.0 0.196 
(a) Values from ChemDraw; (b) Values from StarDrop; (c) n = 1; (d) With respect to MDMX 
 
5.3.2.1 Synthesis of 3-Hydroxyheterocycles 183a and 183b 
 
Replacing the hydroxyphenyl ring of 138c with a 3-hydroxyisoxazole or a 3-
hydroxypyrazole was predicted to increase aqueous solubility, as they both have greater 
polarity than a hydroxyphenyl ring. SAR studies around the hydroxyphenyl ring had 
indicated a trend between the acidity of the hydrogen bond donor at the para-position 
and target potency. 3-Hydroxyisoxazoles are approximately 10,000-fold more acidic 
(pKa 5-6) than phenols (pKa 10.0) and 3-hydroxypyrazoles are also more acidic than 
phenols,
136, 137
 so it was predicted that this ring substitution would enhance target 
potency (Figure 50). 
 
 
 
Figure 50: Replacing the hydroxyphenyl ring in 138c with a 3-hydroxyisoxazole (183a) or 3-
hydroxypyrazole (183b) 
 
5-Aryl-3-hydroxyisoxazoles and the corresponding pyrazoles can be synthesised by a 5-
endo-dig cyclisation of the intermediate derived from the reaction between a propiolate 
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ester and hydroxylamine or hydrazine respectively.
138
 Sonogashira coupling of methyl 
propiolate and subsequent cyclisation with hydroxylamine would complete synthesis of 
the 3-hydroxyisoxazole (Scheme 58). 
 
 
 
Scheme 58: Synthesis of a 3-hydroxyisoxazole ring via Sonogashira coupling and 5-endo-dig cyclisation 
 
Optimisation of Sonogashira coupling conditions used 4-bromoanisole (156) as a 
coupling partner. Standard coupling conditions with methyl propiolate gave the desired 
methyl 4-methoxyphenylpropiolate (157) in 7% isolated yield when the reaction was 
conducted in THF (Table 36). Attempts in 1,4-dioxane, acetonitrile and DMF were 
comparatively less clean than with THF (LC-MS analysis). The low yield was possibly 
due to the poor reactivity of 4-bromoanisole, the relatively high electron density of 
which would have slowed the rate of oxidative addition of palladium across the C-Br 
bond, and the poor reactivity of methyl propiolate. Sonogashira has described high-
yielding couplings of aryl bromides using electron-rich phosphine ligands, explaining 
that the high electron density of the catalyst accelerated oxidative addition across the C-
Br bond.
139
 However, when (PPh3)2PdCl2 was replaced by catalysts possessing strongly 
electron-donating ligands (Table 36, entries 5-7), all reactions gave poor conversion by 
LC-MS and produced several unidentified impurities.  
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Table 36: Attempted optimisation of the Sonogashira coupling of 4-bromoanisole (156) with methyl 
propiolate
a 
 
Entry
 
Catalyst Solvent % Yield
b 
1 (PPh3)2PdCl2 THF 7 
2 (PPh3)2PdCl2 1,4-Dioxane 0 
3 (PPh3)2PdCl2 MeCN 0 
4 (PPh3)2PdCl2 DMF 0 
5 Pd(dtbpf)Cl2 THF 0 
6 (MeCN)2PdCl2, P
t
Bu3 THF 0 
7 (PhCN)2PdCl2, P
t
Bu3 THF 0 
(a) 156 (200 mg, 1.0 equiv.), methyl propiolate (1.5 equiv.), catalyst (5.0 mol%), ligand (10.0 mol%), CuI 
(5.0 mol%) and Et3N (3.0 equiv.) at 0.3 M; (b) Isolated yield 
 
Sonogashira coupling of 156 with TMS-acetylene, in the presence of 
(PhCN)2PdCl2/P
t
Bu3 and CuI gave just 10% isolated yield of 159, following desilylation 
with potassium carbonate. Finke has described the use of ZnCl2 as a co-catalyst in 
Sonogashira couplings in place of CuI, explaining that ZnCl2 did not facilitate 
homocoupling of the acetylene substrate (Scheme 59).
140
 This meant that larger 
catalytic amounts of ZnCl2 could be used without the risk of homocoupling occurring. 
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Scheme 59: Sonogashira coupling with an aryl halide (A) and a terminal alkyne (B) to give a substituted 
alkyne (C) and potential homocoupling to give a conjugated acetylene (D).
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Coupling 156 with TMS-acetylene using ZnCl2 gave full conversion of the aryl bromide 
in under 3 h. Under the same conditions with CuI, full conversion was not achieved 
until after 24 h and a greater number of impurities were produced. Subsequent 
desilylation with TBAF gave 159 in 68-80% yield (Scheme 60). 
 
 
 
Scheme 60: Optimised Sonogashira coupling conditions 
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Deprotonation of 159 with LDA, followed by addition of methyl chloroformate, gave 
propiolate ester 157 in 68% overall yield. Formation of the 3-hydroxyisoxazole ring 
followed the procedure outlined by Iwai, using hydroxylamine hydrochloride in 
aqueous base.
138
 The reaction mechanism involves addition to the propiolate ester 
carbonyl carbon by the amino group of hydroxylamine to give hydroxamic acid 160. A 
5-endo-dig cyclisation forms isoxazol-3(2H)-one 161a and subsequent tautomerisation 
completes the transformation (Scheme 61). Theoretical studies of the tautomeric 
equilibria of 3-hydroxyisoxazoles have revealed that the enol tautomer (162a) 
predominates over the oxo form (161a) in aqueous solution.
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Scheme 61: Reaction mechanism for the formation of isoxazole 162a from ester 157 
 
Cyclisation of 160 at room temperature gave 162a in 35% yield. 
1
H NMR analysis 
indicated incomplete cyclisation of hydroxamic acid 160. One impurity had an identical 
mass and a similar 
1
H NMR spectrum to the product, suggesting it was the 
regioisomeric isoxazole 162b. This was predicted to form when hydroxylamine attacked 
ester 157 by conjugate addition instead of 1,2-addition (Scheme 62). The resulting α,β-
unsaturated ester 163b would then undergo a base-mediated 5-exo-trig cyclisation to 
form 162b. 
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Scheme 62: Proposed mechanism for the formation of 162b 
 
Cyclisation at 0 
o
C instead of at room temperature gave full conversion to a mixture of 
isoxazole 162a and hydroxamic acid 160. None of the regioisomeric isoxazole 162b 
was observed and subsequent heating fully converted 160 to 162a in 93% yield 
(Scheme 63). 
 
 
 
Scheme 63: Final reaction conditions for the formation of ester 157 and isoxazole 162a 
 
When the optimised Sonogashira coupling conditions were applied to aryl bromide 
135a, multiple impurities were generated. Using conditions described by Shimada, aryl 
bromide 139 was coupled with TIPS-acetylene using CuI to give 164 in excellent yield 
after 1 h at 70 
o
C.
143
 Analogous coupling with ZnCl2 gave no conversion after the same 
time period. Aromatic substitution with 4-chlorophenol generated an impurity which 
was identified by 
1
H NMR analysis as the de-silylated biaryl ether 165. The crude 
material was therefore mixed with TBAF to complete formation of 165. Tin-mediated 
reduction of the nitro group proceeded quantitatively to 166, but Buchwald coupling 
using conditions previously described for compound 138c (cf. Scheme 44), gave an 
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indistinguishable mass of impurities (Scheme 64). It was clear that the terminal 
acetylene group was not compatible with the coupling conditions. 
 
 
 
Scheme 64: (i) TIPS-acetylene, (PPh3)2PdCl2, CuI, 
i
Pr2NH, THF, 70 
o
C, 1 h; (ii) 4-chlorophenol, K2CO3, 
MeCN, 90 
o
C, MW, 1 h; (iii) TBAF, THF, RT, 30 min; (iv) SnCl2.2H2O, EtOH, 70 
o
C, 30 min; (v) 1-
bromo-4-fluorobenzene, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h 
 
The terminal acetylene group of 165 was therefore converted to the 3-hydroxyisoxazole. 
Formation of propiolate ester 168 proceeded in high yield, but formation of isoxazole 
169 proceeded in a poor yield of 28%. The major impurity was phenol 170, formed by 
displacement of 4-chlorophenoxide by the excess sodium hydroxide (Scheme 65).  
 
 
 
Scheme 65: (i) 
i
Pr2NH, n-BuLi, THF, -78 
o
C; ClCO2Me, THF, -78 
o
C-RT; (ii) H2N-OH.HCl, 3 M aq. 
NaOH, 0-70 
o
C; Conc. HCl, 0 
o
C 
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Reduction of the nitro group of 169 proceeded as before; however, Buchwald coupling 
generated several impurities and purification was unable to isolate sufficient material 
for complete characterisation and screening. Buchwald coupling of aniline 171 with an 
excess of 1-bromo-4-fluorobenzene did not prove to be scaleable due to the generation 
of multiple impurities. This was possibly the result of dimerisation of the starting 
material and further coupling of 172 and 171 (Scheme 66). 
 
 
 
Scheme 66: (i) 1-Bromo-4-fluorobenzene (10 equiv.), Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h 
 
Coupling of 171 with 4-fluoroaniline gave compound 173. A large excess of 4-
fluoroaniline was used to prevent dimerisation of 171. However, column 
chromatographic purification could achieve only partial separation from the excess of 4-
fluoroaniline, and the purity of 173 never exceeded 70% (
1
H NMR analysis). Attempts 
to convert 173 to aryl iodide 174 were unsuccessful and generated only impurities 
(Scheme 67).  
 
 
 
Scheme 67: (i) 4-Fluoroaniline, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h; (ii) KI, NaNO2, 
AcOH, CSA, RT, dark 
 
Buchwald coupling of aryl bromide 135a with 4-fluoroaniline gave side-product 175 
(
1
H NMR analysis) (Scheme 68). This was possibly due to the electron-withdrawing 
influence of the nitro group facilitating substitution at the aryl chloride, as this reaction 
was not observed when coupling 4-fluoroaniline with 171 under analogous conditions. 
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Scheme 68: (i) 4-Fluoroaniline, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h 
 
Acetylene 165 was treated with n-BuLi before mixing with TIPS-chloride to give 176 
and reduction of the nitro group gave aniline 177. Using sodium tert-butoxide in place 
of potassium carbonate, Buchwald coupling of 177 gave the desired product 178 in high 
yield. Removal of the TIPS group with TBAF gave acetylene 167 (Scheme 69). 
 
 
 
Scheme 69: (i) n-BuLi, THF, -78 
o
C, 15 min; TIPSCl, THF, RT, 2 h; (ii) SnCl2.2H2O, EtOH, 70 
o
C, 15 
min; (iii) 1-bromo-4-fluorobenzene, Pd2dba3, XPhos, NaO
t
Bu, MeCN, 120 
o
C, MW, 3 h; (iv) TBAF, 
THF, RT, 20 min 
 
Treatment of 167 with LDA followed by methyl chloroformate generated carbamate 
179 on a 20 mg scale reaction, with acylation occurring on the acetylene and aniline 
nitrogen. However, this result was not reproducible, with carbamate 180 being the only 
product isolated on a 250 mg scale with increased equivalents of LDA and methyl 
chloroformate (Scheme 70). 
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Scheme 70: (i) 167 (20 mg, 1.0 equiv.), 
i
Pr2NH (1.1 equiv.), n-BuLi (1.1 equiv.), THF (1.9 mL), -78 
o
C to 
RT to -78 
o
C, 20 min; ClCO2Me (1.1 equiv.), THF, -78 
o
C-RT; (ii) 167 (250 mg, 1.0 equiv.), 
i
Pr2NH (1.3 
equiv.), n-BuLi (1.3 equiv.), THF (13.3 mL), -78 
o
C to RT to -78 
o
C, 20 min; ClCO2Me (2.5 equiv.), 
THF, -78 
o
C-RT 
 
Carbamate 180 was converted to aniline 167 by refluxing in sodium hydroxide. 
Protection of the aniline nitrogen with Boc2O, followed by acylation of the terminal 
acetylene using LDA and methyl chloroformate, gave ester 182. Ring-closure with 
hydroxylamine and quenching with concentrated HCl simultaneously formed the 
isoxazole ring and removed the Boc group to give 183a. Treating 182 with hydrazine 
hydrate formed 183b (Scheme 71).  
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Scheme 71: (i) 2 M aq. NaOH, MeOH (1:1), 70 
o
C, 8 h; (ii) Boc2O, DMAP, MeCN, 50 
o
C, 3 h; (iii) 
i
Pr2NH, n-BuLi, THF, -78 
o
C to 0 
o
C to -78 
o
C, 20 min; ClCO2Me, THF, -78 
o
C-RT, 20 min; (iv) H2N-
OH.HCl, NaOH, 0-60-0 
o
C, 4 h; Conc. HCl, 0-50 
o
C, 1 h; (v) H2N-NH2.H2O, 0-60-0 
o
C; Conc. HCl, 0-50 
o
C, 1 h 
 
5.3.2.2 Formation of Triazole 185 and Carboxylic Acid 187 
 
Huisgen-style cycloaddition of acetylene 166 with TMS-azide and catalytic 
CuSO4.5H2O and sodium ascorbate did not proceed beyond 70% conversion (LC-MS 
analysis) and adding more CuSO4 and sodium ascorbate only produced impurities. 
Cycloaddition of acetylene 181 using CuI also did not reach full conversion and 
produced more impurities than the reaction using CuSO4 and sodium ascorbate. The 
incomplete conversion was possibly due to chelation of the copper to the aniline and 
triazole nitrogen atoms, preventing further catalysis from occurring. With an excess of 
CuSO4 and sodium ascorbate, acetylene 181 was converted to triazole 184 (Table 37). 
Removal of the Boc group with TFA gave triazole 185 (Scheme 72). 
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Table 37: Optimisation of the cycloaddition of acetylenes 166 and 181 with TMS-azide
a 
 
 
Entry ID R Cu source 
(equiv.) 
Reducing 
agent 
(equiv.) 
Solvent Temp. 
(
o
C) 
Results 
1 166 NH2 CuSO4.5H2O 
(5 mol%) 
Sodium 
ascorbate 
(10 mol%) 
EtOH, 
H2O (1:1) 
25 No product 
2 181 
 
CuI (20 
mol%) 
- DMF, 
MeOH 
(9:1) 
100 No product 
3 181 
 
CuSO4.5H2O 
(2.0) 
Sodium 
ascorbate 
(3.0) 
EtOH, 
H2O (1:1) 
25 184 formed, 
73% yield 
(a) 166 or 181 (35-100 mg, 1.0 equiv) and TMS-azide (2.0 equiv.) at 0.5 M 
 
 
 
Scheme 72: (i) TMS-azide, CuSO4.5H2O, sodium ascorbate, 50% H2O, EtOH, 50 
o
C, o/n; (ii) 17% TFA, 
DCM, RT, 1 h 
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Hydrolysis of ester 182 with lithium hydroxide gave carboxylic acid 186 and removal of 
the Boc group with TFA generated 187 (Scheme 73). Treatment of 182 with TFA 
removed the Boc group to give propiolate ester 188. All carboxylic acids, triazoles, 3-
hydroxyisoxazoles and the corresponding pyrazoles were subsequently screened by 
ELISA against MDMX and MDM2 (Table 38). 
 
 
 
Scheme 73: (i) LiOH.H2O, 50% THF, H2O, 60 
o
C, 2 h; (ii) 17% TFA, DCM, RT, 1 h 
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Table 38: ELISA data for 1,2,3-trisubstituted benzene derivatives 183a, 183b and 184-187 (conducted by 
Dr Yan Zhao at the NICR) 
 
 
ID R R’ MDMX 
IC50 
(µM)
a 
MDM2 
IC50 
(µM)
a 
Ratio 
(MDMX : 
MDM2) 
LE
b 
LipE
b,c 
 
183a 
 
 
H 
 
30.3 
 
29.1 
 
0.96 
 
0.221 
 
- 0.61 
 
183b 
 
 
H 
 
27.9 
 
 
25.0 
 
0.90 
 
0.223 
 
- 0.08 
184 
  
67.8 
 
73.7 1.09 0.168 - 1.24 
185 
 
H 29.1 
 
39.3 1.35 
 
0.230 + 0.02 
 
186 
 
 
 
104 
 
 
46.9 
 
0.45 
 
0.161 
 
+ 1.92 
 
187 
 
 
H 
 
77.3 
 
 
47.3 
 
0.61 
 
0.209 
 
+ 2.09 
(a) n = 1; (b) With respect to MDMX; (c) LipE = pIC50 – clogD7.4 (clogD values from StarDrop) 
 
Replacing the hydroxyphenyl ring of 138c with a 3-hydroxyisoxazole (183a), 3-
hydroxypyrazole (183b) or a 1,2,3-triazole (185) did not compromise potency against 
MDMX or MDM2. None of the compounds increased potency relative to 138c (cf. 
Table 31) against either protein but they did significantly improve LipE. Only 
compounds possessing an acidic hydrogen bond donor motif had any activity against 
MDMX or MDM2. Propiolate esters 179 and 188 and acetylenes 167 and 178 were all 
weaker inhibitors (IC50 > 160 µM) against both targets. Compound 169 gave an IC50 of 
237 µM against MDMX and only 31% inhibition at 200 µM against MDM2, despite the 
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presence of a 3-hydroxyisoxazole moiety. Compounds with carbamate-protected 
anilines (179, 184 and 186) were less active than their unprotected analogues.  
 
5.3.2.3 Replacing the 4-Chlorophenoxy Ring with a 6-Chloroindol-3-yl 
Ring  
 
Imidazole-based MDM2 inhibitors have described the 6-chloroindol-3-yl ring as an 
optimal substituent for binding into the p53-W23 pocket.
104
 The 6-chloroindole ring 
exploits the hydrogen bond formed between the indole NH of tryptophan and the 
carbonyl oxygen of MDM2-L54. The crystal structure of compound 50 with MDMX 
has shown the 6-chloroindol-3-yl ring makes an analogous interaction with MDMX-
M53 (Figure 51).
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Figure 51: Crystal structure of 50 (green) in the p53 binding domain of MDMX (yellow). The p53 
binding subpockets F19, W23 and L26 are highlighted. Image modified using CCP4mg (resolution, 1.5 
Å; PDB code: 3LBJ)
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It was of interest to see if replacing the 4-chlorophenoxy substituent in the 1,2,3-
trisubstituted benzenoid series with a 6-chloroindol-3-yl ring, could afford a similar 
enhancement in activity against MDMX and MDM2 (Figure 52). 
 
p53-L26 
p53-W23 
p53-F19 
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Figure 52: Replacing the 4-chlorophenoxy group in 138c with a 6-chloroindol-3-yl ring (195) 
 
The proposed synthesis of 195 started from 2-bromo-3-nitroanisole (189). Suzuki 
coupling with an indolyl substituent, followed by demethylation and sulfonylation 
would form triflate 192. Suzuki coupling with 4-hydroxybenzeneboronic acid, reduction 
of the nitro group and Buchwald coupling with 1-bromo-4-fluorobenzene completes the 
synthesis (Scheme 74). 
 
 
 
Scheme 74: Retrosynthesis of indole 195 
 
Starting from 6-chloroindole (199), silylation using TIPS-chloride with n-BuLi formed 
200 in high yield. An attempt was made to synthesise boronic ester 201 directly 
following the synthesis described by Del Grosso using B-chlorocatecholborane (196).
144
 
In the presence of aluminium chloride, the chloro group from B-chlorocatecholborane-
triethylamine adduct 197 is abstracted, forming borenium cation 198 that poorly 
nucleophilic indoles will attack at C-3 (Scheme 75).
144
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Scheme 75: The formation of borenium cation 102 by halide abstraction with aluminium chloride
144
 
 
However, under these conditions, no reaction was observed between indole 200 and 198 
even after heating at 50 
o
C. The authors had reported that N-silylated indoles were 
inadequately nucleophilic due to the negligible electron donation to the indole ring by 
the silyl group. Only indoles substituted on nitrogen by electron-donating substituents, 
e.g. alkyl groups, were sufficiently reactive.
144
  
 
Bromination of 200 using N-bromosuccinimide (NBS) proceeded in excellent yield and 
regioselectively at C-3 (NMR analysis) to give 202 (Scheme 76).  
 
 
 
Scheme 76: (i) n-BuLi, THF, -78 
o
C, 1 h; TIPSCl, THF, -78 
o
C-RT, 1 h; (ii) 198, AlCl3, Et3N, DCM, 0 
o
C; Et3N, pinacol, RT-50 
o
C; (iii) NBS, THF, -78 
o
C, 2 h  
 
Borylation of 202 using B2(pin)2 gave 201, but only in 23% yield. Yang had previously 
described a high-yielding synthesis of 3-indolylboronic acids from the corresponding 3-
bromoindoles via halogen-lithium exchange and addition of a trialkylborate followed by 
hydrolysis to the desired boronic acid (Scheme 77).
145
 
 
 
155 
 
 
 
Scheme 77: (i) n-BuLi, THF, -78 
o
C; (ii) B(O
i
Pr)3, THF, -78 
o
C; 50% MeOH, H2O, -78 
o
C-RT
145
 
 
Bromoindole 202 underwent complete halogen-lithium exchange upon treatment with 
n-BuLi within 5 min at -78 
o
C. Addition of triisopropylborate gave a 5:2 ratio of 
boronic acid 203 and indole 200 (LC-MS analysis). However, isolation of the pure 
product resulted in rapid deborylation to 200 (
1
H NMR analysis). Halogen-lithium 
exchange followed by addition of methoxyboronic acid pinacol ester (MeOB(pin)) gave 
a 2:1 ratio of 201 and 200 but the product could be isolated in pure form without any 
degradation observed. Reducing the equivalents of MeOB(pin) from three to two gave a 
201:200 ratio of 1:6. Increasing the equivalents of MeOB(pin) from three to six restored 
the 201:200 ratio to 2:1 (Table 39).  
 
 
 
Table 39: Optimisation of the borylation of 202 via halogen-lithium exchange 
 
Entry Borate (equiv.) Target 
product 
Product:200 
Ratio
a 
Results 
1 B(O
i
Pr)3 (3.0) 203 5:2 Product not isolated 
2 MeOB(pin) (3.0) 201 2:1 201 isolated, 56% 
yield. 
3 MeOB(pin) (2.0) 201 1:6 Product not isolated 
4 MeOB(pin) (6.0) 201 2:1 Product not isolated 
(a) LC-MS UV trace 
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Borylation of anisole 189 with B2(pin)2 and (PPh3)2PdCl2 proceeded to > 90% 
conversion by LC-MS with low levels of homocoupling observed. Replacing 
(PPh3)2PdCl2 with Pd(dppf)Cl2.DCM produced a greater number of impurities, as did 
switching from 1,4-dioxane to DMF or DMSO. Increasing the equivalents of 
(PPh3)2PdCl2 accelerated the reaction but also increased the levels of homocoupling. 
Increasing the equivalents of B2(pin)2 enhanced the reaction rate but homocoupling 
remained at low levels (Table 40).  
 
 
 
Table 40: Optimisation of the borylation of anisole 189
a 
 
Entry Catalyst (mol%) Solvent B2Pin2 
Equiv. 
Results 
1 (PPh3)2PdCl2 (3.0) 1,4-Dioxane 1.5 No product. 
2 Pd(dppf)Cl2.DCM (3.0) 1,4-Dioxane 1.5 No product. 
3 (PPh3)2PdCl2 (3.0) DMF 1.5 No product. 
4 (PPh3)2PdCl2 (3.0) DMSO 1.5 No product. 
5 (PPh3)2PdCl2 (5.0) 1,4-Dioxane 1.5 No product. 
6 (PPh3)2PdCl2 (3.0) 1,4-Dioxane 2.0 201 isolated, 78% yield. 
(a) 189 (100 mg, 1.0 equiv.) and KOAc (3.0 equiv.) at 0.5 M for at least 24 h by conventional heating 
 
Suzuki coupling of 202 and 204 resulted in total deborylation of 204 within 30 min at 
120 
o
C with no observed product formation. Switching from Pd(dtbpf)Cl2to Pd(PPh3)4 
had no effect on the level of deborylation under similar conditions. Reducing the 
temperature to 80 
o
C and heating conventionally significantly reduced deborylation and 
formed the desired product 205 (
1
H NMR analysis). However, difficulties with 
purification from the excess of boronic ester 204 meant that the product could not be 
isolated in pure form and the yield was poor. Reducing the equivalents of 
Pd(dtbpf)Cl2slowed the rate of the reaction and did not affect the levels of deborylation 
observed (Table 41). 
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Table 41: Optimisation of the Suzuki coupling between 202 and 204
a 
 
Entry Catalyst (mol%) Heating 
method 
Temp. 
(
o
C) 
Time 
(min) 
Results 
1 Pd(dtbpf)Cl2 
(5.0) 
MW 120 30 No product 
2 Pd(PPh3)4 (5.0) MW 120 30 No product 
3 Pd(dtbpf)Cl2 
(5.0) 
Conventional 120 30 No product 
4 Pd(dtbpf)Cl2 
(5.0) 
Conventional 80 180 205 isolated, ~35% 
yield (80% purity) 
5 Pd(dtbpf)Cl2 
(1.5) 
Conventional 80 180 No product 
(a) 202 (30 mg, 1.0 equiv.), 204 (1.5 equiv.), 2 M aq. Na2CO3 (2.0 equiv.) at 0.2 M 
 
It was becoming clear that facile debromination and deborylation, both of the indole 
substituent and the benzenoid scaffold, were severely abrogating yields, both in the 
formation of these coupling partners and in the subsequent attempt to join them together 
by Suzuki coupling. An alternative coupling strategy was therefore needed and it was 
decided to investigate nucleophilic aromatic substitution.  
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5.3.2.4 Replacing the 4-Chlorophenoxy Ring with a 6-Chloroindol-3-yl 
Ring by the SNAr Reaction 
 
There are no reported examples of nucleophilic aromatic substitutions in which an 
indole attacking at the C-3 position is the nucleophile. There are literature examples of 
stabilised carbanion nucleophiles being used in this transformation such as 1,3-
dicarbonyls
146, 147
 or 9H-fluorene anions,
148
 with high yields being obtained.  
 
Reaction of indole 199 with PMB-chloride in DMF gave 206 in high yield (Scheme 
78). An electron-donating protecting group was selected to increase the indole’s 
nucleophilicity.  
 
 
Scheme 78: (i) PMB-Cl, NaH, DMF, 80 
o
C, 2 h 
 
2-Fluoronitrobenzene (207) was selected as a model system. Attempts to couple indole 
199 or 206 with 207 using microwave-assisted irradiation in acetonitrile at 120 
o
C gave 
no reaction after 2 h. 
 
Indole 199 was deprotonated using either n-BuLi, sodium hydride or methylmagnesium 
chloride (MeMgCl) before addition of 207. The n-BuLi and sodium hydride reactions 
did not proceed at 0 
o
C or room temperature, but at 60 
o
C reacted to give the N-arylated 
product 208 with 100% regioselectivity over the desired C-3-arylated indole 209 
(Scheme 79). This was not unexpected, as the ionic indole salts formed from 
deprotonation with a lithium or sodium base would predominatly react via the more 
electronegative nitrogen atom instead of the C-3 carbon.The reaction using MeMgCl 
did not proceed even when heated to 80 
o
C, most likely due to the increased covalent 
character of the indole Grignard reagent, which rendered the indole less reactive 
towards electrophiles than the corresponding lithium or sodium salts.  
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Scheme 79: (i) n-BuLi, THF, 0 
o
C; 207, THF, 0-60 
o
C; (ii) NaH, THF, RT; 207, THF, RT-60 
o
C 
 
Transmetallation of n-BuLi with anhydrous ZnCl2 or CuCl, generating an organozincate 
or organocopper reagent respectively, was done prior to addition of 207. However, no 
reaction was observed after heating both reactions at 80 
o
C (Table 42).  
 
 
 
 
Table 42: Attempts made to react indole 199 with aryl fluoride 207 by SNAr
a 
 
Entry Base Temp. (
o
C) Results 
1 n-BuLi
b 
0-60 208 isolated, 68% yield 
2 NaH
c 
0-60 208 isolated, 84% yield 
3
 MeMgCl
d 
0-80 No reaction 
4 n-BuLi
b
, then ZnCl2
e 
0-80 No reaction 
5 n-BuLi
b
, then CuCl
 
0-80 No reaction 
(a) 199 (100 mg, 1.0 equiv.), 207 (1.0 equiv.), n-BuLi, MeMgCl, ZnCl2, CuCl (1.1 equiv.) or NaH (2.0 
equiv.) at 0.3 M;
 
(b) 2.5 M in hexanes; (c)
 
60% in mineral oil; (d)
 
3.0 M in THF; (e)
 
pre-dried at 150 
o
C 
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Indole 206 was brominated at C-3 to give 210 (Scheme 80). 
 
 
 
Scheme 80: (i) NBS, THF, -78 
o
C, 2 h 
 
Bromoindole 210 was treated with either n-BuLi or MeMgCl at 0 
o
C
 
before addition of 
excess 207. Bromine-lithium exchange went to completion within 30 min (LC-MS 
analysis) and gave a 1:1 mixture of 206 and the desired product 211 upon addition of 
207, with the latter being isolated in 53% yield. The analogous reaction with MeMgCl 
failed to undergo magnesium-bromine exchange and no reaction occurred with 207. 
Conducting the reactions with n-BuLi at -78 
o
C hindered bromine-lithium exchange and 
subsequent addition of 207 gave only a mixture of 206 and 210. Halogen-lithium 
exchange at 0 
o
C, followed by addition of 207 at -20 
o
C formed 206 as the major 
product and various impurities. However, if 207 was added at 0 
o
C or room temperature, 
211 was the predominant product formed. Reducing the equivalents of 207 did not 
affect product distribution, indicating reaction temperature to be a key variable in the 
success of this reaction (Table 43). This is the first documented aromatic substitution 
using an indol-3-yl carbanion as the nucleophile. Halogen-lithium exchange and the 
subsequent SNAr reaction can be completed within one hour at 0 
o
C without the need for 
a palladium catalyst. This reaction offers a novel procedure for the rapid formation of 3-
arylindoles using inexpensive reagents and with fewer variables to optimise relative to 
organometallic coupling reactions. 
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Table 43: Optimisation of the conditions for halogen-metal exchange and SNAr with 207
a
 
 
Entry Base Equiv. of 
207 
Temp. for 
step (i) (
o
C) 
Temp. for 
step (ii) (
o
C) 
Results 
1 n-BuLi
b 
2.0 0-RT 0 211 isolated, 53% 
yield 
2 MeMgCl
c 2.0 0-RT 0 No reaction 
3 n-BuLi
b 2.0 -78 -78 210 major product 
4 n-BuLi
b 2.0 0 -78 210 major product 
5 n-BuLi
b 2.0 0 -20 210 major product 
6 n-BuLi
b 2.0 0-RT RT 211 major product 
7
 n-BuLi
b 
1.5 0 0 211 major product 
(a) 210 (50-100 mg, 1.0 equiv.) and n-BuLi or MeMgCl (1.1 equiv.) at 0.4 M; (b)
 
2.5 M in hexanes; (c)
 
3.0 M in THF 
 
Indole 199 was also reacted with Boc2O to give indole 212 (Scheme 81). The Boc-
group was investigated for the SNAr reaction to see what effect an electron-withdrawing 
protecting group would have on the stability of the C-3 carbanion and the ratio of SNAr 
product to de-bromination product observed.  
 
 
 
Scheme 81: (i) Boc2O, DMAP, MeCN, 50 
o
C, 3 h 
 
Under previous conditions (cf. Scheme 80), bromination of 212 achieved only partial 
conversion and additional NBS formed an inseparable mixture of the 3-bromo- and 2,3-
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dibromoindole products 213 and 214, respectively. Replacing THF with DMF, heating 
to 60 
o
C and reducing the excess of NBS resulted in a faster reaction that gave 213 as 
the major product (Table 44). 
 
 
 
Table 44: Optimisation of the bromination of 212
a 
 
Entry NBS 
Equiv. 
Solvent Temp. 
(
o
C) 
Time 
(h) 
213:214 
Ratio
b 
Results 
1 2.5 THF 25 24 3:2 213 yield 47%, 214 
yield 25% 
2 1.1 THF 60 2 > 95:5 Incomplete reaction 
3 1.1 DMF 60 2 > 95:5 213 isolated, 86% 
yield 
(a) 212 (50-300 mg, 1.0 equiv.) at 1.0 M; (b) LC-MS UV trace 
 
Reaction of 213 with n-BuLi followed by addition of 207 produced a greater number of 
impurities than the reaction with indole 210 and none of the desired SNAr product. A 
similar number of impurities were generated when the lithiated species was quenched 
with deionised water in place of 207. It is possible that the Boc-protected 3-lithioindole 
was undergoing ring-opening to give acetylene 215 (Scheme 82). This is known to 
happen when the indole nitrogen is conjugated with electron-withrawing groups, 
including carbonyls. 
149
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Scheme 82: Proposed ring-opening of 213 upon treatment with n-BuLi to give 215
149
 
 
From these experiments, it was clear that: 
 
1. N-Boc-protected 3-bromoindoles were less stable towards lithiation than the 
corresponding N-PMB-protected indoles. 
 
2. N-PMB-protected indoles undergo lithium-bromine exchange to completion 
within 30 min at 0 
o
C and reaction with aryl fluoride 207 at 0 
o
C or room 
temperature forms the desired product 211. Lower temperatures result in 
increased de-bromination. 
 
Bromine-lithium exchange with 210 followed by addition of 3-bromo-2-
fluoronitrobenzene (139) at 0 
o
C produced a mixture of four species: 210, de-
brominated indole 206, aryl fluoride 207 and unreacted 139 (Scheme 83). None of the 
desired SNAr product was formed. The fact some of 210 remained suggested that the 3-
lithioindole had abstracted bromine from 139 to give 207, instead of substituting for 
fluoride. The remaining 3-lithioindole would be protonated upon quenching to give 206.  
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Scheme 83: Attempted SNAr reaction between 210 and 139, the subsequent products identified and their 
approximate ratio (
1
H and 
19
F NMR analysis) 
 
The bromine substituent of 139 was therefore inhibiting the ability of the 3-lithioindole 
to undergo SNAr. Suzuki coupling of 139 with the appropriate boronic acid would 
therefore allow the SNAr reaction to proceed, as previously with 207, to give 217 
(Scheme 84). Reduction of the nitro group and Buchwald coupling of 218 with 1-
bromo-4-fluorobenzene, followed by removal of all protecting groups, was predicted to 
give the target compound 195. However, due to the problems already encountered in 
this synthesis, it was decided to investigate other targets of interest. 
 
 
 
Scheme 84: Proposed route to indole 195 (i) PMB-Cl, NaH, DMF, 80 
o
C; (ii) NBS, THF, -78 
o
C; (iii) 4-
methoxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW; (iv) n-BuLi, THF, 0 
o
C; (v) 
SnCl2.2H2O, EtOH, 70 
o
C; (vi) 1-bromo-4-fluorobenzene, Pd2dba3, XPhos, NaO
t
Bu, MeCN, 120 
o
C, 
MW; (vii) Removal of PMB and phenoxymethyl group 
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5.3.3 Addition of Water-Solubilising Groups to the Benzenoid Scaffold 
 
During lead optimisation of the benzenoid series of MDMX inhibitors, optimisation of 
the corresponding pyrrole-based inhibitors at Newcastle University (S. Adhikari, PhD 
2012-2015) had found that having a carboxy group at the 3-position of the pyrrole 
scaffold (220c) enhanced potency against MDMX and MDM2 relative to the 
unsubstituted pyrrole 220a (Table 45). The carboxy group could obviously make a 
favourable interaction with the protein, a hypothesis supported by the fact that the 
corresponding methyl ester (220b) was inactive. 
 
Table 45: ELISA data for pyrroles 220a-220c (conducted by Dr Yan Zhao at the NICR) 
 
 
ID R MDMX IC50 (µM) MDM2 IC50 (µM) 
220a H 198
a 
38.3%
a,d 
220b CO2Me 189
a 
24.8%
a,d 
220c CO2H 14.6
c 
11.2
b 
(a) n = 1; (b) n = 2; (c) n = 3; (d) 200 µM 
 
It was of interest to determine whether addition of the same functionality would achieve 
a similar increase in potency in the benzenoid series. Starting from 4-fluoro-3-
nitrobenzoic acid (221), regioselective bromination with NBS in concentrated H2SO4 
afforded aryl bromide 222. Nucleophilic aromatic substitution with 4-chlorophenol, 
Suzuki coupling with 4-hydroxybenzeneboronic acid and tin-mediated nitro reduction 
gave the desired intermediates 223, 224 and 225, respectively in moderate to high 
yields, but Buchwald coupling failed to give target 226 (Scheme 85). It was clear that 
the failure of this reaction was due to the carboxy group, as coupling of the same aryl 
bromide to aniline 137a (cf. Scheme 44), which has no carboxy group, proceeded in 
greater than 80% yield under the same conditions. 
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Scheme 85: (i) NBS, conc. H2SO4, 80 
o
C, 3 h; (ii) 4-chlorophenol, K2CO3, MeCN, 90 
o
C, MW, 45 min; 
(iii) 4-hydroxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 20 min; (iv) 
SnCl2.2H2O, EtOH, 70 
o
C, 20 min; (v) 1-bromo-4-fluorobenzene, Pd2dba3, XPhos, NaO
t
Bu, MeCN, 120 
o
C, MW, 4 h 
 
Aryl ether 223 was esterified under acidic conditions to give ester 227 in near 
quantitative yield. It was later found that the bromination, SNAr and esterification could 
all be done without the need for chromatographic purification. Suzuki coupling and 
nitro reduction proceeded as before to give 228 and 229, respectively. Buchwald 
coupling gave aniline 230 in high yield and hydrolysis of the ester with lithium 
hydroxide gave 226. The ester of 230 was also reduced to give alcohol 231 using 
DIBAL-H (Scheme 86). Compounds 226, 230 and 231 were screened by ELISA (Table 
46). 
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Scheme 86: (i) MeOH, conc. H2SO4, 80 
o
C, 1 h; (ii) 4-hydroxybenzeneboronic acid, Pd(dtbpf)Cl2, 
Na2CO3, 1,2-DME, 120 
o
C, MW, 20 min; (iii) SnCl2.2H2O, EtOH, 70 
o
C, 20 min; (iv) 1-bromo-4-
fluorobenzene, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h; (v) LiOH.H2O, 50% THF, H2O, 60 
o
C, 
o/n; (vi) DIBAL-H, THF, -78 
o
C-0 
o
C, 4 h 
 
Table 46: ELISA data for 1,2,3,5-tetrasubstituted benzene derivatives 226, 230 and 231(conducted by Dr 
Yan Zhao at the NICR) 
 
 
ID R MDMX IC50 
(µM)
a
 
MDM2 IC50 
(µM)
a
 
Ratio (MDMX : 
MDM2) 
LE
b 
LipE
b,c 
226 CO2H 29.1 3.23 0.11 0.194 + 1.85 
230 CO2Me 45.6 94.7 2.08 0.180 - 1.64 
231 CH2OH 22.8 11.4 0.50 0.205 - 0.52 
(a) n = 1; (b)
 
With respect to MDMX; (c)
 
LipE = pIC50 – clogD7.4 (clogD values from StarDrop) 
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Addition of carboxy and hydroxymethyl groups to the 5-position of the benzenoid 
scaffold was tolerated with both protein targets. Compounds 226 and 231 were similarly 
potent to parent compound 138c (cf. Table 31), but ester 230 was half as active. None of 
the compounds was more active against MDMX than 138c, but 226 and 231 did have 
improved LipE. Ester 230 was four-fold less potent than 138c against MDM2, but 231 
was twice as active and 226 was eight-fold more potent and almost ten-fold selective for 
MDM2. 
 
5.3.3.1 Homologation of the Carboxy Group of 226 
 
The carboxy group of 226 was homologated to investigate whether this would allow the 
functionality to make a better interaction with the protein. Attempts to reduce aryl acid 
223 using sodium borohydride and iodine
150
 generated a large number of impurities and 
using borane-THF only went to 30% conversion (LC-MS analysis). However, ester 227 
was reduced to alcohol 232 using DIBAL-H. Initial attempts to form nitrile 234 
involved sulfonylation with methanesulfonyl chloride followed by reaction with sodium 
cyanide in acetonitrile.
151
 However, stirring at 60 
o
C gave no conversion of mesylate 
233. Repeating the cyanation in DMF generated a large number of unidentifiable 
impurities. When the mesylation and cyanation were repeated at 0 
o
C on a 50 mg scale 
of 232, clean conversion of the alcohol to a single product was observed (
1
H NMR 
analysis). It was later found that the product isolated was benzyl chloride 235, formed 
by displacement of the mesylate in 233 with chloride (Scheme 87). Compound 235 did 
not react with sodium cyanide at room temperature (Table 47).  
 
 
Scheme 87: Mesylation of alcohol 232 followed by displacement with chloride to give 235 
169 
 
 
 
Table 47: Optimisation of the mesylation/cyanation of 232 using sodium cyanide
a 
 
Entry NaCN Formulation NaCN 
Equiv. 
Solvent
b
 Temp. (
o
C)
b 
Results 
1 Powder 1.1 MeCN 25-60 235 only product 
2 Powder 1.1 DMF 0-25 235 only product 
3 0.15 M in DMF 1.1 DMF 0-25 235 only product 
4 0.15 M in DMF 1.5 DMF 0-25 235 only product 
(a) 232 (200 mg, 1.0 equiv.), MsCl (1.1 equiv.), Et3N (1.5 equiv.) at 0.5 M for the mesylation and 0.2 M 
for the cyanation; (b) With respect to the cyanation 
 
Alcohol 232 was reacted with methanesulfonic anhydride (Ms2O), in place of mesyl 
chloride, giving mesylate 233. Cyanation followed the procedure described by Soli 
using TMS-cyanide and TBAF in acetonitrile.
152
 In this reaction, TBAF reacts with 
TMS-cyanide (236) to form pentavalent silicon species 237 that is the nucleophilic 
source of cyanide (Scheme 88).
152
  
 
 
Scheme 88: Coordination of fluoride to TMS-cyanide (236) to give pentavalent silicon complex 237
152
 
 
When mesylate 233 was mixed with TMS-cyanide and TBAF, LC-MS showed full 
conversion to the desired product after 30 min at room temperature. Conducting the 
reaction at 0 
o
C produced fewer impurities and nitrile 234 was obtained in 29% yield.  
 
An Arndt-Eistert homologation was also trialled using 3-nitrobenzoic acid (238) as a 
model system. Reaction with thionyl chloride formed the desired acid chloride and 
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subsequent treatment with TMS-diazomethane gave diazoketone 239 within 2 h. No 
conversion was observed upon treating 239 with methanol in the presence of catalytic 
PhCO2Ag, even after prolonged heating. However, when stoichiometric quantities of 
PhCO2Ag were added, conversion to the homologated ester 240 was observed and the 
product was isolated in 27% yield (Scheme 89).   
 
 
 
Scheme 89: (i) SOCl2, DMF, THF, 0 
o
C-RT, 5 h; TMSCHN2, Et3N, 60% THF, MeCN, 0 
o
C, 2 h; 
PhCO2Ag, MeOH, Et3N, RT 
 
Although Arndt-Eistert homologation did produce 240, the yield was no better than that 
obtained with benzyl alcohol 232 using Ms2O and substituting with cyanide. While the 
yield for the mesylation/cyanation procedure was poor, it was scaleable (Table 48). 
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Table 48: Optimisation of the mesylation/cyanation of 232 using TMS-cyanide and TBAF
a 
 
Entry Cyanation time (min) Results 
1 15 234 isolated, 16% yield. 
2 90 234 isolated, 29-33% yield. 
(a) 232 (100-1000 mg, 1.0 equiv.), Ms2O (1.5 equiv.), Et3N (1.5 equiv.), TMS-cyanide (1.5 equiv.), 
TBAF (1.5 equiv.) at 0.5 M for the mesylation and 0.2 M for the cyanation 
 
Suzuki coupling of 234 with 4-hydroxybenzeneboronic acid followed by tin-mediated 
reduction of the nitro group gave aniline 242. However, Buchwald coupling gave a 
large number of unidentifiable impurities, which were not observed with aniline 
substrates in which the cyanomethyl group was absent (cf. Scheme 44). Despite this, 
aniline 243 was isolated in 4.3% yield and hydrolysis in aqueous sodium hydroxide 
successfully gave homologated acid 244 (Scheme 90).  
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Scheme 90: (i) NBS, conc. H2SO4, 80 
o
C, 3 h; (ii) 4-chlorophenol, K2CO3, MeCN, 90 
o
C, MW, 45 min; 
(iii) MeOH, conc. H2SO4, 80 
o
C, 1 h; (iv) DIBAL-H, THF, -78-0 
o
C, 4 h; (v) Ms2O, Et3N, DCM, 0 
o
C-
RT, 1 h; (vi) TMS-cyanide, TBAF, MeCN, 0 
o
C-RT, 90 min; (vii) 4-hydroxybenzeneboronic acid, 
Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 20 min; (viii) SnCl2.2H2O, EtOH, 70 
o
C, 20 min; (ix) 1-
bromo-4-fluorobenzene, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h; (x) 15% aq. NaOH, 130 
o
C, 
o/n 
 
The low yields in the cyanation of 232 may have been due to unwanted side reactions 
by other substituents on the benzenoid scaffold, e.g. the bromo or nitro groups. These 
functionalities were consequently transformed, e.g. by Suzuki coupling of the aryl 
bromide or reduction of the nitro group (Scheme 91). Nitro reduction was found to 
proceed in excellent yields with zinc powder in acetic acid. Mesylation and cyanation 
reactions were then attempted on alcohols 249 and 250 to see if they afforded any 
improvement in yield over the same reaction with alcohol 232 (Table 49). 
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Scheme 91: (i) 4-Methoxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 20 min; 
(ii) Zn, AcOH, RT 1 h; (iii) 1-bromo-4-fluorobenzene, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW, 3 h; 
(iv) Boc2O, DMAP, MeCN, 50 
o
C, 3 h; (v) DIBAL-H, THF, -78-0 
o
C, 4 h 
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Table 49: Mesylation and cyanation on alcohols 249 and 250  
 
Alcohol R R’ Nitrile Yield (%)a 
249 
 
 
249a 4.3 
250 
 
NO2 250a 21 
(a) Isolated yield 
 
The bromo and nitro substituents were not responsible for the low yields recorded for 
the cyanation of mesylate 233, as the mesylation and cyanation of alcohols 249 and 250 
gave even poorer yields of their respective nitriles 249a and 250a. 
 
5.3.3.2 Carboxylic Acid Regioisomers of 226 
 
It was of interest to explore attaching the carboxy group of 226 at different positions on 
the benzenoid scaffold to determine if one of the regioisomers afforded the same 
enhancement in activity seen in the pyrrole series (cf. Table 45). Synthesis of the 
1,2,3,4-tetrasubstituted compound 258 started from aryl bromide 139. Reduction of the 
nitro group and Boc-protection of the aniline would give a directed ortho metalation 
(DoM) group (253) allowing for insertion of the carboxy group at the 4-position of the 
benzenoid scaffold (254) (Scheme 92).
153
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Scheme 92: (i) 4-Methoxybenzeneboronic acid, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 1 h; (ii) 
4-chlorophenol, K2CO3, MeCN, 90 
o
C, MW, 1 h; (iii) SnCl2.2H2O, EtOH, 70 
o
C, 30 min; (iv) Boc2O, 
DMAP, MeCN, 50 
o
C, 3 h; NaOH, 33% THF, MeOH, RT, 1 h; (v) organolithium base; CO2(s); (vi) 
mineral acid, MeOH; (vii) 1-bromo-4-fluorobenzene, Pd2dba3, XPhos, K2CO3, MeCN, 120 
o
C, MW; (viii) 
LiOH.H2O, 50% THF, H2O, 60 
o
C; (ix) BBr3, DCM, 0 
o
C 
 
Suzuki coupling of 139 with 4-methoxybenzeneboronic acid gave 216 in 88% yield. 
Nucleophilic aromatic substitution and tin-mediated nitro reduction also proceeded in 
high yields to obtain aniline 252. The nitro reduction was later found to give similarly 
high yields when conducted in the presence of zinc powder in glacial acetic acid. Boc-
protection using excess Boc2O and catalytic DMAP gave only the di-Boc-protected 
species 259 in 71% yield. However, it was later found that this compound could be 
converted to the desired mono-Boc-protected compound 253 by treatment with sodium 
hydroxide. Subsequent repeats of this synthesis deliberately allowed formation of di-
176 
 
Boc-protected aniline 259 before mixing the crude material with sodium hydroxide to 
give 253 in 78% overall yield (Scheme 93).  
 
 
 
Scheme 93: (i) Boc2O, DMAP, MeCN, 50 
o
C, 3 h; (ii) NaOH, 33% THF, MeOH, RT, 1 h 
 
Treating 253 with n-BuLi and N,N,N’,N’-tetramethylethylenediamine (TMEDA) at -78 
o
C for 2 h, followed by quenching with solid CO2 gave a 1:3 mixture of 254 and 253. 
However, deprotonation with n-BuLi and TMEDA at 0 
o
C, or using sec-BuLi in place 
of n-BuLi gave superior conversion to 254 (Table 50). Due to time constraints, full 
completion of the synthesis of 258 could not be achieved. 
 
 
 
Table 50: Optimisation of the DoM reaction with carbamate 253
a 
 
Entry Base Step (i) Temp. (
o
C) 253:254 Ratio
b 
1 n-BuLi
c 
-78 3:1 
2 n-BuLi
c 
0 1:7 
3 sec-BuLi
d 
-78 1:7 
(a) 253 (30 mg, 1.0 equiv.), TMEDA (2.1 equiv.) and solid CO2 (excess) at 0.1 M; (b) LC-MS UV trace; 
(c) 2.5 M in hexanes; (d) 1.4 M in cyclohexane 
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5.4 The 2,4-Disubstituted Thiazole MDMX Inhibitors 
 
Preliminary SAR studies on the thiazole-based MDMX inhibitors had already been 
conducted at Newcastle University (E. Bulatov, MPhil 2009-10).
114
 Thiazole 44j 
displayed single-digit micromolar activity against MDMX and MDM2 in an ELISA. 
The fact that the 5-position of the thiazole scaffold had never been investigated in SAR 
studies meant that superior potency against MDMX could potentially be achieved. It 
had also been shown in the benzenoid series that truncation of the amino substituent 
increased MDMX potency 4-fold and MDM2 potency 6-fold (cf. Table 31, 138a vs. 
138c). It was therefore of interest to investigate whether truncation of the 4-
fluorobenzylamino group in 44j and the corresponding phenol 44c would improve 
target activity. Thiazole 44r was synthesised by heating 2-bromo-4’-
hydroxyacetophenone (260) and 4-fluorophenylthiourea (261) in ethanol (Scheme 94). 
 
 
 
Scheme 94: (i) EtOH, 70 
o
C, MW, 5 min 
 
Thiazole 44s was synthesised from 4-aminoacetophenone (262). Sulfonation with Tf2O 
gave trifluoromethylsulfonamide 263. Bromination of the α-carbon using pyridinium 
tribromide in acetic acid gave a 7:3 mixture of bromoketone 264 and di-bromoketone 
265 (
1
H NMR analysis). Irradiation of this mixture with 261 gave thiazole 44s in 37% 
yield, with the di-bromoketone 265 not participating in the reaction (Scheme 95).  
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Scheme 95: (i) Tf2O, 
i
Pr2NEt, DCM, 0 
o
C-RT, 5 h; 3M NaOH, H2O (1:3), RT, o/n; (ii) pyridinium 
tribromide, AcOH, RT, 2 h; (iii) 261, EtOH, 70 
o
C, MW, 15 min 
 
Only phenol, catechol and trifluoromethylsulfonamide analogues had demonstrated 
activity against MDMX or MDM2. Indazoles have been used as bioisosteres for phenols 
and catechols, giving similar or greater potency against a biological target while also 
being more stable towards metabolism.
154
 
 
Starting from 2-amino-5-bromo-1,3-thiazole hydrobromide (266), coupling with 4-
fluorobenzoyl chloride in DCM gave amide 267 in 36% yield. Using THF in place of 
DCM resulted in a much slower reaction and using DMF generated multiple impurities. 
Acetonitrile gave rapid conversion, generated fewer impurities, and afforded amide 267 
in 92% yield following quenching with methanolic sodium hydroxide (Table 51). 
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Table 51: Optimisation of the coupling of thiazole 266 with 4-fluorobenzoyl chloride
a 
 
Entry Solvent Results 
1 DCM 267 isolated, 36% yield 
2 THF Slow, incomplete reaction 
3 DMF Multiple impurities generated 
4 MeCN 267 isolated, 92% yield. 
(a) 266 (50 mg, 1.0 equiv.), 4-fluorobenzoyl chloride (1.5 equiv.) and pyridine (3.0 equiv.) at 0.3 M 
 
Following the procedure described by Stanetty, amide 267 was converted to the 4-
bromo regioisomer 268 upon treatment with LDA in a halogen ‘dance’ (HD) 
reaction.
155
 The mechanism of the HD reaction is shown in Scheme 96. Following 
deprotonation of the amide NH by one equivalent of strong base to give 267a, a second 
equivalent deprotonates at the 4-position of the thiazole to give di-lithiated species 
267b, which can undergo halogen-lithium exchange with another 267a. This generates a 
mixture of des-bromothiazole 269a and 4,5-dibromothiazole 270a. These two species 
can react with each other to generate a mixture of the starting thiazole 267b and the 
desired 4-bromothiazole 268a. Depending on when the reaction is quenched, four 
products can potentially be isolated: (267, 268, 269 and 270).
155, 156
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Scheme 96: Mechanism of the HD reaction on 2-aminothiazoles
155, 156
 
 
The HD reaction could also allow for addition of various groups to the 5-position of the 
thiazole scaffold by replacing water as the quenching agent with electrophilic species, 
e.g. haloalkanes or aldehydes.
155
 
 
5-Bromo-1H-indazole (271) was coupled with B2(pin)2 in the presence of 
Pd(dppf)Cl2.DCM to give 272. Suzuki coupling of 272 with thiazole 268 resulted in no 
conversion; however, protection of 272 with 3,4-dihydro-2H-pyran (DHP), followed by 
Suzuki coupling with 268, gave thiazole 274 in 78% yield. Following THP deprotection 
to give indazole 275, attempts to reduce the amide with lithium aluminium hydride were 
hindered by the insolubility of 275 in organic solvents (Scheme 97).  
 
181 
 
 
 
Scheme 97: (i) 1 M HCl, MeOH, 50 
o
C, o/n; (ii) LiAlH4, THF, 0-60 
o
C, 24 h 
 
Reduction of indazole 274 with lithium aluminium hydride gave 276. This intermediate 
had greater organic solubility than 275 and the THP ring was removed in dilute HCl, 
yielding indazole 44t (Scheme 98), which was analysed by ELISA against MDMX and 
MDM2 (Table 52). 
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Scheme 98: (i) 4-Fluorobenzoyl chloride, pyridine, MeCN, RT, 1 h; (ii) 
i
Pr2NH, n-BuLi, THF, -78-0 
o
C, 
30 min; H2O, 0 
o
C-RT, o/n; (iii) B2(pin)2, Pd(dppf)Cl2.DCM, KOAc, DMF, 90 
o
C, 15 h; (iv) DHP, pTSA, 
DCM, RT, 2 h; (v) 268, Pd(dtbpf)Cl2, Na2CO3, 1,2-DME, 120 
o
C, MW, 40 min; (vi) LiAlH4, THF, 0-60 
o
C, 24 h; (vii) 1 M HCl, MeOH, 50 
o
C, o/n 
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Table 52: ELISA data for thiazoles 44r-44t and 276 (conducted by Dr Yan Zhao at the NICR) 
 
ID Structure MDMX 
IC50 
(µM)
a 
MDM2 
IC50 
(µM)
a 
Ratio 
(MDMX : 
MDM2) 
LE
b 
LipE
b,d 
 
44r
 
 
 
52.7
 
 
8.30 
 
0.16 
 
0.293 
 
+ 0.60 
 
44s
 
 
 
16.7
 
 
21.3 
 
1.28 
 
0.242 
 
+ 0.09 
 
44t 
 
 
64.0
 
 
34.4%
c
 
 
- 
 
0.248 
 
+ 1.59 
 
276 
 
 
90.0
 
 
38.6%
c
 
 
- 
 
0.185 
 
- 0.49 
(a)
 
n = 1; (b)
 
With respect to MDMX; (c) 200 µM; (d) LipE = pIC50 – clogD7.4 (clogD values from 
StarDrop) 
 
Truncation of the amino substituent (44r and 44s) did not enhance MDMX or MDM2 
activity over the corresponding truncated benzenoid compounds (cf. Table 31, 138c). 
Compound 44s had 3-fold weaker MDMX activity and 2-fold weaker MDM2 activity 
compared to the homologated derivative (cf. Table 20, 44j). Thiazole 44r was 
equipotent against MDMX and 2-fold more active against MDM2 than the homologated 
analogue (cf. Table 20, 44c) and was one of the most ligand efficient compounds 
synthesised. Indazole 44t had equivalent MDMX activity to 44c, meaning the indazole 
was a suitable isosteric replacement for the phenol against MDMX. However, indazoles 
44t and 276 were inactive against MDM2. Due to its relatively high MDMX and 
MDM2 potency and low cLogD7.4 (+ 3.07), compound 44j was selected for co-
crystallisation trials with MDMX and MDM2 (cf. Chapter 6.1). 4-Fluorobenzylamine 
(277) was reacted with benzoyl isothiocyanate, giving full conversion to 278 and 
cleavage with potassium carbonate gave N-(4-fluorobenzyl)thiourea (279). Cyclisation 
with α-bromoketone 264 (cf. Scheme 95) gave 44j (Scheme 99). 
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Scheme 99: (i) Benzoyl isothiocyanate, DCM, 0 
o
C-RT, 1 h; (ii) K2CO3, MeOH, RT, o/n; (iii) 264, EtOH, 
70 
o
C, MW, 30 min 
 
5.5 The 1,2,3,5-Tetrasubstituted Pyrrole MDMX Inhibitors 
 
The pyrrole series had produced some of the most potent MDMX inhibitors.
107
 
However, a significant drawback of the pyrrole compounds was their low solubility in 
both aqueous and organic solvents. The presence of a barbituric or thiobarbituric acid 
ring increased compound lipophilicity and previous attempts to remove the ring (e.g. by 
replacement with malonamide derivatives) had resulted in a loss of activity against both 
targets. Subsequent analysis (S. Adhikari, PhD 2012-15) had found that insertion of a 
methylene linker between the pyrrole scaffold and the 2-phenyl ring granted increased 
organic solubility. Compounds with a methylene linker were less active against MDMX 
and MDM2 than the corresponding truncated compounds. However, the barbituric acid 
ring could be replaced with a carboxy group (220c), giving compounds of similar 
activity to the most active compounds in the benzenoid and thiazole series (Table 53). 
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Table 53: ELISA data for pyrroles 220a-220f
a
 (conducted by Dr Yan Zhao at the NICR) 
 
 
ID
 
R R’ MDMX 
IC50 (µM) 
MDM2 IC50 
(µM) 
Ratio (MDMX 
: MDM2) 
LE
e 
LipE
e,g 
220a H F 198
b 
38.3%
b,f
 - 0.188 - 3.33 
220b CO2Me F 189
b 
24.8%
b,f
 - 0.165 - 3.19 
220c CO2H F 14.6
d 
11.2
c
 0.77 0.221 + 1.47 
220d CH2OH F 49.5%
b,f 
17.1%
b,f
 - - - 
 
220e 
 
 
F 
 
4.51
b 
 
3.54
b
 
 
0.78 
 
0.198 
 
+ 0.36 
220f CO2H H 7.88
b 
14.7
b
 1.87 0.241 + 1.70 
(a)
 
Synthesised by S. Adhikari; (b) n = 1; (c)
 
n = 2; (d)
 
n = 3; (e)
 
With respect to MDMX; 
 
(f) 200 µM; (g) 
LipE = pIC50 – clogD7.4 (clogD values from StarDrop) 
 
1,2,5-Trisubstituted pyrroles were inactive against MDMX or MDM2 (220a). However, 
incorporation of a carboxy group at the 3-position (220c) enhanced potency against both 
proteins, similar to that obtained with the barbituric acid (220e). The fact that methyl 
ester 220b was inactive highlighted the importance of the carboxy group, suggesting 
that this group was making a favourable interaction with the protein. Alcohol 220d also 
had no potency against either protein, suggesting that the acidity of 220c was 
significant, hinting that the carboxy group may be positioned in a predominantly basic 
region of the protein. Removal of the fluoro substituent (220f) doubled MDMX activity 
compared to 220c, giving one of the most ligand efficient compounds in this series. 
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5.5.1 Synthesis of 220c and Regioisomer 220g 
 
4-Chlorophenylacetyl chloride (280) was reacted with Meldrum’s acid, followed by 
treatment with ethanol to give β-ketoester 281. Deprotonation of 281 with sodium 
hydride followed by addition of 2’-bromo-4-fluoroacetophenone gave 1,4-diketone 
282a. Paal-Knorr condensation of 282a with 4-chloroaniline in acetic acid afforded 
pyrrole 283a, which was hydrolysed using aqueous sodium hydroxide to give 220c 
(Scheme 100). 
 
 
Scheme 100: (i) Meldrum’s acid, pyridine, DCM, 0 oC-RT, 4 h; EtOH, 100 oC, 2 h; (ii) NaH, THF, 0 oC, 
20 min; 2’-bromo-4-fluoroacetophenone, THF, 0 oC-RT, 3 h; (iii) 4-chloroaniline, AcOH, 170 oC, MW, 
12 min; (iv) NaOH, 75% MeOH, H2O, 90 
o
C, 3 h 
 
It was also of interest to determine whether placing the carboxy group at the 4-position 
of the pyrrole scaffold would improve activity. Starting from acid chloride 280, reaction 
with a mixture of MeLi and CuI gave ketone 284 quantitatively. Bromination of 284 
was complicated by the fact that two different α-carbons could potentially be 
brominated. Following the procedure described by Lee, bromination of ketone 284 
using an excess of NBS in acetonitrile generated a mixture of 285 and 286 (
1
H NMR 
analysis), with 285 being the major product.
157
 
1
H NMR analysis also showed that some 
starting material had been dibrominated to 1,3-dibromoketone 287. Subsequent heating 
with additional NBS led to full consumption of 285 and 286 to give a 3:1 ratio of 287 
and 1,3,3-tribrominated ketone 288. Following the procedure described by Choi, 
treatment of the crude material with hydrobromic acid and acetone gave 286 in 49-55% 
yield (Scheme 101).
158
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Scheme 101: Non-selective bromination of ketone 284,
157
 followed by selective de-bromination to give 
α-bromoketone 286.158 (i) NBS (2.2 equiv.), pTSA, MeCN, 100 oC, o/n; (ii) NBS (1.0 equiv.), pTSA, 
MeCN, 100 
o
C, 1 h; (iii) Me2CO, AcOH, 45% HBr in AcOH, RT, o/n 
 
Bromoketone 286 was reacted with ethyl 3-(4-fluorophenyl)-3-oxopropanoate in the 
presence of sodium hydride to give 1,4-diketone 282b. Paal-Knorr condensation of the 
latter with 4-chloroaniline gave 283b, which was hydrolysed with sodium hydroxide to 
give pyrrole 220g (Scheme 102). Pyrroles 283b and 220g were analysed using a HTRF 
assay (cf. Chapter 6.2). 
 
 
 
Scheme 102: (i) MeLi, CuI, Et2O, 0 to -78 
o
C, 45 min; (ii) NBS, pTSA, MeCN, 100 
o
C, 3 h; Me2CO, 
AcOH, 45% HBr in AcOH, RT, o/n; (iii) ethyl 3-(4-fluorophenyl)-3-oxopropanoate, NaH, THF, 0 
o
C-RT, 
8 h; (iv) 4-chloroaniline, AcOH, 170 
o
C, MW, 12 min; (v) NaOH, 75% MeOH, H2O, 90 
o
C, 3 h 
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5.6 Conclusion 
 
Several 1,3-disubstituted benzenoid compounds (118a-118d and 118f-118o) were 
synthesised and MDMX and MDM2 inhibitory activity was confirmed using an ELISA. 
The majority of the active compounds had similar activity to the corresponding 
thiazole-based derivatives, and in both series, only compounds possessing acidic 
hydrogen bond donating functionalities, e.g. phenols or trifluoromethylsulfonamides, 
were active against MDMX or MDM2. 1,3-Disubstituted pyridyl scaffolds were 
considerably less active than the corresponding benzenoid compounds. Introduction of a 
2-(4-chlorophenoxy) substituent in the benzenoid series was tolerated against MDMX 
and MDM2, with truncation of the 4-fluorobenzyl substituent enhancing potency 
against both proteins (Table 31, 138a vs.138c). 
 
Substitution by methyl or chloro at the 2-position of the 4-fluorophenyl ring abrogated 
activity against both proteins but substitution by the same groups at the 2-position of the 
4-hydroxyphenyl ring of 138c was tolerated (138k and 138l). The fluoro and hydroxy 
groups of 138c could be interchanged without compromising activity against either 
target, suggesting the compounds could adopt alternative binding modes (138o). The 4-
hydroxyphenyl ring of 138c could be replaced with a 3-hydroxyisoxazole (183a), 3-
hydroxypyrazole (183b) or 1,2,3-triazole (185) and retain potency. Attempts to replace 
the 4-chlorophenoxy group of 138c with a 6-chloroindol-3-yl ring were unsuccessful, 
but did achieve the first documented example of an SNAr reaction using a 3-lithioindole 
to synthesise 211. Addition of small functionalities, e.g. a carboxy group, to the 5-
position of the benzenoid scaffold was tolerated against MDMX and MDM2. However, 
attempts to measure the activity of the homologated derivative (244) using an HTRF 
assay gave inconclusive results. Addition of small functionalities to the 4-position of the 
benzenoid scaffold in place of the 5-position is ongoing. 
 
In the thiazole series, truncation of the 4-fluorobenzyl substituent did not achieve the 
increase in target potency observed in the benzenoid series. The 4-hydroxyphenyl ring 
of 44c could be substituted by an indazole (44t) without compromising activity against 
MDMX or MDM2. In the pyrrole series, compounds 220c and 220g were synthesised 
regioselectively. Pyrrole 220c had already been analysed using an ELISA; however, 
attempts to evaluate the potency of 220g using an HTRF assay gave inconclusive 
results, possibly due to the poor solubility of 220g.  
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Chapter Six: MDMX and MDM2 Structural Biology 
 
6.1 Protein Crystallography of Benzenoid and Thiazole-based 
Inhibitors of MDMX and MDM2  
 
Crystal structures of MDMX have been reported where the protein is interacting with 
various substrates, including p53 (Figure 53)
100
 and imidazole-based small 
molecules,
104, 106
 but no crystal structure was available for any small-molecule 
Newcastle inhibitor bound to MDMX.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53: X-ray structure of MDMX (yellow) bound to p53 (purple). The p53 residues F19, W23 and 
L26 are highlighted (green). Image created using COOT with CCP4mg plug-in (resolution, 1.9 Å; PDB: 
3DAB).
100
 
 
MDMX is a 490-amino acid protein with an overall 34.0% sequence identity to 
MDM2.
159
 At the N-terminal end of both proteins is the p53-binding domain, which is 
the most conserved region, at 53.6% sequence identity. The Really Interesting New 
Gene (RING) domain is located at the C-terminus and is essential for 
heterodimerisation between MDMX and MDM2, sharing 53.2% sequence identity 
between the two proteins. The C-terminus also contains the nucleolar localisation signal 
(NoLS), which encodes the ability of the protein to localise to the nucleolus (Figure 
54).  
 
 
F19 
L26 
W23 
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Figure 54: The primary sequence of hMDM2 and hMDMX. The numbers along the top of the proteins 
show the lengths of key domains and the percentages refer to sequence identity of the regions they are 
situated between.
160
  
 
Crystal structures of MDM2 with various substrates have also been obtained, including 
p53
95
 and several members of the isoindolinone series developed at Newcastle.
159
 Co-
crystals of isoindolinones with MDM2 were difficult to acquire, as usually compounds 
need to have high binding affinity to stabilise the protein sufficiently for crystallisation 
to occur.
159
 However, compound WK298 (51), an MDM2 inhibitor with only moderate 
potency against MDMX, was successfully crystallised with MDMX (Figure 55),
106
 
suggesting that MDMX may be more amenable to crystallisation. 
 
 
 
 
 
 
 
 
 
 
 
       
       
hMDM2 
hMDMX 
53.6% 41.9% 53.2% 
1 18 101 237 288 289 331 436 466 473 482 
1 19 102 215 255 290 332 437 465 469 483 
p53 binding domain Acidic 
domain 
Zinc- 
finger 
RING domain 
(NoLS) 
p53 binding domain Acidic 
domain 
Zinc- 
finger 
RING domain 
(NoLS) 
191 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Crystal structure of 51 (green) in the p53 binding domain of MDMX (yellow). The p53 
binding subpockets F19, W23 and L26 are highlighted. Image modified using CCP4mg (resolution, 1.5 
Å; PDB code: 3LBJ)
106
 
 
To guide rational drug design, a co-crystal of a small molecule in either the benzenoid, 
thiazole or pyrrole series with MDMX was necessary and a two-month placement in the 
structural biology laboratories at Newcastle University aimed to achieve this. Five 
compounds from the benzenoid and thiazole series were selected for co-crystallisation 
trials (Table 54). Compounds were selected based on having moderate MDMX 
inhibitory activity in the ELISA, a low clogD7.4 and structural diversity. 
  
p53-L26 
p53-W23 
p53-F19 
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Table 54: Benzenoid and thiazole-based inhibitors selected for co-crystallisation trials with MDMX and 
MDM2 
 
ID Structure MDMX 
IC50 (µM) 
MDM2 
IC50 (µM) 
Ratio 
(MDMX : 
MDM2) 
clogD7.4
d 
 
44j 
 
 
5.75
b 
 
11.3
b
 
 
1.97 
 
+ 3.07 
 
118c 
 
 
64.7
a 
 
35.0
a
 
 
0.54 
 
+ 2.04 
 
185 
 
 
29.1
a 
 
 
39.3
a
 
 
1.35 
 
+ 4.52 
 
226 
 
 
29.1
a 
 
3.23
b
 
 
0.11 
 
+ 2.69 
 
244 
 
 
Unknown
c 
 
Unknown
c
 
 
- 
 
+ 2.79 
(a) 
 
n = 1; (b) n = 2; (c) Not tested in ELISA; (d) Values from StarDrop  
 
The most active thiazole-based MDMX inhibitor was selected (44j) as more potent 
compounds are generally more likely to crystallise with their target protein. From the 
benzenoid series, a mixture of di-, tri- and tetra-substituted compounds were selected. 
Despite not being analysed by ELISA, compound 244 was selected due to its relatively 
low clogD7.4 value and its structural similarity to compound 226, for which an ELISA 
value had been measured.  
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6.1.1 Expression and Purification of MDMX and MDM2  
 
Co-crystallisation had been achieved with MDM2 and isoindolinone-based inhibitors
159
 
so MDM2 was also expressed and purified as a control. Conditions that had been 
previously used to crystallise isoindolinones with MDM2 were also tested to determine 
whether they would be as effective at crystallising a benzenoid or thiazole-based 
compound with MDMX. Three MDM2 and MDMX constructs were selected for co-
crystallisation trials, each encompassing the p53-binding domain. Constructs were 
selected based on previous knowledge of their ease of expression and handling and 
success at crystallising compounds reported in the literature (Table 55). 
 
Table 55: Constructs of MDMX and MDM2 used for co-crystallisation trials 
 
Protein Construct Amino acid range Mutations 
MDMX 1 18-111 - 
MDMX 2 22-111 - 
MDMX 3 26-111 - 
MDM2 1 17-125 K51A 
MDM2 2 17-109 E69A/K70A 
MDM2 3 17-125 E69A/K70A 
 
Recombinant MDMX and MDM2 constructs were expressed in E. coli 
Rosetta(DE3)pLys S and BL21(DE3) pLys S strains, respectively, by insertion of the 
pre-cloned DNA coding for each construct into the pGEX-6P-1 vector (Figure 56).  
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Figure 56: The pGEX-6P-1 expression vector, showing the genes for ampicillin (289) resistance (Amp
r
), 
the GST protein tag (glutathione S-transferase), the cleavage codon (PreScission
TM
 Protease) and the lac 
operon (lac l 
q
)
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The pGEX-6P-1 plasmid contains a series of genes essential for targeted protein 
expression. In addition to a gene conferring its resistance to ampicillin (289), the 
plasmid also possesses genes encoding for a glutathione S-transferase (GST) protein tag 
to assist separation of the desired protein construct from the cellular media following 
expression. A 3C viral protease cleavage site was also present to cleave specifically the 
GST-tag from the MDMX and MDM2 sequence. MDMX and MDM2 expression is 
induced by addition of isopropyl-β-D-thiogalactoside (IPTG) (290) that binds to the lac 
repressor to relieve repression of the lac promoter to permit binding of E. coli RNA 
polymerase and gene transcription (Figure 57).  
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Figure 57: The lac operon mechanism: RNA polymerase binds to the promoter gene (Plac) and transcribes 
the genes lacZ, lacY and LacA. Normally, the lac repressor binds to the lac operator (O), preventing RNA 
polymerase from binding to Plac when lactose is absent. When an inducer, e.g. IPTG (290), binds to the 
repressor, it can no longer bind to the operator, allowing for continued transcription of lacZ, lacY and 
lacA, promoting the metabolism of lactose.
162
  
 
Full details of the expression and purification of recombinant GST-MDM2 and GST-
MDMX are given in Chapters 7.4 and 7.5. Following separation of the expressed 
protein from the E. coli with lysozyme, incubation with glutathione-agarose and 
filtration separated the protein from the cellular extract. The protein was eluted in 1 mL 
samples by washing with mHBS buffer, pH 7.4, containing 25 mM glutathione. Protein 
concentration was determined for each 1 mL fraction (Nanodrop 2000, Thermo 
Scientific) and an SDS-PAGE was also run on the crude protein (Figure 58). 
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Figure 58: SDS-PAGE (12% acrylamide) of crude GST-MDMX fractions (constructs 1-3). The position 
of GST-MDMX
18-111
 (lane 10) is highlighted. Lane 1, MWt marker; lane 2, GST-MDMX
18-111
 total cell; 
lane 3, GST-MDMX
18-111
 cell-free extract; lane 4, GST-MDMX
22-111
 total cell; lane 5, GST-MDMX
22-111
 
cell-free extract, lane 6, GST-MDMX
26-111
 total cell; lane 7, GST-MDMX
26-111
 cell-free extract; lanes 8-9, 
GST-MDMX
18-111
 washes with mHBS buffer, pH 7.4; lane 10, GST-MDMX
18-111
 fraction 3 
 
Fractions containing the desired protein were pooled and incubated overnight at 4 
o
C 
with 1 mg/mL 3C protease (50:1 (w/v) protein:3C protease). This step cleaved the GST 
tag from the desired protein. The protein was purified by size exclusion chromatography 
on a Superdex 75 HR 26/600 column (GE Healthcare), equilibrated with mHBS buffer 
(Figure 59).  
  
kDa 
10 
15 
25 
35 
55 
70 
130 
Lanes 
1 2 3 4 5 6 7 8 9 10 
GST-MDMX
18-111
 
(MWt 40.0 kDa) 
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Figure 59: Size exclusion chromatograph of MDMX
18-111
 following 3C digest. MDMX is well resolved 
from the GST tag. A) GST tag (MWt 26.9 kDa); B) MDMX
18-111
 (MWt 11.0 kDa) 
 
Purification gave protein of sufficient purity for structural studies, as determined by 
SDS-PAGE analysis (Figure 60). Pure protein fractions were pooled, concentrated by 
ultrafiltration and stored at -80 
o
C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: SDS-PAGE (16% acrylamide) of purified MDMX
18-111
 fractions. The position of the MDMX 
protein is highlighted. Similar results were obtained for MDMX constructs 2-3 and MDM2 constructs 1-
3. Lanes 1-7 and 9-12, column fractions; lane 8, MWt marker 
  
A 
B 
kDa 
10 
15 
25 
35 
55 
70 
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18-111
 
(MWt 11.0 kDa) 
11 12 
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6.1.2 Crystallisation Trials of MDMX and MDM2 Constructs 1-3 with 
Benzenoid and Thiazole-based Inhibitors 
 
MDM2 construct 2 (cf. Table 55) did not express readily and gave a reduced mass of 
pure protein following gel filtration, so was used in a more focussed library of screens. 
Supplies of compound 244 were limited so crystallisation trials with this compound 
used MDMX
18-111
 and MDMX
22-111
 only.  
 
Selected inhibitors were incubated overnight at 4 
o
C with the concentrated protein in a 
3:2 ratio (inhibitor:protein). Competitor compound RO-2443 (57), for which the crystal 
structure with both proteins was already known,
109
 was used as a control.  
 
 
 
Protein-inhibitor complexes were concentrated to between 5 and 10 mg/mL (Nanodrop 
2000, Thermo Scientific) (Table 56). Complexes of MDMX were more difficult to 
concentrate than the corresponding MDM2 complexes. Precipitation was observed with 
all benzenoid inhibitors, which precluded reaching the desired concentration range in 
some cases. No precipitation was observed for any of the MDM2 complexes. 
Compounds 57 and 44j did not precipitate when mixed with either MDMX or MDM2. 
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Table 56: Protein-inhibitor concentrations for co-crystallisation trials 
 
Protein Construct Inhibitor Complex Concentration (mg/mL)
a,b 
 
 
 
 
 
 
 
 
 
MDMX 
 
 
 
1 
44j 
118c 
185 
226 
244 
57 
5.4 
4.3 
4.6 
3.5 
4.1 
7.9 
 
 
 
2 
44j 
118c 
185 
226 
244 
57 
12.0 
3.4 
4.2 
5.2 
2.2 
5.5 
 
 
3 
44j 
118c 
185 
226 
57 
6.9 
3.1 
2.9 
2.4 
3.7 
 
 
 
 
 
 
 
MDM2 
 
 
1 
44j 
118c 
185 
226 
57 
10.4 
7.6 
11.5 
13.3 
4.2 
 
 
2 
 
 
44j 
118c 
185 
226 
57 
3.7 
2.4 
3.1 
-
c 
-
c
 
 
 
3 
44j 
118c 
185 
226 
57 
9.5 
14.7 
16.2 
15.5 
4.8 
(a) Nanodrop 2000 (Thermo Scientific); (b) Average of 3 readings; (c) Insufficient protein available 
 
Full details of the preparation of each protein construct for crystallography are given in 
Chapter 7.6. Two screens were used to find appropriate conditions for co-crystallisation: 
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ammonium sulfate (AmSO4) (Qiagen) and JCSG+ (Molecular Dimensions). Screening 
solutions were arranged in a 96-well format, with each well differing in precipitants, pH 
range, salts and buffers. Complexes and screening solutions were combined in 2-
subwell 96-well crystallisation trays using a Mosquito
®
 robot and the sitting drop 
method. Each complex and screening solution was mixed in sub-wells in a 1:1 and 2:1 
ratio (complex:screen). Plates were stored at 4 
o
C in a Rikagu Minstrel tray hotel for a 
maximum period of 8 weeks. Images were taken of each sub-well at set time points to 
monitor crystal formation (Figure 61).  
 
 
 
 
 
 
 
 
 
A)                                                          B)                                C) 
Figure 61: A) 2-subwell 96-well tray used for co-crystallisation trials; B) Mosquito
®
 robot; C) Rikagu 
Minstrel tray hotel 
 
A total of 30 protein-inhibitor complexes were prepared using MDMX and MDM2 
constructs 1-3. Each complex was screened using AmSO4 and JCSG+ in 2-subwell 96-
well trays, giving a total of 384 crystallisation conditions trialled for each complex. 
Overall, more than 11,000 conditions were trialled in an attempt to crystallise MDMX 
or MDM2 with a benzenoid or thiazole-based inhibitor.  
  
Main well Sub-wells 
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6.1.3 Crystal Formation and Data Collection 
 
Crystals were obtained for compound 226 with MDM2 construct 3; however, the 
crystals were too small to be suitable for data collection (Figure 62). Work is ongoing 
to optimise crystallisation conditions for this complex. The conditions which resulted in 
crystal formation differed only in the salt used (Table 57). 
 
 
 
 
 
 
 
 
 
 
 
A)                                                               B) 
 
 
 
 
 
 
 
 
 
 
C)                                                                        D) 
Figure 62: Small crystals obtained for MDM2 construct 3 with 226 in a JCSG+ screen  
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Table 57: Crystallisation conditions for Figure 62, A-D 
 
Well Complex Conc. 
(mg/mL)
a,b
 
Screen Complex 
: Screen 
ratio 
Salt Polymer Buffer 
(pH) 
A MDM2 
c3-226 
15.5 JCSG+ 2:1 - 25% 
(w/v) 
PEG 
3350 
0.1 M 
Bis-tris 
(5.5) 
B MDM2 
c3-226 
15.5 JCSG+ 2:1 0.2 M 
NaCl 
25% 
(w/v) 
PEG 
3350 
0.1 M 
Bis-tris 
(5.5) 
C MDM2 
c3-226 
15.5 JCSG+ 2:1 0.2 M 
Li2SO4 
25% 
(w/v) 
PEG 
3350 
0.1 M 
Bis-tris 
(5.5) 
D MDM2 
c3-226 
15.5 JCSG+ 2:1 0.2 M 
NH4OAc 
25% 
(w/v) 
PEG 
3350 
0.1 M 
Bis-tris 
(5.5) 
(a) Nanodrop 2000 (Thermo Scientific); (b) Average of 3 readings 
 
6.2 Measuring the Potency of Benzenoid, Thiazole- and Pyrrole-based 
MDMX Inhibitors by Homogeneous Time-Resolved Fluorescence  
 
All compounds screened against MDMX or MDM2 had been assessed using an 
enzyme-linked immunosorbent assay (ELISA) (cf. Chapter 7.3). This assay provided 
repeatable potency values, but limited supplies of the desired antibody and a 
comparatively long testing period for each compound necessitated a higher throughput 
assay. Discrepancies between inhibition data for competitor compounds in the ELISA 
and what had been previously reported in the literature also cast doubt on the ability of 
the ELISA to accurately compare potencies of the Newcastle inhibitors with the 
competitor compounds (Table 58).  
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Table 58: Comparison of IC50 values for known MDMX inhibitors recorded at Newcastle and in the 
literature 
 
ID Structure Literature 
MDMX 
Ki/IC50 
(µM) 
Newcastle 
MDMX 
Ki/IC50 
(µM)
a
 
Fold 
Difference 
 
WK-298 
(51)
104
 
 
 
19.7
b 
 
Not tested 
 
- 
 
52
104
 
 
 
19.0
b 
 
139
e 
 
7.3 
 
55d
108
 
 
 
2.68
c 
 
0%
f,h 
 
- 
 
RO-2443 
(57)
109
 
 
 
0.041
b 
 
10.6
g 
 
259 
 
RO-5963 
(58)
109
 
 
 
0.024
b 
 
20.2
d 
 
842 
(a) ELISA; (b) TR-FRET assay; (c) FP assay; (d) n = 1; (e) n = 2; (f) n = 3; (g) n = 4; (h) 200 µM 
 
Homogeneous time-resolved fluorescence (HTRF) evaluates compound potency by the 
measurement of fluorescence resonance energy transfer (FRET). FRET is the transfer of 
energy between two fluorophores (a donor and an acceptor), which can only occur when 
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the fluorophores are in sufficiently close proximity. Excitation of the donor triggers the 
transferral of energy to the acceptor, which in turn emits energy at a specific 
wavelength; this wavelength is the variable detected to measure binding affinity. In 
HTRF, there is a time delay of 50-150 µs between excitation of the donor and the 
measurement of FRET, so as to allow for the clearance of short-lived background 
fluorescence that would complicate the results. HTRF acceptors emit a far longer-lived 
fluorescence when engaged in the FRET process. 
 
In the assays conducted at Newcastle, GST-tagged MDMX
22-111
 was mixed with 
fluorescein-coupled IP3 peptide (Ac-16-MPRFMDYWQGLN-27-NH2).
163, 164
 IP3 is a 
p53-mutant sequence with enhanced affinity for MDMX and MDM2 over the authentic 
p53 sequence (16-QETFSDLWKLLP-27)
98, 164
 and fluorescein was the acceptor 
fluorophore. In addition, a terbium (Tb)-labelled anti-GST antibody was coordinated to 
the GST-MDMX fusion protein and functioned as the donor fluorophore.  
 
In the absence of a small-molecule inhibitor, excitation of the terbium would lead to 
energy transfer to the fluorescein, which would in turn emit FRET. Coordination of an 
inhibitor to MDMX, in place of IP3, would mean the two fluorophores were not 
sufficiently close for FRET to occur. More potent MDMX inhibitors would give a 
reduced FRET readout (Figure 63).  
 
 
 
 
 
 
 
A)                                                                            B) 
Figure 63: A) In the absence of an inhibitor, excitation of the donor (terbium) bound to the GST (TAG1) 
causes energy transfer to the fluorescein (TAG2), which in turn emits FRET; B) In the presence of an 
inhibitor (SM), MDMX (PROT1) and IP3 (PROT2) can no longer bind and the two fluorophores are not 
close enough for FRET to occur.
165, 166
  
  
Excitation (λ
1
) 
  
Energy Transfer FRET 
2
Excitation (λ
1
) 
  
Energy Transfer 
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The advantages of the HTRF assay over the ELISA were that no washing steps were 
required, speeding up the analytical process. HTRF could also be adapted to a 384-well 
plate format, meaning multiple inhibitors could be tested simultaneously using minute 
quantities of protein and fluorophore. 
 
Full details of the HTRF assay are given in Chapter 7.7. Twelve Newcastle inhibitors in 
the benzenoid, thiazole and pyrrole series were screened against MDMX
22-111
 to 
compare the IC50 values obtained to those acquired by ELISA, including 44j, 118c, 185, 
226 and 244 (cf. Table 54). Compounds were selected for HTRF based on having 
moderate activity against MDMX by ELISA (IC50 of 1-80 µM), or not having been 
measured for potency before in any assay, and having as low a clogD7.4 as possible 
(Table 59). Four competitor compounds were selected to compare the potency of these 
compounds in the HTRF assay with those reported in the literature. These were WK-
298 (51) (synthesised in house), RO-2443 (57) (synthesised in house), p53 17-30, N30F 
(kindly donated by David Lane, A*Star, Singapore) and p53 17-27 (Astex, UK). 
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Table 59: Newcastle MDMX inhibitors selected for HTRF analysis in addition to 44j, 118c, 185, 226 and 
244 
 
ID Structure MDMX 
IC50 (µM) 
MDM2 
IC50 (µM) 
Ratio 
(MDMX : 
MDM2) 
clogD7.4
c 
 
118d 
 
 
61.2
a
 
 
49.8
a
 
 
0.81 
 
+ 3.48 
 
118e 
 
 
48.9
a
 
 
59.9
a
 
 
1.22 
 
+ 3.44 
 
187 
 
 
77.3
a 
 
47.3
a
 
 
0.61 
 
+ 2.02 
 
44r 
 
 
52.7
a
 
 
8.30
a
 
 
0.16 
 
+ 3.68 
 
44s 
 
 
16.7
a
 
 
21.3
a
 
 
1.28 
 
+ 4.69 
 
 
283b 
 
 
 
Unknown
b 
 
 
Unknown
b
 
 
 
- 
 
 
+ 7.23 
 
 
220g 
 
 
 
Unknown
b 
 
 
Unknown
b
 
 
 
- 
 
 
+ 3.37 
(a)
 
n = 1; (b) Not tested in ELISA; (c) Values from StarDrop 
 
As the benzenoid series had been explored the most extensively, more compounds were 
selected from this series than from the thiazoles and pyrroles, and involved a mixture of 
di-, tri- and tetrasubstituted derivatives. Compounds were arranged in a 384-well plate 
at 10 concentrations varying on a semi-log scale (Figure 64). Positions 21-22 in each 
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row were positive controls (GST-MDMX, IP3-fluorescein and DMSO) and positions 
23-24 in each row were negative controls (IP3-fluorescein in DMSO and buffer).  
 
 
Figure 64: Layout of the 384-well plate used for the HTRF assay. Numbers refer to the 16 compounds 
analysed, including controls; (+) = positive control, (-) = negative control 
 
Individual compounds and DMSO were dispensed into each well using an Echo
®
 550 
liquid handler (Labcyte). Following incubation with the Tb-linked antibody, FRET 
detection was measured using a PHERAstar FS microplate reader (Figure 65).  
 
 
 
 
 
 
 
 
A)                                            B) 
Figure 65: A) Echo
®
 550 liquid handler (Labcyte) B) PHERAstar FS microplate reader  
 
Data points of the FRET readouts for each compound at the ten concentrations were 
tabulated, giving a Z’ value of 0.44. IC50 values for the two p53 peptides and for WK-
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298 were similar to the literature values.
98, 104
 However, there was a larger than 100-fold 
discrepancy between the IC50 recorded for RO-2443 and that presented in the 
literature.
109
 None of the Newcastle inhibitors returned a measurable IC50, either 
because of no observed inhibition of FRET or because inhibition did not reach a plateau 
concentration (Figure 66).  
 
  
 
 
 
 
 
Peptide MDMX IC50 (µM) 
p53 17-27 11.0 
p53 17-30, N30F 1.49 
 
A)                                                                     B)  
 
 
 
 
 
 
 
 
C)                                                                      D)  
Figure 66: A) HTRF assay results for p53 17-30, N30F (David Lane, A*Star, Singapore) and p53 17-27 
(Astex, UK); B) HTRF assay results for RO-2443 (57) and WK-298 (51); C) HTRF assay results for 
Newcastle inhibitors 118c, 118d, 118e, 185, 187 and 226; D) HTRF assay results for Newcastle inhibitors 
44r, 44s, 44j, 220g, 283b and 244  
 
Compound 185 showed negligible activity despite being moderately potent by ELISA 
(29.3 µM). In contrast, compounds 187 and 226 gave high percentage inhibition, but 
were similarly active to 185 in the ELISA. Compounds 244 and 44j also gave high 
percentage inhibition. Generally, compounds with lower clogD7.4 values were more 
Literature Compound MDMX IC50 (µM) 
RO-2443 8.16 
WK-298 17.9 
244 
283b 
220
g 44r 
44s 
44j 
Newcastle Inhibitors  
Peptides 
p53 17-27 
p53 17-30, 
N30F 
Competitor Compounds 
RO-2443 
(57) 
WK-298 
(51) 
Newcastle Inhibitors 
118c 
118d 
118e 
187 
185 
226 
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active in the HTRF assay, suggesting that poor compound solubility was preventing 
accurate comparison between the activities determined in this assay with those of the 
ELISA. 
 
6.3 Analysing MDMX Stabilisation by Benzenoid, Thiazole- and 
Pyrrole-based Inhibitors using Fluorescence-based Thermal Shift 
 
Thermal shift, also known as Differential Scanning Fluorimetry (DSF), is a denaturation 
assay for hit identification.
167, 168
 It provides an estimate of ligand-binding affinity by 
measuring the change in the unfolding transition temperature (ΔTm) of a protein in the 
presence of a ligand, relative to the unfolding temperature in the absence of a ligand (the 
apoprotein). Protein unfolding is monitored using a dye which fluoresces in 
hydrophobic environments but is quenched in polar environments, e.g. water. As the 
protein unfolds, the dye binds to the exposed hydrophobic regions of the protein 
resulting in an increase in fluorescence (Figure 67).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67: DSF graph showing how fluorescence intensity increases with protein denaturation, exposing 
the dye SYPRO orange.
169
  
 
DSF is a high-throughput, rapid method for screening compounds, requiring low 
quantities of protein. However, DSF should not be used as the sole method for hit 
identification. Two different compounds with equal affinity for the same protein may 
give different Tm values, as binding is dependent on multiple factors, including enthalpy 
and entropy.
168
 Compounds which stabilise a protein significantly often bind more 
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entropically (e.g. through hydrophobic interactions) and these modes of binding can 
compete with each other and complicate the results obtained.  
 
Full details of the DSF assay are given in Chapter 7.8. Twenty-nine benzenoid, thiazole- 
and pyrrole-based compounds were screened, in addition to five competitor compounds 
and peptides: p53 17-30, N30F (David Lane, A*Star, Singapore), WK-298 (51), RO-
2443 (57), RO-5963 (58) and RG7388 (291).
170
 All compounds were screened against 
MDMX
18-111
, MDMX
22-111
 and MDMX
26-111
, using a 384-well plate format, in the 
presence of SYPRO orange dye. Plates were heated from 25-95 
o
C at 3 
o
C/min and the 
differences in melting temperature in the presence of a ligand relative to the apoprotein 
(ΔTm) for each MDMX construct are shown in Tables 60-62.  
 
 
 
Table 60: ΔTm values observed for benzenoid, thiazole- and pyrrole-based inhibitors against MDMX
18-111
 
(Tm, apoprotein = 55.9 
o
C)  
 
Inhibitor
a ΔTm 1 (
o
C)
b ΔTm 2 (
o
C)
b ΔTm 3 (
o
C)
b Average ΔTm 
(
o
C)
b 
118b -0.1 -0.2 -0.1 -0.1 
118c -0.2 0.6 -0.3 0.0 
118d -0.2 0.0 -1.3 -0.5 
118i 0.0 0.2 -0.1 0.0 
118l -0.1 -0.1 0.0 -0.1 
118m -0.1 0.1 0.0 0.0 
118o -0.3 0.4 0.0 0.0 
118e -0.3 -0.2 0.0 -0.2 
128b -0.5 0.1 -0.2 -0.2 
137b -0.1 0.1 -0.1 0.0 
138c -0.2 -0.3 -0.2 -0.2 
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138d -0.9 0.5 0.0 -0.1 
138i -0.2 -0.1 -0.1 -0.1 
138j 0.6 0.3 0.3 0.4 
151a 0.5 0.3 0.3 0.4 
183a -1.0 0.5 -0.3 -0.3 
185 -0.3 0.3 0.2 0.1 
186 0.3 -0.1 0.2 0.1 
187 -1.7 -0.5 -2.6 -1.6 
226 -15.5 0.0 -13.0 -9.5 
231 0.8 0.2 0.5 0.5 
244 -0.4 -0.2 -0.7 -0.4 
44j -2.9 -1.0 -0.9 -1.6 
44r 0.4 0.3 0.4 0.4 
44s -0.8 -0.9 -0.9 -0.9 
44t -0.1 -0.2 0.0 -0.1 
220c 0.1 0.1 0.0 0.0 
283b -0.1 0.0 0.0 0.0 
220g -0.1 -0.1 -0.5 -0.2 
p53 17-30, 
N30F 1.2 0.9 3.4 1.8 
RO-2443 0.1 0.2 0.2 0.2 
RO-5963 0.1 0.2 0.3 0.2 
RG7388 -0.3 -0.4 -0.4 -0.4 
WK-298 1.0 0.6 0.7 0.8 
(a)
 
Benzenoid inhibitor numbers are written in black, thiazole-based inhibitors are in green and pyrrole-
based compounds are in blue; (b) Boxes that are coloured green signify protein stabilisation by at least 
+0.5 
o
C and boxes in red signify destabilisation by at least -0.5 
o
C 
 
Several compounds were destabilising to MDMX
18-111
, giving an average change in 
melting temperature (ΔTm) below that of the apoprotein. Compounds which strongly 
destabilised the protein all possessed acidic functional groups. The most potent 
destabilising compound was 226, with a benzoic acid substituent, but the corresponding 
benzyl alcohol 231 had a stabilising effect. This observation was also seen in the 
thiazole series, where compounds 44j and 44s, which both have 
trifluoromethylsulfonamide groups, reduced melting temperature but the analogous 
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phenol 44r did not. The pyrrole series did not affect melting temperature, even though 
two possessed acidic functional groups (220c and 220g).  
 
Table 61: ΔTm values observed for benzenoid, thiazole- and pyrrole-based inhibitors against MDMX
22-111
 
(Tm, apoprotein = 55.0 
o
C)  
 
Inhibitor
a ΔTm 1 (
o
C)
b ΔTm 2 (
o
C)
b ΔTm 3 (
o
C)
b Average ΔTm 
(
o
C)
b 
118b -0.2 -0.5 0.1 -0.2 
118c 0.1 0.5 0.6 0.4 
118d -0.2 -1.3 -0.7 -0.7 
118i 0.5 0.1 0.3 0.3 
118l -0.3 0.0 0.3 0.0 
118m 0.5 0.0 0.1 0.2 
118o -0.3 0.2 0.0 0.0 
118e 0.0 -0.5 -0.3 -0.3 
128b -0.5 0.2 0.2 -0.1 
137b -0.3 0.1 0.0 -0.1 
138c -0.1 0.3 0.2 0.1 
138d -0.5 -0.1 0.2 -0.2 
138i 0.2 0.0 -0.1 0.0 
138j 0.3 0.2 0.5 0.3 
151a 0.3 0.4 0.7 0.5 
183a -0.4 0.2 0.3 0.0 
185 -0.3 0.3 0.5 0.2 
186 0.1 -0.8 0.4 -0.1 
187 -0.2 -1.0 -0.2 -0.5 
226 -0.9 -0.1 0.4 -0.2 
231 0.2 0.4 0.4 0.3 
244 -1.2 -0.6 -0.5 -0.8 
44j 0.0 -0.2 0.0 -0.1 
44r 1.0 0.3 0.5 0.6 
44s 0.1 0.2 0.4 0.3 
44t 0.2 0.0 0.2 0.1 
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220c -0.6 -0.1 0.1 -0.2 
283b -0.2 -0.1 0.0 -0.1 
220g 0.0 0.1 -0.3 -0.1 
p53 17-30, 
N30F 2.3 1.2 2.4 1.9 
RO-2443 0.2 0.3 0.0 0.2 
RO-5963 0.8 0.6 0.2 0.5 
RG7388 -0.2 0.0 0.0 -0.1 
WK-298 2.1 2.2 2.3 2.2 
(a)
 
Benzenoid inhibitor numbers are written in black, thiazole-based inhibitors are in green and pyrrole-
based compounds are in blue; (b) Boxes that are coloured green signify protein stabilisation by at least 
+0.5 
o
C and boxes in red signify destabilisation by at least -0.5 
o
C 
 
Three compounds on average destabilised MDMX
22-111
: 118d, 187 and 244. Similar to 
MDMX
18-111
, these compounds all possessed acidic functional groups. Thiazole 44r and 
RO-5963 gave a mildly stabilising effect on melting temperature that was not observed 
with MDMX
18-111
. 
 
Table 62: ΔTm values observed for benzenoid, thiazole- and pyrrole-based inhibitors against MDMX
26-111
 
(Tm, apoprotein = 53.7 
o
C) 
 
Inhibitor
a ΔTm 1 (
o
C)
b ΔTm 2 (
o
C)
b ΔTm 3 (
o
C)
b Average ΔTm 
(
o
C)
b 
118b -0.3 -0.5 -0.5 -0.4 
118c 0.0 0.5 0.1 0.2 
118d -0.4 0.2 -0.4 -0.2 
118i -0.2 -0.3 0.2 -0.1 
118l -0.5 -0.7 -0.5 -0.6 
118m -0.1  0.2 0.1 
118o -0.9 -0.1 -0.1 -0.4 
118e 0.5 0.3 -0.8 0.0 
128b -0.7 -0.3 -0.2 -0.4 
137b -0.5 0.6 -0.3 -0.1 
138c -0.4 -0.8 -0.4 -0.5 
138d -0.6 -0.2 -0.7 -0.5 
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138i -0.7 -0.5 -0.4 -0.5 
138j 0.2 0.3 0.0 0.2 
151a 0.1 0.0 0.0 0.0 
183a -0.3 0.9 -0.4 0.1 
185 -0.7 0.3 -0.1 -0.2 
186 0.9 1.2 0.6 0.9 
187 -0.8 1.0 -0.5 -0.1 
226 -1.0 -8.7 -0.4 -3.4 
231 -0.5 -0.1 0.4 -0.1 
244 0.2 0.4 -0.5 0.0 
44j 0.3 0.2 -0.3 0.1 
44r 0.4 0.7 0.4 0.5 
44s -0.3 -0.7 -0.4 -0.4 
44t -0.7 0.0 -0.5 -0.4 
220c -0.7 0.1 -0.1 -0.2 
283b -0.4 -0.2 -0.2 -0.3 
220g -0.4 -0.3 -0.7 -0.5 
p53 17-30, 
N30F 1.1 1.9 1.8 1.6 
RO-2443 -0.6 -0.4 -0.1 -0.3 
RO-5963 -0.4 -0.3 1.2 0.1 
RG7388 -1.0 -1.0 -0.5 -0.8 
WK-298 2.3 1.1 0.6 1.3 
(a)
 
Benzenoid inhibitor numbers are written in black, thiazole-based inhibitors are in green and pyrrole-
based compounds are in blue; (b) Boxes that are coloured green signify protein stabilisation by at least 
+0.5 
o
C and boxes in red signify destabilisation by at least -0.5 
o
C 
 
More compounds destabilised MDMX
26-111
 than had been observed for MDMX
18-111
 
and MDMX
22-111
 and some of these, e.g. 118l, did not possess acidic functional groups. 
Compound 226 was the most destabilising compound and compound 186 gave a 
reproduceable yet significant stabilising effect. RG7388 destabilised this construct, but 
p53 17-30, N30F and WK-298 stabilised it.  
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6.4 Conclusion 
 
Three MDMX and three MDM2 constructs were successfully expressed in E. coli 
Rosetta(DE3)pLys S and BL21(DE3) pLys S strains and purified using size exclusion 
chromatography. Attempts were made to crystallise five benzenoid and thiazole-based 
compounds, 44j, 118c, 185, 226 and 244, and control compound 57, with these six 
constructs, trialling over 11,000 conditions with AmSO4 and JCSG+ screens. Needle-
like crystals were observed for 226 with MDM2 construct 3 in several wells with 
similar conditions, but the crystals were too small for data collection. Optimisation of 
these crystallisation conditions is ongoing. Twelve benzenoid, thiazole- and pyrrole-
based compounds were assessed for potency against MDMX
22-111
 using an HTRF assay 
with fluorescein-coupled IP3 peptide. However, none of the compounds returned a 
measurable IC50, either due to weak FRET inhibition or because inhibition never 
reached a plateau concentration. Twenty-nine benzenoid, thiazole- and pyrrole-based 
compounds were also screened against MDMX
18-111
, MDMX
22-111
 and MDMX
26-111
 
using a DSF assay. Compounds with strongly acidic functional groups, e.g. carboxy or 
trifluoromethylsulfonamido groups, often destabilised the construct relative to the 
apoprotein, with 226 being the most strongly destabilising compound against MDMX
18-
111
 and MDMX
26-111
. Most compounds did not affect the melting temperature of any 
MDMX construct by more than 1 
o
C. 
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Chapter Seven: Experimental 
 
7.1 Computer Software 
 
All chemical structures were drawn and values for clogP were calculated using 
ChemDraw Ultra v12.0 (PerkinElmer Informatics). Chemical reaction conditions were 
sourced, where possible, from Reaxys (Elsevier) and SciFinder (Chemical Abstracts 
Service). Values for ligand efficiency (LE), lipophilic efficiency (LipE) and clogD7.4 
were calculated using StarDrop (Optibrium). 
1
H, 
13
C and 
19
F NMR data were analysed 
using TopSpin v3.2 (Bruker). Crystallographic Object-Orientated Toolkit (COOT) (Paul 
Emsley, Cambridge) with CCP4mg plug-in (Martin Noble, Oxford) was used for the 
construction of molecular models.  
 
7.2 SKP2 Sulforhodamine B Assay 
 
SRB assays were undertaken by Laura Evans at the Northern Institute for Cancer 
Research (NICR) and followed the procedure described by Skehan.
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 Pre-cultured 
stocks of HeLa cervical cancer cells were seeded (2,000 cells per well) in a tissue 
culture-treated 96-well plate (Corning) and left to attach overnight. All compounds were 
screened on a log scale at 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30 and 100 µM. Compounds 
were suspended in 100% DMSO to 100 mM, when solubility allowed, and stored at -20 
o
C. Final compound concentrations added to each well were in 100 µL medium, 0.5% 
DMSO and each concentration was replicated in 6 wells. After treatment, cells were 
incubated for 72 h at 37 
o
C, 5% CO2. DMSO only was used as a negative control and a 
day 0 plate was fixed and stained on the day of drug treatment to correct for cell growth 
overnight. Cells were fixed by adding cold 50% (w/v) aqueous trichloroacetic acid 
(TCA) (25 µL, per well) and incubating at 4 
o
C for 1 h. The wells were washed with 
deionised water and stained with 0.4% (w/v) sulforhodamine B (SRB) (100 µL per 
well) at room temperature for 30 min. Unbound dye was removed using 1% (v/v) acetic 
acid and left to dry in air at room temperature overnight. Bound dye was solubilised 
using 10 mM Tris buffer, pH 9.5 (100 µL per well) and optical density measured using 
a spectrophotometric plate reader (Model 680, Microplate reader, Bio-Rad) at 570 nm.  
 
Cell growth inhibition was calculated using GraphPad Prism Version 6.0 software 
(GraphPad Software Inc.). Readings were corrected for one day cell growth and the 
percentage growth inhibition relative to the DMSO-only control determined for each 
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concentration. GI50 values were calculated using a plot of concentration versus 
percentage of DMSO-only control on a standard point-to-point gradient with 1,000 
segments. 
 
7.3 MDMX-p53 and MDM2-p53 Enzyme-linked Immunosorbent 
Assay 
 
ELISA assays were undertaken by Dr Yan Zhao at the Northern Institute for Cancer 
Research (NICR). In vitro-translated full-length MDMX and MDM2 (MDMX-IV and 
MDM2-IV) constructs were prepared by mixing the following components together at 0 
o
C, heating at 30 
o
C for 2 h and storing at -20 
o
C overnight (Table 63). 
 
Table 63: Composition of the in vitro transcription/translation reaction mixture to 
prepare MDMX and MDM2 proteins for the ELISA  
 
 MDM2 MDMX 
Component Volume (µL) Volume (µL) 
T7 buffer 80 80 
T7 polymerase 40 40 
Amino acid mix, Complete
a 
80 40 
Rnasin 40 40 
Plasmid DNA
b 
160 40 
Sterile H2O 750 760 
Reticulocyte lysate 1000 1000 
(a) 1 mM each of the 20 essential amino acids;
 
(b) 1 mg/mL 
 
Compounds were dissolved to 2 mM in 100% DMSO and plated out in 10 µL aliquots 
into a clear, non-coated 96-well plate (Nunc, Thermo Scientific). DMSO alone was used 
as a negative control. Nutlin-3a was used as a positive control for MDM2, tested in 
triplicate at final concentrations 50, 100 and 200 nM (starting concentrations of 1, 2 and 
10 µM). IP3 peptide was used as a positive control for MDMX, tested in triplicate at 
final concentrations of 0.5, 2 and 10 µM (starting concentrations of 10, 40 and 200 µM).  
MDM2-IV (or MDMX-IV) (800 µL) was added to phosphate-buffered saline (PBS) (20 
mL), mixed and plated out in 190 µL aliquots to each well of the clear 96-well plate. 
The plate was left to stand at room temperature (no shaking) for 20 min.  
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A 100 µg/mL PBS aliquot of biotinylated IP3 peptide (IP3: Ac-16-
MPRFMDYWQGLN-27-NH2) (200 µL) was added to PBS (20 mL), mixed and 
distributed in 200 µL aliquots to each well of a Streptavidin-coated 96-well plate 
(Wallac) and stored on a shaking platform at 4 
o
C for 1 h. The contents of the plate were 
discarded and the plate was washed with PBS (3 × 200 µL per well). The MDMX/2-
compound mixtures were transferred to the b-IP3-Streptavidin plate, which was 
incubated at 4 
o
C on a shaking platform for 90 min.  
 
The contents of the plates were discarded and the plate was washed with PBS (3 × 200 
µL per well). Primary mouse monoclonal anti-MDM2 antibody (MDM2 Ab-5, 
Calbiochem) (100 µL) was added to TBS-Tween (50 mM Tris, pH 7.5, 150 mM NaCl, 
0.05% Tween 20 nonionic antibody) (20 mL) and mixed. This was repeated for MDMX 
Ab-5 (BETHYL(A300-287A)) (10 µL) in TBS-Tween (20 mL). Antibody solutions 
were transferred to the analogous protein-containing wells and incubated at room 
temperature on a platform shaker for 1 h. The primary antibody was discarded from the 
plates, which were washed with TBS-Tween (3 × 200 µL per well). Goat anti-mouse 
HRP-conjugated antibody (Dako) (for MDM2) or goat anti-rabbit HRP-conjugated 
antibody (Dako) (for MDMX) (10 µL) was mixed with TBS-Tween (20 mL) and 
aliquots (200 µL) were added to each well of the plate, which was incubated at room 
temperature on a platform shaker for 45 min. The contents of the plates were discarded. 
TBS-Tween (200 µL per well) was added, the plate was shaken briefly and the contents 
discarded. TBS-Tween (200 µL per well) was added, the plate was shaken vigorously 
on a platform shaker for 5 min and the contents discarded. This process was repeated 
twice with TBS-Tween (200 µL per well each time), shaking the plate vigorously for 10 
and 15 min respectively before discarding the contents. 
 
Bound HRP activity was measured by enhanced chemiluminescence (ECL, Amersham 
Biosciences) using the oxidation of luminol to generate a quantifiable light signal. The 
luminol and enhancer were injected into each well and the relative luminescence units 
(RLU) measured over 30 s using a Berthold MicroLumat-Plus LB 96 V microplate 
luminometer. The percentage MDM2/X inhibition at a given concentration was 
calculated using Equation 1 and IC50 was calculated using a plot of % MDM2/X 
inhibition versus concentration.  
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% MDM2/X inhibition = RLU (compound-treated sample) ÷ RLU (DMSO controls) x 
100%. 
Equation 1 
 
7.4 Expression of Recombinant GST-MDMX and GST-MDM2 in E. 
coli 
 
Recombinant MDMX pGEX-6P-1 expression vector plasmids were transformed into 
competent Rosetta(DE3)pLys S (Novagen) E. coli, whilst recombinant MDM2 pGEX-
6P-1 plasmids were transformed into competent BL21(DE3) pLys S E. coli (Novagen) 
(cf. Table 64). Competent cells (50 µL) were incubated on ice with plasmid DNA (1 µL, 
~100 ng) for 30 min before being heatshocked at 42 
o
C for 30 s and then cooled on ice 
for 2 min. The cells were recovered by adding SOB media (200 µL) before incubating 
at 37 
o
C and 200 RPM for 1 h. The transformed cells (200 µL) were then spread onto 
LB-agar supplemented with 100 µg/mL ampicillin and 34 µg/mL chloramphenicol, 
before being incubated at 37 
o
C overnight. Single transformed colonies were incubated 
into LB-media (for the expression of recombinant MDM2) (10 mL) or TB-media (for 
the expression of recombinant MDMX) (10 mL), with both media supplemented with 
100 µg/mL ampicillin and 34 µg/mL chloramphenicol. These starter cultures were 
incubated at 37 
o
C and 200 RPM overnight and then inoculated into a 5 L wide-neck 
Erlenmeyer flask containing LB-media (1 L) or TB-media (1 L) for the expression of 
MDM2 and MDMX respectively. The expression media was supplemented with 50 
µg/mL ampicillin and 34 µg/mL chloramphenicol. The inoculated media was incubated 
at 37 
o
C with shaking at 160 RPM until the cultures had grown to an OD600 in the range 
0.6-1.0, at which point the media were supplemented with 0.2 mM IPTG. The 
incubation temperature and shaking speed was reduced to 20 
o
C and 100 RPM, 
respectively, overnight before harvesting the cells by centrifugation at 5,000 RPM for 
10 min at 4 
o
C (Rotor JLA 8.1, Beckman Coulter). Cell pellets resulting from 1 L of 
culture were suspended in ice-cooled mHBS buffer (30 mL) containing one solubilised 
protease inhibitor tablet (Roche). The resuspended cells were flash-frozen in liquid 
nitrogen or dry ice and then stored at -80 
o
C. 
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7.5 Purification of Recombinant GST-MDMX and GST-MDM2 
 
Frozen cells were defrosted and treated with 25 mg/mL lysozyme (400 µL), 10 mg/mL 
RNase A (200 µL), 2 mg/mL DNase I (200 µL) and 2 M MgCl2 (100 µL), whilst being 
kept on ice. The cell suspension was sonicated on ice at 30% amplitude (15 times, 20 s 
on/40 s off) before being centrifuged at 20,000 RPM for 1 h at 4 
o
C (Rotor JA 25.50, 
Beckman Coulter). The supernatant was retained and incubated with pre-equilibrated 
glutathione Sepharose 4B GST affinity resin (GE Healthcare) whist being mixed on a 
motorised roller at 4 
o
C overnight. The incubated resin was poured into an empty 
gravity column (bed volume circa 2 mL) and then washed with mHBS buffer (2 × 50 
mL) to remove E. coli contaminants. The GST-bound protein was eluted from the 
column in 1 mL fractions using mHBS buffer, pH 7.4 containing 25 mM glutathione. 
Protein concentrations were determined using a Nanodrop 2000 (Thermo Scientific) by 
UV absorbance at 280 nm and protein-containing fractions were pooled. GST was 
cleaved by mixing with 3C protease (stock at 1 mg/mL, cleavage ratio 1:50 3C:GST-
fusion) and purified by size-exclusion chromatography on an Äkta FPLC system using a 
HiLoad 26/600 Superdex 75 column (mHBS, isocratic gradient, 4 mL/min, UV 
absorbance 280 nm). Protein-containing fractions were analysed by SDS-PAGE (cf. 
Chapter 7.9.3), before concentrating fractions containing purified MDMX or MDM2 by 
ultrafiltration using an Allegra
TM
 25R centrifuge (Beckman Coulter). 
 
7.6 Protein Preparation for Crystallography 
 
Following purification, MDMX and MDM2 were concentrated by ultrafiltration using 
15 mL Amicon Ultra 3 kDa columns (3 kDa MWCO, Millipore), centrifuged at 5,000 
RCF and 4 °C. During ultrafiltration, protein concentration was determined using a 
Nanodrop 2000 (Thermo Scientific) according to protein construct molecular weights 
and extinction coefficients (cf. Table 64). Once concentration values could be 
ascertained, a suitable amount of protein was incubated overnight at 4
 o
C with selected 
inhibitors at a 1.5-fold excess. The inhibitors had been previously resuspended to 20 
mM in 100% DMSO. The incubated protein-inhibitor mixture was then concentrated 
using either 15 mL or 4 mL Amicon Ultra 3 kDa columns (3 kDa MWCO) until a 
protein concentration of 3-10 mg/mL had been achieved.  
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The concentrated protein was used to set up 2-subwell 96-well crystallisation trays after 
dispensing reservoir solutions from commercially available ammonium sulfate 
(AmSO4) (Qiagen) and JCSG+ screen (Molecular Dimensions) deep-well blocks. The 
protein-inhibitor complex (100 nL and 200 nL drops) was mixed with the reservoir 
solution (100 nL) using a Mosquito
®
 robot to dispense sitting drops. The plates were 
sealed and stored in a Rikagu Minstrel tray hotel at 4 
o
C until seven time-points had 
been imaged over an eight-week period. 
 
7.7 GST-MDMX
22-111
 Homogeneous Time-resolved Fluorescence Assay 
 
Compounds were dissolved to 20 mM in 100% DMSO and plated out into a black, low 
volume, low binding, round-bottom 384-well plate (Corning) using an Echo
®
 550 liquid 
handler (Labcyte). Each well was backfilled with DMSO to a volume of 250 nL. The 
peptides p53 17-27 (Pamela Williams, Astex, UK) and p53 17-30, N30F (David Lane, 
A*Star, Singapore), RO-2443 (synthesised in house) and WK-298 (synthesised in 
house) were used as control compounds. Each compound was screened at 10 
concentrations using a semi-log scale starting at 500 µM, except for p53 17-30, N30F, 
which started at 200 µM. Each concentration was tested in duplicate. Each well was 
charged with 500 nM fluorescein-labelled IP3 peptide in buffer A (50 mM Tris, pH 7.5, 
100 mM NaCl, 100 µg/mL bovine serum albumin (BSA) and 1 mM dithiothreitol 
(DTT)) containing 4.2% DMSO (6 µL) (final concentration 300 nM) followed by 25 
nM GST-MDMX 22-111 in buffer A (4 µL) (final concentration 10 nM). The final 
concentration of DMSO in each well was 5%. Positive controls contained IP3 peptide, 
GST-MDMX and DMSO. Negative controls contained IP3 peptide and DMSO with 
buffer A replacing the protein. The plate was incubated on a shaking platform at room 
temperature for 1 h. To each well was added 20 nM LanthaScreen
®
 Tb-anti-GST 
antibody (Life Technologies) in buffer B (50 mM Tris, pH 7.5, 100 mM NaCl and 100 
µg/mL BSA) (10 µL) (final concentration 10 nM) and the plate was incubated on a 
shaking platform at room temperature for 45 min.  
 
The homogeneous time-resolved fluorescence (HTRF) ratio was measured using a 
PheraStar FS microplate reader (donor excitation at 337 nm, donor emission at 490 nm, 
acceptor emission at 520 nm). The HTRF ratio was calculated using Equation 2 and 
converted to a percentage inhibition using Equation 3. IC50 values were calculated with 
GraphPad Prism Version 6.0 software (GraphPad Software Inc.), using a plot of log 
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inhibitor concentration versus percentage inhibition with the data fitted to a sigmoidal 
dose-response curve.  
 
HTRF ratio = FRET λ ÷ acceptor emission λ x 10,000 
Equation 2  
 
% Inhibition (compound X) = [(positive control FRET λ - compound X FRET λ)] ÷ 
positive control FRET λ x 100% 
Equation 3   
 
7.8 MDMX Thermal Shift (Differential Scanning Fluorimetry) Assay 
 
Compounds were dissolved to 20 mM in 100% DMSO and plated out (45 nL per well) 
in a MicroAmp
®
 optical 384-well plate (Life Technologies) using an Echo
®
 550 liquid 
handler (Labcyte). Echo dispensing was designed to test each compound and control in 
triplicate, with a total reaction volume of 15 µL/well to give a final inhibitor 
concentration of 60 µM. Test reactions contained 30 µM MDMX, SYPRO orange 
(1:1000, 5 X stock), 4% DMSO and mHBS buffer to bring the reaction volume to 15 
µL/well. Positive control reactions were performed using the same conditions and 
selected compounds: RG-7388 (synthesised in house), p53 17-30, N30F (David Lane, 
A*Star, Singapore), RO-2443 (synthesised in house), RO-5963 (synthesised in house) 
and WK-298 (synthesised in house). Negative control reactions were set up without 
MDMX or without DMSO (mHBS was used as a replacement in both instances). Once 
dispensed, the plates were centrifuged at 1,250 RCF for 5 min at 4 
o
C and heated from 
25-95 
o
C at 3 
o
C/min using a ViiA
TM
 7 Real-Time PCR System (Applied Biosystems).  
 
Tm values were calculated using an Excel-based DSF analysis Transformation tool 
downloaded from ftp://ftp.sgc.ox.ac.uk/pub/biophysics (Frank Neisen, SGC, Oxford). 
Data was compiled using GraphPad Prism Version 6.0 software (GraphPad Software 
Inc.). 
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7.9 General Biology Procedures and Reagents  
7.9.1 MDMX and MDM2 protein constructs  
 
Genes encoding human MDMX and MDM2 were cloned into pGEX-6P-1 to yield 
several GST-MDMX and GST-MDM2 constructs (Table 64).   
 
Table 64: MDMX and MDM2 protein constructs used 
 
Protein Construct Amino Acid 
Range 
Molecular 
Weight (g 
mol 
-1
) 
Extinction 
Coefficient 
(M
-1
 cm
-1
)
a
 
Mutations 
MDMX 1 18-111 11070.9 7450 None 
MDMX 2 22-111 10617.4 7450 None 
MDMX 3 26-111 10204.9 7450 None 
MDM2 1 17-125 12874.7 10430 K51A 
MDM2 2 17-109 11067.9 10430 E69A/K70A 
MDM2 3 17-125 12816.7 10430 E69A/K70A 
(a) Measured at 280 nm in H2O 
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7.9.2 Culture media protein buffer and stock solutions  
 
The compositions of the culture media and stock solutions are provided in Table 65. 
 
Table 65: Culture media protein buffer and stock solutions  
 
Solution Components (quantities) Additional 
Information 
Lysogeny broth 
(LB) 
Tryptone (10 g), yeast extract (5 g), 
NaCl (10 g) in distilled water (1 L) 
Autoclaved at 121 
o
C 
for 20 min before use 
Terrific broth 
(TB) 
Enzymatic casein digest (12 g), yeast 
extract (24 g), potassium phosphate, 
dibasic, anhydrous (9.4 g), potassium 
phosphate, monobasic, anhydrous (2.2 g) 
in distilled water (1 L) and glycerol (4 
mL) 
Autoclaved at 121 
o
C 
for 20 min before use 
mHBS buffer
a
 5 M NaCl (20 mL), 1 M DTT (5 mL) 
and 1 M HEPES, pH 7.4 (20 mL) in 
distilled water (955 mL) 
Vacuum filtered through 
a 0.4 µM membrane and 
degassed in vacuo for 
10 min before use 
IPTG (100 mM) DTT (1 g) in distilled water (42 mL) Filter sterilised and 
stored at -20 
o
C 
Glutathione (20 
mM) 
Glutathione (307 mg) in mHBS (50 mL) pH adjusted to 7.4 with 
aqueous NaOH before 
use 
Ampicillin Dissolved in distilled water to 50 mg/mL Stored at -20 
o
C 
Chloramphenicol Dissolved in 100% ethanol to 34 mg/mL Stored at -20 
o
C 
(a) Final concentrations of NaCl, DTT and HEPES were 100 mM, 5 mM and 20 mM 
respectively 
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7.9.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
 
SDS-PAGE was used for protein identification, estimation of sample impurity and 
semi-quantitative analysis. Pre-cast 12-well 12% or 16% acrylamide gels (RunBlue) 
were used with SDS-PAGE running buffer (25 mM Tris, pH 9.5, 192 mM glycine, 0.1% 
SDS) (1 L). Samples (2.5-15 µL) were mixed with SDS-PAGE loading buffer (0.25% 
(w/v) bromophenol blue, 0.5 M DTT, 50% (v/v) glycerol, 10% (w/v) sodium dodecyl 
sulfate (SDS) and 0.25 M Tris-Cl, pH 6.8) (5 µL per sample) and made up to 20 µL 
with distilled water, then denatured at 100 
o
C for 5 min before loading onto the gel. 
PageRuler pre-stained protein ladder (170-10 kDa, Thermo Scientific) (7.5 µL) was also 
used (Figure 68). Electrophoresis was carried out at 180 V and the gel was 
subsequently stained with Instant Blue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: PageRuler pre-stained protein ladder (170-10 kDa, Thermo Scientific) 
 
7.10 Chemicals and solvents 
 
Chemicals were purchased from Sigma Aldrich Chemical Company, Alfa Aesar, 
Fluorochem, Apollo Scientific, Frontier Scientific, TCI UK, ChemBridge and Acros 
Organics. Reactions were routinely performed under an atmosphere of nitrogen, 
employing anhydrous solvents, including DCM, methanol, ethanol, DMF, TFE, 
acetone, 2-butanol, 1,4-dioxane, DMSO, toluene, α,α,α-TFT, acetonitrile, 1,2-DME, 
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diethyl ether and THF purchased from Sigma Aldrich Chemical Company in SureSeal 
bottles. Diisopropylamine (DIPA), 2-butanol and acetone were distilled over calcium 
hydride or potassium hydroxide and butyllithium was titrated using a quantitative 
analytical solution purchased from Aldrich, containing 1.0 M 2-propanol in toluene with 
0.2% 1,10-phenanthroline. Bottles of lithium aluminium hydride were purchased from 
Aldrich, as a 1.0 M or 2.0 M solution in anhydrous THF, and inspected by eye to be 
clear with little or no traces of sediment present before use. All hydrogenation reactions 
except transfer hydrogenations and those performed with tin(II) chloride, iron or zinc 
powder were performed in a ‘H-cube’ hydrogenation reactor supplied by ThalesNano 
Inc. 10% Pd/C and Raney Nickel CatCarts
®
 were purchased from ThalesNano Inc., 
Product ID: THS 01111 and THS 01112 respectively. All uses were logged and 
CatCarts
®
 were flushed with IPA after each use. All microwave-assisted reactions were 
performed in an Initiator Sixty Biotage apparatus with a robotic samples bed, using 
‘Hold Temperature’ mode in all cases. Reactions were irradiated at 2.45 GHz, with 
temperatures able to reach 250 
o
C and pressures able to reach 20 bar.  
 
7.11 Chemistry Analytical Techniques 
 
Proton (
1
H), carbon (
13
C) and fluorine (
19
F) nuclear magnetic resonance (NMR) 
experiments were conducted on a Bruker Avance 500 (
1
H at 500 MHz, 
13
C at 125 MHz 
and 
19F at 470 MHz). Chemical shifts (δ) are quoted in parts per million (ppm), 
referenced to the appropriate deuterated solvent used, and coupling constants (J) are 
quoted in Hertz (Hz). The deuterated solvents used were chloroform-d (99.8 atom% D), 
methanol-d4 (99.8 atom% D) or DMSO-d6 (99.9 atom% D) purchased from Sigma 
Aldrich Chemical Company, unless otherwise specified. Multiplicities are given as 
singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad (br) or a combination 
of these and correspond to those observed in the spectrum rather than those predicted to 
be observed. Liquid chromatography-mass spectrometry (LC-MS) was conducted on a 
Waters Acquity UPLC system with PDA and ELSD, using an Acquity UPLC BEH C18 
column measuring 1.7 µm, 2.1 x 50 mm. The mobile phase consisted of either 0.1% 
(v/v) formic acid in water or 0.1% (v/v) formic acid in acetonitrile. Gradients were 
measured over two minutes with a flow rate of 0.6 mL/min and an injection volume of 2 
µL. Mass spectrometry was conducted using a Waters SQD with ESCi source in ES 
mode. Capillary voltage was 3 kV, cone voltage was 30 V, source temperature was 150 
o
C, desolvation temperature was 450 
o
C, desolvation gas was used at a rate of 800 L/h 
227 
 
and cone gas was used at a rate of 50 L/h. Analytical high performance liquid 
chromatography (HPLC) was used to provide an estimate of compound purity and was 
conducted on an Agilent 1200 HPLC system with a diode array detector (DAD) 
monitoring wavelengths at 210, 230, 254, 280, 310 and 340 nm. Chromatography was 
performed on a 4.6 x 150 mm Waters XTerra RP18 5 µm column with a mobile phase 
consisting of either 0.1% (v/v) aqueous ammonia in acetonitrile or 0.1% (v/v) aqueous 
formic acid in acetonitrile. Gradient programs were run over 25 min (5-100% 
acetonitrile) followed by column clean-up and equilibrium at a flow rate of 1.0 mL/min. 
A HPLC in acidic and basic media was recorded for each compound that was screened 
and the lowest measured percentage purities are quoted. Chiral HPLC was used to 
determine the enantiomeric excess and was conducted on a Daicel Chiralpak AD-H 250 
x 4.6 mm i.d., 5 µm (Chiral Technologies Europe, Illkirch, France). 
 
Infrared (IR) spectra were recorded on a Bio-Rad FTS 3000MX diamond ATR as a neat 
sample or on an Agilent Technologies Cary 630 FTIR Spectrometer with Diamond 
ATR accessory (Agilent Technologies, Santa Clara, California, USA) as a neat sample. 
Ultraviolet (UV) spectra were recorded in ethanol on a U-2800A Spectrophotometer or 
a Hitachi U-2900 UV-Visible Spectrophotometer (Hitachi High-Technologies 
Corporation, Tokyo, Japan), using Hitachi UV Solutions 2.0 software, in Hellma 100-
QG 10 mm synthetic quartz glass cuvettes (matched pair). Optical rotations were 
recorded on a PolAAr 3001 Automatic Polarimeter (Optical Activity Ltd., 
Cambridgeshire, UK). High resolution mass spectrometry (HRMS) was performed 
using a Thermofisher LTQ Orbitrap XL Finnigan or a MAT95 or MAT900 by the 
EPSRC National Mass Spectrometry Service Centre, Grove Building, Swansea 
University, Singleton Park, Swansea, Wales, UK, SA2 8PP. Melting points were 
recorded on a Stuart SMP40 Automatic Melting Point VWR
®
 and are uncorrected. 
Combustion analysis was conducted at the Chemical Analytical Services, Newcastle 
University, using a CARLO ERBA 1108 elemental analyser system controlled with CE 
Eager 200 software and calibrated with Acetanilide Organic Analytical Standard. 
Samples were weighed using a certified Mettler MX5 Microbalance. Confidence limits 
are < 0.3% for solids and < 0.5% for liquids and oils.  
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7.11.1 Chromatography 
 
Thin Layer Chromatography (TLC) was conducted on Merck silica gel 60F254 and 
NH2F254 on aluminium sheets. All sheets were dried after use and visualised using short 
wave (254 nm) and long wave (365 nm) UV light and/or using an appropriate staining 
agent, including potassium permanganate, ninhydrin, ammonium molybdate, 
phosphomolybdic acid (PMA), iodine, iron(III) chloride, 50% sulfuric acid in distilled 
water and anisaldehyde. Column chromatography was carried out either under medium 
pressure using Davisil silica gel 40-63µ 60Å from Fisher Scientific or from Fluorochem 
or on a Biotage SP4 purification system. GraceResolv Silica Cartridges, Grace 
Reveleris Amino Cartridges or Grace Reveleris C18 Cartridges (Grace Discovery 
Sciences, Lokeren, Belgium) or Agilent Si50 cartridges were used. Semi-preparative 
HPLC was performed using an Agilent 1200 system equipped with preparative pumps, 
fraction collector, autosampler and diode array detector (DAD), with an Agilent 
ChemStation data system. Samples were run on a 21.2 x 250 mm Phenomenex Luna 5 
µm C8(2) (S/No. 313467-1) column, with a mobile phase consisting of either: (A) 0.1% 
(v/v) aqueous formic acid in acetonitrile or (B) 0.1% (v/v) aqueous ammonia in 
acetonitrile, running at the specified flow rate.  
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7.12 General Procedures 
7.12.1 SKP2 
 
A) 4-(((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutyl)amino)methyl)-
N,N-dimethylaniline (16a)
78, 79
 
 
 
 
 
 
4-(N,N-dimethylamino)benzaldehyde (154 mg, 1.03 mmol) was added to a solution of 
amine 28 (200 mg, 0.86 mmol) and excess anhydrous magnesium sulfate in DCM (4.3 
mL) and the reaction was stirred at room temperature. After 18 h, the reaction was 
filtered, washing with DCM (20 mL), and concentrated in vacuo. The oil was dissolved 
in methanol (4.1 mL) before gradual addition of sodium borohydride (127 mg, 3.35 
mmol). After 1 h, the reaction was quenched with distilled water (10 mL) and 
partitioned with EtOAc (2 × 20 mL). Organic fractions were washed with brine (20 
mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 20% 
EtOAc, DCM, followed by 2% c. NH3(aq)/MeOH, DCM) afforded a yellow oil. The oil 
was partitioned between brine (10 mL) and DCM (3 × 10 mL), dried (Na2SO4) and 
concentrated in vacuo to give 16a, as an inseparable mixture of diastereoisomers (dr = 
5:2), as a yellow oil (293 mg, 93%); Rf = 0.49 (silica, 2% c. NH3(aq)/MeOH, DCM); UV 
λmax (EtOH/nm) 263.0; IR νmax/cm
-1
 2926 (C-H), 2854 (C-H), 2801 (C-H), 1614, 1521, 
1452, 1344, 1228, 1162, 1085, 946, 803, 737, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.11 
(2.2H, s, Alk-CH3 (major)), 1.13 (0.9H, s, Alk-CH3 (minor), 1.20 (2.2H, s, Alk-CH3 
(major)), 1.22 (0.9H, s, Alk-CH3 (minor), 1.22-1.29 (1H, m, Alk-H (major and minor)), 
1.34-1.43 (2H, m, Alk-H (major and minor)), 1.43-1.50 (2H, m, Alk-H (major and 
minor)), 1.50-1.61 (2H, br, m, Alk-H (major and minor)), 1.67-1.80 (1H, m, Alk-H 
(major and minor)), 2.40 (1H, dd, J = 8.3 and 13.6 Hz, Alk-H (major and minor)), 2.48-
2.61 (2H, m, CH2CH2NH (major and minor)), 2.68 (1H, dd, J = 5.4 and 13.6 Hz, Alk-H 
(major and minor)), 2.92 (6H, s, N(CH3)2 (major and minor)), 3.56-3.63 (1H, m, Alk-
H), 3.61 (1.4H, s, NHCH2Ar (major)), 3.63 (0.5H, s, NHCH2Ar (minor)) 3.69-3.74 (1H, 
m, Alk-H (major and minor)), 6.66-6.71 (2H, m, Ar-H (major and minor)), 7.09-7.15 
(4H, m, Ar-H (major and minor)), 7.15-7.20 (1H, m, Ar-H (major and minor)), 7.23-
7.29 (2H, m, Ar-H (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 29.4, 29.6, 
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30.0, 31.9, 32.9, 33.1, 37.2, 39.5, 39.8, 40.7, 42.9, 43.0, 46.9, 53.0, 61.9, 71.8, 112.7, 
125.8, 128.3, 129.1, 129.2, 141.5, 149.9; LC-MS (ESI+) m/z = 395.2 [M+H]
+
; HRMS 
calcd. for C26H39N2O [M+H]
+
 395.3057, found 395.3060; Analytical HPLC: 95.2% 
 
B) 4-(Dimethylamino)-N-(3-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-4-
phenylbutyl)benzamide (16i)
79
 
 
 
 
 
 
4-(N,N-dimethylamino)benzoyl chloride (105 mg, 0.57 mmol) was added to a solution 
of amine 28 (90 mg, 0.34 mmol) and triethylamine (80 µL, 58.1 mg, 0.57 mmol) in 
DCM (2.0 mL) and the reaction was stirred at room temperature. After 90 min, the 
reaction was partitioned with distilled water (10 mL) and DCM (3 × 10 mL). Organic 
layers were washed with 1 M HCl (2 × 10 mL), brine (10 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Chromatography (silica, 18% EtOAc, DCM) afforded 16i as 
an inseparable mixture of diastereoisomers (dr = 5:2), as a white solid (87 mg, 63%); Rf 
= 0.29 (silica, 20% EtOAc, DCM); UV λmax (EtOH/nm) 300.0; IR νmax/cm
-1
 3316 (N-
H), 2970 (C-H), 2928 (C-H), 2860 (C-H), 1737 (C=O), 1606, 1545, 1511, 1445, 1364, 
1296, 1233, 1202, 1130, 1071, 946, 828, 737, 700; 
1H δ/ppm (500 MHz, CDCl3) 1.17 
(3H, s, Alk-CH3 (major and minor)), 1.23 (3H, s, Alk-CH3 (major and minor)), 1.28-
1.30 (1H, m, Alk-H (major and minor)), 1.36-1.72 (7H, m, Alk-H (major and minor)), 
1.82-1.85 (1H, m, Alk-H (major and minor)), 2.45 (1H, dd, J = 8.9 and 13.6 Hz, Alk-H 
(major and minor)), 2.75 (1H, dd, J = 4.9 and 13.6 Hz, Alk-H (major and minor)), 3.01 
(6H, s, N(CH3)2 (major and minor)), 3.34-3.40 (2H, m, CH2CH2NH (major and minor)), 
3.58-3.67 (1H, m, Alk-H (major and minor)), 3.73-3.79 (1H, m, Alk-H (major and 
minor)), 5.65-5.68 (1H, m, NH (major and minor)), 6.64 (2H, d, J = 9.0 Hz, Ar-H 
(major and minor)), 7.17-7.22 (3H, m, Ar-H (major and minor)), 7.29 (2H, t, J = 7.6 
Hz, Ar-H (major and minor)), 7.56 (2H, d, J = 8.9 Hz, Ar-H (major and minor)); 
13
C 
δ/ppm (125 MHz, CDCl3) 21.9, 29.4, 29.5, 30.1, 30.2, 31.9, 33.0, 33.4, 37.1, 38.0, 39.7, 
40.0, 40.1, 42.8, 42.9, 61.8, 71.8, 111.0, 121.4, 125.9, 128.2, 128.5, 129.1, 141.1, 152.4; 
LC-MS (ESI+) m/z = 409.5 [M+H]
+
; HRMS calcd. for C26H36N2O2 [M+H]
+
 409.2850, 
found 409.2851; Analytical HPLC: 95.1% 
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C) 4-(((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-
phenylbutyl)(methyl)amino)methyl)-N,N-dimethylaniline (74a) 
 
 
 
 
 
Formic acid (95%, 32 µL, 0.74 mmol) was added to a solution of amine 16a (60 mg, 
0.15 mmol) in ethanol (0.72 mL) at 40 
o
C and stirred for 30 min. Formaldehyde (37%, 
31 µL, 0.41 mmol) was added and the solution was stirred for 90 min before cooling to 
room temperature and quenching with 10% NaOH (1 mL). The reaction was partitioned 
with DCM (3 × 10 mL) and distilled water (10 mL). Organic layers were washed with 
brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography 
(silica, 0-10% MeOH, DCM) afforded 74a as an inseparable mixture of 
diastereoisomers (dr = 5:2), as a yellow gum (24 mg, 39%); Rf = 0.41 (silica, 10% 
MeOH, DCM); UV λmax (EtOH/nm) 260.0; IR νmax/cm
-1
 2926 (C-H), 2855 (C-H), 2785 
(C-H), 1614, 1521, 1453, 1345, 1229, 1185, 1162, 1084, 947, 858, 803, 737, 699; 
1
H 
δ/ppm (500 MHz, CDCl3) 1.07 (2.3H, s, Alk-CH3 (major)), 1.11 (0.8H, s, Alk-CH3 
(minor)), 1.20 (2.4H, s, Alk-CH3 (major)), 1.21 (0.9H, s, Alk-CH3 (minor)), 1.21-1.25 
(1H, m, Alk-H), 1.36-1.47 (5H, m, Alk-H (major and minor)), 1.58 (2H, m, Alk-H 
(major and minor)), 1.71 (1H, m, Alk-H (major and minor)), 2.10 (3H, s, N-CH3 (major 
and minor)), 2.27-2.45 (3H, m, Alk-H (major and minor)), 2.61-2.70 (1H, m, Alk-H 
(major and minor)), 2.93 (6H, s, N(CH3)2 (major and minor)), 3.33 (2H, s, Alk-H (major 
and minor)), 3.58 (1H, dt, Alk-H, J = 2.5 and 12.0 Hz (major and minor)), 3.70-3.76 
(1H, m, Alk-H (major and minor)), 6.67-6.69 (2H, m, Ar-H (major and minor)), 7.10-
7.13 (4H, m, Ar-H (major and minor)), 7.15-7.18 (1H, m, Ar-H (major and minor)), 
7.24-7.27 (2H, m, Ar-H (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 29.5, 
29.7, 31.9, 32.8, 37.0, 37.2, 39.4, 39.7, 40.7, 42.6, 43.0, 54.5, 61.9, 71.8, 112.5, 125.7, 
128.3, 129.1, 130.2; LC-MS (ESI+) m/z = 409.5 [M+H]
+
; HRMS calcd. for C27H40N2O 
[M+H]
+
 409.3213, found 409.3212; Analytical HPLC: 95.1%  
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D) 4-(((4-Phenyl-3-(tetrahydro-2H-pyran-4-yl)butyl)amino)methyl)aniline (68h) 
 
 
 
 
 
Amine 68g (286 mg, 0.78 mmol) was dissolved in methanol (15.6 mL) and 
hydrogenated in a H-cube hydrogen reactor at atmospheric temperature and pressure, 
flow rate 1 mL/min. After 3 h, the reaction was concentrated in vacuo to afford 68h as a 
white solid (261 mg, 99%); Rf = 0.27 (silica, 10% MeOH, DCM); m.p. decomposed; 
UV λmax (EtOH/nm) 248.0; IR νmax/cm
-1
 3320 (N-H), 2935 (C-H), 2841 (C-H), 1638, 
1557, 1439, 1390, 1277, 1222, 1193, 1125, 1107, 873, 780, 738, 700; 
1H δ/ppm (500 
MHz, CDCl3) 1.46-1.66 (8H, m, Alk-H), 1.78-1.82 (1H, m, NH), 2.34 (1H, dd, PhCH2-
Alk, J = 8.1 and 13.5 Hz), 2.49-2.55 (1H, m, AlkCH2-NH), 2.58-2.64 (1H, m, AlkCH2-
NH), 2.71 (1H, dd, PhCH2-Alk, J = 5.4 and 13.8 Hz), 3.27-3.31 (2H, m, CH2-O), 3.67-
3.73 (4H, m, ArNH2 and HN-CH2Ar), 3.94-3.96 (2H, m, CH2-O), 6.61 (2H, d, Ar-H, J 
= 7.0 Hz), 7.11 (2H, d, Ar-H, J = 7.5 Hz), 7.14 (2H, d, Ar-H, J = 7.2 Hz), 7.18 (1H, t, 
Ar-H, J = 7.3 Hz), 7.25-7.27 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 27.4, 29.5, 
31.0, 37.2, 37.7, 42.9, 44.5, 50.4, 68.3, 115.1, 126.1, 128.5, 129.0, 131.0, 140.7, 146.9; 
LC-MS (ESI+) m/z = 339.4 [M+H]
+
; HRMS calcd. for C22H31ON2 [M+H]
+
 339.2431, 
found 339.2433; Analytical HPLC: 96.3% 
 
E) N-(4-Azidobenzyl)-4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-amine (68i) 
 
 
 
 
 
Aniline 68h (100 mg, 0.30 mmol) was suspended in 5 M HCl (1.2 mL) in darkness and 
cooled to 0 
o
C. Sodium nitrite (28 mg, 0.40 mmol) in distilled water (0.8 mL, 0.5 M) 
was added dropwise over 2 min. After 40 min, sodium azide (85 mg, 1.3 mmol) was 
carefully added and the reaction was stirred for 30 min then allowed to reach room 
temperature. After 2 h the reaction was diluted with distilled water (1 mL) and 
quenched with saturated aqueous NaHCO3 to pH 9. The reaction was partitioned using 
EtOAc (10 mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
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Chromatography (silica, 0-5% MeOH, DCM) afforded 68i as a yellow solid (84 mg, 
75%); Rf = 0.28 (silica, 5% MeOH, DCM); UV λmax (EtOH/nm) 252.5; IR νmax/cm
-1
 
2927 (C-H), 2842 (C-H), 2749 (C-H), 2103 (N≡N, strong), 1604, 1507, 1454, 1281, 
1124, 1091, 1013, 824, 739, 700; 
1H δ/ppm (500 MHz, CDCl3) 1.46-1.58 (7H, m, Alk-
H), 1.75 (1H, m, NH), 2.34 (1H, dd, PhCH2, J = 7.9 and 13.7 Hz), 2.46-2.51 (1H, m, 
AlkCH2-NH), 2.55-2.61 (1H, m, AlkCH2-NH), 2.72 (1H, dd, PhCH2, J = 4.8 and 13.7 
Hz), 3.27-3.32 (2H, m, CH2-O), 3.73 (2H, s, HN-CH2Ar), 3.95-3.98 (2H, m, CH2-O), 
6.97 (2H, d, Ar-H, J = 8.3 Hz), 7.11 (2H, d, Ar-H, J = 7.7 Hz), 7.17-7.20 (1H, m, Ar-
H), 7.24-7.27 (2H, m, Ar-H), 7.33 (2H, d, Ar-H, J = 8.2 Hz); 
13C δ/ppm (125 MHz, 
CDCl3) 28.1, 29.58, 29.64, 37.3, 37.9, 42.9, 45.4, 50.7, 68.3, 119.4, 126.1, 128.5, 129.0, 
130.9, 140.3, 140.8; LC-MS (ESI+) m/z = 365.4 [M+H]
+
; HRMS calcd. for C22H29ON4 
[M+H]
+
 365.2336, found 365.2338; Analytical HPLC: 97.5% 
 
F) Ethyl 3-((4-dimethylamino)benzyl)amino)propanoate (76) 
 
 
 
 
Sodium triacetoxyborohydride (2.84 g, 13.4 mmol) was added to a solution of β-alanine 
ethyl ester hydrochloride (2.06 g, 13.4 mmol) (75) in DMF (16.8 mL) and glacial acetic 
acid (0.34 mL). After 10 min, 4-(N,N-dimethylamino)benzaldehyde (1.00 g, 6.70 mmol) 
in DMF (16.8 mL, 0.4 M) was added dropwise over 3 min and the solution was stirred 
at room temperature. After 5 h, the reaction was partitioned with brine (100 mL), 
saturated aqueous NaHCO3 (100 mL) and diethyl ether (10 × 20 mL), dried (MgSO4), 
filtered and concentrated in vacuo. Chromatography (silica, 0-10% MeOH, DCM) 
afforded 76 as a yellow oil (1.39 g, 83%); Rf = 0.31 (silica, 5% MeOH, DCM); UV λmax 
(EtOH/nm) 302.0 and 257.0; IR νmax/cm
-1
 2801 (C-H), 1730 (C=O), 1615, 1522, 1445, 
1346, 1213, 1164, 1121, 946, 806; 
1H δ/ppm (500 MHz, CDCl3) 1.25 (3H, t, 
CO2CH2CH3, J = 7.2 Hz) 1.63 (1H, s, br, NH), 2.52 (2H, t, CH2, J = 6.5 Hz), 2.89 (2H, 
t, CH2, J = 6.5 Hz), 2.93 (6H, s, N(CH3)2) 3.71 (2H, s, HN-CH2Ar), 4.13 (2H, q, 
CO2CH2CH3, J = 7.1 Hz) 6.69-6.72 (2H, m, Ar-H), 7.17-7.20 (2H, m, Ar-H); 
13C δ/ppm 
(125 MHz, CDCl3) 14.2, 34.8, 40.8, 44.4, 53.3, 60.4, 112.8, 128.2, 129.0, 149.9, 172.8; 
LC-MS (ESI+) m/z = 251.4 [M+H]
+
; HRMS calcd. for C14H23N2O2 [M+H]
+
 251.1754, 
found 251.1756 
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G Ethyl 3-((tert-butoxycarbonyl)(4-(dimethylamino)benzyl)amino)propanoate (77) 
 
 
 
 
Method 1: 
Amine 76 (1.39 g, 5.53 mmol) was added to a solution of Boc2O (1.33 g, 6.08 mmol) in 
DCM (12 mL) at 0 
o
C and stirred for 5 min before warming to room temperature. After 
1 h, the reaction was partitioned between saturated aqueous NaHCO3 (20 mL) and 
DCM (3 × 10 mL). Organic layers were washed with brine (10 mL), dried (Na2SO4), 
filtered and concentrated in vacuo. Chromatography (silica, 0-15% EtOAc, hexane) 
afforded 77 as a pale yellow oil (1.80 g, 93%); Rf = 0.32 (silica, 20% EtOAc, hexane); 
UV λmax (EtOH/nm) 302.5 and 258.5; IR νmax/cm
-1
 2976 (C-H), 2934 (C-H), 2805 (C-
H), 1732 (C=O), 1688, 1614, 1522, 1464, 1409, 1364, 1243, 1156, 1107, 1045, 1019, 
946, 885, 802, 772; 
1H δ/ppm (500 MHz, CDCl3) 1.24 (3H, t, CO2CH2CH3, J = 7.2 Hz), 
1.48 (9H, s, C(CH3)3), 2.47-2.52 (2H, m, CH2), 2.93 (6H, s, N(CH3)2), 3.39-3.46 (2H, 
m, CH2), 4.10 (2H, q, CO2CH2CH3, J = 7.2 Hz), 4.35 (2H, s, BocN-CH2Ar), 6.68-6.70 
(2H, m, Ar-H), 7.12 (2H, m, br, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 14.2, 28.5, 40.7, 
60.4, 79.8, 112.7, 126.1, 128.5, 129.0, 150.0; LC-MS (ESI+) m/z = 351.4 [M+H]
+
; 
HRMS calcd. for C19H31N2O4 [M+H]
+
 351.2278, found 351.2276 
 
Method 2: 
4-(N,N-dimethylamino)benzaldehyde (3.49 g, 23.4 mmol) was added to a solution of β-
alanine ethyl ester hydrochloride (3.00 g, 19.5 mmol) (75), sodium acetate trihydrate 
(3.18 g, 23.4 mmol) and excess anhydrous magnesium sulfate in THF (66 mL) and 
stirred at room temperature. After 24 h, the reaction was filtered and concentrated in 
vacuo, then dissolved in ethanol (55 mL) and mixed carefully with sodium borohydride 
(2.21 g, 58.5 mmol). After 30 min, the reaction was cooled to 0 
o
C and quenched with 
ice-cooled distilled water (10 mL). The solution was concentrated to a small volume in 
vacuo and partitioned with diethyl ether (4 × 20 mL). Organic layers were washed with 
brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. The oil was dissolved 
in DCM (50 mL), washed with saturated aqueous NaHCO3 (6 × 20 mL), brine (20 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The oil was dissolved in anhydrous 
DCM (31.5 mL), cooled to 0 
o
C and mixed with Boc2O (3.15 g, 14.4 mmol). After 1 h, 
the reaction was partitioned with distilled water (2 × 20 mL), washed with brine (20 
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mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-5% 
EtOAc, DCM) afforded 77 as a yellow oil (1.44 g, 21%); Analysis data as above 
 
H) tert-Butyl 4-(dimethylamino)benzyl-(3-(methoxy(methyl)amino)-3-
oxopropyl)carbamate (78) 
 
 
 
 
Isopropylmagnesium chloride (2 M in THF, 15.8 mL, 31.6 mmol) was added dropwise 
to a suspension of N,O-dimethylhydroxylamine hydrochloride (1.54 g, 15.8 mmol) in 
THF (42 mL) at -20 
o
C. After 20 min, ester 77 (1.38 g, 3.94 mmol) was added and the 
reaction was stirred at -20 
o
C. After 1 h, the reaction was quenched with saturated 
aqueous NH4Cl (20 mL) and stirred at -20 
o
C for 5 min. The reaction was partitioned 
between distilled water (10 mL) and diethyl ether (4 × 20 mL). Organic layers were 
washed with brine (50 mL), dried (Na2SO4), filtered and concentrated in vacuo to afford 
78 as a yellow oil (1.34 g, 93%); Rf = 0.33 (silica, 15% EtOAc, DCM); UV λmax 
(EtOH/nm) 302.5 and 258.5; IR νmax/cm
-1
 2972 (C-H), 2932 (C-H), 2800 (C-H), 1686 
(C=O), 1660 (C=O), 1614, 1522, 1462, 1409, 1364, 1244, 1160, 1130, 992, 946, 886, 
802, 773; 
1H δ/ppm (500 MHz, CDCl3) 1.48 (9H, s, C(CH3)3), 2.58-2.66 (2H, m, CH2), 
2.92 (6H, s, N(CH3)2), 3.15 (3H, s, NCH3), 3.42-3.47 (2H, m, CH2), 3.63 (3H, s, OCH3), 
4.36 (2H, s, BocN-CH2Ar), 6.68-6.69 (2H, m, Ar-H), 7.15 (2H, m, Ar-H); LC-MS 
(ESI+) m/z = 366.4 [M+H]
+
 
 
I) tert-Butyl 4-(dimethylamino)benzyl-(3-oxo-4-phenylbutyl)carbamate (79) 
 
 
 
 
Cerium trichloride heptahydrate (608 mg, 1.63 mmol) was heated to 140 
o
C in vacuo for 
2 h then cooled to 0 
o
C and suspended in THF (9.5 mL). The suspension was warmed to 
room temperature with vigorous stirring. After 4 h, amide 78 (567 mg, 1.55 mmol) was 
added and the reaction was stirred at room temperature. After 1 h, the reaction was 
cooled to 0 
o
C and benzylmagnesium chloride (2 M in THF, 1.17 mL, 2.34 mmol) was 
added dropwise. After 30 min, the reaction was quenched with 10% acetic acid (5 mL) 
236 
 
and partitioned between distilled water (5 mL) and diethyl ether (10 mL). The organic 
layer was washed with distilled water (2 × 10 mL) and the aqueous layer was extracted 
with diethyl ether (3 × 20 mL). The organic layer was washed with brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Chromatography (C18, 70-80% MeOH, 
H2O) afforded 79, which was dissolved in DCM (10 mL) and partitioned with distilled 
water (10 mL), washed with brine (2 × 20 mL), dried (MgSO4), filtered and 
concentrated in vacuo to afford 79 as a yellow oil (464 mg, 75%); Rf = 0.29 (silica, 
100% DCM); UV λmax (EtOH/nm) 302.0 and 259.5; IR νmax/cm
-1
 2976 (C-H), 1684 
(C=O), 1614, 1522, 1463, 1414, 1364, 1243, 1161, 946, 873, 802, 771, 733, 699; 
1
H 
δ/ppm (500 MHz, CDCl3) 1.45 (9H, s, C(CH3)3), 2.58-2.69 (2H, m, CH2), 2.93 (6H, s, 
N(CH3)2), 3.33-3.41 (2H, m, CH2), 3.64 (2H, m, PhCH2-CO), 4.28 (2H, s, BocN-
CH2Ar), 6.66-6.68 (2H, m, Ar-H), 7.09 (2H, m, br, Ar-H), 7.15 (2H, d, Ar-H, J = 7.3 
Hz), 7.24-7.27 (1H, m, Ar-H), 7.30-7.33 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 
28.5, 40.7, 40.9, 41.8, 50.1, 79.7, 112.6, 126.1, 127.0, 128.7, 129.1, 129.4, 134.0, 150.0, 
155.6, 207.1; LC-MS (ESI+) m/z = 397.5 [M+H]
+
 
 
J) tert-Butyl 4-(dimethylamino)benzyl-(3-oxopropyl)carbamate (84) 
 
 
 
 
Lithium aluminium hydride (2 M in THF, 0.81 mL, 1.62 mmol) was added dropwise to 
a solution of amide 78 (454 mg, 1.24 mmol) in THF (35 mL, 35 mM) at 0 
o
C. After 1 h, 
the reaction was quenched with sodium bisulfate (694 mg, 5.78 mmol) in distilled water 
(25 mL, 0.2 M) and warmed to room temperature. The reaction was partitioned with 
distilled water (20 mL) and EtOAc (2 × 10 mL). Organic layers were washed with brine 
(20 mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-
5% EtOAc, DCM) afforded 84 as a colourless oil (273.6 mg, 72%); 
1H δ/ppm (500 
MHz, CDCl3) 1.48 (9H, s, br, C(CH3)3), 2.51-2.60 (2H, m, CH2), 2.93 (6H, s, N(CH3)2), 
3.46-3.48 (2H, m, CH2), 4.34 (2H, s, br, BocN-CH2Ar), 6.68-6.70 (2H, m, Ar-H), 7.11 
(2H, m, br, Ar-H); LC-MS (ESI+) m/z = 307.4 [M+H]
+ 
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K) tert-Butyl 4-(dimethylamino)benzyl-(3-morpholino-4-phenylbutyl)carbamate 
(83) 
 
 
 
 
 
Morpholine (96 µL, 96 mg, 1.10 mmol) was added to a mixture of 1H-benzotriazole 
(217 mg, 1.82 mmol), aldehyde 84 (280 mg, 0.91 mmol) and 3 Å molecular sieves (600 
mg) in DCM (3.8 mL) and stirred at room temperature. After 16 h, the reaction was 
filtered and concentrated in vacuo, then partitioned with DCM (15 mL) and 2 M NaOH 
(2 × 10 mL) followed by distilled water (2 × 10 mL). The aqueous layer was extracted 
with DCM (2 × 10 mL) and the organic layer was washed with brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo, then dissolved in THF (5.5 mL) and 
cooled to 0 
o
C. Benzylmagnesium chloride (2 M in THF, 0.91 mL, 1.82 mmol) was 
added dropwise and the reaction was warmed to room temperature. After 24 h, the 
reaction was partitioned with 2 M NaOH (2 × 10 mL) followed by distilled water (3 × 
10 mL). The aqueous layer was extracted with diethyl ether (2 × 10 mL) and the organic 
layer was washed with brine (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo. Chromatography (silica, 2-50% EtOAc, DCM) afforded 83 as a yellow oil (254 
mg, 61%); Rf = 0.29 (20% EtOAc, DCM); UV λmax (EtOH/nm) 258.5; IR νmax/cm
-1
 
2930 (C-H), 2851 (C-H), 2810 (C-H), 1684 (C=O), 1614, 1522, 1453, 1414, 1364, 
1233, 1152, 1115, 947, 880, 802, 733, 699; 
1H δ/ppm (500 MHz, DMSO-d6, 130 
o
C) 
1.39 (9H, s,
 
C(CH3)3), 1.43-1.48 (1H, m, Alk-H), 1.49-1.56 (1H, m, Alk-H), 1.60-1.66 
(1H, m, Alk-H), 2.41 (1H, dd, PhCH2-Alk, J = 8.2 and 13.3 Hz), 2.56-2.58 (2H, m, Alk-
H), 2.63-2.66 (1H, m, Alk-H), 2.91-2.94 (7H, m, N(CH3)2 and Alk-H), 3.04-3.09 (1H, 
m, Alk-H), 3.20-3.25 (1H, m, Alk-H), 3.52-3.59 (4H, m, CH2-O and BocN-CH2Ar), 
4.18-4.27 (2H, m, CH2-O), 6.70 (2H, d, Ar-H, J = 8.6 Hz), 7.04 (2H, d, Ar-H, J = 8.2 
Hz), 7.18-7.19 (3H, m, Ar-H), 7.26-7.29 (2H, m, Alk-H); 
13C δ/ppm (125 MHz, DMSO-
d6, 130 
o
C) 27.9, 28.0, 28.1, 40.2, 63.5, 66.8, 112.3, 125.6, 125.8, 128.1, 128.5, 129.1, 
149.7; LC-MS (ESI+) m/z = 468.6 [M+H]
+
; Analytical HPLC: 93.7% 
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L) N,N-Dimethyl-4-(((3-morpholino-4-phenylbutyl)amino)methyl)aniline (80) 
 
 
 
 
 
Trifluoroacetic acid (0.7 mL) was added to a solution of carbamate 83 (100 mg, 0.21 
mmol) in DCM (0.7 mL, 0.3 M) and stirred at room temperature. After 1 h, the reaction 
was concentrated in vacuo and quenched with saturated aqueous NaHCO3 (10 mL). The 
solution was partitioned with EtOAc (2 × 10 mL) and the organic layer was washed 
with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo to afford 80 as a 
brown oil (77 mg, 100%); Rf = 0.43 (silica, 10% MeOH, DCM); UV λmax (EtOH/nm) 
263.5; IR νmax/cm
-1
 3418 (N-H), 2923 (C-H), 2852 (C-H), 2813 (C-H), 1677, 1614, 
1526, 1454, 1354, 1197, 1168, 1113, 1065, 945, 798, 700; 
1H δ/ppm (500 MHz, CDCl3) 
1.24-1.27 (1H, m, Alk-H), 1.52-1.57 (1H, m, Alk-H), 2.02-2.09 (1H, m, Alk-H), 2.31 
(1H, dd, Alk-H, J = 10.8 and 12.9 Hz), 2.45-2.49 (2H, m, Alk-H), 2.66-2.71 (1H, m, 
Alk-H), 2.72-2.77 (1H, m, Alk-H), 2.92-3.01 (9H, m, N(CH3)2 and Alk-H), 3.12-3.15 
(1H, m, Alk-H), 3.54-3.59 (4H, m, Alk-H), 3.67 (1H, d, Alk-H, J = 13.1 Hz), 4.10 (1H, 
d, Alk-H, J = 12.8 Hz), 6.69 (2H, d, Ar-H, J = 8.9 Hz), 7.08 (2H, d, Ar-H, J = 7.5 Hz), 
7.18-7.23 (3H, m, Ar-H), 7.26-7.29 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 24.3, 
31.0, 34.1, 40.3, 47.7, 51.1, 66.9, 69.0, 112.5, 126.5, 128.7, 129.1, 130.3, 138.9, 151.0; 
LC-MS (ESI+) m/z = 368.6 [M+H]
+
; HRMS calcd. for C23H34ON3 [M+H]
+
 368.2696, 
found 368.2699; Analytical HPLC: 95.4%  
 
M) Methyl 2-(dihydro-2H-pyran-4-(3H)-ylidene) acetate (61) 
 
 
 
 
Sodium hydride (60% in mineral oil, 390 mg, 9.75 mmol) was suspended in THF (35 
mL) and cooled to 0 
o
C. Trimethyl phosphonoacetate (1.52 mL, 9.36 mmol), dissolved 
in THF (7 mL, 1.3 M), was added dropwise. After 40 min, pyranone 60 (1.00 g, 7.80 
mmol), in THF (7 mL, 1.1 M), was added dropwise and the flask was warmed to room 
temperature. After 19 h the reaction was quenched with saturated aqueous NH4Cl (10 
mL). The precipitate was removed by filtration and the layers were separated. The 
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aqueous layer was extracted with diethyl ether (2 × 20 mL) and the organic layer was 
dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 5-50% 
Et2O, DCM) afforded 61 as a pale yellow oil (1.27 g, 88%); Rf = 0.75 (silica, 33% 
EtOAc, hexane); UV λmax (EtOH/nm) 225.5; IR νmax/cm
-1
 2953 (C-H), 2847 (C-H), 
1712 (C=O), 1652, 1435, 1387, 1250, 1201, 1174, 1147, 1096, 1029, 987, 852, 683; 
1
H 
δ/ppm (500 MHz, CDCl3) 2.31-2.34 (2H, m, CH2), 2.99-3.01 (2H, m, CH2), 3.69 (3H, s, 
CO2CH3), 3.73 (2H, t, CH2-O, J = 5.6 Hz), 3.76 (2H, t, CH2-O, J = 5.5 Hz), 5.68 (1H, 
m, CHCO2Me); 
13C δ/ppm (125 MHz, CDCl3) 31.1, 37.5, 51.0, 68.5, 69.1, 114.1, 157.6, 
166.8; LC-MS (ESI+) m/z = 157.2 [M+H]
+ 
 
N) Methyl 2-(tetrahydro-2H-pyran-4-yl) acetate (62) 
 
 
 
 
Ester 61 (1.30 g, 7.06 mmol) was dissolved in methanol (7 mL) and cooled to 0 
o
C. 10% 
Pd/C (226 mg, 2.12 mmol) was added, followed by methanol (55 mL). Ammonium 
formate (2.23 g, 35.3 mmol) was added portion-wise and the flask was heated to 80 
o
C. 
After 90 min the reaction was cooled to room temperature and filtered through celite, 
giving 62 as a pale yellow oil (1.21 g, 92%); Rf = Spot not observed by UV or stains; 
UV λmax (EtOH/nm) No distinguished peak; IR νmax/cm
-1
 2920 (C-H), 2842 (C-H), 1733 
(C=O), 1437, 1363, 1271, 1244, 1168, 1136, 1092, 1015, 984, 854, 814, 701; 
1H δ/ppm 
(500 MHz, CDCl3) 1.28-1.37 (2H, m, CH2), 1.60-1.64 (2H, m, CH2), 1.96-2.05 (1H, m, 
CH), 2.24 (2H, d, CH2CO2Me, J = 7.1 Hz), 3.39 (2H, td, CH2-O, J = 11.8 and 2.2 Hz), 
3.66 (3H, s, CO2CH3), 3.91-3.94 (2H, m, CH2-O); 
13C δ/ppm (125 MHz, CDCl3) 32.2, 
32.7, 41.2, 51.5, 67.7, 172.8; LC-MS (ESI+) m/z = 159.1 [M+H]
+
; HRMS calcd. for 
C8H15O3 [M+H]
+
 159.1016, found 159.1013 
 
O) Methyl 3-phenyl-2-(tetrahydro-2H-pyran-4-yl)propanoate (63) 
 
 
 
 
Diisopropylamine (1.00 mL, 7.08 mmol) was dissolved in THF (4 mL) and cooled to -
78 
o
C. Butyllithium (2.36 M, 3.00 mL, 7.08 mmol) was added dropwise over 15 min. 
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The flask was allowed to reach room temperature over 40 min and cooled to -78 
o
C. 
Ester 62 (1.20 g, 6.44 mmol) was dissolved in THF (13 mL, 0.5 M) and added 
dropwise. The solution was stirred at -78 
o
C for 90 min before dropwise addition of 
benzyl bromide (0.92 mL, 1.32 g, 7.73 mmol) as a solution in THF (3 mL, 2.6 M) and 
warmed to room temperature. After 21 h, the reaction was quenched with saturated 
aqueous NH4Cl (10 mL) and the layers were separated. The organic layer was washed 
with saturated aqueous NH4Cl (10 mL) and the aqueous layer was extracted with EtOAc 
(10 mL). Organic layers were washed with brine (20 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Chromatography (silica, 0-20% Et2O, hexane) afforded 63 as a 
pale yellow oil (1.58 g, 89%); Rf = 0.57 (silica, 33% EtOAc, hexane); UV λmax 
(EtOH/nm) 258.5; IR νmax/cm
-1
 2949 (C-H), 2842 (C-H), 1730 (C=O), 1496, 1441, 
1365, 1236, 1161, 1092, 1017, 985, 882, 842, 745, 699; 
1H δ/ppm (500 MHz, CDCl3) 
1.41-1.54 (3H, m, Alk-H), 1.73-1.77 (1H, m, Alk-H), 1.82-1.90 (1H, m, Alk-H), 2.51-
2.56 (1H, m, Alk-H), 2.84 (1H, dd, Alk-H, J = 10.5 and 13.5 Hz), 2.91 (1H, dd, Alk-H, 
J = 5.0 and 13.6 Hz), 3.34-3.42 (2H, m, CH2-O), 3.52 (3H, s, OCH3), 3.96-4.02 (2H, m, 
CH2-O), 7.14 (2H, d, Ar-H, J = 7.3 Hz), 7.19 (1H, t, Ar-H, J = 7.4 Hz), 7.27 (2H, t, Ar-
H, J = 7.4 Hz); 
13C δ/ppm (125 MHz, CDCl3) 30.7, 30.9, 35.4, 37.7, 51.2, 53.7, 67.9, 
126.4, 128.4, 128.7, 139.3, 174.8; LC-MS (ESI+) m/z = 249.3[M+H]
+
; Analytical 
HPLC: 98.8% 
 
P) (±)-3-Phenyl-2-(tetrahydro-2H-pyran-4-yl)propan-1-ol (64) 
 
 
 
 
Lithium aluminium hydride (2 M in THF, 3.20 mL, 6.40 mmol) was added dropwise 
over 1 min to a solution of ester 63 (1.57 g, 5.68 mmol) in THF (12 mL, 0.5 M) at 0 
o
C. 
After 90 min, the solution was warmed to room temperature and quenched with 
saturated aqueous Rochelle salt (10 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (2 × 20 mL). The organic layer was washed with brine 
(20 mL), dried (MgSO4), filtered and concentrated in vacuo to give 64 as an oil (1.42 g, 
100%); Rf = 0.33 (silica, 50% EtOAc, hexane); UV λmax (EtOH/nm) 259.5; IR νmax/cm
-1
 
3427 (O-H), 2932 (C-H), 2845 (C-H), 1602, 1495, 1454, 1387, 1267, 1244, 1142, 1087, 
1031, 1016, 995, 980, 921, 870, 838, 742, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.14 (1H, 
t, CH, J = 5.1 Hz), 1.46-1.55 (2H, m, CH2), 1.63-1.68 (3H, m, CH2 and OH), 1.74-1.81 
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(1H, m, CH), 2.55 (1H, dd, Ph-CH2, J = 9.5 and 13.6 Hz), 2.78 (1H, dd, Ph-CH2, J = 
5.1 and 13.6 Hz), 3.36-3.41 (2H, m, CH2-O), 3.52-3.62 (2H, m, CH2-OH), 3.99-4.02 
(2H, m, CH2-O), 7.18-7.21 (3H, m, Ar-H), 7.27-7.30 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 30.3, 30.4, 34.3, 35.7, 47.6, 61.8, 68.4, 126.0, 128.5, 129.0, 141.0; LC-
MS (ESI+) m/z = 221.3 [M+H]
+
; HRMS calcd. for C14H21O2 [M+H]
+
 221.1536, found 
221.1536 
 
(R)- and (S)-3-Phenyl-2-(tetrahydro-2H-pyran-4-yl)propan-1-ol ((R)- and (S)-64) 
 
 
 
Lithium triethylborohydride (1 M in THF, 5.0 equiv.) was added dropwise over 1-2 min 
to a solution of either (R,R)- or (S,S)-oxazolidin-2-one (R,R)-114 (1.86 g, 4.73 mmol) or 
(S,S)-114  (1.57 g, 4.00 mmol) in diethyl ether (28 mL, 0.2 M) at -78 
o
C and stirred 
overnight, allowing the reaction to reach room temperature. Saturated aqueous NH4Cl 
(10 mL) was added dropwise at room temperature, followed by 3 M NaOH (20 mL), 
and the layers were separated. The organic layer was washed with 3 M NaOH (10 mL) 
and distilled water (10 mL) and the aqueous layer was extracted with diethyl ether (10 
mL). The organic layer was washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Chromatography (silica, 60% Et2O, petrol) afforded (R)-
enantiomer (R)-64 and (S)-enantiomer (S)-64 as yellow oils (453 mg, 41% and 380 mg, 
41% respectively). Analytical data equivalent to (±)-64; [α]D
21.4
 +16.1
o
 (R) (c 0.87 in 
EtOH), [α]D
21.2
 -16.0
o
 (S) (c 0.84 in EtOH) 
 
Q) 3-Phenyl-2-(tetrahydro-2H-pyran-4-yl)propylmethanesulfonate (65) 
 
 
 
 
 
Methanesulfonyl chloride (487 µL, 721 mg, 6.29 mmol) was added dropwise to a 
solution of alcohol 64 (1.42 g, 5.72 mmol) and diisopropylethylamine (1.50 mL, 1.11 g, 
8.58 mmol) in DCM (20.5 mL) at 0 
o
C and warmed to room temperature. After 90 min, 
the reaction was partitioned with distilled water (2 × 20 mL), 1 M HCl (2 × 10 mL) and 
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brine (20 mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo 
to give 65 as a brown solid (1.82 g, 97%); Rf = 0.38 (silica, 50% EtOAc, hexane); m.p. 
66-68 
oC; UV λmax (EtOH/nm) 258.5; IR νmax/cm
-1
 3017 (C-H), 2899 (C-H), 2841 (C-
H), 1467, 1344, 1248, 1173, 1136, 1089, 974, 924, 820, 747, 699; 
1H δ/ppm (500 MHz, 
CDCl3) 1.43-1.54 (2H, m, Alk-H), 1.65-1.73 (2H, m, Alk-H), 1.75-1.89 (2H, m, Alk-H), 
2.54 (1H, dd, PhCH2, J = 9.8 and 13.8 Hz), 2.88 (1H, dd, PhCH2, J = 5.1 and 14.2 Hz) 
2.91 (3H, s, SO2CH3), 3.37-3.42 (2H, m, CH2-O), 4.01-4.03 (2H, m, CH2-O), 4.06 (1H, 
dd, CH2-OMs, J = 4.7 and 9.9 Hz), 4.16 (1H, dd, CH2-OMs, J = 4.2 and 9.8 Hz), 7.16-
7.18 (2H, m, Ar-H), 7.21-7.24 (1H, m, Ar-H), 7.29-7.32 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 30.2, 30.3, 33.9, 35.6, 37.0, 45.0, 68.1, 68.7, 126.5, 128.7, 129.0, 139.5; 
LC-MS (ESI+) m/z = 299.3 [M+H]
+
; HRMS mass not observed 
 
R) (±)-4-Phenyl-3-(tetrahydro-2H-pyran-4-yl)butanenitrile (66) 
 
 
 
 
Sodium cyanide (297 mg, 6.06 mmol) was added to a solution of sulfonate 65 (1.80 g, 
5.51 mmol) in DMF (11.5 mL) at room temperature and heated to 100 
o
C. After 7 h, the 
reaction was cooled to room temperature and partitioned with diethyl ether (5 × 15 mL) 
and distilled water (10 mL). The organic layer was washed with distilled water (5 × 10 
mL) and brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo to give 66 as 
a brown solid, which could be taken forward without further purification (1.27 g, 90%). 
Chromatography (silica, 10% EtOAc, hexane) afforded pure 66 as a colourless oil; Rf = 
0.42 (silica, 33% EtOAc, hexane); UV λmax (EtOH/nm) 258.5; IR νmax/cm
-1
 2945 (C-H), 
2916 (C-H), 2856 (C-H), 2242 (C≡N), 1600, 1493, 1452, 1420, 1247, 1139, 1095, 1024, 
984, 887, 856, 748, 703; 
1H δ/ppm (500 MHz, CDCl3) 1.41-1.52 (2H, m, Alk-H), 1.66-
1.69 (1H, m, Alk-H), 1.74-1.83 (3H, m, Alk-H), 2.20 (1H, dd, Alk-H, J = 5.1 and 17.0 
Hz), 2.31 (1H, dd, Alk-H, J = 4.1 and 17.0 Hz), 2.49 (1H, dd, Alk-H, J = 10.1 and 13.8 
Hz), 3.01 (1H, dd, Alk-H, J = 4.2 and 13.7 Hz), 3.40-3.45 (2H, m, CH2-O), 4.02-4.06 
(2H, m, CH2-O), 7.17-7.19 (2H, m, Ar-H), 7.23-7.26 (1H, m, Ar-H), 7.31-7.34 (2H, m, 
Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 18.1, 30.2, 30.3, 36.4, 37.5, 42.6, 67.9, 118.5, 
126.7, 128.8, 129.0, 139.0; LC-MS (ESI+) m/z = 230.3 [M+H]
+
; HRMS calcd. for 
C15H20NO [M+H]
+
 230.1539, found 230.1542; Analytical HPLC: 99.5% 
 
243 
 
(R)- and (S)-4-Phenyl-3-(tetrahydro-2H-pyran-4-yl)butanenitrile ((R)- and (S)-66) 
 
 
 
General procedure R i): Using either (R)- or (S)-mesolate (R)-65 or (S)-65 (569 mg, 
1.91 mmol and 479 mg, 1.61 mmol respectively), chromatography (silica, 10-30% 
EtOAc, hexane) afforded (S)- or (R)-66 as colourless oils (316 mg, 72% and 274 mg, 
74% respectively). Analytical data equivalent to (±)-66; [α]D
22.1
 -55.4
o
 (R) (c 1.01 in 
EtOH), [α]D
22.5
 +55.4
o
 (S) (c 1.01 in EtOH) 
 
S) (±)-4-Phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-amine (67) 
 
 
 
 
Nitrile 66 (100 mg, 0.44 mmol) was dissolved in ethanol (22.7 mL) and hydrogenated 
using an H-cube over a Raney Nickel CatCart
®
 at 50 bar, 70 
o
C, at 1 mL/min. After 17 
h, the solvent was removed in vacuo to give 67 as a colourless oil (74 mg, 73%); Rf = 
0.13 (silica, 20% MeOH, DCM); UV λmax (EtOH/nm) 259.5; IR νmax/cm
-1
 3385 (N-H), 
3320 (N-H), 2929 (C-H), 2843 (C-H), 1601, 1494, 1453, 1387, 1243, 1090, 1014, 982, 
841, 739, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.31-1.38 (4H, m, Alk-H), 1.44-1.64 (7H, 
m, Alk-H, NH2 and H2O), 2.44 (1H, dd, PhCH2, J = 7.8 and 13.6 Hz), 2.59-2.72 (3H, m, 
PhCH2 and AlkCH2NH2), 3.30-3.37 (2H, m, CH2-O), 3.97-4.02 (2H, m, CH2-O), 7.14-
7.15 (2H, m, Ar-H), 7.17-7.20 (1H, m, Ar-H), 7.26-7.29 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 29.5, 29.8, 34.4, 37.4, 40.5, 42.7, 68.5, 125.8, 128.3, 129.0, 141.5; LC-
MS (ESI+) m/z = 234.3 [M+H]
+
; HRMS calcd. for C15H23NO [M+H]
+
 234.1852, found 
234.1852; Analytical HPLC: 93.3% 
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(R)- and (S)-4-Phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-amine ((R)- and (S)-67) 
 
 
 
Lithium aluminium hydride (2 M in THF, 1.4 equiv.) was added dropwise to a solution 
of either (R)- or (S)-nitrile (R)- or (S)-66 (264  mg, 1.15 mmol and 316 mg, 1.38 mmol 
respectively) in THF (0.2 M) at 0 
o
C and stirred at room temperature. After 15 h, the 
reaction was quenched with distilled water (0.26 mL), 3 M NaOH (0.26 mL) and more 
distilled water (0.78 mL). The reaction was filtered through celite, washing with DCM 
(20 mL), and concentrated in vacuo. Chromatography (silica, 10% MeOH, EtOAc) 
afforded (R)- and (S)-67 as yellow oils (132 mg, 47% and 148 mg, 44% respectively). 
Analytical data equivalent to (±)-67; [α]D
23.5
 +9.6
o
 (R) (c 1.02 in EtOH), [α]D
23.3
 -9.0
o
 
(S) (c 1.03 in EtOH) 
 
T) 3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutan-1-amine (28)
79
 
 
 
 
 
Lithium aluminium hydride (2 M in THF, 3.45 mL, 6.90 mmol) was added dropwise to 
a solution of nitrile 27 (1.27 g, 4.93 mmol) in THF (24 mL) at 0 
o
C and stirred at room 
temperature. After 15 h, the reaction was quenched with distilled water (0.26 mL), 3 M 
NaOH (0.26 mL) and more distilled water (0.78 mL). The reaction was filtered through 
celite, washing with DCM (20 mL), and concentrated in vacuo. Chromatography (silica, 
0-30% MeOH/DCM) afforded 28 as an inseparable mixture of diastereoisomers (dr = 
5:2), as a yellow oil (1.07 g, 83%); Rf = 0.17 (silica, 10% MeOH, DCM); UV λmax 
(EtOH/nm) 207.5; IR ν/cm-1 3371 (N-H), 3290 (N-H), 2970 (C-H), 2927 (C-H), 2858 
(C-H), 1583, 1494, 1453, 1364, 1285, 1203, 1084, 1014, 857, 737, 699; 
1
H δ/ppm (500 
MHz, CDCl3) 1.15 (3H, s, Alk-CH3 (major and minor)), 1.22 (2H, s, Alk-CH3 (major)), 
1.23 (1H, s, Alk-CH3 (minor)), 1.23-1.25 (2H, m, Alk-H (major and minor)), 1.28-1.51 
(6H, m, Alk-H (major and minor)), 1.53-1.60 (1H, m, Alk-H (major and minor)), 1.73-
1.81 (1H, m, Alk-H (major and minor)), 2.40 (0.8H, dd, CH2Ph, J = 8.5 and 13.6 Hz 
(major)), 2.46 (0.3H, dd, CH2Ph, J = 8.5 and 13.6 Hz (minor)), 2.57-2.67 (2H, m, 
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CH2CH2NH2 (major and minor)), 2.72 (1H, dd, CH2Ph, J = 5.8 and 13.7 Hz (major and 
minor)), 3.63 (1H, td, CH2-O, J = 2.6 and 12.2 Hz (major and minor)), 3.73-3.79 (1H, 
m, CH2-O (major and minor)), 7.14 (2H, d, Ar-H, J = 7.3 Hz (major and minor)), 7.19 
(1H, t, Ar-H, J = 7.5 Hz (major and minor)), 7.26-7.29 (2H, m, Ar-H (major and 
minor)); 
13
C δ/ppm (125 MHz, CDCl3) 29.5, 29.8, 34.5, 37.4, 37.5, 40.6, 42.7, 68.5, 
125.8, 128.3, 129.0, 141.5; LC-MS (ESI+) m/z = 234.3 [M+H]
+
; HRMS cald. for 
C17H28NO [M+H]
+
 262.2165, found 262.2164 
 
U) 2-(Tetrahydro-2H-pyran-4-yl)acetic acid (112) 
 
 
 
 
Lithium hydroxide monohydrate (6.37 g, 152 mmol), as a solution in distilled water 
(79.5 mL, 1.9 M), was added to a solution of methyl ester 62 (1.20 g, 7.59 mmol) in 
THF (79.5 mL, 0.1 M) at room temperature in air and stirred at 60 
o
C for 90 min. The 
reaction was cooled to room temperature, acidifed to pH 0 with 1 M HCl and 
partitioned with EtOAc (20 mL). The aqueous layer was extracted with EtOAc (20 mL) 
and the organic layer was washed with brine (20 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give 112 as a yellow solid (1.04 g, 95%); Rf = 0.26 (silica, 80% 
EtOAc, petrol); m.p. 56-60 
oC;  UV λmax (EtOH/nm) No distinguished peak; IR νmax/cm
-
1
 2934 (C-H), 2914 (br) (O-H), 2841 (C-H), 1703 (C=O), 1640, 1444, 1411, 1303, 1279, 
1233, 1173, 1132, 1086, 1018, 981, 916, 885, 855; 
1H δ/ppm (500 MHz, CDCl3) 1.37 
(2H, qd, CH2CH, J = 4.3 and 12.0 Hz), 1.67-1.70 (2H, m, CH2CH), 1.98-2.07 (1H, m, 
CH), 2.30 (2H, d, CH2CO2H, J = 7.1 Hz), 3.42 (2H, td, CH2-O, J = 1.9 and 12.0 Hz), 
3.95-3.98 (2H, m, CH2-O), 10.88 (1H, s, br, CO2H); 
13C δ/ppm (125 MHz, CDCl3) 31.8, 
32.6, 41.0, 67.7, 177.8; LC-MS (ESI+) m/z = 143.1 [M-H]
-
; HRMS calcd. for C7H11O3 
[M-H]
-
 143.0714, found 143.0718 
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V) (R)- and (S)-4-Benzyl-3-(2-(tetrahydro-2H-pyran-4-yl)acetyl)oxazolidin-2-one 
((R)- and (S)-113) 
 
 
 
Triethylamine (2.07 mL, 1.50 g, 14.8 mmol) was added to a solution of pyran 112 (1.07 
g, 7.42 mmol) in THF (31.0 mL, 0.2 M) at room temperature, stirred for 10 min and 
then cooled to 0 
o
C before addition of pivaolyl chloride (1.09 mL, 1.07 g, 8.90 mmol). 
After 30 min at 0 
o
C, lithium chloride (0.5 M in THF, 17.8 mL, 8.90 mmol) was added, 
followed by either (R)-(+)- or (S)-(-)-4-benzyloxazolidin-2-one (1.58 g, 8.90 mmol) and 
the reaction was stirred at room temperature for 20 h. The reaction was partitioned with 
EtOAc (20 mL) and 1 M HCl (20 mL), the organic layer was washed with 1 M HCl (2 × 
20 mL), 1 M K2CO3 (3 × 20 mL) and the acidic aqueous layer was extracted with 
EtOAc (20 mL). The organic layer was washed with brine (10 mL), dried (MgSO4), 
filtered and concentrated in vacuo. Chromatography (silica, 30% EtOAc, petrol) 
afforded either (R)-113 or (S)-113 as white solids (1.59 g, 66% and 1.72 g, 73% 
respectively); Rf = 0.29 (silica, 30% EtOAc, petrol); m.p. 102-104 
oC; [α]D
24.5
 -83.3
o
 (R) 
(c 1.02 in EtOH), [α]D
24.1
 +92.1
o
 (S) (c 1.01 in EtOH); UV λmax (EtOH/nm) 205.0; IR 
νmax/cm
-1
 2948 (C-H), 2912 (C-H), 2832 (C-H), 1760 (C=O), 1687 (C=O), 1395, 1354, 
1279, 1211 (C-O), 1141, 1092, 1053, 984, 850, 765, 697; 
1
H δ/ppm (500 MHz, CDCl3) 
1.36-1.47 (2H, m, OCH2CH2CH), 1.67-1.73 (2H, m, OCH2CH2CH), 2.11-2.20 (1H, m, 
CHCH2CO), 2.76 (1H, dd, CH2CO, J = 9.7 and 13.4 Hz), 2.84 (1H, dd, PhCH2, J = 7.0 
and 16.7 Hz), 2.95 (1H, dd, PhCH2, J = 6.6 and 16.7 Hz), 3.30 (1H, dd, CH2CO, J = 3.3 
and 13.3 Hz), 3.41-3.47 (2H, m, CH2-O), 3.95-3.98 (2H, m, CH2-O), 4.16-4.23 (2H, m, 
CH2OCON), 4.66-4.70 (1H, m, CHN), 7.21(2H, d, Ar-H, J = 7.0 Hz), 7.28-7.30 (1H, m, 
Ar-H), 7.32-7.36 (2H, m, Ar-H); 
13
C δ/ppm (125 MHz, CDCl3) 31.4, 32.8, 38.0, 42.2, 
55.2, 66.3, 67.8, 67.9, 127.4, 129.0, 129.4, 135.2, 153.5, 171.8; LC-MS (ESI+) m/z = 
304.4 [M+H]
+
; HRMS calcd. for C17H22O4N [M+H]
+ 
304.1543, found 304.1546 
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N-Benzyl-3-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutan-1-amine (16b) 
 
 
 
 
 
General Procedure A: Using amine 28 (212 mg, 0.81 mmol) and benzaldehyde (0.10 
mL, 0.10 g, 0.97 mmol), chromatography (silica, 20% EtOAc, DCM followed by 2% 
NH3(aq), MeOH) afforded 16b, as an inseparable mixture of diastereoisomers (dr = 5:2), 
as a yellow oil (171 mg, 60%); Rf = 0.39 (silica, 5% NH3(aq)/MeOH, DCM); IR νmax/cm
-
1
 3025 (C-H), 2970 (C-H), 2927 (C-H), 2855 (C-H), 1602, 1494, 1453, 1364, 1285, 
1202, 1085, 1029, 963, 909, 857, 733, 697; 
1H δ/ppm (500 MHz, CDCl3) 1.11 (2.4H, s, 
Alk-CH3 (major)), 1.13 (0.7H, s, Alk-CH3 (minor)) 1.21 (2.2H, s, Alk-CH3 (major)), 
1.22 (0.8H, s, Alk-CH3 (minor)) 1.23-1.29 (2H, m, Alk-H (major and minor)), 1.34-1.62 
(6H, m, Alk-H (major and minor)), 1.70-1.79 (1H, m, NH (major and minor)), 2.41 (1H, 
dd, Alk-H, J = 8.2 and 13.7 Hz (major and minor)), 2.50-2.61 (2H, m, CH2CH2NH 
(major and minor)), 2.68 (1H, dd, Alk-H, J = 5.6 and 13.7 Hz (major and minor)), 3.58-
3.63 (1H, m, Alk-H (major and minor)), 3.70 (1.4H, s, NHCH2Ar (major)), 3.72 (0.5H, 
s, NHCH2Ar (minor)) 3.75-3.78 (1H, m, Alk-H (major and minor)), 7.12 (2H, d, Ar-H, 
J = 8.2 Hz (major and minor)), 7.16-7.19 (1H, m, Ar-H (major and minor)), 7.23-7.32 
(2H, m, Ar-H (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 29.4, 29.7, 30.3, 
31.9, 33.0, 33.2, 37.2, 37.3, 39.5, 39.8, 42.8, 43.0, 47.4, 53.8, 61.9, 71.8, 125.8, 127.0, 
128.2, 128.3, 128.4, 129.1, 141.0; LC-MS (ESI+) m/z = 352.2 [M+H]
+
; HRMS calcd. 
for C24H34NO [M+H]
+
 352.2635, found 352.2626; Analytical HPLC: 95.7% 
 
3-(((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutyl)amino)methyl)-N,N-
dimethylaniline (16c) 
 
 
 
 
 
General Procedure A: Using amine 28 (100 mg, 0.38 mmol) and 3-(N,N-
dimethylamino)benzaldehyde (69 mg, 0.46 mmol), chromatography (silica, 20% 
EtOAc, DCM followed by 10% MeOH, DCM) afforded 16c, as an inseparable mixture 
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of diastereoisomers (dr = 5:2), as a yellow oil (71 mg, 53%); Rf = 0.40 (silica, 10% 
MeOH, DCM); UV λmax (EtOH/nm) 302.5 and 256.0; IR νmax/cm
-1
 2970 (C-H), 2927 
(C-H), 2856 (C-H), 2804 (C-H), 1602, 1495, 1453, 1363, 1230, 1204, 1116, 1085, 997, 
961, 857, 738, 697; 
1H δ/ppm (500 MHz, CDCl3) 1.11 (2.2H, s, Alk-CH3 (major)), 1.13 
(0.8H, s, Alk-CH3 (minor)), 1.21 (2.3H, s, Alk-CH3 (major)), 1.22 (0.7H, s, Alk-CH3 
(minor)), 1.23-1.29 (1H, m, Alk-H (major and minor)), 1.35-1.61 (7H, m, Alk-H (major 
and minor)), 1.72-1.79 (1H, m, NH (major and minor)), 2.42 (1H, dd, PhCH2-Alk, J = 
8.3 and 13.7 Hz (major and minor)), 2.52-2.63 (2H, m, AlkCH2NH (major and minor)), 
2.68 (1H, dd, PhCH2-Alk, J = 5.5 and 13.8 Hz (major and minor)), 2.94 (6H, s, 
ArN(CH3)2 (major and minor)), 3.57-3.63 (1H, m, CH2-O (major and minor)), 3.67 
(1.4H, s, HNCH2Ar (major)), 3.69 (0.4H, s, HNCH2Ar (minor)) 3.71-3.78 (1H, m, CH2-
O (major and minor)), 6.61-6.67 (3H, m, Ar-H (major and minor)), 7.11-7.13 (2H, m, 
Ar-H (major and minor)), 7.16-7.19 (2H, m, Ar-H (major and minor)), 7.24-7.27 (2H, 
m, Ar-H (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 29.4, 29.7, 30.3, 31.9, 
32.9, 33.1, 37.2, 37.3, 39.4, 39.8, 40.7, 42.8, 43.0, 47.3, 47.4, 54.3, 61.9, 71.8, 111.4, 
112.4, 116.5, 125.8, 128.3, 129.1, 141.5, 150.8; LC-MS (ESI+) m/z = 395.5 [M+H]
+
; 
Analytical HPLC: 95.4% 
 
3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-N-(4-isopropylbenzyl)-4-phenylbutan-
1-amine (16d)
79
 
 
 
 
 
 
General Procedure A: Using amine 28 (200 mg, 0.77 mmol) and 4-
isopropylbenzaldehyde (0.14 mL, 0.16 g, 0.92 mmol), chromatography (silica, 20% 
EtOAc, DCM followed by 5% NH3(aq)/MeOH, DCM) eluted 16d, as an inseparable 
mixture of diastereoisomers (dr = 5:2), as a yellow oil (47 mg, 16%); Rf = 0.37 (silica, 
5% NH3(aq)/MeOH, DCM); IR νmax/cm
-1
 3026 (C-H), 2960 (C-H), 2927 (C-H), 2865 (C-
H), 2818 (C-H), 1602, 1495, 1454, 1364, 1203, 1086, 818, 737, 699; 
1H δ/ppm (500 
MHz, CDCl3) 1.10 (2.3H, s, Alk-CH3 (major), 1.12 (0.8H, s, Alk-CH3 (minor)), 1.20 
(2.5H, s, Alk-CH3 (major), 1.22 (0.9H, s, Alk-CH3 (minor)), 1.25 (3H, s, ArCH(CH3)2 
(major and minor)), 1.26 (3H, s, ArCH(CH3)2 (major and minor)), 1.25-1.28 (2H, m, 
Alk-H (major and minor)), 1.36-1.62 (7H, m, Alk-H (major and minor)), 1.72-1.79 (1H, 
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m, NH (major and minor)), 2.41 (1H, dd, Alk-H, J = 8.5 and 13.7 Hz (major and 
minor)), 2.50-2.61 (2H, m, CH2CH2NH (major and minor)), 2.67 (1H, dd, Alk-H, J = 
5.6 and 13.6 Hz (major and minor)), 2.89 (1H, hep, Alk-H, J = 6.9 Hz, ArCH(CH3)2 
(major and minor)), 3.58-3.63 (1H, m, Alk-H (major and minor)), 3.68 (1.5H, s, 
NHCH2Ar (major)), 3.70 (0.5H, s, NHCH2Ar (minor)), 3.72-3.78 (1H, m, Alk-H (major 
and minor)), 7.11 (2H, d, Ar-H, J = 7.4 Hz (major and minor)), 7.16-7.18 (5H, m, Ar-H 
(major and minor)), 7.24-7.27 (2H, m, Ar-H (major and minor)); 
13C δ/ppm (125 MHz, 
CDCl3) 21.8, 24.0, 29.4, 29.7, 30.3, 31.9, 32.9, 33.1, 33.8, 37.2, 39.5, 39.8, 42.8, 43.0, 
47.4, 53.7, 61.9, 71.8, 125.8, 126.4, 128.1, 128.3, 129.1, 137.7, 141.5, 147.6; LC-MS 
(ESI+) m/z = 394.2 [M+H]
+
; HRMS calcd. for C27H40NO [M+H]
+
 394.3104, found 
394.3091; Analytical HPLC: 99.8% 
 
N-(4-Chlorobenzyl-3-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutan-1-
amine (16e)
79
 
 
 
 
 
 
General Procedure A: Using amine 28 (212 mg, 0.81 mmol) and 4-
chlorobenzaldehyde (137 mg, 0.97 mmol), chromatography (silica, 20% EtOAc, DCM 
followed by 5% NH3(aq)/MeOH, DCM) afforded 16e, as an inseparable mixture of 
diastereoisomers (dr = 5:2), as a yellow oil (80 mg, 26%); Rf = 0.34 (silica, 5% 
NH3(aq)/MeOH, DCM); IR νmax/cm
-1
 2970 (C-H), 2929 (C-H), 2857 (C-H), 1601, 1491, 
1453, 1365, 1285, 1202, 1086, 1015, 962, 801, 738, 699; 
1H δ/ppm (500 MHz, CDCl3) 
1.12 (2.5H, s Alk-CH3 (major)), 1.14 (0.8H, s Alk-CH3 (minor)) 1.21 (2.2H, s Alk-CH3 
(major)), 1.23 (0.7H, s Alk-CH3 (minor)) 1.23-1.29 (2H, m, Alk-H (major and minor)), 
1.34-1.61 (6H, m, Alk-H (major and minor)), 1.73-1.80 (1H, m, NH (major and minor)), 
2.40 (1H, dd, Alk-H, J = 8.6 and 13.7 Hz (major and minor)), 2.46-2.60 (2H, m, 
CH2CH2NH (major and minor)), 2.68 (1H, dd, Alk-H, J = 5.9 and 13.7 Hz (major and 
minor)), 3.58-3.64 (1H, m, Alk-H (major and minor)), 3.65 (1.4H, s, NHCH2Ar 
(major)), 3.67 (0.5H, s, NHCH2Ar (minor)) 3.71-3.79 (1H, m, Alk-H(major and 
minor)), 7.11 (2H, d, Ar-H, J = 8.2 Hz (major and minor)), 7.17-7.20 (3H, m, Ar-H 
(major and minor)), 7.25-7.28 (4H, m, Ar-H (major and minor)); 
13C δ/ppm (125 MHz, 
CDCl3) 21.8, 29.4, 29.7, 30.4, 31.9, 33.0, 33.3, 37.3, 39.5, 39.8, 42.8, 43.0, 47.5, 53.2, 
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53.4, 61.9, 71.8, 125.8, 128.3, 128.5, 129.0, 129.4, 132.6, 138.9, 141.5; LC-MS (ESI+) 
m/z = 386.2 [M+H]
+
; HRMS calcd. for C24H33
35
ClNO [M+H]
+
 386.2245, found 
386.2236; Analytical HPLC: 97.4% 
 
4-(((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-
phenylbutyl)amino)methyl)benzonitrile (16f) 
 
 
 
 
 
General Procedure A: Using amine 28 (100 mg, 0.38 mmol) and 4-formylbenzonitrile 
(61 mg, 0.46 mmol), chromatography (silica, 10-50% EtOAc, DCM) afforded 16f, as an 
inseparable mixture of diastereoisomers (dr = 5:2), as a yellow oil (82 mg, 64%); Rf = 
0.17 (silica, 50% EtOAc, DCM); UV λmax (EtOH/nm) 279.0 and 268.0; IR νmax/cm
-1
 
2926 (C-H), 2857 (C-H), 2228 (C≡N), 1608, 1494, 1453, 1365, 1204, 1084, 1041, 857, 
817, 738, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.12 (2.2H, s, Alk-CH3 (major)), 1.14 
(0.9H, s, Alk-CH3 (minor)), 1.21 (2.3H, s, Alk-CH3 (major)), 1.23 (0.8H, s, Alk-CH3 
(minor)), 1.26-1.29 (1H, m, Alk-H (major and minor)), 1.35-1.59 (8H, m, Alk-H (major 
and minor)), 1.73-1.80 (1H, m, NH (major and minor)), 2.39 (1H, dd, Alk-H, J = 8.7 
and 13.7 Hz (major and minor)), 2.46-2.57 (2H, m, CH2CH2NH (major and minor)), 
2.70 (1H, dd, Alk-H, J = 5.5 and 13.7 Hz (major and minor)), 3.61 (1H, t, Alk-H, J = 
12.1 Hz (major and minor)), 3.73 (1.6H, s, NHCH2Ar (major)), 3.75 (0.5H, s, 
NHCH2Ar (minor)), 3.76-3.79 (1H, m, Alk-H (major and minor)), 7.11 (2H, d, Ar-H, J 
= 7.2 Hz (major and minor)), 7.16-7.19 (1H, m, Ar-H (major and minor)), 7.24-7.27 
(2H, m, Ar-H (major and minor)), 7.35-7.38 (2H, m, Ar-H (major and minor)), 7.58 
(2H, d, Ar-H, J = 8.2 Hz (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 29.4, 
29.7, 30.5, 31.9, 33.1, 33.4, 37.4, 39.5, 39.9, 42.8, 42.9, 47.7, 53.4, 61.8, 71.8, 110.7, 
119.0, 125.9, 128.3, 128.6, 129.0, 132.2, 141.4, 146.1; LC-MS (ESI+) m/z = 377.4 
[M+H]
+
; Analytical HPLC: 95.8% 
  
251 
 
3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-N-(4-methoxybenzyl)-4-phenylbutan-1-
amine (16g)
79
 
 
 
 
 
 
General Procedure A: Using amine 28 (100 mg, 0.38 mmol) and 4-anisaldehyde (56 
µL, 62.7 mg, 0.46 mmol), chromatography (silica, 10-20% EtOAc, DCM followed by 
10% MeOH, Et2O) afforded 16g, as an inseparable mixture of diastereoisomers (dr = 
5:2), as a colourless oil (69 mg, 53%); Rf = 0.39 (silica, 10% MeOH, Et2O); UV λmax 
(EtOH/nm) 275.0; IR νmax/cm
-1
 2930 (C-H), 2856 (C-H), 1584, 1511, 1453, 1379, 1243, 
1179, 1084, 1037, 822, 737, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.12 (2.3H, s, Alk-CH3 
(major)), 1.13 (0.8H, s, Alk-CH3 (minor)), 1.21 (2.3H, s, Alk-CH3 (major)), 1.22 (0.8H, 
s, Alk-CH3 (minor)), 1.23-1.29 (1H, m, Alk-H (major and minor)), 1.33-1.60 (8H, m, 
Alk-H (major and minor)), 1.73-1.76 (1H, m, NH (major and minor)), 2.40 (1H, dd, J = 
8.5 and 13.7 Hz, Alk-H (major and minor)), 2.48-2.59 (2H, m, CH2CH2NH (major and 
minor)), 2.66 (1H, dd, Alk-H, J = 5.7 and 13.6 Hz (major and minor)), 3.58-3.61 (1H, 
m, Alk-H (major and minor)), 3.63 (1.7 H, s, NHCH2Ar (major)), 3.65 (0.5 H, s, 
NHCH2Ar (minor)), 3.72-3.79 (4H, m, Alk-H and OCH3 (major and minor)), 6.85 (2H, 
d, Ar-H, J = 8.6 Hz (major and minor)), 7.11 (2H, d, Ar-H, J = 7.3 Hz (major and 
minor)), 7.16-7.19 (3H, m, Ar-H (major and minor)), 7.25-7.28 (2H, m, Ar-H (major 
and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 29.4, 29.7, 30.3, 30.4, 31.9, 32.9, 33.1, 
37.2, 37.3, 39.5, 39.8, 42.9, 43.0, 47.4, 53.3, 55.3, 61.9, 71.8, 113.8, 125.8, 128.3, 
129.1, 129.2, 132.5, 141.5, 158.6; LC-MS (ESI+) m/z = 382.5 [M+H]
+
; Analytical 
HPLC: 98.8% 
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5-(((3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutyl)amino)methyl)-N,N-
dimethylpyridin-2-amine (16h) 
 
 
 
 
 
General Procedure A: Using amine 28 (100 mg, 0.38 mmol) and 6-(N,N-
dimethylamino)nicotinaldehyde (69 mg, 0.46 mmol), chromatography (silica, 5% 
MeOH, Et2O followed by 20% MeOH, EtOAc) afforded 16h, as an inseparable mixture 
of diastereoisomers (dr = 5:2), as a dark yellow oil (63 mg, 47%); Rf = 0.33 (silica, 10% 
MeOH, DCM); UV λmax (EtOH/nm) 253.5; IR νmax/cm
-1
 2926 (C-H), 2856 (C-H), 1608, 
1559, 1511, 1453, 1398, 1364, 1318, 1208, 1178, 1085, 1015, 958, 858, 806, 738, 700; 
1H δ/ppm (500 MHz, CDCl3) 1.11 (2.2H, s, Alk-CH3 (major)), 1.12 (0.7H, s, Alk-CH3 
(minor)), 1.20 (2.2H, s, Alk-CH3 (major)), 1.22 (2.2H, s, Alk-CH3 (minor)), 1.25-1.27 
(1H, m, Alk-H (major and minor)), 1.34-1.59 (7H, m, Alk-H (major and minor)), 1.71-
1.77 (1H, m, NH (major and minor)), 2.39 (1H, dd, PhCH2-Alk, J = 8.4 and 13.7 Hz 
(major and minor)), 2.46-2.58 (2H, m, AlkCH2-NH (major and minor)), 2.67 (1H, dd, 
PhCH2-Alk, J = 5.3 and 13.7 Hz (major and minor)), 3.07 (6H, s, Ar-N(CH3)2 (major 
and minor)), 3.56 (1.6H, s, HN-CH2Ar (major)), 3.58 (0.5H, s, HN-CH2Ar (minor)), 
3.58-3.62 (1H, m, CH2-O (major and minor)), 3.71-3.77 (1H, m, CH2-O (major and 
minor)), 6.47-6.49 (1H, m, Ar-H (major and minor)), 7.10-7.12 (2H, m, Ar-H (major 
and minor)), 7.15-7.18 (1H, m, Ar-H (major and minor)), 7.24-7.27 (2H, m, Ar-H 
(major and minor)), 7.41-7.44 (1H, m, Ar-H (major and minor)), 8.01-8.03 (1H, m, Ar-
H (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 29.4, 29.6, 29.9, 31.9, 33.0, 
33.2, 37.2, 37.3, 38.2, 39.4, 39.8, 42.8, 43.0, 46.7, 50.3, 61.8, 71.8, 105.7, 125.8, 128.3, 
129.0, 129.1, 137.8, 141.3, 147.8, 158.9; LC-MS (ESI+) m/z = 396.5 [M+H]
+
; HRMS 
calcd. for C26H39N2O [M+H]
+
 396.3009, found 396.3011; Analytical HPLC: 97.6% 
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(±)-N,N-Dimethyl-4-(((4-phenyl-3-(tetrahydro-2H-pyran-4-
yl)butyl)amino)methyl)aniline (68a)
79
 
 
 
 
 
 
General Procedure A: Using amine 67 (200 mg, 0.86 mmol) and 4-(N,N-
dimethylamino)benzaldehyde (154 mg, 1.03 mmol), chromatography (silica, 20% 
EtOAc, DCM followed by 2% NH3(aq), MeOH) afforded 68a as a yellow oil (299 mg, 
95%); Rf = 0.54 (silica, 2% NH3(aq), MeOH); UV λmax (EtOH/nm) 302.0 and 263.0; IR 
νmax/cm
-1
 3024 (C-H), 2928 (C-H), 2840 (C-H), 1614, 1521, 1443, 1342, 1228, 1091, 
1014, 946,  804, 740, 699 
1H δ/ppm (500 MHz, CDCl3) 1.36-1.65 (9H, m, Alk-H and 
NH), 2.44 (1H, dd, Alk-H, J = 7.72 and 13.7 Hz), 2.53-2.63 (2H, m, CH2CH2NH), 2.67 
(1H, dd, Alk-H, J = 6.2 and 13.7 Hz), 2.93 (6H, s, N(CH3)2), 3.29-3.35 (2H, m, Alk-H), 
3.61 (2H, s, NHCH2Ar), 3.95-4.02 (2H, m, Alk-H), 6.70 (2H, d, Ar-H, J = 8.7 Hz) 7.10-
7.15 (4H, m, Ar-H), 7.18 (1H, t, Ar-H, J = 7.4 Hz), 7.24-7.29 (2H, m, Ar-H); 
13C δ/ppm 
(125 MHz, CDCl3) 29.5, 29.8, 30.5, 37.3, 37.4, 40.8, 43.0, 47.4, 53.5, 68.5, 112.7, 
125.8, 128.3, 128.5, 129.0, 129.1, 141.5, 149.8; LC-MS (ESI+) m/z = 367.4 [M+H]
+
; 
HRMS calcd. for C24H35N2O [M+H]
+
 367.2744, found 367.2743; Analytical HPLC: 
97.9% 
 
(R)- and (S)-N,N-Dimethyl-4-(((4-phenyl-3-(tetrahydro-2H-pyran-4-
yl)butyl)amino)methyl)aniline ((R)- and (S)-68a) 
 
 
 
General Procedure A: Using either (R)- or (S)-amine (R)-67 or (S)-67 (115 mg, 0.49 
mmol and 133 mg, 0.57 mmol respectively), chromatography (silica, 5-15% MeOH, 
DCM) afforded (R)- and (S)-68 as yellow oils (29 mg, 16% and 137 mg, 65% 
respectively). Analytical data equivalent to (±)-68; [α]D
26.5
 +11.4
o
 (R) (c 1.97 in EtOH), 
[α]D
26.5
 -11.0
o
 (S) (c 1.97 in EtOH) 
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4-Phenyl-N-(4-(pyrrolidin-1-yl)benzyl)-3-(tetrahydro-2H-pyran-4-yl)butan-1-
amine (68b) 
 
 
 
 
 
General Procedure A: Using amine 67 (50 mg, 0.21 mmol) and 4-(1-
pyrrolidinyl)benzaldehyde (45.6 mg, 0.26 mmol), chromatography (silica, 20% EtOAc, 
DCM followed by 5-10% MeOH, DCM) afforded 68b as a yellow oil (392 mg, 77%); 
Rf = 0.35 (silica, 10% MeOH, DCM); UV λmax (EtOH/nm) 262.0; IR νmax/cm
-1
 2930 (C-
H), 2838 (C-H), 1614, 1521, 1488, 1454, 1368, 1181, 1092, 1014, 963, 802, 738, 700; 
1H δ/ppm (500 MHz, CDCl3) 1.42-1.59 (9.5H, m, Alk-H, NH and H2O), 1.97-2.00 (4H, 
m, (CH2)2, pyrrolidino ring),  2.42 (1H, dd, PhCH2, J = 7.5 and 13.6 Hz), 2.53-2.61 (2H, 
m, AlkCH2-NH), 2.66 (1H, dd, PhCH2, J = 5.7 and 13.6 Hz), 3.25-3.27 (4H, m, (CH2)2, 
pyrrolidino ring), 3.28-3.35 (2H, m, CH2-O), 3.61 (2H, s, HN-CH2Ar), 3.95-4.00 (2H, 
m, CH2-O), 6.50-6.52 (2H, m, Ar-H), 7.11-7.13 (4H, m, Ar-H), 7.16-7.19 (1H, m, Ar-
H), 7.25-7.28 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 25.5, 29.5, 29.7, 37.2, 37.4, 
43.0, 47.7, 68.5, 111.6, 125.8, 128.3, 129.1, 129.4, 141.4, 147.3; LC-MS (ESI+) m/z = 
393.3 [M+H]
+
; HRMS calcd. for C26H37ON2 [M+H]
+ 
393.2900, found 393.2901; 
Analytical HPLC: 97.9% 
 
4-Phenyl-3-(tetrahydro-2H-pyran-4-yl)-N-(4-(trifluoromethyl)benzyl)butan-1-
amine (68c) 
 
 
 
 
 
General Procedure A: Using amine 67 (50 mg, 0.21 mmol) and 4-
(trifluoromethyl)benzaldehyde (35 µL, 44.6 mg, 0.25 mmol), chromatography (silica, 0-
10% MeOH, DCM) afforded 68c as a yellow oil (73 mg, 85%); Rf = 0.36 (silica, 5% 
MeOH, DCM); UV λmax (EtOH/nm) 258.5; IR νmax/cm
-1
 2928 (C-H), 2843 (C-H), 1619, 
1454, 1323 (sharp), 1161, 1117, 1065, 1017, 822, 739, 699; 
1H δ/ppm (500 MHz, 
CDCl3) 1.37-1.63 (11.5H, m, Alk-H, NH and H2O), 2.41 (1H, dd, PhCH2, J = 8.1 and 
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13.6 Hz), 2.50-2.60 (2H, m, AlkCH2-NH), 2.70 (1H, dd, PhCH2, J = 5.9 and 13.6 Hz), 
3.29-3.36 (2H, m, CH2-O), 3.74 (2H, s, HN-CH2Ar), 3.96-4.01 (2H, m, CH2-O), 7.12 
(2H, d, Ar-H, J = 7.6 Hz), 7.17-7.19 (1H, m, Ar-H), 7.25-7.28 (2H, m, Ar-H), 7.37 (2H, 
d, Ar-H, J = 8.0 Hz), 7.56 (2H, d, Ar-H, J = 8.1 Hz); 
13C δ/ppm (125 MHz, CDCl3) 
29.5, 29.8, 30.5, 37.5, 42.9, 47.6, 53.4, 68.4, 125.18, 125.24, 125.9, 128.2, 128.3, 129.0, 
129.3, 141.4, 144.5; LC-MS (ESI+) m/z = 392.1 [M+H]
+
; HRMS calcd. for C23H29ONF3 
[M+H]
+
 392.2196, found 392.2195; Analytical HPLC: 95.4% 
 
N-(4-(Methylthio)benzyl)-4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-amine 
(68d) 
 
 
 
 
 
General Procedure A: Using amine 67 (100 mg, 0.43 mmol) and 4-
(thiomethyl)benzaldehyde (70 µL, 80.1 mg, 0.52 mmol), chromatography (silica, 0-10% 
MeOH, DCM) afforded 68d as a yellow oil (127 mg, 77%); Rf = 0.27 (silica, 5% 
MeOH, DCM); UV λmax (EtOH/nm) 257.5; IR νmax/cm
-1
 2924 (C-H), 2838 (C-H), 1601, 
1493, 1453, 1090, 1014, 800, 739, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.37-1.61 (11.5H, 
m, Alk-H, NH and H2O), 2.42 (1H, dd, PhCH2, J = 7.9 and 13.6 Hz), 2.47 (3H, s, 
SCH3), 2.50-2.61 (2H, m, AlkCH2-NH), 2.68 (1H, dd, PhCH2, J = 6.1 and 13.8 Hz), 
3.29-3.35 (2H, m, CH2-O), 3.65 (2H, s, HN-CH2Ar), 3.96-4.01 (2H, m, CH2-O), 7.12 
(2H, d, Ar-H, J = 7.1 Hz), 7.17-7.22 (5H, m, Ar-H), 7.25-7.28 (2H, m, Ar-H); 
13
C 
δ/ppm (125 MHz, CDCl3) 16.1, 29.5, 29.7, 30.4, 37.4, 43.0, 47.4, 53.4, 68.4, 125.8, 
126.9, 128.3, 128.7, 129.1, 136.8, 141.4; LC-MS (ESI+) m/z = 370.4 [M+H]
+
; HRMS 
calcd. for C23H32ONS [M+H]
+
 370.2199, found 370.2202; Analytical HPLC: 96.3% 
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N-(4-Chlorobenzyl)-4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-amine (68e)
79
 
 
 
 
 
 
General Procedure A: Using amine 67 (100 mg, 0.43 mmol) and 4-
chlorobenzaldehyde (74 mg, 0.52 mmol), chromatography (silica, 0-10% MeOH, DCM) 
afforded 68e as a yellow oil (116 mg, 72%); Rf = 0.38 (silica, 5% MeOH, DCM); UV 
λmax (EtOH/nm) 260.0; IR νmax/cm
-1
 2928 (C-H), 2841 (C-H), 1601, 1490, 1453, 1242, 
1089, 1014, 982, 801, 739, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.36-1.61 (12H, m, Alk-
H, NH and H2O), 2.41 (1H, dd, PhCH2, J = 7.8 and 13.8 Hz), 2.49-2.59 (2H, m, 
AlkCH2-NH), 2.69 (1H, dd, PhCH2, J = 5.4 and 13.2 Hz), 3.29-3.36 (2H, m, CH2-O), 
3.66 (2H, s, HN-CH2Ar), 3.96-4.01 (2H, m, CH2-O), 7.12 (2H, d, Ar-H, J = 7.5 Hz), 
7.17-7.20 (3H, m, Ar-H), 7.25-7.28 (4H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 29.5, 
29.7, 30.5, 37.5, 43.0, 47.5, 53.2, 68.4, 125.8, 128.3, 128.5, 129.0, 129.4, 132.6, 138.9, 
141.4; LC-MS (ESI+) m/z = 358.4 [M+H]
+
; HRMS calcd. for C22H29ON
35
Cl [M+H]
+
 
358.1932, found 358.1936; Analytical HPLC: 93.8% 
 
N-(4-Fluorobenzyl)-4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-amine (68f)
79
 
 
 
 
 
 
General Procedure A: Using amine 67 (50 mg, 0.21 mmol) and 4-fluorobenzaldehyde 
(27 µL, 31.2 mg, 0.25 mmol), chromatography (silica, 0-10% MeOH, DCM) afforded 
68f as a yellow oil (43 mg, 58%); Rf = 0.30 (silica, 5% MeOH, DCM); UV λmax 
(EtOH/nm) 264.0; IR νmax/cm
-1
 2928 (C-H), 2842 (C-H), 1602, 1508, 1454, 1387, 1219, 
1091, 1014, 822, 739, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.37-1.62 (11H, m, Alk-H, NH 
and H2O), 2.42 (1H, dd, PhCH2, J = 8.0 and 13.6 Hz), 2.50-2.60 (2H, m, AlkCH2-NH), 
2.69 (1H, dd, PhCH2, J = 5.8 and 13.7 Hz), 3.29-3.36 (2H, m, CH2-O), 3.66 (2H, s, HN-
CH2Ar), 3.96-4.01 (2H, m, CH2-O), 6.97-7.00 (2H, m, Ar-H), 7.12 (2H, d, Ar-H, J = 7.4 
Hz), 7.17-7.22 (3H, m, Ar-H), 7.25-7.28 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 
29.5, 29.7, 30.4, 37.4, 43.0, 47.5, 53.1, 68.4, 115.1, 125.8, 128.3, 129.0, 129.6, 141.4, 
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160.9, 162.9; LC-MS (ESI+) m/z = 342.1 [M+H]
+
; HRMS calcd. for C22H29ONF 
[M+H]
+
 342.2228, found 342.2230; Analytical HPLC: 95.4% 
 
N-(4-Nitrobenzyl)-4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-amine (68g) 
 
 
 
 
 
General Procedure A: Using amine 67 (450 mg, 1.93 mmol) and 4-nitrobenzaldehyde 
(351 mg, 2.32 mmol), chromatography (silica, 5% EtOAc, DCM followed by 10% 
MeOH, DCM) afforded 68g as a yellow gum (467 mg, 66%); Rf = 0.38 (silica, 2% 
MeOH, DCM); m.p. 39-45 
oC; UV λmax (EtOH/nm) 266.5; IR νmax/cm
-1
 3409 (N-H), 
2932 (C-H), 2845 (C-H), 2752 (C-H), 1605, 1519, 1454, 1344, 1090, 1014, 982, 856, 
739, 698; 
1H δ/ppm (500 MHz, CDCl3) 1.42-1.69 (8H, m, Alk-H), 1.80-1.87 (1H, m, 
NH), 2.31 (1H, dd, PhCH2, J = 9.0 and 13.8 Hz), 2.41-2.47 (1H, m, AlkCH2-NH), 2.54-
2.60 (1H, m, AlkCH2-NH), 2.76 (1H, dd, PhCH2, J = 4.9 and 13.8 Hz), 3.27-3.32 (2H, 
m, CH2-O), 3.89 (2H, s, HN-CH2Ar), 3.94-3.97 (2H, m, CH2-O), 7.09 (2H, d, Ar-H, J = 
7.0 Hz), 7.17 (1H, t, Ar-H, J = 7.4 Hz), 7.22-7.25 (2H, m, Ar-H), 7.56 (2H, d, Ar-H, J = 
8.7 Hz), 8.17 (2H, d, Ar-H, J = 8.8 Hz); 
13C δ/ppm (125 MHz, CDCl3) 27.4, 29.5, 29.7, 
37.5, 38.2, 42.9, 45.2, 49.7, 68.2, 124.1, 126.3, 128.6, 128.9, 130.7, 140.5, 148.2; LC-
MS (ESI+) m/z = 369.7 [M+H]
+
; HRMS calcd. for C22H29O3N2 [M+H]
+
 369.2173, 
found 369.2175; Analytical HPLC: 98.7%  
 
2-(Methyl-(4-(((4-phenyl-3-(tetrahydro-2H-pyran-4-
yl)butyl)amino)methyl)phenyl)amino)ethanol (68j) 
 
 
 
General Procedure A: Using amine 67 (100 mg, 0.43 mmol) and 4-(N-methyl-N-(2-
hydroxyethyl)amino)benzaldehyde (93.2 mg, 0.52 mmol), chromatography (silica, 5-
20% MeOH, Et2O) afforded 68j as a yellow gum (93 mg, 55%); Rf = 0.14 (silica, 20% 
258 
 
MeOH, DCM); UV λmax (EtOH/nm) 262.5; IR νmax/cm
-1
 3368 (br) (N-H and O-H), 2929 
(C-H), 2846 (C-H), 1613, 1521, 1453, 1369, 1189, 1091, 1051, 803, 740, 700; 
1H δ/ppm 
(500 MHz, CDCl3) 1.42-1.61 (9H, m, Alk-H and NH), 1.94 (1H, s, br, OH), 2.42 (1H, 
dd, PhCH2, J = 7.6 and 13.7 Hz), 2.53-2.63 (2H, m, AlkCH2-NH), 2.67 (1H, dd, PhCH2, 
J = 5.8 and 13.7 Hz), 2.94 (3H, s, NCH3), 3.28-3.34 (2H, m, CH2-O), 3.44 (2H, t, MeN-
CH2, J = 5.6 Hz), 3.61 (2H, s, HN-CH2Ar), 3.79 (2H, t, CH2OH, J = 5.7 Hz), 3.95-3.99 
(2H, m, CH2-O), 6.73-6.75 (2H, m, Ar-H), 7.11-7.15 (4H, m, Ar-H), 7.17-7.20 (1H, m, 
Ar-H), 7.25-7.28 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 29.4, 29.7, 29.9, 37.3, 
37.4, 38.9, 43.0, 47.0, 52.9, 55.6, 60.1, 68.4, 113.1, 125.9, 128.4, 129.1, 129.5, 141.4, 
149.4; LC-MS (ESI+) m/z = 397.4 [M+H]
+
; HRMS calcd. for C25H37O2N2 [M+H]
+
 
397.2850, found 397.2852; Analytical HPLC: 96.8% 
 
N-(4-(Methylsulfonyl)benzyl)-4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-
amine (68k) 
 
 
 
 
 
General Procedure A: Using amine 67 (50 mg, 0.21 mmol) and 4-
(methanesulfonyl)benzaldehyde (47.9 mg, 0.26 mmol), chromatography (silica, 17% 
EtOAc, DCM followed by 20% MeOH, DCM) afforded 68k as a blue/green oil (63 mg, 
75%); Rf = 0.22 (silica, 5% MeOH, DCM); UV λmax (EtOH/nm) No distinguishable 
peak; IR νmax/cm
-1
 2929 (C-H), 2843 (C-H), 1600, 1454, 1408, 1304 (S=O asym. 
stretch), 1148 (S=O sym. stretch), 1089, 1016, 956, 735, 701; 
1H δ/ppm (500 MHz, 
CDCl3) 1.39-1.66 (10.5H, m, Alk-H, NH and H2O), 2.41 (1H, dd, PhCH2, J = 8.1 and 
13.6 Hz), 2.49-2.60 (2H, m, AlkCH2-NH), 2.71 (1H, dd, PhCH2, J = 5.8 and 13.7 Hz), 
3.04 (3H, s, SO2CH3), 3.29-3.36 (2H, m, CH2-O), 3.78 (2H, s, HN-CH2Ar), 3.97-4.03 
(2H, m, CH2-O), 7.12-7.13 (2H, m, Ar-H), 7.17-7.20 (1H, m, Ar-H), 7.25-7.28 (2H, m, 
Ar-H), 7.46-7.47 (2H, m, Ar-H), 7.86-7.89 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, 
CDCl3) 29.5, 29.7, 30.3, 37.4, 37.6, 42.9, 44.6, 47.6, 50.9, 53.0, 53.4, 68.4, 125.9, 
127.5, 128.4, 128.9, 129.0, 139.2, 141.3; LC-MS (ESI+) m/z = 402.7 [M+H]
+
; HRMS 
calcd. for C23H32O3NS [M+H]
+
 402.2097, found 402.2098; Analytical HPLC: 97.4% 
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N-(4-Chlorobenzyl)-3-methyl-4-phenylbutan-1-amine (109) 
 
 
 
 
General Procedure A: Using amine 108 (43 mg, 0.26 mmol) and 4-
chlorobenzaldehyde (43 mg, 0.31 mmol), chromatography (silica, 5% MeOH, DCM) 
afforded 109 as a yellow oil (20 mg, 27%); Rf = 0.33 (silica, 5% MeOH, DCM); UV 
λmax (EtOH/nm) No distinguishable peak; IR νmax/cm
-1
 3026 (C-H), 2918 (C-H), 1598, 
1490, 1453, 1089, 1015, 803, 738, 699; 
1H δ/ppm (500 MHz, CDCl3) 0.90 (3H, d, CH3, 
J = 6.6 Hz), 1.29-1.41 (2H, m, Alk-H and NH), 1.57-1.64 (1H, m, Alk-H), 1.79-1.89 
(1H, m, Alk-H), 2.45 (1H, dd, PhCH2, J = 7.9 and 13.4 Hz), 2.60-2.65 (2H, m, AlkCH2-
NH), 2.71 (1H, dd, PhCH2, J = 5.6 and 9.4 Hz), 3.75 (2H, s, HN-CH2Ar), 7.15-7.17 
(2H, m, Ar-H), 7.19-7.22 (1H, m, Ar-H), 7.25-7.32 (6H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 19.6, 33.2, 36.8, 43.9, 47.3, 53.3, 125.8, 128.2, 128.5, 129.2, 129.5, 
132.6, 138.9, 141.2; LC-MS (ESI+) m/z = 288.3 [M+H]
+
; HRMS calcd. for C18H23N
35
Cl 
[M+H]
+
 288.1514, found 288.1518; Analytical HPLC: 95.2% 
 
N-(4-Chlorobenzyl)-3-methylbutan-1-amine (111) 
 
 
 
 
General Procedure A: Using isopentylamine (267 µL, 200 mg, 2.29 mmol) (110) and 
4-chlorobenzaldehyde (394 mg, 2.80 mmol), chromatography (silica, 33% Et2O, 
hexane) afforded 111 as a yellow oil (231 mg, 48%); Rf = 0.36 (silica, 5% MeOH, 
DCM); UV λmax (EtOH/nm) 218.0; IR νmax/cm
-1
 2955 (C-H), 2923 (C-H), 2869 (C-H), 
2822 (C-H), 1597, 1490, 1461, 1407, 1366, 1091, 1015, 806, 745; 
1
H δ/ppm (500 MHz, 
CDCl3) 0.89 (6H, d, CH(CH3)2, J = 6.6 Hz), 1.37-1.43 (3H, m, CH2-CH2-NH), 1.62 
(1H, sep, CH(CH3)2, J = 6.7 Hz), 2.60-2.63 (2H, m, CH2-NH), 3.75 (2H, s, HN-CH2Ar), 
7.25-7.30 (4H, m, Ar-H); 
13
C δ/ppm (125 MHz, CDCl3) 22.7, 26.2, 39.2, 47.6, 53.4, 
128.5, 129.4, 132.5, 139.0; LC-MS (ESI+) m/z = 213.2 [M+H]
+
; HRMS calcd. for 
C12H19N
35
Cl [M+H]
+
 212.1201, found 212.1202; Analytical HPLC: 98.1% 
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4-Chloro-N-(4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butyl)benzamide (68l) 
 
 
 
 
 
General Procedure B: Using amine 67 (50 mg, 0.21 mmol) and 4-chlorobenzoyl 
chloride (54 µL, 73.7 mg, 0.42 mmol), chromatography (silica, 10% EtOAc, DCM) 
afforded 68l as a brown solid (73 mg, 94%); Rf = 0.23 (silica, 10% EtOAc, DCM); m.p. 
110-112 
oC; UV λmax (EtOH/nm) 235.0; IR νmax/cm
-1
 3304 (N-H), 2956 (C-H), 2837 (C-
H), 1627 (C=O), 1595, 1530, 1484, 1271, 1145, 1093, 1015, 844, 748, 702; 
1H δ/ppm 
(500 MHz, CDCl3) 1.45-1.73 (14H, m, Alk-H and H2O), 2.43 (1H, dd, PhCH2, J = 8.9 
and 13.7 Hz), 2.80 (1H, dd, PhCH2, J = 5.1 and 13.7 Hz), 3.34-3.40 (4H, m, CH2-O and 
AlkCH2-NH), 3.99-4.03 (2H, m, CH2-O), 5.72 (1H, m, NH), 7.17 (2H, d, Ar-H, J = 7.5 
Hz), 7.19-7.22 (1H, m, Ar-H), 7.27-7.30 (2H, m, Ar-H), 7.37-7.38 (2H, m, Ar-H), 7.55-
7.56 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 29.6, 29.8, 30.0, 30.9, 37.2, 37.8, 
38.5, 43.0, 68.4, 126.1, 128.2, 128.6, 128.8, 129.1, 132.9, 137.6, 141.3, 166.3; LC-MS 
(ESI+) m/z = 372.4 [M+H]
+
; HRMS calcd. for C22H27O2N
35
Cl [M+H]
+
 372.1725, found 
372.1728; Analytical HPLC: 97.3% 
 
4-(Dimethylamino)-N-(3-(2,2dimethyltetrahydro-2H-pyran-4-yl)-4-
phenylbutyl)benzenesulfonamide (16j) 
 
 
 
 
 
General Procedure B: Using amine 28 (100 mg, 0.38 mmol) and 4-(N,N-
dimethylamino)benzenesulfonyl chloride (71) (101 mg, 0.46 mmol), chromatography 
(silica, 0-10% EtOAc, DCM) afforded 16j, as an inseparable mixture of 
diastereoisomers (dr = 5:2), as a white solid (134 mg, 89%); Rf = 0.57 (silica, 10% 
MeOH, DCM); UV λmax (EtOH/nm) 278.0; IR νmax/cm
-1
 3268 (N-H), 2930 (C-H), 2863 
(C-H), 1596, 1516, 1446, 1365 (S=O asym. stretch), 1311, 1229, 1144 (S=O sym. 
stretch), 1093, 1000, 944, 858, 815, 772, 737, 700; 
1
H δ/ppm (500 MHz, CDCl3) 1.10 
(2.3H, s, Alk-CH3 (major)), 1.11 (0.8H, s, Alk-CH3 (minor)), 1.14-1.20 (1H, m, Alk-H 
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(major and minor)), 1.19 (2.4H, s, Alk-CH3 (major)), 1.20 (0.8H, s, Alk-CH3 (minor)), 
1.24-1.54 (6H, m, Alk-H (major and minor)), 1.64-1.69 (1H, m, Alk-H (major and 
minor)), 2.32 (1H, dd, PhCH2, J = 8.8 and 13.7 Hz (major and minor)), 2.65 (1H, dd, 
PhCH2, J = 5.5 and 13.7 Hz (major and minor)), 2.78-2.87 (2H, m, AlkCH2-NH (major 
and minor)), 3.04 (6H, s, Ar-N(CH3)2  (major and minor)), 3.52-3.58 (1H, m, CH2-O 
(major and minor)), 3.68-3.73 (1H, m, CH2-O (major and minor)), 4.02 (1H, dt, NH, J = 
6.1 and 17.0 Hz (major and minor)), 6.66 (2H, dd, Ar-H, J = 2.8 and 9.0 Hz (major and 
minor)), 7.06 (2H, d, Ar-H J = 7.3 Hz (major and minor)), 7.16-7.19 (1H, m, Ar-H 
(major and minor)), 7.23-7.26 (2H, m, Ar-H (major and minor)), 7.62-7.64 (2H, m, Ar-
H (major and minor)); 
13
C δ/ppm (125 MHz, CDCl3) 21.8, 29.3, 29.5, 29.9, 30.0, 31.9, 
32.8, 33.0, 36.9, 39.3, 39.7, 40.1, 41.2, 41.3, 41.9, 42.1, 61.7, 71.7, 110.9, 111.0, 125.0, 
126.0, 128.4, 128.9, 129.0, 140.9, 152.8; LC-MS (ESI+) m/z = 445.5 [M+H]
+
; HRMS 
calcd. for C25H36N2O3S [M+H]
+
 445.2519, found 445.2519; Analytical HPLC: 96.6% 
 
4-Chloro-N-(4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butyl)benzenesulfonamide 
(68m) 
 
 
 
 
 
General Procedure B: Using amine 67 (50 mg, 0.21 mmol) and 4-
chlorobenzenesulfonyl chloride (89 mg, 0.42 mmol), chromatography (silica, 5% 
EtOAc, DCM) afforded 68m as a colourless oil (67 mg, 79%); Rf = 0.45 (silica, 10% 
EtOAc, DCM); UV λmax (EtOH/nm) 230.5; IR νmax/cm
-1
 3280 (N-H), 2934 (C-H), 2849 
(C-H), 1586, 1328 (S=O asym. stretch), 1159 (S=O sym. stretch), 1084, 1014, 827, 751, 
700; 
1
H δ/ppm (500 MHz, CDCl3) 1.30-1.56 (13.5H, m, Alk-H and H2O), 2.32 (1H, dd, 
PhCH2, J = 8.6 and 13.6 Hz), 2.71 (1H, dd, PhCH2, J = 5.2 and 13.6 Hz), 2.79-2.88 (2H, 
m, AlkCH2-NH), 3.29-3.35 (2H, m, CH2-O), 3.96-4.00 (2H, m, CH2-O), 4.08-4.10 (1H, 
m, NH), 7.07 (2H, d, Ar-H, J = 7.1 Hz), 7.18-7.21 (1H, m, Ar-H), 7.25-7.28 (2H, m, Ar-
H), 7.45-7.47 (2H, m, Ar-H), 7.69-7.70 (2H, m, Ar-H); 
13
C δ/ppm (125 MHz, CDCl3) 
29.46, 29.54, 30.4, 37.2, 37.7, 41.6, 42.2, 68.3, 126.2, 128.46, 128.54, 128.9, 129.4, 
138.4, 139.1, 140.7; LC-MS (ESI+) m/z = 408.3 [M+H]
+
; HRMS calcd. for 
C21H27O3N
35
ClS [M+H]
+
 408.1395, found 408.1397; Analytical HPLC: 99.2% 
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N-(4-Chlorobenzyl)-N-methyl-4-phenyl-3-(tetrahydro-2H-pyran-4-yl)butan-1-
amine (74b) 
 
 
 
 
 
General Procedure C: Using amine 68e (100 mg, 0.28 mmol), chromatography (silica, 
3% MeOH, DCM) afforded 74b as a yellow oil (75 mg, 69%); Rf = 0.42 (silica, 5% 
MeOH, DCM); UV λmax (EtOH/nm) No distinguishable peak; IR νmax/cm
-1
 2933 (C-H), 
2840 (C-H), 2789 (C-H), 1681, 1600, 1490, 1451, 1364, 1243, 1087, 1014, 841, 803, 
739, 700; 
1H δ/ppm (500 MHz, CDCl3) 1.43-1.65 (8H, m, Alk-H), 2.11 (3H, s, N-CH3), 
2.30-2.31 (2H, m, Alk-CH2-NMe), 2.43 (1H, dd, PhCH2, J = 8.1 and 13.6 Hz), 2.69 
(1H, dd, PhCH2, J = 5.8 and 13.3 Hz), 3.30-3.38 (4H, m, CH2-O and MeN-CH2Ar), 
3.98-4.03 (2H, m, CH2-O), 7.14 (2H, d, Ar-H, J = 7.5 Hz), 7.21-7.22 (3H, m, Ar-H), 
7.28-7.31 (4H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 27.3, 29.5, 29.8, 37.3, 42.1, 
42.7, 53.4, 55.2, 61.6, 68.4, 125.8, 128.3, 129.1, 130.3, 141.4; LC-MS (ESI+) m/z = 
372.4 [M+H]
+
; HRMS calcd. for C23H31ON
35
Cl [M+H]
+
 372.2089, found 372.2092; 
Analytical HPLC: 92.4%  
 
Tert-butyl-(3-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutyl)carbamate 
(101) 
 
 
 
 
General Procedure G i: Using amine 28 (291 mg, 1.11 mmol) and Boc2O (255 mg, 
1.17 mmol) at room temperature overnight, chromatography (silica, 0-5% EtOAc, 
hexane) afforded 101, as an inseparable mixture of diastereoisomers (dr = 5:2), as a 
yellow oil (243 mg, 65%); Rf = 0.25 (silica, 10% EtOAc, DCM); UV λmax (EtOH/nm) 
259.5; IR νmax/cm
-1
 3338 (N-H), 2973 (C-H), 2930 (C-H), 2868 (C-H), 1698 (C=O), 
1521, 1454, 1365, 1250, 1169, 1086, 739, 700; 
1H δ/ppm (500 MHz, CDCl3) 1.15 (3H, 
s, Alk-CH3 (major and minor)), 1.22 (2.3H, s, Alk-CH3 (major)), 1.23 (0.9H, s, Alk-
CH3 (minor)), 1.23-1.39 (4H, m, Alk-H (major and minor)), 1.42 (9H, s, C(CH3)3 
(major and minor)), 1.47-1.53 (3H, m, Alk-H (major and minor)), 1.76-1.81 (1H, m, 
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Alk-H (major and minor)), 2.39-2.49 (1H, m, PhCH2 (major and minor)), 2.69 (1H, dd, 
PhCH2, J = 5.2 and 13.5 Hz (major and minor)), 3.01-3.12 (2H, m, AlkCH2-NH (major 
and minor)), 3.56-3.65 (1H, m, CH2-O (major and minor)), 3.72-3.79 (1H, m, CH2-O 
(major and minor)), 4.24-4.34 (1H, m, NH (major and minor)), 7.13 (2H, d, Ar-H, J = 
7.2 Hz (major and minor)), 7.17-7.20 (1H, m, Ar-H, J = 7.3 Hz (major and minor)), 
7.26-7.29 (2H, m, Ar-H (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 28.4, 
29.2, 29.5, 30.1, 31.9, 33.0, 37.0, 38.8, 39.3, 40.0, 42.6, 61.8, 71.8, 125.9, 128.4, 129.0, 
141.2, 155.9; LC-MS (ESI+) m/z = mass not observed; HRMS calcd. for C22H36O3N 
[M+H]
+
 362.2690, found 362.2693; Analytical HPLC: 99.5% 
 
(E)- and (Z)-Methyl 2-(2,2-dimethyldihydro-2H-pyran-4-(3H)-ylidene) acetate 
(22)
79
 
 
 
 
 
General Procedure M: Using pyranone 21 (600 mg, 4.68 mmol) and trimethyl 
phosphonoacetate (0.91 mL, 1.02 g, 5.62 mmol), chromatography (silica, 20% EtOAc, 
petrol) eluted 22 as a pale yellow oil (707 mg, 80%, E:Z ratio 3:2); Rf = 0.23 (silica, 5% 
EtOAc, petrol); UV λmax (EtOH/nm) 228.0; IR ν/cm
-1
 2974 (C-H), 2950 (C-H), 2871 
(C-H), 1715 (C=O), 1653, 1435, 1367, 1245, 1183, 1149, 1127, 1080, 1049, 1024, 847, 
756; 
1H δ/ppm (500 MHz, CDCl3) 1.21 (6H, s, gem-CH3 (E)), 1.23 (4H, s gem-CH3 
(Z)), 2.19 (2H, s, Alk-H (E)), 2.25-2.27 (1.4H, m, Alk-H (Z)), 2.88 (1.4H, s, Alk-H (Z)), 
2.93-2.96 (2H, m, Alk-H (E)), 3.69 (2H, s, CO2CH3 (Z)), 3.70 (3H, s, CO2CH3 (E)), 
3.77 (2H, t, CH2-O, (E), J = 5.8 Hz), 3.81 (1.4H, t, CH2-O, (Z), J = 5.8 Hz), 5.65 (1H, s, 
CHCO2Me, (E)), 5.77 (0.66H, m, CHCO2Me, (Z)); 
13C δ/ppm (125 MHz, CDCl3) 26.4, 
26.5, 30.3, 37.2, 41.4, 48.3, 50.9, 51.0, 61.8, 62.5, 74.1, 74.3, 115.1, 115.2, 157.2, 
157.4, 166.76, 166.84; LC-MS (ESI+) m/z = 185.1 [M+H]
+
; HRMS calcd. for C10H17O3 
[M+H]
+
 185.1172, found 185.1170 
  
264 
 
(E)-Ethyl 2-methyl-3-phenylacrylate (103) 
 
 
 
 
General Procedure M: Using benzaldehyde (0.67 mL, 700 mg, 6.60 mmol) (102) and  
triethyl 2-phosphonopropionate (1.70 mL, 1.89 g, 7.92 mmol) at 40 
o
C, chromatography 
(silica, 5% EtOAc, hexane) afforded 103 as a pale yellow oil (417 mg, 33%); Rf = 0.33 
(silica, 5% EtOAc, hexane); UV λmax (EtOH/nm) 268.0; IR νmax/cm
-1
 2937 (C-H), 1704 
(C=O), 1635, 1447, 1366, 1248, 1200, 1110, 1032, 763, 703; 
1H δ/ppm (500 MHz, 
CDCl3) 1.36 (3H, t, CO2CH2CH3, J = 7.2 Hz), 2.12 (3H, d, CH3CCO2Et, J = 1.5 Hz), 
4.28 (2H, q, CO2CH2CH3, J = 7.1 Hz), 7.30-7.35 (1H, m, Ar-H), 7.37-7.41 (4H, m, Ar-
H), 7.69 (1H, m, CH=C); 
13C δ/ppm (125 MHz, CDCl3) 14.1, 14.4, 60.9, 128.3, 128.4, 
128.7, 129.6, 136.0, 138.7, 168.7; LC-MS (ESI+) m/z = 191.2 [M+H]
+ 
 
Methyl 2-(2,2-dimethyltetrahydro-2H-pyran-4-yl) acetate (23)
79 
 
 
 
 
General Procedure N: Using ester 22 (700 mg, 3.80 mmol, E:Z ratio 3:2), partitioning 
with distilled water (10 mL) and EtOAc (2 × 10 mL), washing with brine (10 mL), 
drying (MgSO4), filtration and concentration in vacuo afforded 23 as a pale yellow oil 
(646 mg, 90%); Rf = 0.28 (silica, 10% EtOAc, petrol); UV λmax (EtOH/nm) No 
distinguishable peak; IR ν/cm-1 2973 (C-H), 2926 (C-H), 2859 (C-H), 1736 (C=O), 
1437, 1366, 1283, 1259, 1196, 1167, 1139, 1087, 1057, 1001, 691, 916, 856, 734; 
1
H 
δ/ppm (500 MHz, CDCl3) 1.12 (1H, t, CH, J = 12.4 Hz), 1.16-1.19 (1H, m, Alk-H), 
1.20 (3H, s, Alk-CH3), 1.22 (3H, s, Alk-CH3), 1.54-1.62 (2H, m, Alk-H), 2.16-2.21 (3H, 
m, CHCH2CO2Me), 3.66 (1H, td, CH2-O, J = 2.4 and 12.1 Hz), 3.67 (3H, s, CO2CH3), 
3.72 (1H, qd, CH2-O, J = 1.6 and 5.3 Hz); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 28.6, 
31.6, 32.4, 41.6, 43.1, 51.5, 61.3, 71.6, 172.9; LC-MS (ESI+) m/z = mass not found; 
HRMS calcd. for C10H19O3 [M+H]
+
 187.1329, found 187.1329 
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Ethyl 2-methyl-3-phenylpropanoate (104) 
 
 
 
General Procedure N: Using (E)-ester 103 (400 mg, 2.10 mmol), partitioning with 
distilled water (10 mL) and EtOAc (2 × 10 mL), washing with brine (10 mL), drying 
(MgSO4), filtration and concentration in vacuo afforded 104 as a pale yellow oil (375 
mg, 93%); Rf = No spot seen by UV or stains; UV λmax (EtOH/nm) 258.5; IR νmax/cm
-1
 
2978 (C-H), 2937 (C-H), 1730 (C=O), 1454, 1376, 1283, 1251, 1163, 1117, 1029, 744, 
699; 
1H δ/ppm (500 MHz, CDCl3) 1.16 (3H, d, CH3CHCO2Et, J = 6.8 Hz), 1.19 (3H, t, 
CO2CH2CH3, J = 7.2 Hz), 2.64-2.76 (2H, m, CH and PhCH2), 3.02 (1H, dd, PhCH2, J = 
6.6 and 13.0 Hz), 4.09 (2H, q, CO2CH2CH3, J = 7.2 Hz), 7.16-7.21 (3H, m, Ar-H), 7.26-
7.29 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 14.2, 16.8, 39.8, 41.5, 60.3, 126.3, 
128.3, 129.0, 139.5, 176.2; LC-MS (ESI+) m/z = 193.2 [M+H]
+
; HRMS calcd. for 
C12H17O2 [M+H]
+
 193.1223, found 193.1223 
 
Methyl 2-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-phenylpropanoate (24)
79
 
 
 
 
 
General Procedure O: Using ester 23 (640 mg, 3.44 mmol) and benzyl bromide (491 
µL, 706 mg, 4.13 mmol), chromatography (silica, 5-15% EtOAc, petrol) eluted 24, as 
an inseparable mixture of diastereoisomers (dr = 5:2), as a pale, yellow solid (1.18 g, 
86%); Rf = 0.30 (silica, 10% EtOAc, petrol); m.p. 56-62 
oC; UV λmax (EtOH/nm) 206.0; 
IR ν/cm-1 2934 (C-H), 2859 (C-H), 1732 (C=O), 1603, 1496, 1366, 1202, 1162, 1089, 
1031, 960, 840, 745, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.18-1.23 (2H, m, Alk-H), 1.22 
(3H, s, gem-CH3 (major and minor)), 1.25 (3H, s, gem-CH3 (major and minor)), 1.30-
1.39 (1H, m, Alk-H (major and minor)), 1.43-1.49 (1H, m, Alk-H (major and minor)), 
1.68-1.72 (1H, m, Alk-H (major and minor)), 1.98-2.06 (1H, m, Alk-H (major and 
minor)), 2.43-2.49 (1H, m, Alk-H (major and minor)), 2.78-2.85 (1H, m, PhCH2 (major 
and minor)), 2.88-2.93 (1H, m, PhCH2 (major and minor)), 3.51 (2.2H, s CO2CH3 
(major)), 3.52 (0.7H, s CO2CH3 (minor)), 3.61-3.69 (1H, m, CH2-O (major and minor)), 
3.72-3.80 (1H, m, CH2-O (major and minor)), 7.13 (2H, d, Ar-H, J = 7.3 Hz (major and 
minor)), 7.19 (1H, t, Ar-H, J = 7.4 Hz (major and minor)), 7.24-7.27 (2H, m, Ar-H 
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(major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 21.8, 21.9, 30.4, 30.5, 31.7, 31.9, 
33.9, 34.1, 35.5, 41.1, 51.2, 53.9, 54.1, 61.3, 61.4, 71.6, 71.7, 126.3, 128.4, 128.7, 
139.3, 174.9; LC-MS (ESI+) m/z = 277.3 [M+H]
+
; HRMS Calcd. for C17H25O3 [M+H]
+
 
277.1798, found 277.1797 
 
(R,R)- and (S,S)-4-Benzyl-3-(3-phenyl-2-(tetrahydro-2H-pyran-4-
yl)propanoyl)oxazolidin-2-one ((R,R)- and (S,S)-114) 
 
 
 
General Procedure O: Using either (R)- or (S)-oxazolidin-2-one (R)-113 or (S)-113  
(1.70 g, 5.60 mmol and 1.54 g, 5.08 mmol respectively), deprotonation was achieved 
using diisopropylamine (1.1 equiv.) and n-butyllithium (2.5 M in hexanes, 1.1 equiv.) in 
THF (17.1 and 15.5 mL respectively) and HMPA (1.8 equiv.) before addition of benzyl 
bromide (4.0 equiv.). Partitioning with diethyl ether (20 mL) and 0.5 M HCl (20 mL) 
and washing the organic layer with 1 M HCl (3 × 10 mL), isolated (R,R)-114 and (S,S)-
114 as white solids following filtration (1.87 g, ≥ 96% d.e, 81% and 1.59 g, ≥ 98% d.e, 
79% respectively); Rf = 0.14 (silica, 50% EtOAc, petrol); m.p. 153-156 
oC; [α]D
24.3
 -
38.1
o
 (R,R) (c 0.10 in THF), [α]D
24.1
 +29.5
o
 (S,S) (c 0.10 in THF); UV λmax (EtOH/nm) 
206.2; IR νmax/cm
-1
 2942 (C-H), 2835 (C-H), 1758 (C=O), 1691 (C=O), 1494, 1454, 
1395, 1350, 1224 (C-O), 1188, 1089, 1015, 996, 951, 868, 747, 701; 
1
H δ/ppm (500 
MHz, DMSO-d6) 1.36 (1H, qd, OCH2CH2CH, J = 4.4 and 12.4 Hz), 1.42-1.53 (2H, m, 
OCH2CH2CH), 1.67-1.69 (1H, m, OCH2CH2CH), 1.85-1.91 (1H, m, OCH2CH2CH), 
2.44 (1H, dd, PhCH2, J = 7.0 and 13.6 Hz), 2.63 (1H, dd, PhCH2, J = 3.3 and 13.7 Hz), 
2.88-2.98 (2H, m, PhCH2), 3.23-3.31 (2H, m, O-CH2), 3.84-3.90 (2H, m, O-CH2), 4.03 
(1H, dd, CHCO, J = 2.5 and 8.9 Hz), 4.19-4.27 (2H, m, CH2OCON), 4.62-4.66 (1H, m, 
CHN), 6.70 (2H, d, Ar-H, J = 6.9 Hz), 7.11-7.25 (6H, m, Ar-H), 7.32 (2H, t, Ar-H, J = 
7.5 Hz); 
13
C δ/ppm (125 MHz, DMSO-d6) 29.4, 30.1, 34.1, 36.0, 37.8, 48.6, 54.1, 65.3, 
67.0, 126.2, 126.7, 128.3, 128.4, 129.2, 129.3, 135.1, 139.5, 153.0, 173.8; LC-MS 
(ESI+) m/z = 394.5 [M+H]
+
; HRMS calcd. for C24H28O4N [M+H]
+ 
394.2013, found 
394.2014 
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2-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-3-phenylpropan-1-ol (25)
79
 
 
 
 
 
General Procedure P: Using ester 24 (850 mg, 3.08 mmol), partitioning with EtOAc 
(2 × 10 mL), washing with brine (10 mL), drying (MgSO4), filtering and concentrating 
in vacuo afforded 25, as an inseparable mixture of diastereoisomers (dr = 5:2), as a pale 
yellow oil (787 mg, 93%); Rf = 0.45 (silica, 40% EtOAc, petrol); UV λmax (EtOH/nm) 
207.0; IR ν/cm-1 3392 (O-H), 2933 (C-H), 2845 (C-H), 1495, 1454, 1388, 1244, 1142, 
1087, 1031, 921, 870, 838, 742, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.07 (1H, t, Alk-H, J 
= 5.3 Hz (major and minor)), 1.20 (0.9H, s, Alk-CH3 (minor)), 1.21 (2.1H, s, Alk-CH3 
(major)), 1.24 (0.8H, s, Alk-CH3 (minor)), 1.25 (2.3H, s, Alk-CH3 (major)), 1.25-1.30 
(1H, m, Alk-H (major and minor)), 1.32-1.40 (1H, m, Alk-H (major and minor)), 1.56-
1.65 (3H, m, Alk-H (major and minor)), 1.90-1.98 (1H, m, OH (major and minor)), 
2.50-2.57 (1H, m, PhCH2 (major and minor)), 2.74-2.81 (1H, m, PhCH2 (major and 
minor)), 3.50-3.56 (1H, m, CH2-OH (major and minor)), 3.56-3.61 (1H, m, CH2-OH 
(major and minor)), 3.62-3.69 (1H, m, CH2-O (major and minor)), 3.76-3.80 (1H, m, 
CH2-O (major and minor)), 7.18-7.21 (3H, m, Ar-H (major and minor)), 7.29 (2H, t, Ar-
H, J = 7.4 Hz (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 30.3, 34.3, 35.7, 47.6, 
61.8, 68.4, 126.0, 128.5, 129.1, 141.0; LC-MS (ESI+) m/z = mass not found; HRMS 
calcd. for C16H25O2 [M+H]
+
 249.1849, found 249.1851 
 
2-Methyl-3-phenylpropan-1-ol (105) 
 
 
 
General Procedure P: Using ester 104 (440 mg, 2.47 mmol), partitioning with EtOAc 
(2 × 10 mL), washing with brine (10 mL), drying (MgSO4), filtering and concentrating 
in vacuo afforded 105 as a pale yellow oil (339 mg, 87%); Rf = 0.27 (silica, 20% 
EtOAc, hexane); UV λmax (EtOH/nm) 209.0; IR νmax/cm
-1
 3330 (O-H), 2955 (C-H), 
2919 (C-H), 1495, 1453, 1030, 986, 738, 698; 
1H δ/ppm (500 MHz, CDCl3) 0.93 (3H, 
d, CH3, J = 6.7 Hz), 1.35 (1H, s, br, OH), 1.91-2.00 (1H, m, CH), 2.43 (1H, dd, PhCH2, 
J = 8.0 and 13.5 Hz), 2.76 (1H, dd, PhCH2, J = 6.4 and 13.5 Hz), 3.49 (1H, dd, CH2OH, 
J = 6.0 and 10.6 Hz), 3.55 (1H, dd, CH2OH, J = 5.9 and 10.5 Hz), 7.17-7.21 (3H, m, 
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Ar-H), 7.27-7.30 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 16.5, 37.8, 39.7, 67.7, 
125.9, 128.3, 129.2, 140.6; LC-MS (ESI+) m/z = 151.2 [M+H]
+
; HRMS calcd. for 
C10H15O [M+H]
+
 151.1117, found 151.1113 
 
2-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-3-phenylpropyl methanesulfonate (26)
79
 
 
 
 
 
 
General Procedure Q: Using alcohol 25 (760 mg, 3.06 mmol), partitioning with 
distilled water (2 × 10 mL) and 1 M HCl (2 × 10 mL), washing with brine (10 mL) 
drying (MgSO4), filtering and concentration in vacuo afforded 26, as an inseparable 
mixture of diastereoisomers (dr = 5:2), as a brown solid (1.010 g, 96%); Rf = 0.32 
(silica, 30% EtOAc, petrol); m.p. 66-68 
oC; UV λmax (EtOH/nm) 205.5; IR ν/cm
-1
 3018 
(C-H), 2900 (C-H), 2841 (C-H), 1602, 1468, 1345, 1248, 1173, 1089, 973, 925, 821, 
747, 699; 
1H δ/ppm (500 MHz, CDCl3) 1.20 (0.9H, s, Alk-CH3 (minor)), 1.21 (2.3H, s, 
Alk-CH3 (major)), 1.24-1.27 (1H, m, Alk-H (major and minor)), 1.24 (0.9H, s, Alk-CH3 
(minor)), 1.25 (2.1H, s, Alk-CH3 (major)), 1.31-1.40 (1H, m, Alk-H (major and minor)), 
1.60-1.69 (2H, m, Alk-H (major and minor)), 1.77-1.84 (1H, m, Alk-H (major and 
minor)), 1.90-1.97 (1H, m, Alk-H (major and minor)), 2.50 (0.8H, dd, PhCH2, J = 10.2 
and 13.8 Hz (major)), 2.56 (0.2H, dd, PhCH2, J = 10.2 and 13.8 Hz (minor)), 2.87 (1H, 
dd, PhCH2, J = 4.8 and 12.3 Hz (major and minor)), 2.90 (2.2H, s, SO2CH3 (major)), 
2.91 (0.7H, s, SO2CH3 (minor)), 3.63-3.69 (1H, m, CH2-O (major and minor)), 3.77-
3.81 (1H, m, CH2-O (major and minor)), 4.03-4.07 (1H, m, CH2-OMs (major and 
minor)), 4.13-4.16 (1H, m, CH2-OMs (major and minor)), 7.17 (2H, d, Ar-H, J = 7.4 Hz 
(major and minor)), 7.22 (1H, t, Ar-H, J = 7.4 Hz (major and minor)), 7.31 (2H, t, Ar-H, 
J = 7.3 Hz (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 30.2, 30.3, 33.9, 35.6, 
37.0, 45.0, 68.1, 68.7, 126.5, 128.7, 129.0, 139.6; LC-MS (ESI+) m/z = 299.2 [M+H]
+
; 
HRMS mass not observed 
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2-Methyl-3-phenylpropyl methanesulfonate (106) 
 
 
 
 
General Procedure Q: Using alcohol 105 (330 mg, 2.20 mmol), partitioning with 
distilled water (2 × 10 mL) and 1 M HCl (2 × 10 mL), washing with brine (10 mL) 
drying (MgSO4), filtering and concentration in vacuo afforded 106 as a brown oil (508 
mg, 96%); Rf = 0.30 (silica, 20% EtOAc, hexane); UV λmax (EtOH/nm) No 
distinguishable peak; IR νmax/cm
-1
 3028 (C-H), 2968 (C-H), 1455, 1350, 1171, 959, 832, 
740, 701; 
1H δ/ppm (500 MHz, CDCl3) 1.01 (3H, d, CH3, J = 6.7 Hz), 2.21 (1H, oct, 
CH, J = 6.6 Hz), 2.53 (1H, dd, PhCH2, J = 7.7 and 13.6 Hz), 2.76 (1H, dd, PhCH2, J = 
6.7 and 13.6 Hz), 2.99 (3H, s, SO2CH3), 4.05 (1H, dd, CH2OMs, J = 5.9 and 9.4 Hz), 
4.09 (1H, dd, CH2OMs, J = 5.6 and 9.5 Hz), 7.15-7.17 (2H, m, Ar-H), 7.20-7.23 (1H, 
m, Ar-H), 7.28-7.31 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 16.4, 35.0, 37.2, 
39.2, 73.7, 126.4, 128.5, 129.1, 139.2; LC-MS (ESI+) m/z = mass peak not observed; 
HRMS mass not observed 
 
3-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-4-phenylbutanenitrile (27)
79
 
 
 
 
 
General Procedure R: Using sulfonate 26 (1.00 g, 3.06 mmol), the reaction was 
partitioned with diethyl ether (10 mL) and saturated aqueous K2CO3 (40 mL) with brine 
(10 mL). The aqueous layer was extracted with diethyl ether (3 × 10 mL) and the 
organic layer was washed with 50% distilled water, brine (6 × 10 mL), brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo to afford 27, as an inseparable 
mixture of diastereoisomers (dr = 5:2), as a brown solid (652 mg, 83%); Rf = 0.40 
(silica, 20% EtOAc, petrol); m.p. 62-64 
oC; UV λmax (EtOH/nm) 207.0; IR ν/cm
-1
 2945 
(C-H), 2915 (C-H), 2855 (C-H), 2242 (C≡N), 1676, 1600, 1493, 1452, 1420, 1247, 
1138, 1095, 1023, 984, 887, 855, 805, 748, 703; 
1H δ/ppm (500 MHz, CDCl3) 1.21-1.26 
(1H, m, Alk-H (major and minor)), 1.23 (1H, s, Alk-CH3 (minor)), 1.24 (2.2H, s, Alk-
CH3 (major)), 1.25 (1H, s, Alk-CH3 (minor)), 1.27 (2.3H, s, Alk-CH3 (major)), 1.30-
1.36 (1H, m, Alk-H (major and minor)), 1.58-1.65 (1H, m, CH (major and minor)), 
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1.70-1.76 (2H, m, Alk-H (major and minor)), 1.89-1.97 (1H, m, Alk-H (major and 
minor)), 2.19 (1H, dd, PhCH2, J = 5.5 and 17.1 Hz (major and minor)), 2.30 (1H, dd, 
PhCH2, J = 5.1 and 17.2 Hz (major and minor)), 2.46 (0.8H, dd, CH2CN, J = 10.6 and 
13.8 Hz (major)), 2.49 (0.2H, dd, CH2CN, J = 10.6 and 13.8 Hz (minor)), 3.00 (1H, dd, 
CH2CN, J = 4.4 and 13.8 Hz (major and minor)), 3.69 (1H, td, CH2-O, J = 2.3 and 12.3 
Hz (major and minor)), 3.79-3.83 (1H, m, CH2-O (major and minor)), 7.18 (2H, d, Ar-
H, J = 7.3 Hz (major and minor)), 7.24 (1H, t, Ar-H, J = 7.5 Hz (major and minor)), 
7.30-7.33 (2H, m, Ar-H, J = 7.2 Hz (major and minor)); 
13C δ/ppm (125 MHz, CDCl3) 
18.1, 30.2, 30.3, 36.4, 37.4, 42.6, 67.9, 118.5, 126.7, 128.8, 129.0, 139.1; LC-MS (ESI) 
m/z = 230.2 [M+H]
+
; HRMS mass not observed 
 
3-Methyl-4-phenylbutanenitrile (107) 
 
 
 
General Procedure R: Using methanesulfonate 106 (500 mg, 2.19 mmol), the reaction 
was partitioned with diethyl ether (10 mL) and saturated aqueous K2CO3 (20 mL) with 
brine (10 mL). The aqueous layer was extracted with diethyl ether (3 × 10 mL) and the 
organic layer was washed with 50% distilled water, brine (6 × 10 mL), brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo to afford 107 as a brown oil (283 mg, 
81%); Rf = 0.33 (silica, 10% EtOAc, hexane); 
1H δ/ppm (500 MHz, CDCl3) 1.13 (3H, d, 
CH3, 6.7 Hz), 2.12-2.17 (1H, m, CH), 2.20 (1H, dd, PhCH2, J = 6.6 and 16.5 Hz), 2.30 
(1H, dd, PhCH2, J = 4.9 and 16.2 Hz), 2.67 (2H, dd, CH2CN, J = 2.7 and 6.8 Hz), 7.16-
7.18 (2H, m, Ar-H), 7.21-7.25 (1H, m, Ar-H), 7.28-7.33 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 19.5, 23.7, 32.5, 42.1, 118.7, 126.6, 128.6, 129.0, 139.0; LC-MS (ESI+) 
m/z = 160.2 [M+H]
+
; HRMS calcd. for C11H14N [M+H]
+
 160.1121, found 160.1119 
 
3-Methyl-4-phenylbutan-1-amine (108) 
 
 
 
General Procedure T: Using nitrile 107 (310 mg, 1.95 mmol), the crude material was 
partitioned with EtOAc (30 mL) and 1 M HCl (4 × 10 mL). The aqueous layer was 
neutralised with 2 M NaOH and partitioned with EtOAc (2 × 20 mL). The organic layer 
was washed with brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo to 
271 
 
give 108 as a yellow oil (145 mg, 43%); Rf = 0.10 (silica, 20% MeOH, DCM); UV λmax 
(EtOH/nm) 205.0; IR νmax/cm
-1
 3400 (N-H), 3282 (N-H), 2922 (C-H), 1668, 1603, 
1494, 1454, 1377, 737, 699; 
1H δ/ppm (500 MHz, CDCl3) 0.88 (3H, d, CH3, J = 6.7 
Hz), 1.24-1.57 (4H, m, CHCH2CH2NH2), 1.78-1.85 (1H, m, CH), 2.42 (1H, dd, PhCH2, 
J = 8.0 and 13.4 Hz), 2.61 (1H, dd, PhCH2, J = 6.5 and 13.4 Hz), 2.71-2.80 (2H, m, 
CH2NH2), 7.14-7.15 (2H, m, Ar-H), 7.16-7.19 (1H, m, Ar-H), 7.25-7.28 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 19.5, 32.8, 32.9, 33.2, 43.9, 125.7, 128.2, 129.2, 141.2; 
LC-MS (ESI+) m/z = 164.2 [M+H]
+
; HRMS calcd. for C11H18N [M+H]
+ 
164.1434, 
found 164.1431 
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7.12.2 MDMX 
 
A) 3’-Amino-[1,1’-biphenyl]-4-ol (117a) 
 
 
 
 
Bromophenol (100 mg, 0.58 mmol), boronic acid 116 (108 mg, 0.79 mmol) and 
Pd(PPh3)4 (20.1 mg, 0.02 mmol) were dissolved in 2 M Na2CO3 (0.3 mL, 0.6 mmol), 
ethanol (0.4 mL) and toluene (5.8 mL) and heated to 100 
o
C. After 22 h, the reaction 
was partitioned with EtOAc (20 mL) and distilled water (10 mL). The organic layer was 
filtered through celite, washing with EtOAc (10 mL) and distilled water (10 mL). The 
aqueous layer was extracted with EtOAc (10 mL) and the organic layer was washed 
with brine (15 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 0-40% EtOAc, hexane) afforded 117a as a brown solid (27.6 
mg, 26%); Rf = 0.22 (silica, 40% EtOAc, hexane); m.p. 190 
oC (decomposed); UV λmax 
(EtOH/nm) 239.0; IR νmax/cm
-1
 3357 (N-H), 3292 (N-H), 2595 (br) (O-H), 1588, 1523, 
1481, 1461, 1425, 1378, 1270, 1240, 1210, 931, 834, 782, 690; 
1H δ/ppm (500 MHz, 
DMSO-d6) 5.07 (2H, s, NH2), 6.48 (1H, d, Ar-H, J = 8.0 Hz), 6.69 (1H, d, Ar-H, J = 7.8 
Hz), 6.75 (1H, s, Ar-H), 6.80-6.82 (2H, m, Ar-H), 7.04 (1H, t, Ar-H, J = 7.7 Hz), 7.35-
7.37 (2H, m, Ar-H), 9.46 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 111.6, 112.2, 
113.8, 115.5, 127.4, 129.2, 131.8, 140.9, 148.9, 156.7; LC-MS (ESI+) m/z = 186.1 
[M+H]
+
; HRMS calcd. for C12H12ON [M+H]
+ 
186.0913, found 186.0913; HRMS calcd. 
for C12H10ON [M-H]
- 
184.0768, found 184.0767 
 
B) 3’-Amino-[1,1’-biphenyl]-3-ol (117b) 
 
 
 
 
3-Bromophenol (61 µL, 100 mg, 0.58 mmol), boronic acid 116 (112 mg, 0.81 mmol) 
and Pd(dtbpf)Cl2 (19.0 mg, 0.03 mmol) were dissolved in 2 M Na2CO3 (0.58 mL, 1.16 
mmol) and 1,2-DME (3.5 mL) and irradiated at 120 
o
C. After 30 min, the reaction was 
partitioned with EtOAc (20 mL) and saturated aqueous NH4Cl (20 mL). The organic 
layer was washed with distilled water (20 mL) and the aqueous layer was extracted with 
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EtOAc (2 × 10 mL). The organic layer was washed with brine (15 mL), dried (MgSO4), 
filtered and concentrated in vacuo. Chromatography (silica, 40% EtOAc, hexane) 
afforded 117b as a light brown solid (101 mg, 94%); Rf = 0.23 (silica, 40% EtOAc, 
hexane); m.p. 156-159 
oC; UV λmax (EtOH/nm) 292.5 and 216.5; IR νmax/cm
-1
 3389 (N-
H), 3307 (N-H), 2590 (br) (O-H), 1585, 1484, 1433, 1313, 1259, 1196, 1166, 857, 771, 
691; 
1H δ/ppm (500 MHz, MeOH-d4) 6.74 (2H, qd, Ar-H, J = 0.9 and 2.5 Hz), 6.91-
6.93 (1H, m, Ar-H), 6.97 (1H, t, Ar-H, J = 1.9 Hz), 7.01 (1H, t, Ar-H, J = 2.1 Hz), 7.04-
7.06 (1H, m, Ar-H), 7.17 (1H, t, Ar-H, J = 7.8 Hz), 7.23 (1H, t, Ar-H, J = 7.8 Hz); 
13
C 
δ/ppm (125 MHz, MeOH-d4) 114.8, 115.0, 115.2, 115.7, 118.1, 119.3, 130.4, 130.6, 
143.5, 144.5, 149.0, 158.7; LC-MS (ESI+) m/z = 186.1 [M+H]
+
; HRMS calcd. for 
C12H12ON [M+H]
+ 
186.0913, found 186.0913; HRMS calcd. for C12H10ON [M-H]
- 
184.0768, found 184.0767 
 
C) 3’-((4-Fluorobenzyl)amino)-[1,1’-biphenyl]-4-ol (118a) 
 
 
 
 
4-Fluorobenzaldehyde (17.4 µL, 20.1 mg, 0.17 mmol) was added to a mixture of aniline 
117a (26 mg, 0.14 mmol) and anhydrous magnesium sulfate in THF (0.8 mL) and 
stirred at room temperature. After 16 h, the reaction was filtered and concentrated in 
vacuo, then dissolved in methanol (1.0 mL) and mixed with sodium borohydride (15.3 
mg, 0.42 mmol) at room temperature. After 1 h, the reaction was quenched with 
distilled water (10 mL) and partitioned with EtOAc (10 mL) and distilled water (2 × 10 
mL). The aqueous layer was extracted with EtOAc (10 mL) and the organic layer was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 20% EtOAc, hexane) afforded 118a as a brown gum (27.7 mg, 
68%); Rf = 0.39 (silica, 30% EtOAc, hexane); m.p. 75-82 
oC; UV λmax (EtOH/nm) 
252.0; IR νmax/cm
-1
 3402 (br) (N-H and O-H), 3035 (C-H), 1604, 1489, 1443, 1329, 
1265, 1219, 1190, 1159, 825, 772, 690; 
1H δ/ppm (500 MHz, CDCl3) 4.35 (2H, s, CH2), 
4.68 (1H, s, OH), 4.73 (1H, s, br, NH), 6.58-6.60 (1H, m, Ar-H), 6.79-6.80 (1H, m, Ar-
H), 6.85-6.88 (2H, m, Ar-H), 6.91-6.93 (1H, m, Ar-H), 7.02-7.07 (2H, m, Ar-H), 7.20-
7.23 (1H, m, Ar-H), 7.33-7.37 (2H, m, Ar-H), 7.41-7.44 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 47.9, 111.6, 115.4, 115.6, 116.8, 128.4, 129.1, 129.7, 134.3, 134.8, 142.0, 
148.0, 155.0, 161.1, 163.1; LC-MS (ESI+) m/z = 294.3 [M+H]
+
; HRMS calcd. for 
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C19H17ONF [M+H]
+
 294.1289, found 294.1294; HRMS calcd. for C19H15ONF [M-H]
-
 
292.1143, found 292.1136; Analytical HPLC: 99.2%  
 
D) N-(4-Fluorobenzyl)-4’-methoxy-[1,1’-biphenyl]-3-amine (118i) 
 
 
 
 
3-Amino-4’-methoxybiphenyl hydrochloride (200 mg, 0.85 mmol) (117f) and sodium 
triacetoxyborohydride (180 mg, 0.85 mmol) were dissolved in DMF (4.26 mL) and 
glacial acetic acid (42.6 µL). After 10 min, 4-fluorobenzaldehyde (46.2 µL, 53.4 mg, 
0.43 mmol) was added at room temperature. After 20 h, the reaction was partitioned 
with diethyl ether (10 mL), distilled water (20 mL) and brine (10 mL). The aqueous 
layer was extracted with diethyl ether (2 × 10 mL) and the organic layer was washed 
with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 0-5% EtOAc, petrol) eluted 118i as a yellow solid (100 mg, 
74%); Rf = 0.16 (silica, 5% EtOAc, petrol); m.p. 93-96 
oC; UV λmax (EtOH/nm) 252.0; 
IR νmax/cm
-1
 3416 (N-H), 2932 (C-H), 2837 (C-H), 1602, 1488, 1437, 1329, 1298, 1232, 
1214, 1184, 1146, 1080, 1028, 988, 830, 821, 778, 695; 
1H δ/ppm (500 MHz, CDCl3) 
3.84 (3H, s, OCH3), 4.14, (1H, s, br, NH), 4.35 (2H, s, CH2), 6.58 (1H, dd, Ar-H, J = 
2.2 and 8.0 Hz), 6.80-6.81 (1H, m, Ar-H), 6.91-6.97 (3H, m, Ar-H), 7.01-7.06 (2H, m, 
Ar-H), 7.23 (1H, t, Ar-H, J = 7.8 Hz), 7.35-7.37 (2H, m, Ar-H), 7.46-7.49 (2H, m, Ar-
H); 
13C δ/ppm (125 MHz, CDCl3) 47.8, 55.3, 111.5, 114.1, 115.4, 115.6, 116.8, 128.1, 
129.1, 129.6, 134.1, 134.9, 142.1, 148.1, 159.1, 161.1, 163.1; LC-MS (ESI+) m/z = 
308.3 [M+H]
+
; HRMS calcd. for C20H19ONF [M+H]
+
 308.1445, found 308.1445; 
Analytical HPLC: 98.0%  
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E) N-(4-(((2-(4-Chlorophenoxy)-4’-fluoro-[1,1’biphenyl]-3-
yl)amino)methyl)phenyl)-1,1,1-trifluoromethanesulfonamide (138n) 
 
 
 
 
 
Aniline 137f (40 mg, 0.13 mmol) and aldehyde 155 (59.5 mg, 0.24 mmol) were 
dissolved in TFE (0.7 mL) at room temperature and heated to 40 
o
C. After 24 h, the 
solution was cooled to room temperature before addition of sodium borohydride (15 
mg, 0.39 mmol). After 1 h, the reaction was quenched with distilled water (10 mL) and 
the layers were separated. The aqueous layer was extracted with DCM (2 × 10 mL) and 
the organic layer was washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Chromatography (silica, 10-15% EtOAc, petrol) eluted 138n as a 
yellow oil (45 mg, 64%); Rf = 0.26 (silica, 20% EtOAc, petrol); UV λmax (EtOH/nm) 
231.2; IR νmax/cm
-1
 3401 (N-H), 3272 (N-H), 3048 (C-H), 2858 (C-H), 1607, 1513, 
1484, 1416, 1365, 1338, 1280, 1212 (C-O), 1160, 1135, 1092, 1020, 939, 820, 782, 749; 
1H δ/ppm (500 MHz, CDCl3) 4.38 (2H, d, CH2, J = 3.9 Hz), 4.55 (1H, s, br, amino NH), 
6.61-6.64 (4H, m, Ar-H and sulfonamido NH), 6.74 (1H, dd, Ar-H, J = 1.2 and 7.7 Hz), 
6.93-6.96 (2H, m, Ar-H), 7.06-7.09 (2H, m, Ar-H), 7.13 (1H, t, Ar-H, J = 7.9 Hz), 7.21-
7.22 (2H, m, Ar-H), 7.26-7.29 (2H, m, Ar-H), 7.35-7.38 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 47.0, 111.2, 114.9, 115.1, 116.3, 119.2, 124.2, 126.5, 126.8, 128.2, 129.4, 
130.5, 130.6, 132.5, 133.5, 133.6, 134.6, 137.9, 139.0, 141.2, 155.8, 161.1, 163.1;  
19
F 
δ/ppm (470 MHz, CDCl3) -75.3, -115.4; LC-MS (ESI+) m/z = 549.2 [M-H]
+
; HRMS 
calcd. for C26H18O3N2
35
ClF4S [M-H]
- 
549.0668, found 549.0659; Analytical HPLC: 
95.5%  
 
F) 1-Bromo-2-(4-chlorophenoxy)-3-nitrobenzene (135a) 
 
 
 
 
 
4-Chlorophenol (116 mg, 0.90 mmol), aryl fluoride 139 (100 mg, 0.45 mmol) and 
anhydrous K2CO3 (124 mg, 0.90 mmol) were dissolved in DMF (2.25 mL) and 
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irradiated at 120 
o
C for 20 min. The reaction was partitioned with distilled water (40 
mL), brine (10 mL) and diethyl ether (3 × 10 mL). The organic layer was washed with 2 
M NaOH (2 × 10 mL), brine (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo to afford 135a as a brown oil (135 mg, 92%); Rf = 0.48 (silica, 20% EtOAc, 
hexane); UV λmax (EtOH/nm) 221.0; IR νmax/cm
-1
 3086 (C-H), 1581, 1527, 1483, 1445, 
1347, 1247 (C-O), 1194, 1163, 1090, 1010, 824, 789, 747, 708; 
1H δ/ppm (500 MHz, 
DMSO-d6) 6.89-6.93 (2H, m, Ar-H), 7.40-7.43 (2H, m, Ar-H), 7.55 (1H, t, Ar-H, J = 
8.1 Hz), 8.16-8.19 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, DMSO-d6) 116.9, 118.9, 
125.4, 126.9, 128.1, 129.7, 138.9, 143.5, 144.4, 155.4; LC-MS (ESI+) m/z = Mass not 
observed; HRMS calcd. for C12H8O3N
79
Br
35
Cl [M+H]
+
 327.9371, found 327.9370 
 
G) 3’-Amino-2’-(4-chlorophenoxy)-[1,1’-biphenyl]-4-ol (137a) 
 
 
 
 
 
Iron powder (324 mg, 5.8 mmol) was added to a solution of nitro 136a (197 mg, 0.58 
mmol) in glacial acetic acid (5.8 mL) and heated to 50 
o
C. After 45 min, the reaction 
was filtered, washing with EtOAc (15 mL), and concentrated in vacuo. The oil was 
partitioned with distilled water (2 × 10 mL) and EtOAc (15 mL). The aqueous layer was 
extracted with EtOAc (4 × 10 mL) and the organic layer was washed with brine (10 
mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-
20% EtOAc, hexane) afforded 137a as a white solid (134 mg, 78%); Rf = 0.20 (silica, 
20% EtOAc, hexane); m.p. 58 
oC (decomposed); UV λmax (EtOH/nm) 231.5; IR 
νmax/cm
-1
 3658 (N-H), 3381 (br) (N-H and O-H), 2981 (C-H), 2889 (C-H), 1612, 1518, 
1470, 1430, 1381, 1217 (C-O), 1173, 1087, 954, 825, 783, 748; 
1H δ/ppm (500 MHz, 
DMSO-d6) 4.92 (2H, s, br, NH2), 6.59 (1H, dd, Ar-H, J = 1.6 and 7.6 Hz), 6.64-6.68 
(2H, m, Ar-H), 6.77 (1H, dd, Ar-H, J = 1.5 and 8.0 Hz), 7.03 (1H, t, Ar-H, J = 7.8 Hz), 
7.18-7.24 (4H, m, Ar-H), 9.38 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 114.4, 
114.9, 116.5, 117.5, 124.7, 126.1, 128.2, 129.0, 129.7, 135.0, 136.6, 141.7, 155.9, 
156.4; LC-MS (ESI+) m/z = 312.2 [M+H]
+
; HRMS calcd. for C18H15O2NCl [M+H]
+
 
312.0786, found 312.0789; HRMS calcd. for C18H13O2N
35
Cl [M-H]
-
 310.0640, found 
310.0632 
 
277 
 
H) N-(2-Bromopyridin-4-yl)-4-fluorobenzamide (130) 
 
 
 
 
4-Fluorobenzoyl chloride (206 µL, 276 mg, 1.74 mmol) was added to a solution of 
aminopyridine 126c (200 mg, 1.16 mmol) and pyridine (282 µL, 275 mg, 3.48 mmol) in 
acetonitrile (12.8 mL) and stirred at room temperature. After 15 h, the reaction was 
quenched with 2.5 M NaOH (2.32 mL) in methanol (6.96 mL). After 15 min, the 
reaction was partitioned with 60% distilled water, brine (50 mL) and EtOAc (3 × 10 
mL). The organic layer was washed with distilled water (3 × 10 mL) and the aqueous 
layer was extracted with EtOAc (10 mL). The organic layer was washed with brine (10 
mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-5%, 
EtOAc, DCM) afforded 130 as a yellow/white solid (293 mg, 86%); Rf = 0.34 (silica, 
10% EtOAc, DCM); m.p. 129-131 
oC; UV λmax (EtOH/nm) 262.5; IR νmax/cm
-1
 3305 
(N-H), 3137 (C-H), 3070 (C-H), 2963 (C-H), 1670 (C=O), 1575, 1490, 1372, 1303, 
1275, 1222, 1159, 1094, 1073, 988, 914, 845, 809, 758, 706; 
1H δ/ppm (500 MHz, 
CDCl3) 7.16-7.20 (2H, m, Ar-H), 7.55 (1H, dd, Ar-H, J = 1.9 and 5.6 Hz), 7.87-7.91 
(3H, m, Ar-H), 8.12 (1H, s, br, NH), 8.28 (1H, d, Ar-H, J = 5.6 Hz); 
13C δ/ppm (125 
MHz, CDCl3) 113.1, 116.1, 116.3, 117.5, 129.8, 143.0, 146.7, 150.7, 165.0; LC-MS 
(ESI+) m/z = 297.2 [M+H]
+
; HRMS calcd. for C12H9ON2BrF [M+H]
+
 294.9877, found 
294.9884; HRMS calcd. for C12H7ON2
79
BrF [M-H]
-
 292.9731, found 292.9724 
 
I) N-(4-Bromophenyl)-1,1,1-trifluoromethanesulfonamide (120) 
 
 
 
 
Trifluoromethanesulfonic anhydride (429 µL, 719 mg, 2.55 mmol) in DCM (2.55 mL, 1 
M) was added dropwise to a solution of 4-bromoaniline (200 mg, 1.16 mmol) (119) and 
diisopropylethylamine (606 µL, 450 mg, 3.48 mmol) in DCM (4.64 mL) at 0 
o
C and 
stirred at room temperature. After 30 min, the reaction was quenched with 2.5 M NaOH 
(2.32 mL) in methanol (4.64 mL) at room temperature. After 22 h, the reaction was 
partitioned with DCM (2 × 10 mL) and 1 M HCl (10 mL). The organic layer was 
washed with 1 M HCl (10 mL), brine (15 mL), dried (MgSO4), filtered and concentrated 
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in vacuo. Chromatography (silica, 0-10% EtOAc, hexane) afforded 120 as a 
yellow/white solid (268 mg, 76%); Rf = 0.30 (silica, 14% EtOAc, hexane); UV λmax 
(EtOH/nm) 230.0; IR νmax/cm
-1
 3283 (N-H), 1610, 1488, 1404, 1361 (S=O asym. 
stretch), 1201, 1136 (S=O sym. stretch), 1013, 935, 818, 709; 
1H δ/ppm (500 MHz, 
CDCl3) 6.68 (1H, s, br, NH), 7.15-7.18 (2H, m, Ar-H), 7.51-7.54 (2H, m, Ar-H); 
13
C 
δ/ppm (125 MHz, CDCl3) 121.5, 125.4, 132.7, 132.9; LC-MS (ESI+) m/z = 302.0 and 
304.0 [M-H]
-
; HRMS calcd. for C7H4O2N
79
BrF3S [M-H]
-
 301.9104, found 301.9094 
 
J) 4-(4-((4-Fluorobenzyl)amino)pyridin-2-yl)phenol (128c) 
 
 
 
 
Lithium aluminium hydride (2 M in THF, 0.64 mL, 1.28 mmol) was added dropwise to 
a solution of benzamide 131 (80 mg, 0.26 mmol) in THF (10.5 mL) at 0 
o
C and stirred 
at room temperature. After 72 h, saturated aqueous Rochelle salt (5 mL) was added and 
the reaction was partitioned with distilled water (10 mL) and EtOAc (10 mL). The 
organic layer was washed with brine (10 mL), dried (MgSO4), filtered and concentrated 
in vacuo. Trituration with diethyl ether (8 × 5 mL), followed by semi-preparative HPLC 
(C18, 80% H2O with 0.1% (v/v) HCO2H, MeCN at 21.2 mL/min) eluted 128c as a 
red/brown solid (59 mg, 79%); Rf = 0.44 (silica, 20% MeOH, DCM); m.p. 192 
o
C 
(decomposed); UV λmax (EtOH/nm) 259.5; IR νmax/cm
-1
 3239 (N-H), 2919 (br) (O-H), 
2802 (C-H), 1631, 1567, 1508, 1344, 1223, 817, 758; 
1H δ/ppm (500 MHz, DMSO-d6) 
4.39 (2H, d, CH2, J = 5.8 Hz), 6.42 (1H, dd, Ar-H, J = 1.7 and 5.5 Hz), 6.79-6.81 (2H, 
m, Ar-H), 6.91 (1H, m, Ar-H), 7.07-7.10 (1H, m, Ar-H), 7.15-7.19 (2H, m, Ar-H), 7.40-
7.43 (2H, m, Ar-H), 7.75-7.76 (2H, m, Ar-H), 8.03-8.05 (1H, m, Ar-H), 8.27 (1H, s, br, 
OH); 
13C δ/ppm (125 MHz, DMSO-d6) 44.5, 115.0, 115.1, 115.2, 127.6, 129.07, 
129.14, 130.4, 135.43, 135.46, 148.9, 154.3, 156.1, 158.1, 160.2, 162.2); LC-MS (ESI+) 
m/z = 295.3 [M+H]
+
; HRMS calcd. for C18H16ON2F [M+H]
+
 295.1241, found 
295.1246; HRMS calcd. for C18H14ON2F [M-H]
-
 293.1096, found 293.1088; Analytical 
HPLC: 94.9%  
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K) 2’-(4-Chlorophenoxy)-3’-((4-fluorophenyl)amino)-[1,1’-biphenyl]-4-ol (138c) 
 
 
 
 
 
Pd2dba3 (14.7 mg, 0.016 mmol), XPhos (7.63 mg, 0.02 mmol), anhydrous K2CO3 (44.2 
mg, 0.32 mmol), 1-bromo-4-fluorobenzene (35.2 µL, 56 mg, 0.32 mmol) and aniline 
137a (50 mg, 0.16 mmol) were dissolved in acetonitrile (2 mL), purged with nitrogen 
for 5 min and irradiated at 120 
o
C for 3 h. The reaction was partitioned with EtOAc (10 
mL) and 83% distilled water, brine (4 × 12 mL) and the aqueous layer was extracted 
with EtOAc (3 × 10 mL). The organic layer was washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-15% EtOAc, 
petrol) eluted 138n as a grey solid (56 mg, 82%); Rf = 0.31 (silica, 20% EtOAc, petrol); 
m.p. 132-135 
o
C; UV λmax (EtOH/nm) 271.0; IR νmax/cm
-1
 3418 (N-H), 3330 (O-H), 
1598, 1509, 1470, 1335, 1214, 1090, 1006, 922, 824, 775, 747; 
1H δ/ppm (500 MHz, 
DMSO-d6) 6.60-6.63 (2H, m, Ar-H), 6.69-6.72 (2H, m, Ar-H), 6.93 (1H, dd, Ar-H, J = 
1.7 and 7.4 Hz), 7.00-7.06 (4H, m, Ar-H), 7.14-7.22 (4H, m, Ar-H), 7.26-7.28 (2H, m, 
Ar-H), 7.61 (1H, s, NH), 9.46 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 115.0, 
115.3, 115.4, 116.2, 116.6, 119.8, 119.9, 121.9, 124.9, 126.2, 127.7, 128.9, 129.8, 
135.8, 137.6, 139.3, 140.3, 155.7, 156.0, 156.7; LC-MS (ESI+) m/z = 406.3 [M+H]
+
; 
HRMS calcd. for C24H18O2NClF [M+H]
+
 406.1005, found 406.1007; HRMS calcd. for 
C24H16O2N
35
ClF [M-H]
-
 404.0859, found 404.0847; Analytical HPLC: 94.7%  
 
L) 1-Bromo-2-((4-chlorobenzyl)oxy)-3-nitrobenzene (135b) 
 
 
 
 
 
 
Phenol 134 (240 mg, 1.10 mmol), 4-chlorobenzyl bromide (189 mg, 0.92 mmol) and 
anhydrous K2CO3 (254 mg, 1.84 mmol) were dissolved in acetonitrile (2 mL) and 
irradiated at 100 
o
C for 90 min. The reaction was partitioned with EtOAc (10 mL) and 3 
M NaOH (3 × 10 mL). The organic layer was washed with brine (10 mL), dried 
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(MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-5% EtOAc, 
petrol) eluted 135b as a yellow/white solid (304.6 mg, 97%); Rf = 0.37 (silica, 5% 
EtOAc, petrol); m.p. 113-116 
oC; UV λmax (EtOH/nm) 220.5; IR νmax/cm
-1
 3079 (Ar C-
H), 2944, 2894 1589, 1522 (N=O asym. stretch), 1493, 1451, 1362 (N=O sym. stretch), 
1245 (C-O), 1103, 934, 879, 814, 791, 747, 705; 
1H δ/ppm (500 MHz, CDCl3) 5.16 
(2H, s, CH2), 7.17 (1H, t, Ar-H, J = 8.1 Hz), 7.37-7.40 (2H, m, Ar-H), 7.47-7.50 (2H, 
m, Ar-H), 7.80 (1H, dd, Ar-H, J = 1.6 and 8.2 Hz), 7.84 (1H, dd, Ar-H, J = 1.6 and 8.1 
Hz); 
13C δ/ppm (125 MHz, CDCl3) 75.7, 120.2, 124.6, 125.5, 128.8, 130.1, 134.0, 
134.6, 138.0, 149.1; LC-MS (ESI+) m/z = mass not observed; HRMS calcd. for 
C13H8O3N
35
Cl
79
Br [M-H]
-
 339.9371, found 339.9365 
 
M) 3-Bromo-5-((4-fluorobenzyl)amino)pyridine-1-oxide (133) 
 
 
 
 
Meta-chloroperbenzoic acid (≥ 77%, 47.7 mg, 0.21 mmol) was added to a solution of 
aniline 132 (20 mg, 0.07 mmol) in DCM (1.56 mL) at room temperature. After 45 min, 
the reaction was quenched with 3 M NaOH (5 mL) and the layers were separated. The 
organic layer was washed with 3 M NaOH (4 × 5 mL), brine (10 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give 133 as a yellow solid (12 mg, 49%), which 
was taken forward without further purification; Rf = 0.22 (silica, 20% MeOH, DCM); 
1H δ/ppm (500 MHz, CDCl3) 4.25 (2H, d, CH2, J = 5.4 Hz), 4.82 (1H, m, NH), 6.72 
(1H, s, Ar-H), 7.03-7.06 (2H, m, Ar-H), 7.26-7.28 (2H, m, Ar-H), 7.62 (1H, m, Ar-H), 
7.70 (1H, m, Ar-H); LC-MS (ESI+) m/z = 297.1 and 299.2 [M+H]
+ 
 
N) 4-Ethynylanisole (159) 
 
 
 
 
Zinc dichloride (21.9 mg, 0.160 mmol), (PhCN)2PdCl2 (30.8 mg, 0.080 mmol) and 
t
Bu3P (33.5 mg, 0.170 mmol) were dissolved in THF (4.5 mL), mixed with 
diisopropylamine (564 µL, 407 mg, 4.02 mmol) and the solution was degassed with 
nitrogen for 30 min. Anisole 156 (201 µL, 300 mg, 1.61 mmol) and 
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trimethylsilylacetylene (454 µL, 316 mg, 3.22 mmol) were added and the reaction was 
heated to 50 
o
C. After 3 h, the reaction was partitioned with EtOAc (20 mL) and 1 M 
HCl (10 mL). The organic layer was washed with 1 M HCl (2 × 10 mL) and the 
aqueous layer was extracted with EtOAc (10 mL). The organic layer was washed with 
brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo, then dissolved in 
THF (2 mL) and mixed with TBAF (1 M in THF, 4.83 mL, 4.83 mmol) at room 
temperature. After 1 h, the reaction was concentrated to a low volume in vacuo. 
Chromatography (silica, 10% DCM, petrol) eluted 159 as a yellow oil (172 mg, 80%); 
Rf = 0.26 (silica, 10% DCM, petrol); UV λmax (EtOH/nm) 247.5; IR νmax/cm
-1
 3285 
(alkyne C-H), 2960 (C-H), 2838 (C-H), 2106 (C≡C), 1606, 1506, 1290, 1246 (C-O), 
1170, 1030, 832 ; 
1H δ/ppm (500 MHz, CDCl3) 3.00 (1H, s, CCH), 3.82 (3H, s, OCH3), 
6.83-6.86 (2H, m, Ar-H), 7.42-7.45 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 55.3, 
75.8, 83.7, 113.9, 114.2, 133.6, 159.9; LC-MS (ESI+) m/z = mass not observed; HRMS 
calcd. for C9H8O [M+H]
+ 
132.0570, found 132.0567 
 
O) Methyl 3-(4-methoxyphenyl)propiolate (157) 
 
 
 
 
n-Butyllithium (1.5 M in hexanes, 1.28 mL, 1.95 mmol) was added dropwise to a 
solution of diisopropylamine (273 µL, 197 mg, 1.95 mmol) in THF (4.4 mL) at -78 
o
C. 
After 40 min, 4-ethynylanisole (230 µL, 234 mg, 1.77 mmol) (159), as a solution in 
THF (1 mL, 1.8 M), was added dropwise. After 30 min, methyl chloroformate (206 µL, 
251 mg, 2.66 mmol), as a solution in THF (1 mL, 2.7 M), was added dropwise and the 
reaction was warmed to room temperature. After 30 min, the reaction was quenched 
with saturated aqueous NaHCO3 (5 mL) and partitioned with EtOAc (10 mL) and 
distilled water (10 mL). The organic layer was washed with distilled water (2 × 10 mL) 
and the aqueous layer was extracted with EtOAc (10 mL). The organic layer was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 20-35% DCM, petrol) eluted 157 as a yellow solid (285 mg, 
85%); Rf = 0.36 (silica, 5% EtOAc, petrol); m.p. 55-58 
oC; UV λmax (EtOH/nm) 253.0; 
IR νmax/cm
-1
 3074 (C-H), 2963 (C-H), 2226 (C≡C), 1700 (C=O), 1619, 1440, 1247 (C-
O), 1157, 1098, 972, 831, 747, 718; 
1H δ/ppm (500 MHz, CDCl3) 3.79 (3H, s, 
CO2CH3), 3.83 (3H, s, OCH3), 6.48 (2H, d, Ar-H, J = 16.1 Hz), 6.79 (2H, d, Ar-H, J = 
282 
 
16.0 Hz); 
13C δ/ppm (125 MHz, CDCl3) 52.3, 53.1, 81.8, 86.8, 121.7, 135.1, 153.6, 
165.1; LC-MS (ESI+) m/z = mass not observed; HRMS mass not observed 
 
P) 3-Hydroxy-5-(4-methoxyphenyl)isoxazole (162a) 
 
 
 
 
 
Ester 157 (20 mg, 0.11 mmol), as a solution in methanol (0.5 mL, 0.2 M), was added 
dropwise to a solution of hydroxylamine hydrochloride (23 mg, 0.33 mmol) in 3 M 
NaOH (0.28 mL, 33.2 mg, 0.83 mmol) at 0 
o
C. After 30 min, the reaction was heated to 
70 
o
C for 30 min then cooled back to 0 
o
C, quenched with conc. HCl (1 mL) and 
partitioned with EtOAc (10 mL) and 1 M HCl (10 mL). The organic layer was washed 
with 1 M HCl (2 × 10 mL) and the aqueous layer was extracted with EtOAc (2 × 10 
mL). The organic layer was washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo to afford 162a as a light brown solid (18.6 mg, 93%); Rf = 0.25 
(silica, 40% EtOAc, petrol); m.p. 199 
oC (decomposed); UV λmax (EtOH/nm) 273.5; IR 
νmax/cm
-1
 2953 (C-H), 2774 (C-H) and 2612 (br) (O-H), 1629, 1536, 1498, 1358, 1302, 
1253 (C-O), 1179, 956, 829, 775, 726; 
1H δ/ppm (500 MHz, DMSO-d6) 3.82 (3H, s, 
OCH3), 6.40 (1H, s, isoxazole C4-H), 7.06 (2H, d, Ar-H, J = 8.7 Hz), 7.74 (2H, d, Ar-H, 
J = 8.7 Hz), 11.30 (1H, s, br, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 55.3, 90.2, 114.5, 
120.1, 126.9, 160.7, 169.0, 170.9; LC-MS (ESI+) m/z = 192.2 [M-H]
-
; HRMS calcd. for 
C10H8O3N [M-H]
- 
190.0510, found 190.0511 
 
Q) N-(3-Bromo-2-methylphenyl)-4-methoxybenzamide (147a) 
 
 
 
 
Isopropylmagnesium chloride lithium chloride solution (1.3 M in THF, 4.96 mL, 6.45 
mmol) was added dropwise to a solution of aniline 146 (265 µL, 400 mg, 2.15 mmol) 
and methyl 4-methoxybenzoate (358 mg, 2.15 mmol) in 1,2-DME (10.8 mL) at room 
temperature. After 3 h, the reaction was quenched with saturated aqueous NH4Cl (5 mL) 
and partitioned with EtOAc (10 mL) and distilled water (10 mL). The aqueous layer 
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was extracted with EtOAc (10 mL) and the organic layer was washed with brine (10 
mL), dried (MgSO4), filtered and concentrated in vacuo to give 147a as a light brown 
solid (635 mg, 92%); Rf = 0.22 (silica, 20% EtOAc, petrol); m.p. 164-167 
oC; UV λmax 
(EtOH/nm) 258.8; IR νmax/cm
-1
 3275 (N-H), 1642, 1606, 1568, 1504, 1458, 1299, 1253 
(C-O), 1176, 1106, 1024, 915, 843, 774, 688; 
1H δ/ppm (500 MHz, DMSO-d6) 2.27 
(3H, s, Ar-CH3), 3.85 (3H, s, OCH3), 7.06-7.08 (2H, m, Ar-H), 7.18 (1H, t, Ar-H, J = 
7.9 Hz), 7.33 (1H, d, Ar-H, J = 7.8 Hz), 7.53 (1H, d, Ar-H, J = 8.0 Hz), 7.96-7.98 (2H, 
m, Ar-H), 10.01 (1H, s, NH); 
13C δ/ppm (125 MHz, DMSO-d6) 18.4, 55.4, 113.6, 117.4, 
124.6, 126.6, 127.3, 129.6, 129.9, 138.1; LC-MS (ESI+) m/z = 320.3 and 322.3 
[M+H]
+
; HRMS calcd. for C15H15O2N
79
Br [M+H]
+ 
320.0281, found 320.0283 
 
R) 4-((2-(4-Chlorophenoxy)-4’-fluoro-[1,1’-biphenyl]-3-yl)amino)phenol (138o) 
 
 
 
 
 
Boron tribromide (1 M in DCM, 0.4 mL, 0.4 mmol) was added dropwise to a solution 
of anisole 137f (20 mg, 0.05 mmol) in DCM (1.4 mL) at 0 
o
C and stirred at room 
temperature. After 24 h, the reaction was quenched with distilled water (5 mL) and 
partitioned with DCM (10 mL). The organic layer was washed with brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo to give 138o as a magenta solid (12.9 
mg, 66%); Rf = 0.30 (20% EtOAc, petrol); m.p. 148 
oC (decomposed); UV λmax 
(EtOH/nm) 230.8; IR νmax/cm
-1
 3427 (N-H), 3115 (br) (O-H), 3031 (C-H), 2924 (C-H), 
2855 (C-H), 1605, 1517, 1469, 1453, 1390, 1335, 1274, 1215 (C-O), 1159, 1084, 1009, 
923, 869, 825, 773, 743, 722; 
1H δ/ppm (500 MHz, CDCl3) 4.55 (1H, s, br, NH), 5.72 
(1H, s, br, OH), 6.65-6.68 (2H, m, Ar-H), 6.79-6.81 (3H, m, Ar-H), 6.94-6.98 (2H, m, 
Ar-H), 7.01-7.04 (2H, m, Ar-H), 7.04-7.09 (3H, m, Ar-H), 7.11-7.14 (1H, m, Ar-H), 
7.37-7.40 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 113.4, 114.9, 115.1, 116.1, 
116.3, 120.5, 124.3, 126.2, 126.8, 129.4, 130.5, 130.6, 134.5, 135.0, 138.5, 139.6, 
151.9, 155.8; LC-MS (ESI+) m/z = 406.3 [M+H]
+
; HRMS calcd. for C24H16O2N
35
ClF 
[M-H]
- 
404.0859, found 404.0862; Analytical HPLC: 96.3%  
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S) 4-(2-((4-Fluorophenyl)amino)thiazol-4-yl)phenol (44r) 
 
 
 
 
 
Phenacyl bromide 260 (153 mg, 0.71 mmol) and thiourea 261 (100 mg, 0.59 mmol) 
were dissolved in ethanol (2.6 mL) and irradiated at 70 
o
C for 10 min. The mixture was 
filtered through filter paper and the solid was washed with ice-cooled ethanol (10 mL) 
to give 44r as an off-white solid (115 mg, 68%); Rf = 0.26 (silica, 30% EtOAc, petrol); 
m.p. 238 
oC (decomposed); UV λmax (EtOH/nm) 281.6 and 264.2; IR νmax/cm
-1
 3251 (N-
H), 3080 (C-H), 3022 (br) (O-H), 2923 (C-H), 2761 (C-H), 1613, 1585, 1503, 1443, 
1331, 1271, 1210 (C-O), 1179, 1159, 1104, 924, 871, 831, 775, 737, 710, 680; 
1
H 
δ/ppm (500 MHz, DMSO-d6) 6.24 (1H, s, br, NH), 6.80-6.83 (2H, m, Ar-H), 7.06 (1H, 
s, thiazole C5-H), 7.17-7.20 (2H, m, Ar-H), 7.71-7.76 (4H, m, Ar-H), 10.23 (1H, s, br, 
OH); 
13C δ/ppm (125 MHz, DMSO-d6) 99.8, 115.3, 115.4, 115.6, 118.2, 118.3, 125.8, 
127.0, 150.2, 155.8, 157.1, 162.9;
 19F δ/ppm (470 MHz, DMSO-d6) -122.2; LC-MS 
(ESI+) m/z = 287.2 [M+H]
+
 and 285.2 [M-H]
-
; HRMS calcd. for C15H10ON2FS [M-H]
- 
285.0503, found 285.0501; Analytical HPLC: 97.9%  
 
T) 1,1,1-Trifluoro-N-(4-formylphenyl)methanesulfonamide (155) 
 
 
 
 
Dess-Martin periodinane (0.3 M in DCM, 3.4 mL, 1.01 mmol) was added dropwise to a 
solution of benzyl alcohol 154 (170 mg, 0.67 mmol) in DCM (3.3 mL) at room 
temperature. After 2 h, the reaction was quenched with sodium thiosulfate (800 mg, 
5.06 mmol) in distilled water (10 mL, 0.5 M) and the layers were separated. The 
aqueous layer was acidified to pH 1 with 1 M HCl and extracted with DCM (10 × 10 
mL). The organic layer was washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo, then triturated with ice-cooled DCM (8 × 5 mL). 
Chromatography (silica, 0-15% EtOAc, petrol) afforded 155 as a white solid (71 mg, 
42%); Rf = 0.34 (20% EtOAc, petrol); m.p. 91-95 
oC; UV λmax (EtOH/nm) 264.8; IR 
νmax/cm
-1
 3151 (N-H), 3071 (C-H), 2960 (C-H), 2855 (C-H), 1679 (C=O), 1601, 1512, 
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1492, 1422, 1378 (S=O asym. stretch), 1295, 1196, 1170, 1137 (S=O sym. stretch), 
1015, 939, 830, 791, 736; 
1H δ/ppm (500 MHz, CDCl3) 7.21 (1H, s, br, NH), 7.43-7.45 
(2H, m, Ar-H), 7.92-7.94 (2H, m, Ar-H), 10.00 (1H, s, CHO); 
13C δ/ppm (125 MHz, 
CDCl3) 121.5, 131.4, 134.4, 139.5, 190.7; LC-MS (ESI+) m/z = 252.0 [M-H]
-
; HRMS 
calcd. for C8H5O3NF3S [M-H]
- 
251.9948, found 251.9942 
 
U) 4-Bromopyridine-N-oxide (125) 
 
 
 
 
4-Bromopyridine hydrochloride (715 mg, 3.68 mmol) (124) was dissolved in minimal 
distilled water (~ 1 mL) and mixed with 3 M NaOH (1.23 mL, 147 mg, 3.68 mmol). 
After 20 min, the reaction was partitioned with diethyl ether (10 mL) and the aqueous 
layer was extracted with diethyl ether (2 × 10 mL). The organic layer was washed with 
brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo, then dissolved in 
diethyl ether (4.6 mL) and mixed with mCPBA (70%, 1.36 g, 5.52 mmol) at room 
temperature. After 24 h, the reaction was partitioned with 3 M NaOH solution (10 mL) 
and the organic layer was dried (MgSO4), filtered and concentrated in vacuo to give 125 
as a white solid (552 mg, 86%); Rf = 0.41 (silica, 10% MeOH, DCM); m.p. 122 
o
C 
(decomposed); UV λmax (EtOH/nm) 276.2 and 213.8; IR νmax/cm
-1
 3076 (C-H), 3022 (C-
H), 2998 (C-H), 1469, 1445, 1242 (N-O), 1187, 1094, 1038, 863, 696; 
1H δ/ppm (500 
MHz, DMSO-d6) 7.64-7.66 (2H, m, Ar-H), 8.13-8.16 (2H, m, Ar-H); 
13
C δ/ppm (125 
MHz, DMSO-d6) 117.0, 129.5, 140.1;
 
LC-MS (ESI+) m/z = 173.9 and 176.0 [M+H]
+
; 
HRMS calcd. for C5H5NO
79
Br [M+H]
+
 173.9549, found 173.9547 
 
V) 2-(2-Fluoro-3-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (142) 
 
 
 
 
Aryl fluoride 139 (937 mg, 4.26 mg), B2(pin)2 (1.62 g, 6.39 mmol), (PPh3)2PdCl2 (91 
mg, 0.13 mmol) and potassium acetate (836 mg, 8.52 mmol) were dissolved in 1,4-
dioxane (18 mL) and DMSO (0.4 mL), degassed with nitrogen for 35 min and stirred at 
286 
 
90 
o
C. After 17 h, the reaction was partitioned with EtOAc (10 mL) and distilled water 
(20 mL). The aqueous layer was extracted with EtOAc (8 × 8 mL) and the organic layer 
was washed with brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 0-20% EtOAc, petrol) afforded 142 as a sand-coloured solid 
(699 mg, 61%); Rf = 0.18 (silica, 50% EtOAc, petrol stained with ammonium 
molybdate); m.p. 84-87 
oC; UV λmax (EtOH/nm) 252.4 and 210.4; IR νmax/cm
-1
 2979 (C-
H), 2933 (C-H), 1615, 1582, 1533, 1474, 1446, 1395, 1365, 1336 (C-O), 1293, 1271, 
1240, 1214, 1170, 1145, 1121, 1082, 966, 900, 855, 839, 815, 748, 692; 
1H δ/ppm (500 
MHz, CDCl3) 1.37 (12H, s, (CH3)4), 7.28 (1H, t, Ar-H, J = 7.8 Hz), 7.99-8.01 (1H, m, 
Ar-H), 8.08-8.12 (1H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 24.8, 84.7, 124.0, 128.8, 
142.2, 158.2, 160.3; 
19F δ/ppm (470 MHz, CDCl3) -108.4; LC-MS (ESI+) m/z = mass 
not observed;  
 
W) N-(4-Bromothiazol-2-yl)-4-fluorobenzamide (268) 
 
 
 
 
n-Butyllithium (2.7 M in hexanes, 0.21 mL, 0.56 mmol) was added dropwise to a 
solution of diisopropylamine (78.5 µL, 56.7 mg, 0.56 mmol) in THF (1.5 mL) at -78 
o
C 
and stirred at 0 
o
C for 30 min before addition of bromothiazole 267 (50 mg, 0.17 mmol). 
After 30 min, the reaction was quenched with distilled water (10 mL), then warmed to 
room temperature and stirred overnight. The reaction was partitioned with EtOAc (10 
mL) and the organic layer was washed with 2 M HCl (10 mL). The aqueous layer was 
extracted with EtOAc (10 mL) and the organic layer was washed with brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-10% 
EtOAc, petrol) afforded 268 as a white solid (30 mg, 60%); Rf = 0.29 (silica, 10% 
EtOAc, petrol); m.p. 150-153 
oC; UV λmax (EtOH/nm) 292.2 and 229.4; IR νmax/cm
-1
 
3132 (N-H), 2980 (C-H), 2934 (C-H), 1669 (C=O), 1615, 1535, 1509, 1479, 1446, 
1366, 1343, 1292, 1239, 1158, 1123, 1083, 1016, 967, 902, 845, 815, 750, 692; 
1
H 
δ/ppm (500 MHz, DMSO-d6) 7.39 (1H, s, thiazole C5-H), 7.40-7.43 (2H, m, Ar-H), 
8.16-8.20 (2H, m, Ar-H), 12.98 (1H, s, NH); 
13C δ/ppm (125 MHz, DMSO-d6) 111.9, 
115.7, 115.8, 120.3, 128.0, 128.1, 131.0, 131.1, 159.6, 163.8, 164.3, 165.8; 
19F δ/ppm 
(470 MHz, DMSO-d6) -106.5; LC-MS (ESI+) m/z = 303.1 and 301.0 [M+H]
+
; HRMS 
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calcd. for C10H7ON2
79
BrFS [M+H]
+ 
300.9441, found 300.9444; Analytical HPLC: 
96.8% 
 
X) N-(4-Fluorobenzyl)-4-(1H-indazol-5-yl)thiazol-2-amine (44t) 
 
 
 
 
 
Dilute HCl (1 M, 1.0 mL) was added to a solution of thiazole 276 (40 mg, 0.10 mmol) 
in methanol (1.0 mL, 0.1 M) at room temperature in air and stirred at 50 
o
C. After 24 h, 
the reaction was quenched with saturated aqueous NaHCO3 (10 mL) and partitioned 
with EtOAc (10 mL). The organic layer was washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 20-50% EtOAc, 
petrol) followed by semi-preparative HPLC (35% H2O with 0.1% (v/v) HCO2H, 
methanol) afforded 44t as an off-white solid (12 mg, 37%); Rf = 0.28 (silica, 50% 
EtOAc, petrol); m.p. 224-227 
oC (decomposed); UV λmax (EtOH/nm) 233.2; IR νmax/cm
-
1
 3225 (N-H), 3097 (N-H), 3002 (C-H), 2839 (C-H), 2780 (C-H), 1555, 1504, 1465, 
1412, 1346, 1299, 1201, 1154, 1091, 1046, 942, 894, 813, 783, 745, 696, 670; 
1H δ/ppm 
(500 MHz, DMSO-d6) 4.53 (2H, d, CH2, J = 5.8 Hz), 7.00 (1H, s, thiazole C5-H), 7.17-
7.20 (2H, m, Ar-H), 7.45-7.48 (2H, m, Ar-H), 7.52 (1H, d, indazole C7-H, J = 8.8 Hz), 
7.84 (1H, dd, indazole C6-H, J = 1.2 and 8.7 Hz), 8.09 (1H, s, Ar-H), 8.14-8.16 (1H, m, 
amino-NH), 8.22 (1H, s, Ar-H), 13.06 (1H, s, indazole-NH); 
13C δ/ppm (125 MHz, 
DMSO-d6) 47.0, 99.6, 110.0, 114.9, 115.1, 117.3, 123.0, 124.6, 127.7, 129.46, 129.52, 
134.0, 135.5, 139.3, 150.3, 160.3, 162.2, 168.0; 
19F δ/ppm (470 MHz, DMSO-d6) -
116.0; LC-MS (ESI+) m/z = 325.3 [M+H]
+
 and 323.2 [M-H]
-
; HRMS calcd. for 
C17H14N4FS [M+H]
+ 
325.0918, found 325.0919; Analytical HPLC: 99.3% 
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Y) 2-(4-Chlorophenoxy)-3-ethynyl-N-(4-fluorophenyl)aniline (167) 
  
 
 
 
 
TBAF (1 M in THF, 1.31 mL, 1.31 mmol) was added to a solution of acetylene 178 
(499 mg, 1.01 mmol) in THF (5 mL) and stirred at room temperature for 20 min, then 
concentrated to a low volume in vacuo. Chromatography (silica, 0-10% DCM, petrol) 
afforded 167 as a yellow oil (296 mg, 87%); Rf = 0.30 (silica, 20% DCM, petrol); UV 
λmax (EtOH/nm) 280.0 and 230.0; IR νmax/cm
-1
 3408 (N-H), 3290 (C-H), 3062 (C-H), 
2923 (C-H), 2107 (C≡C), 1593, 1506, 1481, 1435, 1389, 1327, 1278, 1208 (C-O), 1091, 
1008, 871, 824, 778, 746; 
1
H δ/ppm (500 MHz, CDCl3) 3.06 (1H, s, CCH), 5.79 (1H, s, 
br, NH), 6.84-6.88 (2H, m, Ar-H), 6.97-7.02 (3H, m, Ar-H), 7.04-7.07 (3H, m, Ar-H), 
7.15 (1H, dd, Ar-H, J = 1.6 and 8.0 Hz), 7.22-7.25 (2H, m, Ar-H; 
13
C δ/ppm (125 MHz, 
CDCl3) 78.8, 82.6, 115.4, 116.0, 116.2, 116.6, 117.3, 123.07, 123.13, 124.3, 125.8, 
127.3, 129.6, 137.1, 138.5, 143.2, 156.1, 158.0, 160.0; 
19
F δ/ppm (470 MHz, CDCl3) -
119.6; LC-MS (ESI+) m/z = 338.3 [M+H]
+
 and 336.3 [M-H]
-
; HRMS calcd. for 
C20H14ON
35
ClF [M+H]
+ 
338.0742, found 338.0743; Analytical HPLC: 99.0% 
 
Z) Tert-butyl-(2-(4-chlorophenoxy)-3-(1H-1,2,3-triazol-4-yl)phenyl)(4-
fluorophenyl)carbamate (184) 
 
 
 
 
 
TMS-azide (61 µL, 52.5 mg, 0.46 mmol) was added to a solution of acetylene 181 (100 
mg, 0.23 mmol) in ethanol (2.8 mL) and distilled water (1.0 mL) followed by sodium 
ascrobate (136 mg, 0.68 mmol), as a solution in distilled water (0.45 mL, 1.5 M), and 
then copper(II) sulfate pentahydrate (114 mg, 0.46 mmol), as a solution in distilled 
water (0.45 mL, 1 M) at room temperature and heated to 50 
o
C. After 24 h, the reaction 
was quenched with saturated aqueous NaHCO3 (5 mL) and distilled water (15 mL) and 
partitioned with EtOAc (10 mL). The organic layer was washed with saturated aqueous 
NaHCO3 (10 mL) and the aqueous layer was extracted with EtOAc (10 mL). The 
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organic layer was washed with brine (10 mL), dried (MgSO4), filtered and concentrated 
in vacuo, then suspended in ethanol (8 mL) and treated with a homogeneous solution of 
EDTA (613 mg, 2.1 mmol) in ethanol (4 mL) and 3 M NaOH (4 mL) and heated to 40 
o
C. After 16 h, the solution was cooled to room temperature, concentrated in vacuo and 
partitioned with EtOAc (10 mL). The organic layer was washed with brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo to give 184 as a pale green solid (109  
mg, 100%); Rf = 0.25 (silica, 5% MeOH, DCM); m.p. 90-92 
o
C; UV λmax (EtOH/nm) 
231.4; IR νmax/cm
-1
 3167 (br) (N-H), 2935 (C-H), 2862 (C-H), 1709 (C=O), 1684, 1505, 
1483, 1461, 1326, 1289, 1219 (C-O), 1152, 1089, 1065, 1009, 824, 755; 
1H δ/ppm (500 
MHz, DMSO-d6) 1.15 (9H, s, C(CH3)3), 6.61-6.63 (2H, m, Ar-H), 6.91-6.94 (2H, m, 
Ar-H), 7.00-7.04 (2H, m, Ar-H), 7.21-7.23 (2H, m, Ar-H), 7.42 (1H, t, Ar-H, J = 7.9 
Hz), 7.54 (1H, d, br, Ar-H, J = 7.4 Hz), 7.76 (1H, s, br, Ar-H), 8.00 (1H, s, br, Ar-H), 
15.10 (1H, s, NH); 
13C δ/ppm (125 MHz, DMSO-d6) 27.5, 80.8, 115.0, 115.2, 116.7, 
125.9, 126.6, 127.5, 129.3, 131.4, 136.1, 137.8, 152.2, 155.0, 158.4, 160.4; 
19F δ/ppm 
(470 MHz, DMSO-d6) -117.1; LC-MS (ESI+) m/z = 479.3 [M-H]
-
; HRMS calcd. for 
C25H23O3N4
35
ClF [M+H]
+ 
481.1437, found 481.1432; Analytical HPLC: 97.3% 
 
A’) 2-(4-Chlorophenoxy)-N-(4-fluorophenyl)-3-(1H-1,2,3-triazol-4-yl)aniline (185) 
 
 
 
 
 
Trifluoroacetic acid (0.15 mL) was added to a solution of carbamate 184 (72 mg, 0.15 
mmol) in DCM (1.5 mL) in air at room temperature. After 1 h, the reaction was 
partitioned with DCM (10 mL) and 1.5 M NaOH (10 mL). The aqueous layer was 
extracted with DCM (2 × 10 mL) and organic layers were washed with 3 M NaOH (2 × 
10 mL), 1 M HCl (10 mL), brine (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo to give 185 as a red solid (43 mg, 75%); Rf = 0.22 (silica, 5% MeOH, DCM); 
m.p. 158-160 
oC; UV λmax (EtOH/nm) 230.0; IR νmax/cm
-1
 3413 (N-H), 3128 (br) 
(triazolo N-H), 2939 (C-H), 2863 (C-H), 1582, 1507, 1482, 1460, 1211 (C-O), 1160, 
1089, 1009, 820, 748; 
1H δ/ppm (500 MHz, DMSO-d6) 6.79-6.81 (2H, m, Ar-H), 7.01-
7.06 (4H, m, Ar-H), 7.19-7.32 (4H, m, Ar-H), 7.52-7.85 (2H, m, Ar-H) (when heated to 
130 
o
C, this signal converges to a broad singlet at 7.60), 7.90-8.11 (2 singlets, 1H, 
aniline NH) (when heated to 130 
o
C, this signal converges to a broad singlet at 7.90), 
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15.01-15.64 (3 singlets, 1H, triazole NH), (when heated to 130 
o
C, this signal converges 
to a broad singlet at 14.75); 
13C δ/ppm (125 MHz, DMSO-d6) 115.3, 115.5, 116.5, 
117.0, 117.2, 119.2, 119.6, 120.07, 120.13, 120.29, 120.35, 121.7, 125.2, 125.5, 126.5, 
126.6, 129.3, 132.8, 137.9, 138.1, 139.0, 139.6, 140.1, 142.1, 155.1, 155.4; 
19F δ/ppm 
(470 MHz, DMSO-d6) -122.3, -122.8 and -123.0 (height ratio, 1:7:4). Heating the 
solution to 130 
o
C causes coalescence into a single peak at -122.8 to -123.0; LC-MS 
(ESI+) m/z = 381.3 [M+H]
+
 and 379.3 [M-H]
-
; HRMS calcd. for C20H13ON4
35
ClF [M-
H]
- 
379.0767, found 379.0754; Analytical HPLC: 94.2% 
 
B’) 3-(3-((tert-butoxycarbonyl)(4-fluorophenyl)amino)-2-(4-
chlorophenoxy)phenyl)propiolic acid (186) 
 
 
 
 
 
Lithium hydroxide monohydrate (269 mg, 6.40 mmol), as a solution in distilled water 
(3.4 mL, 1.9 M) was added to a solution of propiolate ester 182 (160 mg, 0.32 mmol) in 
THF (3.4 mL) in air at room temperature and stirred at 60 
o
C. After 2 h, the reaction 
was cooled to room temperature, acidified to pH 0 with 1 M HCl and extracted with 
EtOAc (2 × 10 mL). The organic layer was washed with distilled water (10 mL), brine 
(10 mL), dried (MgSO4), filtered and concentrated in vacuo to give 186 as a white solid 
(153 mg, 99%); Rf = 0.30 (silica, 15% MeOH, DCM); m.p. 109-112 
oC; UV λmax 
(EtOH/nm) 229.4; IR νmax/cm
-1
 3071 (C-H), 2977 (C-H), 2615 (br) (O-H), 2223 (C≡C), 
1706 and 1684 (C=O), 1506, 1483, 1452, 1333, 1228, 1151 (C-O), 1088, 1008, 926, 
825, 752, 730; 
1H δ/ppm (500 MHz, DMSO-d6) 1.26 (9H, s, C(CH3)3), 6.73-6.75 (2H, 
m, Ar-H), 7.04-7.07 (2H, m, Ar-H), 7.10-7.14 (2H, m, Ar-H), 7.36-7.38 (2H, m, Ar-H), 
7.47 (1H, t, Ar-H, J = 7.8 Hz), 7.72 (1H, dd, Ar-H, J = 1.5 and 7.8 Hz), 7.80 (1H, dd, 
Ar-H, J = 1.0 and 8.1 Hz), 13.80 (1H, s, br, CO2H); 
13C δ/ppm (125 MHz, DMSO-d6) 
27.5, 54.9, 81.1, 86.5, 115.1, 115.3, 115.4, 117.1, 126.3, 126.6, 127.6, 129.3, 133.7, 
134.5, 135.1, 136.0, 137.5, 152.1, 153.8, 155.7, 158.7; 
19F δ/ppm (470 MHz, DMSO-d6) 
-116.6; LC-MS (ESI+) m/z = mass not observed; HRMS mass not observed; Analytical 
HPLC: 99.2% 
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C’) 5-(2-(4-Chlorophenoxy)-3-((4-fluorophenyl)amino)phenyl)-1H-pyrazol-3-ol 
(183b) 
 
 
 
 
 
Hydrazine hydrate (15 µL, 15 mg, 0.30 mmol) was added to a solution of propiolate 
ester 182 (50 mg, 0.10 mmol) in methanol (1.0 mL) at 0 
o
C and stirred at room 
temperature for 45 min, before heating to 60 
o
C for 20 min. The reaction was cooled to 
0 
o
C and quenched with conc. HCl (2.0 mL), then heated to 50 
o
C for 90 min. The 
reacton was cooled to room temperature and partitioned with EtOAc (10 mL) and 1 M 
HCl (10 mL). The organic layer was washed with 1 M HCl (2 × 10 mL) and the 
aqueous layer was extracted with EtOAc (2 × 10 mL). The organic layer was washed 
with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. Preparative 
HPLC (5-100% MeCN, H2O + 0.1% (v/v) HCO2H) afforded 183b as a dark brown solid 
(15 mg, 38%); Rf = 0.36 (silica, 5% MeOH, DCM); m.p. 187-188 
o
C (decomposed); UV 
λmax (EtOH/nm) 263.8 and 229.6; IR νmax/cm
-1
 3406 (amino N-H), 3038 (pyrazolo N-
H), 2921 (C-H), 2653 (br) (O-H), 1585, 1504, 1480, 1322, 1205 (C-O), 1158, 1089, 
1007, 904, 860, 822, 772, 743; 
1H δ/ppm (500 MHz, DMSO-d6) 5.71 (1H, s, pyrazole 
C4-H), 6.74-6.76 (2H, m, Ar-H), 6.98-7.07 (4H, m, Ar-H), 7.16-7.33 (5H, m, Ar-H), 
7.61 (1H, s, amine NH), 9.73 (1H, s, br, pyrazole NH), 12.00 (1H, s, br, OH); 
13C δ/ppm 
(125 MHz, DMSO-d6) 115.3, 115.5, 116.5, 117.0, 118.6, 120.15, 120.21, 125.4, 126.3, 
129.2, 138.1, 139.0, 155.6, 155.9, 157.8, 166.7, 168.7; 
19F δ/ppm (470 MHz, DMSO-d6) 
-122.9; LC-MS (ESI+) m/z = 396.3 [M+H]
+
 and 394.2 [M-H]
-
; HRMS calcd. for 
C21H14O2N3
35
ClF [M-H]
- 
394.0764, found 394.0756; Analytical HPLC: 97.0% 
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D’) 2’-(4-Chlorophenoxy)-3’-((4-fluorophenyl)amino)-5’-(hydroxymethyl)-[1,1’-
biphenyl]-4-ol (231) 
 
 
 
 
 
 
DIBAL-H (1 M in cyclohexane, 1.85 mL, 1.85 mmol) was added dropwise to a solution 
of ester 230 (190 mg, 0.41 mmol) in THF (3.0 mL) at -78 
o
C and stirred for 30 min, 
then warmed to 0 
o
C. After 4 h, the reaction was quenched with saturated aqueous 
Rochelle salt (3 mL), warmed to room temperature and stirred overnight. The reaction 
was partitioned with EtOAc (10 mL) and distilled water (2 × 10 mL) and the aqueous 
layer was extracted with EtOAc (2 × 10 mL). The organic layer was washed with brine 
(10 mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 
20-75% EtOAc, petrol) afforded 231 as a brown solid (165 mg, 93%); Rf = 0.40 (silica, 
50% EtOAc, petrol); m.p. 192-194 
o
C; UV λmax (EtOH/nm) 271.2 and 230.0; IR 
νmax/cm
-1
 3601 (benzyl O-H), 3398 (N-H), 3307 (br) (phenol O-H), 3037 (C-H), 2942 
(C-H), 1589, 1502, 1445, 1376, 1215 (C-O), 1166, 1104, 1029, 825, 739; 
1
H δ/ppm 
(500 MHz, DMSO-d6) 4.49 (2H, d, CH2, J = 5.5 Hz), 5.19 (1H, t, CH2OH, J = 5.8 Hz), 
6.61-6.64 (2H, m, Ar-H), 6.71 (2H, d, Ar-H, J = 8.5 Hz), 6.87 (1H, d, Ar-H, J = 1.7 
Hz), 7.01-7.07 (4H, m, Ar-H), 7.14-7.17 (3H, m, Ar-H), 7.26-7.27 (2H, m, Ar-H), 7.58 
(1H, s, amino NH), 9.45 (1H, s, OH); 
13
C δ/ppm (125 MHz, DMSO-d6) 62.6, 114.0, 
115.0, 115.3, 115.4, 116.6, 119.8, 119.9, 124.8, 127.9, 128.9, 129.7, 135.2, 137.3, 
139.0, 139.4, 140.4, 155.7, 156.1, 156.7, 157.6; 
19
F δ/ppm (470 MHz, DMSO-d6) -
123.3; LC-MS (ESI+) m/z = 436.3 [M+H]
+
 and 434.2 [M-H]
-
; HRMS calcd. for 
C25H18O3N
35
ClF [M-H]
- 
434.0965, found 434.0956; Analytical HPLC: 96.1% 
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E’) Ethyl 5-(4-chlorobenzyl)-1-(4-chlorophenyl)-2-(4-fluorophenyl)-1H-pyrrole-3-
carboxylate (283b) 
 
 
 
 
 
A solution of 1,4-diketone 282b (160 mg, 0.42 mmol) and 4-chloroaniline (268 mg, 
2.10 mmol) in glacial acetic acid (1.4 mL) was irradiated at 170 
o
C for 12 min. The 
reaction was partitioned with EtOAc (10 mL) and saturated aqueous NH4Cl (30 mL). 
The organic layer was washed with saturated aqueous NaHCO3 (10 mL) and the 
aqueous layer was extracted with EtOAc (2 × 10 mL). The organic layer was washed 
with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 0-15% EtOAc, petrol) afforded 283b as a yellow solid (165 
mg, 83%); Rf = 0.30 (silica, 10% EtOAc, petrol); m.p. 132-134 
o
C; UV λmax (EtOH/nm) 
223.0; IR νmax/cm
-1
 3104 (C-H), 2979 (C-H), 2931 (C-H), 1684 (C=O), 1527, 1490, 
1431, 1341, 1295, 1220 (C-O), 1155, 1090, 1016, 835, 776; 
1
H δ/ppm (500 MHz, 
CDCl3) 1.18 (3H, t, CO2CH2CH3, J = 7.1 Hz), 3.71 (2H, s, 4-ClPhCH2), 4.15 (2H, q, 
CO2CH2CH3, J = 7.1 Hz), 6.54 (1H, s, pyrrole C4-H), 6.79-6.81 (2H, m, Ar-H), 6.86-
6.91 (4H, m, Ar-H), 7.08-7.11 (2H, m, Ar-H), 7.17-7.20 (4H, m, Ar-H); 
13
C δ/ppm (125 
MHz, CDCl3) 14.2, 32.7, 59.7, 110.1, 113.8, 114.5, 114.7, 127.26, 127.29, 128.5, 129.1, 
129.9, 130.0, 132.2, 132.78, 132.84, 132.9, 134.3, 135.9, 136.9, 138.1, 161.3, 163.3, 
164.6; 
19
F δ/ppm (470 MHz, CDCl3) -113.4; LC-MS (ESI+) m/z = 468.3 [M+H]
+
; 
HRMS calcd. for C26H21O2N
35
Cl2F [M+H]
+ 
468.0928, found 468.0929; Analytical 
HPLC: 99.2% 
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F’) 2-(6-(4-Chlorophenoxy)-5-((4-fluorophenyl)amino)-4’-hydroxy-[1,1’-biphenyl]-
3-yl)acetic acid (244) 
  
 
 
 
 
 
Nitrile 243 (20 mg, 0.045 mmol) was refluxed in 15% NaOH (2 mL) at 130 
o
C. After 17 
h, the flask was cooled to room temperature and washed with diethyl ether (2 × 10 mL). 
The aqueous layer was acidified to pH 0 with 2 M HCl (20 mL) and extracted with 
diethyl ether (2 × 10 mL). The organic layer was washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Preparative HPLC (25% H2O with 0.1% 
(v/v) HCO2H, MeCN) afforded 244 as a brown solid (7 mg, 33%); Rf = 0.42 (silica, 5% 
MeOH, DCM); UV λmax (EtOH/nm) 273.4 and 231.8; IR νmax/cm
-1
 3405 (N-H), 3033 
(C-H), 2955 (C-H), 2921 (C-H), 2852 (C-H), 2614 (br) (O-H), 1701 (C=O), 1585, 1504, 
1482, 1445, 1420, 1390, 1361, 1262, 1210 (C-O), 1172, 1088, 1008, 823; 
1
H δ/ppm 
(500 MHz, CDCl3) 3.61 (2H, s, CH2), 5.80 (1H, s, br, phenol OH), 6.67 (2H, d, Ar-H, J 
= 8.9 Hz), 6.72 (2H, d, Ar-H, J = 8.6 Hz), 6.79-6.80 (1H, m, Ar-H), 6.97-7.00 (2H, m, 
Ar-H), 7.04-7.07 (5H, m, Ar-H), 7.26 (1H, s, NH), 7.29 (2H, d, Ar-H, J = 8.4 Hz) - The 
CO2H proton was not observed; 
13
C δ/ppm (125 MHz, CDCl3) 40.7, 114.5, 115.1, 
116.0, 116.2, 116.3, 122.3, 122.7, 122.8, 126.8, 129.4, 129.6, 130.3, 131.1, 135.8, 
137.4, 138.4, 138.5, 155.0, 155.8, 157.9, 159.8, 176.3; 
19
F δ/ppm (470 MHz, CDCl3) -
120.0; LC-MS (ESI+) m/z = 464.2 [M+H]
+
 and 462.2 [M-H]
-
; HRMS calcd. for 
C26H18O4N
35
ClF [M-H]
- 
462.0914, found 462.0908; Analytical HPLC: 99.2% 
 
G’) 6-Chloro-1-(triisopropylsilyl)-1H-indole (200) 
 
 
 
n-Butyllithium (2.7 M in hexanes, 0.52 mL, 1.39 mmol) was added dropwise to a 
solution of indole 199 (200 mg, 1.32 mmol) in THF (4.4 mL) at -78 
o
C. After 1 h, TIPS-
chloride (368 µL, 332 mg, 1.72 mmol) was added and the reaction was warmed to room 
temperature. After 1 h, the reaction was quenched with saturated aqueous NH4Cl (5 mL) 
295 
 
and the layers were separated. The organic layer was washed with distilled water (10 
mL) and the aqueous layer was extracted with EtOAc (10 mL). The organic layer was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 0-10% EtOAc, petrol) afforded 200 as a colourless solid (384 
mg, 95%); Rf = 0.75 (silica, 5% EtOAc, petrol); m.p. 50-53 
o
C; UV λmax (EtOH/nm) 
275.4 and 226.8; IR νmax/cm
-1
 2948 (C-H), 2868 (C-H), 1603, 1509, 1457, 1429, 1319, 
1274, 1143, 1072, 1016, 979, 901, 882, 805, 721, 689; 
1
H δ/ppm (500 MHz, CDCl3) 
1.15 (18H, d, Si(CH(CH3)2)3, J = 7.6 Hz), 1.69 (3H, sep, Si(CH(CH3)2)3, J = 7.6 Hz), 
6.60 (1H, dd, C3-H, J = 0.8 and 3.2 Hz), 7.08 (1H, dd, C5-H, J = 1.7 and 8.4 Hz), 7.24 
(1H, d, C2-H, J = 3.2 Hz), 7.47 (1H, s, C7-H), 7.52 (1H, d, C4-H, J = 8.4 Hz); 
13
C δ/ppm 
(125 MHz, CDCl3) 12.8, 18.1, 104.8, 113.7, 120.4, 121.2, 127.2, 130.0, 131.9, 141.2; 
LC-MS (ESI+) m/z = 308.3 [M+H]
+
; HRMS mass not observed 
 
H’) 1-(Tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-indazole (273) 
 
 
 
 
 
3,4-Dihydro-2H-pyran (608 µL, 560 mg, 6.66 mmol) was added to a solution of 
indazole 272 (270 mg, 1.11 mmol) and pTSA (42.2 mg, 0.22 mmol) in DCM (4.5 mL) 
at room temperature. After 2 h, the reaction was diluted with DCM (10 mL) and washed 
with saturated aqueous NaHCO3 (3 × 10 mL). The aqueous layer was extracted with 
DCM (2 × 10 mL) and the organic layer was washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-30% Et2O, 
petrol followed by 0-10% EtOAc, petrol) afforded 273 as a colourless oil (252 mg, 
65%); Rf = 0.31 (silica, 20% EtOAc, petrol); UV λmax (EtOH/nm) 225.4; IR νmax/cm
-1
 
2975 (C-H), 2940 (C-H), 2863 (C-H), 1614, 1364, 1302, 1269, 1211, 1142, 1071, 1042, 
994, 964, 912, 858, 813, 758, 684; 
1
H δ/ppm (500 MHz, DMSO-d6) 1.32 (12H, s, 
(CH3)4), 1.57-1.60 (2H, m, CH2-CH2-O), 1.70-1.80 (1H, m, CH2-CH2-CH2-O), 1.95-
1.98 (1H, m, CH2-CH2-CH2-O), 2.03-2.05 (1H, m, CH2-CH-O), 2.38-2.48 (1H, m, CH2-
CH-O), 3.72-3.77 (1H, m, CH2-O), 3.88-3.91 (1H, m, CH2-O), 5.87 (1H, dd, N-CH-O, J 
= 2.4 and 9.7 Hz), 7.67 (1H, dd, C6-H, J = 0.7 and 8.5 Hz), 7.72 (1H, d, C7-H, J = 8.5 
Hz), 8.16-8.17 (2H, two singlets, C3-H and C4-H); 
13
C δ/ppm (125 MHz, DMSO-d6) 
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22.2, 24.7, 24.8, 28.9, 66.6, 83.6, 84.0, 109.8, 124.0, 128.8, 131.4, 134.2, 140.7; LC-MS 
(ESI+) m/z = 329.5 [M+H]
+
; HRMS calcd. for C18H26O3N2
10
B [M+H]
+ 
329.2031, found 
329.2037  
 
I’) 3-Bromo-6-chloro-1-(triisopropylsilyl)-1H-indole (202) 
 
 
 
N-bromosuccinimide (909 mg, 5.11 mmol), as a solution in THF (10 mL, 0.5 M) was 
added to a solution of indole 200 (1.50 g, 4.87 mmol) in THF (10 mL, 0.5 M) at -78 
o
C 
in air. After 3 h, the reaction was quenched with distilled water (20 mL), warmed to 
room temperature and partitioned with diethyl ether (10 mL). The aqueous layer was 
extracted with diethyl ether (10 mL) and the organic layer was washed with brine (10 
mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-
10% DCM, petrol) afforded 202 as a colourless solid (1.75 g, 93%); Rf = 0.72 (silica, 
20% DCM, petrol); m.p. 59-60 
o
C; UV λmax (EtOH/nm) 285.2 and 231.2; IR νmax/cm
-1
 
2948 (C-H), 2868 (C-H), 1606, 1559, 1459, 1426, 1319, 1281, 1194, 1136, 1069, 1017, 
937, 882, 844, 799, 735, 692; 
1
H δ/ppm (500 MHz, CDCl3) 1.15 (18H, d, 
Si(CH(CH3)2)3, J = 7.6 Hz), 1.66 (3H, sep, Si(CH(CH3)2)3, J = 7.5 Hz), 7.17 (1H, dd, 
C5-H, J = 1.6 and 8.4 Hz), 7.21 (1H, s, C2-H), 7.45 (1H, d, C7-H, J = 1.6 Hz), 7.47 (1H, 
d, C4-H, J = 8.5 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 12.8, 18.0, 93.6, 113.9, 120.0, 
121.3, 128.6, 128.7, 130.5, 140.4; LC-MS (ESI+) m/z = 386.3 and 388.3 [M+H]
+
; 
HRMS mass not observed 
 
 J’) ((2-Fluoro-3-nitrophenyl)ethynyl)triisopropylsilane (164) 
 
 
 
Diisopropylamine (82 µL, 59 mg, 0.58 mmol) was added to a solution of aryl bromide 
139 (50 mg, 0.23 mmol), (PPh3)2PdCl2 (4.8 mg, 0.007 mmol) and CuI (1.3 mg, 0.007 
mmol) in THF (2.3 mL). The solution was degassed with nitrogen for 5 min, mixed 
with TIPS-acetylene (79 µL, 64 mg, 0.35 mmol) and heated to 70 
o
C for 1 h. The 
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reaction was partitioned with EtOAc (10 mL) and 66% distilled water, 1 M HCl (15 
mL). The organic layer was washed with 66% distilled water, 1 M HCl (15 mL) and the 
aqueous layer was extracted with EtOAc (5 × 8 mL). The organic layer was washed 
with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 0-10% DCM, petrol) afforded 164 as a yellow solid (62 mg, 
85%); Rf = 0.32 (silica, 20% DCM, petrol); m.p. 39-41 
o
C; UV λmax (EtOH/nm) 245.4; 
IR νmax/cm
-1
 3088 (C-H), 2939 (C-H), 2864 (C-H), 2160 (C≡C), 1609, 1580, 1542, 
1454, 1346, 1289, 1269, 1192, 1075, 1017, 993, 944, 882, 841, 797, 734, 674; 
1
H δ/ppm 
(500 MHz, CDCl3) 1.12-1.15 (21H, m, Si(CH(CH3)2)3), 7.23 (1H, dd, C5-H, J = 1.1 and 
7.8 Hz), 7.71-7.74 (1H, m, C6-H), 7.95-7.99 (1H, m, C4-H); 
13
C δ/ppm (125 MHz, 
CDCl3) 11.2, 18.6, 97.0, 100.90, 100.94, 115.6, 115.7, 123.8, 123.9, 125.45, 125.47, 
137.8, 138.77, 138.79, 155.2, 157.3; 
19
F δ/ppm (470 MHz, CDCl3) -114.4; LC-MS 
(ESI+) m/z = 320.3 [M-H]
-
; HRMS calcd. for C17H25O2NFSi [M+H]
+ 
322.1633, found 
322.1630 
 
K’) 2-(4-Chlorophenoxy)-3-ethynylaniline (166) 
 
 
 
 
 
Tin(II) chloride dihydrate (2.89 g, 12.8 mmol) was added to a solution of nitro 165 (439 
mg, 1.60 mmol) in ethanol (4.0 mL) room temperature and stirred at 70 
o
C for 30 min. 
The reaction was cooled to room temperatature, quenched with saturated aqueous 
NaHCO3 (10 mL), filtered through celite and partitioned with EtOAc (10 mL) and 
distilled water (10 mL). The organic layer was dried (MgSO4), filtered and concentrated 
in vacuo to give 166 as a brown solid (390 mg, 100%); Rf = 0.28 (silica, 10% EtOAc, 
petrol); m.p. 73-75 
o
C; UV λmax (EtOH/nm) 226.8; IR νmax/cm
-1
 3486 (N-H), 3394 (N-
H), 3286 ( alkyne C-H), 1614, 1471, 1324, 1276, 1219 (C-O), 1163, 1095, 1056, 1009, 
965, 869, 832, 790, 750, 700 (C≡C bond not observed); 1H δ/ppm (500 MHz, CDCl3) 
3.04 (1H, s, CCH), 3.97 (2H, s, br, NH2), 6.82-6.85 (3H, m, 1-H2NPh C6-H, 4-ClPh C3-
H and C5-H), 6.95 (1H, dd, 1-H2NPh C4-H, J = 1.6 and 7.7 Hz), 7.02 (1H, t, 1-H2NPh 
C5-H, J = 7.8 Hz), 7.23 (2H, d, 4-ClPh C2-H and C6-H, J = 8.9 Hz); 
13
C δ/ppm (125 
MHz, CDCl3) 79.0, 82.1, 116.5, 117.2, 117.4, 123.8, 126.0, 127.1, 129.5, 139.7, 142.3, 
156.0; LC-MS (ESI+) m/z = 244.3 [M+H]
+
; HRMS mass not observed 
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L’) Tert-butyl (2-(4-chlorophenoxy)-3-ethynylphenyl)(4-fluorophenyl)carbamate  
(181) 
 
 
 
 
Boc2O (262 mg, 1.20 mmol), as a solution in acetonitrile (0.3 mL, 4 M) was added 
dropwise to a solultion of aniline 167 (201 mg, 0.60 mmol) and DMAP (37 mg, 0.30 
mmol) in acetonitrile (3.6 mL) at room temperature in a sealed vial in air and heated to 
50 
o
C for 1 h. The reaction was cooled to room temperature, concentrated to a low 
volume in vacuo and partitioned with EtOAc (10 mL) and saturated aqueous NaHCO3 
(3 × 10 mL). The organic layer was washed with brine (10 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Chromatography (silica, 0-10% Et2O, petrol) afforded 181 as 
a yellow oil (62 mg, 85%); Rf = 0.25 (silica, 10% Et2O, petrol); UV λmax (EtOH/nm) 
230.0; IR νmax/cm
-1
 3295 (alkyne C-H), 3071 (C-H), 2975 (C-H), 2324 (C≡C), 1706 
(C=O), 1588, 1506, 1484, 1449, 1328, 1227 (C-O), 1152, 1081, 1009, 876, 827, 754; 
1
H 
δ/ppm (500 MHz, CDCl3) 1.32 (9H, s, C(CH3)3) 3.08 (1H, s, CCH), 6.70 (2H, d, 4-ClPh 
C3-H and C5-H, J = 8.9 Hz), 6.90 (2H, t, 4-FPh C3-H and C5-H, J = 8.4 Hz), 6.98-7.01 
(2H, m, 4-FPh C2-H and C6-H), 7.19 (2H, d, 4-ClPh C2-H and C6-H, J = 8.9 Hz), 7.25 
(1H, t, C5-H, J = 7.9 Hz), 7.45 (1H, d, br, C6-H, J = 7.9 Hz), 7.50 (1H, dd, C4-H, J = 1.5 
and 7.8 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 28.0, 78.1, 81.7, 83.3, 115.1, 115.3, 117.0, 
118.6, 125.5, 127.1, 127.5, 129.1, 131.9, 133.2, 136.3, 151.7, 153.1, 156.0, 159.3, 
161.3;
 19
F δ/ppm (470 MHz, CDCl3) -116.7; LC-MS (ESI+) m/z = mass not observed; 
HRMS mass not observed 
 
M’) 6-Chloro-1-(4-methoxybenzyl)-1H-indole (206) 
 
 
 
Indole 199 (100 mg, 0.66 mmol), as a solution in DMF (0.5 mL, 1.3 M), was added 
dropwise to a suspension of sodium hydride (60% in mineral oil, 53 mg, 1.32 mmol) in 
DMF (2.5 mL), followed by p-methoxybenzyl chloride (134 µL, 155 mg, 0.99 mmol) at 
room temperature and then heated to 80 
o
C. After 2 h, the reaction was cooled to room 
temperature, quenched with saturated aqueous NH4Cl (3 mL) and partitioned with 
diethyl ether (10 mL) and distilled water (30 mL). The organic layer was washed with 
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distilled water (30 mL) and the aqueous layer was extracted with diethyl ether (2 × 10 
mL). The organic layer was washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Chromatography (silica, 0-10% DCM, petrol) afforded 206 as a 
yellow oil (147 mg, 85%); Rf = 0.49 (silica, 20% DCM, petrol); UV λmax (EtOH/nm) 
278.2 and 227.0; IR νmax/cm
-1
 3099 (C-H), 2999 (C-H), 2930 (C-H), 2834 (C-H), 1609, 
1509, 1460, 1314, 1243 (C-O), 1173, 1098, 1030, 898, 800, 757, 715, 660; 
1
H δ/ppm 
(500 MHz, CDCl3) 3.78 (3H, s, OCH3), 5.21 (2H, s, NCH2Ar), 6.50 (1H, dd, C3-H, J = 
0.7 and 3.2 Hz), 6.85 (2H, d, 4-MeOPh C2-H and C6-H, J = 8.7 Hz), 7.06 (2H, d, 4-
MeOPh C3-H and C5-H, J = 8.7 Hz), 7.07 (1H, dd, C5-H, J = 1.8 and 8.4 Hz), 7.09 (1H, 
d, C2-H, J = 3.2 Hz), 7.29 (1H, s, br, C7-H), 7.53 (1H, d, C4-H, J = 8.4 Hz); 
13
C δ/ppm 
(125 MHz, CDCl3) 49.7, 55.3, 101.8, 109.7, 114.3, 120.2, 121.8, 127.3, 127.6, 128.2, 
128.8, 128.9, 136.6, 159.2;
 
LC-MS (ESI+) m/z = mass not observed 
 
N’) 6-Chloro-1-(4-methoxybenzyl)-3-(2-nitrophenyl)-1H-indole (211) 
 
 
 
 
 
n-Butyllithium (2.5 M in hexanes, 0.13 mL, 0.32 mmol) was added dropwise to a 
solution of indole 210 (100 mg, 0.29 mmol) in THF (2.2 mL, 0.1 M) at 0 
o
C. After 15 
min, aryl fluoride 207 (61 µL, 81.8 mg, 0.58 mmol) was added. After 30 min, the 
reaction was quenched with distilled water (10 mL), warmed to room temperature and 
partitioned with EtOAc (10 mL). The organic layer was washed with brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-30% 
Et2O, petrol) afforded 211 as a brown solid (64 mg, 53%); Rf = 0.22 (silica, 20% Et2O, 
petrol); m.p. 106-108 
o
C; UV λmax (EtOH/nm) 228.0; IR νmax/cm
-1
 3126 (C-H), 3014 (C-
H), 2932 (C-H), 2833 (C-H), 1606, 1509, 1440, 1377, 1342, 1224 (C-O), 1172, 1089, 
1029, 939, 804; 
1
H δ/ppm (500 MHz, CDCl3) 3.79 (3H, s, OCH3), 5.25 (2H, s, NCH2), 
6.88 (2H, d, 4-MeOPh C2-H and C6-H, J = 8.7 Hz), 7.09-7.11 (3H, m, 4-MeOPh C3-H, 
C5-H and indole C5-H), 7.23 (1H, s, indole C2-H), 7.33 (1H, d, indole C7-H, J = 1.6 Hz), 
7.39 (1H, d, indole C4-H, J = 8.5 Hz), 7.42-7.45 (1H, m, 2-NO2Ph C4-H), 7.58-7.62 
(2H, m, 2-NO2Ph C5-H and C6-H), 7.84 (1H, d, 2-NO2Ph C3-H, J = 8.1 Hz); 
13
C δ/ppm 
(125 MHz, CDCl3) 50.0, 55.3, 110.3, 111.8, 114.1, 114.4, 120.0, 121.2, 124.2, 125.6, 
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127.3, 127.8, 128.2, 128.3, 128.5, 128.6, 132.0, 132.5, 136.8, 159.4; LC-MS (ESI+) m/z 
= 393.0 [M+H]
+
; HRMS calcd. for C22H18O3N2
35
Cl [M+H]
+ 
393.1000, found 393.0999 
 
O’) 3-Bromo-4-fluoro-5-nitrobenzoic acid (222) 
 
 
 
 
Conc. H2SO4 (6.5 mL) was added to a mixture of aryl fluoride 221 (1.00 g, 5.40 mmol) 
and NBS (1.44 g, 8.10 mmol) at room temperature and heated to 80 
o
C. After 1 h, the 
reaction was cooled to room temperature, poured into a beaker of ice-cooled 1 M HCl 
(20 mL) and filtered, washing with ice-cooled 1 M HCl (3 × 10 mL). The solid was 
dissolved in EtOAc (10 mL) and partitioned with distilled water (10 mL). The organic 
layer was washed with brine (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo to give 222 as a yellow solid (1.35 g, 95%); Rf = 0.39 (silica, 20% MeOH, 
DCM); m.p. 164-166 
o
C; UV λmax (EtOH/nm) 220.0; IR νmax/cm
-1
 3081 (C-H), 2965 (C-
H), 2810 (C-H), 2643 (br) (O-H), 1688 (C=O), 1604, 1538, 1482, 1415, 1341, 1274, 
1162, 1083, 912, 749, 729; 
1
H δ/ppm (500 MHz, CDCl3) 6.85 (1H, s, br, CO2H), 8.59 
(1H, dd, Ar-H, J = 2.1 and 5.5 Hz), 8.73 (1H, dd, Ar-H, J = 2.1 and 6.4 Hz); 
13
C δ/ppm 
(125 MHz, CDCl3) 112.7, 112.9, 126.47, 126.51, 127.2, 138.2, 138.3, 140.1, 154.6, 
156.8, 167.1; 
19
F δ/ppm (470 MHz, CDCl3) -101.2; LC-MS (ESI+) m/z = 262.0 and 
264.0 [M-H]
-
; HRMS calcd. for C7H2O4N
79
BrF [M-H]
- 
261.9157, found 261.9148 
 
P’) Methyl 3-bromo-4-(4-chlorophenoxy)-5-nitrobenzoate (227) 
 
 
 
 
 
Conc. H2SO4 (0.70 mL) was added to a solution of carboxylic acid 223 (500 mg, 1.34 
mmol) in methanol (3.5 mL) at room temperature in air and heated to 80 
o
C for 2 h. The 
reaction was cooled to room temperature, concentrated to a low volume in vacuo, 
dissolved in EtOAc (10 mL) and washed with saturated aqueous NaHCO3 (2 × 10 mL). 
The aqueous layer was extracted with EtOAc (2 × 10 mL) and the organic layer was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo to give 
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227 as a brown solid (498 mg, 96%); Rf = 0.27 (silica, 10% EtOAc, petrol); m.p. 111-
113 
o
C; UV λmax (EtOH/nm) 228.0; IR νmax/cm
-1
 3066 (C-H), 2948 (C-H), 1725 (C=O), 
1586, 1532, 1483, 1428, 1344, 1289 (C-O), 1192, 1136, 1083, 983, 911, 819, 757, 726, 
688; 
1
H δ/ppm (500 MHz, DMSO-d6) 3.95 (3H, s, CO2CH3), 6.99 (2H, d, 4-MeOPh C3-
H and C5-H, J = 9.0 Hz), 7.43 (2H, d, 4-MeOPh C2-H and C6-H, J = 9.0 Hz), 8.57 (1H, 
d, 3-BrPh C2-H, J = 2.0 Hz), 8.59 (1H, d, 3-BrPh C6-H, J = 2.0 Hz); 
13
C δ/ppm (125 
MHz, DMSO-d6) 53.1, 117.1, 119.6, 126.1, 127.3, 128.8, 129.8, 138.7, 144.2, 147.2, 
155.0, 163.2; LC-MS (ESI+) m/z = mass not observed; HRMS calcd. for 
C14H10O5N
79
Br
35
Cl [M+H]
+ 
385.9425, found 385.9424 
 
Q’) 1-(4-Chlorophenyl)propan-2-one (284) 
 
 
 
Methyllithium (1.6 M in diethyl ether, 5.96 mL, 9.54 mmol) was added dropwise to a 
suspension of CuI (908 mg, 4.77 mmol) in diethyl ether (12.7 mL) at 0 
o
C. After 10 
min, the solution was cooled to -78 
o
C and mixed with acyl chloride 280 (232 µL, 300 
mg, 1.59 mmol), as a solution in diethyl ether (1.59 mL, 1 M). After 45 min, the 
reaction was quenched with methanol (1.0 mL) and warmed to room temperature. After 
2 h, the reaction was partitioned with 66% saturated aqueous NH4Cl and distilled water 
(15 mL) and the organic layer was washed with distilled water (3 × 10 mL). The organic 
layer was washed with brine (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo. Chromatography (silica, 0-10% EtOAc, petrol) afforded 284 as a yellow oil (268 
mg, 100%); Rf = 0.26 (silica, 10% EtOAc, petrol); UV λmax (EtOH/nm) 222.0; IR 
νmax/cm
-1
 2900 (C-H), 1709 (C=O), 1490, 1409, 1356, 1323, 1225, 1159, 1087, 1015, 
831, 781, 713, 672; 
1
H δ/ppm (500 MHz, CDCl3) 2.17 (3H, s, CH3), 3.68 (2H, s, CH2), 
7.13 (2H, d, C2-H and C6-H, J = 8.3 Hz), 7.31 (2H, d, C3-H and C5-H, J = 8.4 Hz); 
13
C 
δ/ppm (125 MHz, CDCl3) 29.4, 50.1, 128.9, 130.8, 132.6, 133.1, 205.7; LC-MS (ESI+) 
m/z = 169.1 [M+H]
+
; HRMS calcd. for C9H10O
35
Cl [M+H]
+ 
169.0415, found 169.0412 
 
R’) Ethyl 4-(4-chlorophenyl)-3-oxobutanoate (281) 
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Pyridine (1.10 mL, 1.08 g, 13.6 mmol) was added dropwise over 5-7 min to a solution 
of Meldrum’s acid (1.00 g, 6.94 mmol) in DCM (6 mL) at 0 oC, followed by dropwise 
addition over 5-7 min of acyl chloride 280 (1.01 mL, 1.31 g, 6.93 mmol). After 1 h, the 
solution was warmed to room temperature and stirred for 2 h, then partitioned with 2 M 
HCl (20 mL). The aqueous layer was extracted with DCM (4 × 10 mL) and organic 
layers were washed with brine (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo, then dissolved in ethanol (22 mL) and heated to 100 
o
C. After 2 h, the reaction 
was cooled to room temperature and concentrated in vacuo. Chromatography (silica, 0-
20% EtOAc, petrol) afforded 281 as a yellow oil (1.268 g, 76%); Rf = 0.50 (silica, 20% 
EtOAc, petrol); UV λmax (EtOH/nm) 221.4; IR νmax/cm
-1
 2982 (C-H), 2935 (C-H), 1739 
(C=O), 1715 (C=O), 1651, 1491, 1408, 1313, 1231, 1193, 1149, 1088, 1028, 1016, 936, 
823, 793, 677; 
1
H δ/ppm (500 MHz, CDCl3) 1.27 (3H, t, CO2CH2CH3), 3.46 (1.6H, s, 
keto ArCH2), 3.47 (0.3H, s, enol ArCH2), 3.82 (1.7H, s, keto COCH2CO2Et), 4.18 (2H, 
q, CO2CH2CH3, J = 7.1 Hz), 4.90 (0.1H, s, enol COHCHCO2Et), 7.14 (1.6H, d, keto C2-
H and C6-H, J = 8.4 Hz), 7.19 (0.3H, d, enol C2-H and C6-H, J = 8.3 Hz), 7.29 (0.3H, d, 
enol C3-H and C5-H, J = 8.5 Hz), 7.33 (1.6H, d, keto C3-H and C5-H, J = 8.4 Hz); 
13
C 
δ/ppm (125 MHz, CDCl3) 14.1, 14.2, 40.7, 48.5, 49.1, 60.2, 61.6, 90.4, 128.8, 129.0, 
130.6, 131.0, 131.6, 133.0, 133.4, 134.1, 167.0, 172.6, 176.3, 199.9; LC-MS (ESI+) m/z 
= 241.2 [M+H]
+
 and 239.1 [M-H]
-
; HRMS calcd. for C12H14O3
35
Cl [M+H]
+ 
241.0626, 
found 241.0624 
 
S’) Ethyl 4-(4-chlorophenyl)-2-(2-(4’-fluorophenyl)-2-oxoethyl)-3-oxobutanoate 
(282a) 
 
 
 
 
Sodium hydride (60% in mineral oil, 108 mg, 2.70 mmol) was added to a solution of β-
keto ester 281 (500 mg, 2.08 mmol) in THF (1.3 mL) at 0 
oC. After 20 min, 2’-bromo-
4-fluoroacetophenone (497 mg, 2.29 mmol), as a solution in THF (1.0 mL, 2.3 M), was 
added dropwise over 5 min and the reaction was stirred at 0 
o
C for 10 min, then warmed 
to room temperature. After 3 h, the reaction was cooled to 0 
o
C, quenched with distilled 
water (3 mL) and partitioned with EtOAc (10 mL). The organic layer was washed with 
brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography 
(silica, 0-20% EtOAc, petrol) afforded 282a as a colourless solid (395 mg, 51%); Rf = 
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0.17 (silica, 10% EtOAc, petrol); m.p. 53-56 
o
C; UV λmax (EtOH/nm) 244.8 and 226.0; 
IR νmax/cm
-1
 3070 (C-H), 2980 (C-H), 2931 (C-H), 2904 (C-H), 1730 (C=O), 1712 
(C=O), 1679 (C=O), 1594, 1507, 1491, 1406, 1342, 1300, 1249, 1229, 1190, 1157, 
1089, 1039, 1014, 985, 837, 808, 735, 683; 
1
H δ/ppm (500 MHz, CDCl3) 1.29 (3H, t, 
CO2CH2CH3, 7.2 Hz), 3.51 (1H, dd, CH2COAr, J = 4.8 and 18.4 Hz), 3.73 (1H, dd, 
CH2COAr, J = 9.0 and 18.4 Hz), 4.06 (1H, d, ArCH2CO, J = 17.0 Hz), 4.12 (1H, d, 
ArCH2CO, J = 17.0 Hz), 4.22 (2H, q, CO2CH2CH3, J = 7.2 Hz), 4.29 (1H, dd, 
COCHCO2Et, J = 4.7 and 9.0 Hz), 7.13 (2H, t, 4-ClPh C3-H and C5-H, J = 8.6 Hz), 7.18 
(2H, d, 4-FPh C2-H and C6-H, J = 8.5 Hz), 7.32 (2H, d, 4-FPh C3-H and C5-H, J = 8.5 
Hz), 7.99 (2H, dd, 4-ClPh C2-H and C6-H, J = 5.4 and 9.0 Hz); 
13
C δ/ppm (125 MHz, 
CDCl3) 14.0, 14.1, 37.7, 49.2, 52.6, 62.0, 62.1, 115.8, 115.9, 128.7, 129.0, 130.6, 130.8, 
130.9, 131.2, 132.0, 132.4, 133.1, 165.0, 167.1, 168.6, 195.6, 201.8; 
19
F δ/ppm (470 
MHz, CDCl3) -104.2, -108.3; LC-MS (ESI+) m/z = 375.2 [M-H]
-
; HRMS calcd. for 
C20H19O4
35
ClF [M+H]
+ 
377.0950, found 377.0951 
 
T’) 3-Bromo-4-(4-chlorophenoxy)-5-nitrobenzylmethanesulfonate (233) 
 
 
 
Methanesulfonic anhydride (73.2 mg, 0.42 mmol), as a solution in DCM (0.5 mL, 0.84 
M), was added to a solution of alcohol 232 (100 mg, 0.28 mmol) and triethylamine (59 
µL, 42.5 mg, 0.42 mmol) in DCM (0.5 mL) at 0 
o
C and warmed to room temperature. 
After 1 h, the reaction was washed with 20% 1 M HCl, distilled water (2 × 10 mL) and 
the aqueous layer was extracted with EtOAc (8 mL). The organic layer was washed 
with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 10-30% EtOAc, petrol) afforded 233 as a brown solid (66 mg, 
54%); Rf = 0.17 (silica, 30% EtOAc, petrol); m.p. 112-114 
o
C; UV λmax (EtOH/nm) 
222.4; IR νmax/cm
-1
 3077 (C-H), 2936 (C-H), 1589, 1536, 1484, 1341 (S=O asym. 
stretch), 1262, 1166 (S=O sym. stretch), 1088, 972, 902, 816, 752, 727;
 1
H δ/ppm (500 
MHz, CDCl3) 3.13 (3H, s, SO2CH3), 5.27 (2H, s, ArCH2), 6.77 (2H, d, 4-ClPh C3-H and 
C5-H, J = 9.0 Hz), 7.28 (2H, d, 4-ClPh C2-H and C6-H, J = 9.1 Hz), 7.96-7.97 (2H, m, 
3-BrPh C2-H and C6-H); 
13
C δ/ppm (125 MHz, CDCl3) 38.3, 67.5, 116.7, 120.8, 124.5, 
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128.5, 129.8, 133.2, 137.8, 144.8, 145.6, 155.2; LC-MS (ESI+) m/z = mass not 
observed; HRMS mass not observed 
 
U’) 1-Bromo-5-(chloromethyl)-2-(4-chlorophenoxy)-3-nitrobenzene (235) 
 
 
 
 
 
Methanesulfonyl chloride (48 µL, 71 mg, 0.62 mmol) was added to a solution of alcohol 
232 (200 mg, 0.56 mmol) and triethylamine (117 µL, 85 mg, 0.84 mmol) in DCM (2.0 
mL) at 0 
o
C and warmed to room temperature. After 30 min, the reaction was washed 
with 0.3 M HCl (15 mL) and the aqueous layer was extracted with DCM (4 × 6 mL). 
The organic layer was dried (MgSO4), filtered and concentrated in vacuo.  
Chromatography (silica, 0-30% DCM, petrol) afforded 235 as a yellow solid (102 mg, 
48%); Rf = 0.26 (silica, 30% DCM, petrol); m.p. 77-79 
o
C; UV λmax (EtOH/nm) 223.2; 
IR νmax/cm
-1
 3072 (C-H), 2964 (C-H), 2922 (C-H), 2873 (C-H), 1523, 1483, 1461, 
1352, 1259, 1193, 1164, 1088, 1009, 953, 891, 826, 795, 704;
 1
H δ/ppm (500 MHz, 
CDCl3) 4.61 (2H, s, CH2Cl), 6.78 (2H, d, 4-ClPh C3-H and C5-H, J = 9.1 Hz), 7.27 (2H, 
d, 4-ClPh C2-H and C6-H, J = 9.1 Hz), 7.94-7.97 (2H, m, 1-BrPh C2-H and C6-H); 
13
C 
δ/ppm (125 MHz, CDCl3) 43.4, 116.7, 120.5, 124.7, 128.4, 129.8, 136.7, 138.1, 144.6, 
144.9, 155.3; LC-MS (ESI+) m/z = mass not observed; HRMS calcd. for 
C13H9O3N
79
Br
35
Cl2 [M+H]
+ 
375.9137, found 375.9140 
 
V’) 2-(3-Bromo-4-(4-chlorophenoxy)-5-nitrophenyl)acetonitrile (234) 
 
 
 
 
 
TMS-cyanide (53 µL, 42 mg, 0.42 mmol) was added to a solution of mesylate 233 (122 
mg, 0.28 mmol) in acetonitrile (2.2 mL) at 0 
o
C, followed by dropwise addition of 
TBAF (1 M in THF, 0.42 mL, 0.42 mmol) and the reaction was warmed to room 
temperature. After 90 min, the reaction was quenched with distilled water (10 mL), 
partitioned with EtOAc (10 mL) and the organic layer was washed with brine (10 mL), 
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dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-50% 
Et2O, petrol) afforded 234 as a brown solid (29.5 mg, 29%); Rf = 0.40 (silica, 30% 
EtOAc, petrol); m.p. 112-114 
o
C; UV λmax (EtOH/nm) 222.6; IR νmax/cm
-1
 3090 (C-H), 
2919 (C-H), 2854 (C-H), 2253 (C≡N), 1529, 1483, 1349, 1258, 1200 (C-O), 1162, 
1087, 1008, 824, 794, 725;
 1
H δ/ppm (500 MHz, CDCl3) 3.87 (2H, s, CH2CN), 6.77 
(2H, d, 4-ClPh C3-H and C5-H, J = 9.1 Hz), 7.29 (2H, d, 4-ClPh C2-H and C6-H, J = 9.1 
Hz), 7.91-7.93 (2H, m, 3-BrPh C2-H and C6-H); 
13
C δ/ppm (125 MHz, CDCl3) 22.8, 
115.8, 116.7, 121.2, 124.3, 128.6, 129.3, 129.8, 137.6, 144.8, 145.1, 155.2; LC-MS 
(ESI+) m/z = -365.0 and -367.0 [M-H]
-
; HRMS calcd. for C14H9O3N2
79
Br
35
Cl [M+H]
+ 
366.9480, found 366.9480 
 
W’) 1-Bromo-3-(4-chlorophenyl)propan-2-one (286) 
 
 
 
N-bromosuccinimide (683 mg, 3.84 mmol) was added portionwise to a solution of 
ketone 284 (216 mg, 1.28 mmol) and pTSA (365 mg, 1.92 mmol) in acetonitrile (12.8 
mL) at room temperature and heated to 100 
o
C. After 3 h, the reaction was concentrated 
in vacuo, dissolved with EtOAc (10 mL) and washed with distilled water (2 × 10 mL) 
and 1 M HCl (10 mL). The aqueous layer was extracted with EtOAc (10 mL) and the 
organic layer was washed with brine (10 mL), dried (MgSO4), filtered and concentrated 
in vacuo. Crude material was taken up in glacial acetic acid (0.6 mL) and acetone (1.0 
mL) before addition of HBr (45% in acetic acid, 0.1 mL) at room temperature. After 18 
h, the reaction was quenched with saturated aqueous NaHCO3 (10 mL) and partitioned 
with EtOAc (10 mL). The organic layer was washed with saturated aqueous NaHCO3 (2 
× 10 mL) and the aqueous layer was extracted with EtOAc (10 mL). The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-10% 
EtOAc, petrol) afforded 286 as a brown solid (175 mg, 55%); Rf = 0.30 (silica, 10% 
EtOAc, petrol); m.p. 44-46 
o
C; UV λmax (EtOH/nm) 220.4; IR νmax/cm
-1
 3431 (enol O-
H), 2990 (C-H), 2942 (C-H), 2881 (C-H), 1720 (C=O), 1487, 1381, 1337, 1261, 1178, 
1088, 1047, 1014, 807, 718, 700;
 1
H δ/ppm (500 MHz, CDCl3) 3.91 (2H, s, COCH2Br), 
3.94 (2H, s, ArCH2), 7.17 (2H, d, C2-H and C6-H, J = 8.5 Hz), 7.33 (2H, d, C3-H and 
C5-H, J = 8.5 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 33.4, 45.8, 129.1, 130.8, 131.5, 133.5, 
199.0; LC-MS (ESI+) m/z = mass not observed; HRMS calcd. for C9H9O
35
Cl
79
Br 
[M+H]
+ 
246.9520, found 246.9519 
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X’) Methyl 2-(3-nitrophenyl)acetate (240) 
 
 
 
 
Thionyl chloride (440 µL, 715 mg, 6.00 mmol) was added dropwise to a solution of 3-
nitrobenzoic acid (200 mg, 1.20 mmol) (238) in THF (1.2 mL, 1 M) and DMF (2 drops) 
at 0 
o
C and warmed to room temperature. After 5 h, the reaction was concentrated in 
vacuo, dissolved in 60% THF, acetonitrile (1.9 mL), mixed with triethylamine (251 µL, 
182 mg, 1.80 mmol) and cooled to 0 
o
C before treating with TMS-diazomethane (2 M in 
hexanes, 0.6 mL, 1.20 mmol). After 2 h, the reaction was quenched with glacial acetic 
acid (0.5 mL) and distilled water (2.0 mL) and partitioned with diethyl ether (8 mL) and 
distilled water (8 mL). The aqueous layer was extracted with diethyl ether (10 mL) and 
the organic layer was washed with saturated aqueous NaHCO3 (10 mL), brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo. Crude material was dissolved in 
methanol (4.5 mL) and treated with a solution of PhCO2Ag (212 mg, 0.92 mmol) in 
triethylamine (377 µL, 273 mg, 2.7 mmol, 2.4 M) dropwise at room temperature. After 
24 h, the reaction was concentrated in vacuo, dissolved in EtOAc (10 mL), filtered 
through celite and washed with saturated aqueous NaHCO3 (10 mL), 1 M HCl (10 mL), 
brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography 
(silica, 0-20% EtOAc, petrol) afforded 240 as a yellow oil (50 mg, 27%); Rf = 0.26 
(silica, 20% EtOAc, petrol); UV λmax (EtOH/nm) 258.8; IR νmax/cm
-1 
2954 (C-H), 1733 
(C=O), 1524, 1435, 1346, 1224, 1159, 1098, 1006, 900, 805, 712, 672;
 1
H δ/ppm (500 
MHz, CDCl3) 3.73 (3H, s, CO2CH3), 3.75 (2H, s, ArCH2), 7.52 (1H, t, C5-H, J = 7.9 
Hz), 7.63 (1H, d, C6-H, J = 7.6 Hz), 8.15 (1H, d, C4-H, J = 8.4 Hz), 8.17 (1H, s, C2-H); 
13
C δ/ppm (125 MHz, CDCl3) 40.5, 52.4, 122.3, 122.4, 129.5, 135.6, 135.8, 148.4, 
170.8; LC-MS (ESI+) m/z = -194.0 [M-H]
-
; HRMS calcd. for C9H10O4N [M+H]
+ 
196.0604, found 196.0603 
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Y’) Di-tert-butyl (2-(4-chlorophenoxy)-4’-methoxy-[1,1’-biphenyl]-3-
yl)dicarbamate (259) 
 
 
 
 
 
Tin(II) chloride dihydrate (882 mg, 3.91 mmol) was added to a solution of nitro 251 
(278 mg, 0.78 mmol) in ethanol (7.8 mL, 0.1 M) at room temperature and heated to 70 
o
C for 20 min. The reaction was quenched with saturated aqueous NaHCO3 (10 mL), 
filtered through celite and partitioned with EtOAc (20 mL). The organic layer was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo, then 
dissolved in acetonitrile (1.6 mL), mixed with DMAP (48 mg, 0.39 mmol) followed by 
Boc2O (504 mg, 2.31 mmol) in a sealed vial at room temperature and heated to 50 
o
C. 
After 3 h, the reaction was quenched with saturated aqueous NaHCO3 (10 mL), 
partitioned with EtOAc (10 mL) and the organic layer was washed with saturated 
aqueous NaHCO3 (2 × 10 mL). The aqueous layer was extracted with EtOAc (10 mL) 
and the organic layer was washed with brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Chromatography (silica, 0-20% EtOAc, petrol) afforded 259 as a 
white solid (289 mg, 70%); Rf = 0.17 (silica, 70% DCM, petrol); m.p. 120-122 
o
C; UV 
λmax (EtOH/nm) 262.6 and 228.4; IR νmax/cm
-1
 3075 (C-H), 2973 (C-H), 2936 (C-H), 
2851 (C-H), 1777 (C=O), 1707, 1608, 1516, 1484, 1454, 1366, 1279, 1249 (C-O), 1152, 
1099, 1033, 826, 780;
 1
H δ/ppm (500 MHz, CDCl3) 1.36 (18H, s, (C(CH3)3)2), 3.78 (3H, 
s, OCH3), 6.60 (2H, d, Ar-H, J = 9.0 Hz), 6.83 (2H, d, Ar-H, J = 8.8 Hz), 7.02 (2H, d, 
Ar-H, J = 9.0 Hz), 7.18 (1H, dd, Ar-H, J = 1.6 and 7.8 Hz), 7.29 (1H, t, 3-(Boc)2NPh 
C5-H, J = 7.9 Hz), 7.36-7.39 (3H, m, Ar-H); 
13
C δ/ppm (125 MHz, CDCl3) 27.8, 55.2, 
82.6, 113.7, 117.2, 125.5, 126.7, 128.6, 128.9, 129.3, 130.0, 130.2, 133.9, 136.1, 147.4, 
150.9, 156.0, 159.1; LC-MS (ESI+) m/z = mass not observed; HRMS mass not observed 
  
308 
 
Z’) Tert-butyl (2-(4-chlorophenoxy)-4’-methoxy-[1,1’-biphenyl]-3-yl)carbamate 
(253) 
 
 
 
 
Sodium hydroxide (200 mg, 5.00 mmol) was added to a solution of dicarbamate 259 
(270 mg, 0.51 mmol) in 33% THF, methanol (2.7 mL) at room temperature. After 1 h, 
the reaction was partitioned with distilled water (8 mL) and EtOAc (8 mL) and the 
organic layer was washed with distilled water (10 mL). The aqueous layer was extracted 
with EtOAc (10 mL) and the organic layer was washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give 253 as a white solid (170 mg, 
78%); Rf = 0.39 (silica, 10% EtOAc, petrol); m.p. 150-152 
o
C; UV λmax (EtOH/nm) 
233.8; IR νmax/cm
-1
 3439 (N-H), 2976 (C-H), 2932 (C-H), 2835 (C-H), 1728 (C=O), 
1608, 1522, 1482, 1427, 1401, 1367, 1275, 1222 (C-O), 1147, 1089, 1046, 861, 825, 
786, 750;
 1
H δ/ppm (500 MHz, CDCl3) 1.50 (9H, s, C(CH3)3), 3.79 (3H, s, OCH3), 6.62 
(2H, d, 4-ClPh C3-H and C5-H, J = 9.0 Hz), 6.81 (3H, d, Ar-H, J = 8.8 Hz), 7.06-7.09 
(3H, m, 4-ClPh C2-H, C6-H and Ar-H), 7.30 (1H, t, 3-BocHNPh C5-H, J = 8.1 Hz), 7.33 
(2H, d, Ar-H, J = 8.9 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 28.3, 55.2, 80.9, 113.6, 116.6, 
118.6, 124.7, 126.2, 127.0, 129.3, 129.4, 130.0, 132.6, 135.0, 139.9, 152.7, 155.8, 
158.9; LC-MS (ESI+) m/z = 424.3 [M-H]
-
; HRMS calcd. for C24H25O4N
35
Cl [M+H]
+ 
426.1467, found 426.1468 
 
A’’) N-((4-Fluorobenzyl)carbamothioyl)benzamide (278) 
 
 
 
Benzylamine 277 (350 µL, 383 mg, 3.06 mmol) was added dropwise over 1 min to a 
solution of benzoyl isothiocyanate (412 µL, 500 mg, 3.06 mmol) in DCM (6.0 mL, 0.5 
M) at 0 
o
C and warmed to room temperature. After 1 h, the reaction was cooled to 0 
o
C, 
quenched with distilled water (10 mL) and the layers were separated. The aqueous layer 
was extracted with DCM (2 × 10 mL) and the organic layer was washed with brine (10 
mL), dried (MgSO4), filtered and concentrated in vacuo. Chromatography (silica, 0-
20% EtOAc, petrol) afforded 278 as a yellow solid (464 mg, 53%); Rf = 0.32 (silica, 
20% EtOAc, petrol); m.p. 99-102 
o
C; UV λmax (EtOH/nm) 242.4; IR νmax/cm
-1
 3271 (N-
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H), 3173 (N-H), 3035 (C-H), 2936 (C-H), 1677 (C=O), 1599, 1501 (C=S), 1427, 1307 
(C=S), 1242, 1215, 1151, 1082, 1019, 953, 934, 885, 839, 766, 738, 701; 
1
H δ/ppm (500 
MHz, DMSO-d6) 4.87 (2H, d, ArCH2, J = 5.7 Hz), 7.20 (2H, t, 4-FPh C2-H and C6-H, J 
= 8.9 Hz), 7.46 (2H, dd, 4-FPh C3-H and C5-H, J = 5.7 and 8.4 Hz), 7.52 (2H, t, Ph C3-
H and C5-H, J = 7.8 Hz), 7.65 (1H, t, Ph C4-H, J = 7.4 Hz), 7.94 (2H, d, Ph C2-H and 
C6-H, J = 7.7 Hz),  11.20 (1H, t, CSNHCH2, J = 5.1 Hz), 11.40 (1H, s, CONHCS); 
13
C 
δ/ppm (125 MHz, DMSO-d6) 47.8, 115.6, 115.8, 128.9, 129.0, 130.2, 130.3, 132.7, 
133.5, 134.12, 134.15, 160.9, 162.9, 168.5, 181.0; 
19
F δ/ppm (470 MHz, DMSO-d6) -
115.4; LC-MS (ESI+) m/z = 289.2 [M+H]
+
 and 287.1 [M-H]
-
; HRMS calcd. for 
C15H12ON2FS [M-H]
- 
287.0660, found 287.0653 
 
B’’) 1-(4-Fluorobenzyl)thiourea (279) 
 
 
 
Anhydrous K2CO3 (449 mg, 3.25 mmol) was added to a solution of benzamide 278 (468 
mg, 1.62 mmol) in methanol (21 mL) at room temperature. After 18 h, the reaction was 
concentrated in vacuo, partitioned with EtOAc (10 mL) and distilled water (2 × 20 mL) 
and the aqueous layer was extracted with EtOAc (10 mL). The organic layer was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Chromatography (silica, 0-20% EtOAc, DCM) afforded 279 as a white solid (143 mg, 
48%); Rf = 0.22 (silica, 20% EtOAc, petrol); m.p. 119-121 
o
C; UV λmax (EtOH/nm) 
244.2; IR νmax/cm
-1
 3411 (secondary N-H), 3274 (primary N-H), 3177 (primary N-H), 
3057 (C-H), 3016 (C-H), 1623, 1603, 1539, 1505 (C=S), 1440, 1417, 1355, 1314 (C=S), 
1217, 1154, 1114, 1090, 1016, 960, 930, 845, 820, 730; 
1
H δ/ppm (500 MHz, DMSO-
d6) 4.61 (2H, s, br, CH2), 7.10 (2H, s, br, NH2), 7.17 (2H, t, C3-H and C5-H, J = 8.9 Hz), 
7.32-7.35 (2H, m, C2-H and C6-H), 7.98 (1H, s, br, NH); 
13
C δ/ppm (125 MHz, DMSO-
d6) 47.1, 115.4, 115.5, 129.8, 136.0, 160.7, 162.7, 183.9; 
19
F δ/ppm (470 MHz, DMSO-
d6) -116.0; LC-MS (ESI+) m/z = 185.1 [M+H]
+
 and 183.1 [M-H]
-
; HRMS calcd. for 
C8H10N2FS [M+H]
+ 
185.0543, found 185.0542 
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C’’) Methyl 5-amino-6-(4-chlorophenoxy)-4’-methoxy-[1,1’-biphenyl]-3-
carboxylate (246) 
 
 
 
 
 
Zinc powder (316 mg, 4.8 mmol) was added to a solution of nitro 245 (200 mg, 0.48 
mmol) in glacial acetic acid (10 mL, 0.05 M) at room temperature and stirred in air for 1 
h. The reaction was filtered through celite, washing with methanol (20 mL) and 
concentrated in vacuo, then partitioned with EtOAc (10 mL) and 2 M NaOH (2 × 10 
mL). The aqueous layer was extracted with EtOAc (10 mL) and the organic layer was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo to give 
246 as a brown solid (193 mg, 99%); Rf = 0.15 (silica, 20% EtOAc, petrol); m.p. 60-62 
o
C; UV λmax (EtOH/nm) 327.4, 249.6 and 227.2; IR νmax/cm
-1
 3463 (N-H), 3369 (N-H), 
2950 (C-H), 2836 (C-H), 1709 (C=O), 1609, 1513, 1478, 1434, 1358, 1210 (C-O), 
1179, 1088, 1006, 929, 874, 824, 768; 
1
H δ/ppm (500 MHz, DMSO-d6) 3.72 (3H, s, 
ArOCH3), 3.84 (3H, s, CO2CH3), 5.33 (2H, s, NH2), 6.69 (2H, d, 4-ClPh C3-H and C5-
H, J = 9.0 Hz), 6.88 (2H, d, 4-MeOPh C2-H and C6-H, J = 8.7 Hz), 7.18 (1H, d, Ar-H, 
2.1 Hz), 7.21 (2H, d, 4-ClPh C2-H and C6-H, J = 9.0 Hz), 7.36 (2H, d, 4-MeOPh C3-H 
and C5-H, J = 8.7 Hz), 7.45 (1H, d, Ar-H, J = 2.1 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 
52.2, 55.2, 113.6, 116.1, 116.3, 121.9, 127.0, 128.0, 129.1, 129.5, 130.0, 135.8, 140.3, 
141.6, 155.2, 159.1, 166.8; LC-MS (ESI+) m/z = 384.3 [M+H]
+
; HRMS calcd. for 
C21H19O4N
35
Cl [M+H]
+ 
384.0997, found 384.1000 
 
3’-Amino-[1,1’-biphenyl]-3,4-diol (117c) 
 
 
 
 
General Procedure B: Using 4-bromocatechol (110 mg, 0.58 mmol) and boronic acid 
116 (112 mg, 0.81 mmol), chromatography (silica, 60% EtOAc, hexane) afforded 117c 
as a dark brown solid (55 mg, 47%); Rf = 0.24 (silica, 60% EtOAc, hexane); m.p. 143 
oC (decomposed); UV λmax (EtOH/nm) 295.0 and 215.0; IR νmax/cm
-1
 3366 (N-H), 3301 
(N-H), 3054 (C-H), 2934 (C-H), 2552 (br) (O-H), 1584, 1532, 1489, 1426, 1392, 1310, 
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1263, 1206, 1117, 773, 694; 
1H δ/ppm (500 MHz, MeOH-d4) 6.66 (1H, dd, Ar-H, J = 
0.9 and 2.3 Hz), 6.81 (1H, d, Ar-H, J = 8.2 Hz), 6.87-6.89 (1H, m, Ar-H), 6.91-6.93 
(2H, m, Ar-H), 7.03 (1H, d, Ar-H, J = 2.2 Hz), 7.13 (1H, t, Ar-H, 7.8 Hz); 
13C δ/ppm 
(125 MHz, MeOH-d4) 114.8, 115.0, 115.2, 115.6, 116.5, 117.8, 118.2, 119.4, 130.3, 
135.0, 143.5, 145.9, 146.4, 148.8; LC-MS (ESI+) m/z = 202.2 [M+H]
+ 
 
N-(3’-Amino-[1,1’-biphenyl]-4-yl)-1,1,1-trifluoromethanesulfonamide (117d) 
 
 
 
 
General Procedure B: Using aryl bromide 120 and boronic acid 116 (89 mg, 0.65 
mmol), chromatography (silica, 40% EtOAc, hexane) afforded 117d as a brown solid 
(93 mg, 64%); Rf = 0.22 (silica, 40% EtOAc, hexane); m.p. 165-170 
oC; UV λmax 
(EtOH/nm) 243.0; IR νmax/cm
-1
 3414 (aniline N-H), 3345 (aniline N-H), 2655 (br) 
(sulfonamido N-H), 1515, 1449, 1365, 1225, 1193, 1140, 969, 795, 731, 700; 
1H δ/ppm 
(500 MHz, MeOH-d4) 6.73-6.75 (1H, m, Ar-H), 6.95-6.97 (1H, m, Ar-H), 6.99-7.00 
(1H, m, Ar-H), 7.20 (1H, t, Ar-H, J = 7.7 Hz), 7.32-7.35 (2H, m, Ar-H), 7.59-7.62 (2H, 
m, Ar-H); 
13C δ/ppm (125 MHz, MeOH-d4) 115.0, 115.9, 118.0, 124.2, 128.8, 130.6, 
136.0, 141.2, 149.1; LC-MS (ESI+) m/z = 317.2 [M+H]
+ 
 
N-(4’-Amino-[1,1’-biphenyl]-4-yl)-1,1,1-trifluoromethanesulfonamide (117e) 
 
 
 
 
General Procedure B: Using aryl bromide 120 and 4-aminophenylboronic acid pinacol 
ester (143 mg, 0.65 mmol), chromatography (silica, 30-50% EtOAc, hexane) afforded 
117e as a yellow/brown solid (104 mg, 75%); Rf = 0.26 (silica, 40% EtOAc, hexane); 
m.p. 136 
oC (decomposed); UV λmax (EtOH/nm) 287.5; IR νmax/cm
-1
 3443 (amino N-H), 
3361 (amino N-H), 3034 (C-H), 2798 (br) (sulfonamido N-H), 1626, 1500, 1378, 1198, 
1184, 1140, 1009, 955, 817; 
1H δ/ppm (500 MHz, MeOH-d4) 6.80-6.82 (2H, m, Ar-H), 
7.29-7.30 (2H, m, Ar-H), 7.39-7.41 (2H, m, Ar-H), 7.55-7.56 (2H, m, Ar-H); 
13C δ/ppm 
(125 MHz, MeOH-d4) 25.0, 116.8, 124.5, 127.9, 128.6, 141.1; LC-MS (ESI+) m/z = 
317.2 [M+H]
+ 
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N-(3’-((4-Fluorobenzyl)amino)-[1,1’-biphenyl]-4-yl)methanesulfonamide (118f) 
 
 
 
 
General procedure B: Using boronic ester 123 (40 mg, 0.12 mmol) and N-(4-
bromophenyl)methanesulfonamide (46 mg, 0.18 mmol), chromatography (silica, 20-
40% EtOAc, hexane) yielded 118f as a brown solid (43 mg, 95%); Rf = 0.28 (silica, 
40% EtOAc, hexane); m.p. 117-119 
oC; UV λmax (EtOH/nm) 316.5 and 254.0; IR 
νmax/cm
-1
 3413 (secondary amine N-H), 3240 (sulfonamide N-H), 2932 (C-H), 1604, 
1509, 1315 (S=O asym. stretch), 1222, 1146 (S=O sym. stretch), 980, 829, 766, 698; 
1
H 
δ/ppm (500 MHz, CDCl3) 3.04 (3H, s, NHSO2CH3), 4.36 (3H, m, CH2 and amino NH), 
6.44 (1H, s, sulfonamido NH), 6.63 (1H, dd, Ar-H, J = 1.8 and 8.0 Hz), 6.80 (1H, m, 
Ar-H), 6.92 (1H, m, Ar-H), 7.02-7.06 (2H, m, Ar-H), 7.23-7.26 (3H, m, Ar-H), 7.34-
7.37 (2H, m, Ar-H), 7.51-7.53 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 39.5, 48.4, 
113.1, 115.5, 115.7, 121.1, 128.4, 129.4, 129.5, 129.9, 134.0, 135.8, 138.7, 141.3; LC-
MS (ESI+) m/z = 371.3 [M+H]
+
; HRMS calcd. for C20H20O2N2FS [M+H]
+
 371.1224, 
found 371.1227; Analytical HPLC: 99.7%  
 
N-(4-Fluorobenzyl)-[1,1’-biphenyl]-3,4’-diamine (118g) 
 
 
 
 
General procedure B: Using boronic ester 123 (44 mg, 0.13 mmol) and aniline 119 
(33 mg, 0.190 mmol), chromatography (silica, 15-30% EtOAc, hexane) yielded 118g as 
a yellow solid (30 mg, 76%); Rf = 0.22 (silica, 30% EtOAc, hexane); m.p. 94-97 
o
C; UV 
λmax (EtOH/nm) 258.5; IR νmax/cm
-1
 3411 (primary N-H), 3371 (primary N-H), 3028 
(secondary N-H), 2852 (C-H), 1599, 1503, 1327, 1279, 1218, 1183, 1154, 824, 774, 
695; 
1H δ/ppm (500 MHz, CDCl3) 3.87 (3H, s, br, NH), 4.35 (2H, s, CH2), 6.55(1H, dd, 
Ar-H, J = 2.2 and 8.0 Hz), 6.71-6.74 (2H, m, Ar-H), 6.79-6.80 (1H, m, Ar-H), 6.90-6.92 
(1H, m, Ar-H), 6.99-7.06 (2H, m, Ar-H), 7.20 (1H, t, Ar-H, J = 7.8 Hz), 7.34-7.37 (4H, 
m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 47.8, 111.1, 111.2, 115.3, 115.4, 115.6, 116.4, 
128.0, 129.1, 129.2, 129.6, 132.0, 135.1, 142.4, 145.8, 148.1, 161.1, 163.1; LC-MS 
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(ESI+) m/z = 293.3 [M+H]
+
; HRMS calcd. for C19H18N2F [M+H]
+
 293.1449, found 
293.1451; Analytical HPLC: 98.0%  
 
N-(4-Fluorobenzyl)-[1,1’-biphenyl]-3,3’-diamine (118h) 
 
 
 
 
General procedure B: Using boronic ester 123 (40 mg, 0.12 mmol) and 3-
bromoaniline (20.0 µL, 31.5 mg, 0.18 mmol), chromatography (silica, 20-30% EtOAc, 
hexane) yielded 118h as a dark yellow oil (28 mg, 78%); Rf = 0.21 (silica, 30% EtOAc, 
petrol); UV λmax (EtOH/nm) 308.5 and 232.0; IR νmax/cm
-1
 3413 (br) (primary and 
secondary N-H), 3372 (primary N-H), 3042 (C-H), 2848 (C-H), 1597, 1577, 1507, 
1486, 1216, 1154, 856, 826, 771, 695; 
1H δ/ppm (500 MHz, CDCl3) 3.88 (3H, s, br, 
NH), 4.35 (2H, s, CH2), 6.60 (1H, dd, Ar-H, J = 2.4 and 8.1 Hz), 6.66 (1H, dd, Ar-H, J 
= 2.3 and 7.9 Hz), 6.81-6.82 (1H, m, Ar-H), 6.85-6.86 (1H, m, Ar-H), 6.92-6.95 (2H, m, 
Ar-H), 7.02-7.05 (2H, m, Ar-H), 7.20 (1H, t, Ar-H, J = 7.8 Hz), 7.22 (1H, t, Ar-H, J = 
7.8 Hz), 7.34-7.37 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 47.8, 111.9, 112.0, 
114.1, 114.2, 115.4, 115.6, 117.1, 117.8, 129.1, 129.2, 129.55, 129.56, 134.91, 134.94, 
142.6, 142.9, 146.4, 148.0, 161.1, 163.1; LC-MS (ESI+) m/z = 293.3 [M+H]
+
; HRMS 
calcd. for C19H18N2F [M+H]
+
 293.1449, found 293.1451; Analytical HPLC: 97.9%  
 
N-(4-Fluorobenzyl)-3’-methoxy-[1,1’-biphenyl]-3-amine (118j) 
 
 
 
 
General procedure B: Using boronic ester 123  (40 mg, 0.12 mmol) and 3-
bromoanisole (23.2 µL, 34 mg, 0.18 mmol), chromatography (silica, 5% EtOAc, 
hexane) yielded 118j as a brown oil (25 mg, 77%); Rf = 0.22 (silica, 10% EtOAc, 
petrol); UV λmax (EtOH/nm) 241.5; IR νmax/cm
-1
 3416 (N-H), 2835 (C-H), 1599, 1576, 
1508, 1486, 1221, 1163, 1038, 824, 773, 697; 
1H δ/ppm (500 MHz, CDCl3) 3.84 (3H, s, 
OCH3), 4.36 (2H, s, CH2), 6.63 (1H, dd, Ar-H, J = 2.0 and 8.1 Hz), 6.83-6.84 (1H, m, 
Ar-H), 6.87-6.89 (1H, m, Ar-H, J = 2.3 and 8.1 Hz), 6.95-6.97 (1H, m, Ar-H), 7.02-7.07 
(3H, m, Ar-H), 7.12-7.13 (1H, m, Ar-H), 7.24 (1H, t, Ar-H, J = 7.9 Hz), 7.33 (1H, t, Ar-
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H, J = 7.8 Hz), 7.35-7.38 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 47.8, 55.3, 
111.9, 112.2, 112.7, 112.8, 115.4, 115.6, 117.1, 119.7, 129.1, 129.2, 129.62, 129.65, 
142.4, 143.2, 159.8, 161.1, 163.1; LC-MS (ESI+) m/z = 308.3 [M+H]
+
; HRMS calcd. 
for C20H19ONF [M+H]
+
 308.1445, found 308.1445; Analytical HPLC: 97.7%  
 
N-(3’-((4-Fluorobenzyl)amino)-[1,1’-biphenyl]-4-yl)acetamide (118k) 
 
 
 
 
 
General procedure B: Using boronic ester 123 (40 mg, 0.12 mmol) and 4’-
bromoacetanilide (39 mg, 0.18 mmol), chromatography (silica, 5% EtOAc, DCM 
followed by 50-80% Et2O, petrol) yielded 118k as a pale solid (17 mg, 41%); Rf = 0.31 
(silica, 80% Et2O, petrol); m.p. 99-101 
oC; UV λmax (EtOH/nm) 262.5; IR νmax/cm
-1
 
3395 (secondary amine N-H), 3255 (amide N-H), 1661, 1601, 1506, 1323, 1221, 829, 
777, 697; 
1H δ/ppm (500 MHz, CDCl3) 2.20 (3H, s, NHCOCH3), 4.35 (3H, m, CH2 and 
amino NH), 6.60 (1H, dd, Ar-H, J = 1.5 and 7.9 Hz), 6.81 (1H, m, Ar-H), 6.92-6.94 
(1H, m, Ar-H), 7.02-7.05 (2H, m, Ar-H), 7.19 (1H, s, br, amido NH), 7.23 (1H, t, Ar-H, 
J = 7.6 Hz), 7.34-7.37 (2H, m, Ar-H), 7.48-7.54 (4H, m, Ar-H); 
13C δ/ppm (125 MHz, 
CDCl3) 47.8, 111.1, 111.2, 115.3, 115.4, 115.6, 116.4, 128.0, 129.1, 129.2, 129.6, 
132.0, 135.1, 142.4, 145.8, 148.1, 161.1, 163.1; LC-MS (ESI+) m/z = 335.3 [M+H]
+
; 
HRMS calcd. for C21H20ON2F [M+H]
+
 335.1554, found 335.1558; Analytical HPLC: 
95.9%  
 
4-(3-((4-Fluorobenzyl)amino)phenyl)pyridine-1-oxide (118n) 
 
 
 
 
General procedure B: Using aniline 123 (100 mg, 0.31 mmol) and bromopyridine 125 
(97.5 mg, 0.56 mmol), chromatography (silica, 0-5% MeOH, DCM) yielded 118n as a 
brown solid (5.8 mg, 6%); Rf = 0.21 (silica, 5% MeOH, DCM); m.p. 189 
o
C 
(decomposed); UV λmax (EtOH/nm) 295.0 and 244.2; IR νmax/cm
-1
 3235 (N-H), 3106 
(C-H), 3060 (C-H), 2923 (C-H), 2853 (C-H), 1601, 1545, 1508, 1467, 1419, 1343, 1230 
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(C-O), 1173, 1104, 1037, 1014, 987, 833, 783, 701; 
1H δ/ppm (500 MHz, DMSO-d6) 
4.34 (2H, d, CH2, J = 6.0 Hz), 5.77 (1H, s, NH), 6.43-6.46 (1H, m, Ar-H), 6.63-6.65 
(1H, m, Ar-H), 6.90-6.91 (2H, m, Ar-H), 7.14-7.18 (3H, m, Ar-H), 7.41-7.44 (2H, m, 
Ar-H), 7.61-7.63 (2H, m, Ar-H), 8.21-8.23 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, 
DMSO-d6) 45.5, 109.5, 113.0, 113.9, 114.9, 115.1, 123.4, 129.06, 129.13, 129.7, 136.1, 
136.3, 136.9, 138.7, 149.2, 161.9; 
19
F δ/ppm (470 MHz, DMSO-d6) -116.4; LC-MS 
(ESI+) m/z = 295.4 [M+H]
+
; HRMS calcd. for C18H16ON2F [M+H]
+ 
295.1241, found 
295.1243; Analytical HPLC: 96.2%  
 
4-(2-Aminopyridin-4-yl)phenol (127a) 
 
 
 
 
General Procedure B: Using 4-hydroxybenzeneboronic acid (97 mg, 0.70 mmol) and 
aminopyridine 126a (100 mg, 0.58 mmol), chromatography (silica, 10% MeOH, DCM) 
afforded 127a as a brown solid (81.7 mg, 76%); Rf = 0.28 (silica, 10% MeOH, DCM); 
m.p. 220 
oC (decomposed); UV λmax (EtOH/nm) 276.5 and 240.5; IR νmax/cm
-1
 3477 (N-
H), 3383 (N-H), 2925 (C-H), 2583 (br) (O-H), 1582, 1541, 1519, 1438, 1290, 1235, 
1185, 1115, 999, 903, 832, 802, 734, 661; 
1H δ/ppm (500 MHz, DMSO-d6) 5.86 (2H, s, 
br, NH2), 6.63 (1H, m, Ar-H), 6.72 (1H, dd, Ar-H, J = 1.6 and 5.4 Hz), 6.84-6.87 (2H, 
m, Ar-H), 7.47-7.50 (2H, m, Ar-H), 7.90 (1H, d, Ar-H, J = 5.2 Hz), 9.70 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 104.0, 109.5, 115.7, 127.5, 128.8, 148.0, 148.2, 158.1, 
160.3; LC-MS (ESI+) m/z = 187.1 [M+H]
+
; HRMS calcd. for C11H11ON2 [M+H]
+
 
187.0866, found 187.0863; HRMS calcd. for C11H9ON2 [M-H]
-
 185.0720, found 
185.0720 
 
4-(5-Aminopyridin-3-yl)phenol (127b) 
 
 
 
 
General Procedure B: Using 4-hydroxybenzeneboronic acid (97 mg, 0.70 mmol) and 
aminopyridine 126b (100 mg, 0.58 mmol), chromatography (silica, 2% MeOH, EtOAc) 
afforded 127b as a dark yellow solid (69.4 mg, 64%); Rf = 0.31 (silica, 2% MeOH, 
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EtOAc); m.p. 204 
o
C (decomposed); UV λmax (EtOH/nm) 316.0, 243.5; IR νmax/cm
-1
 
3447 (N-H), 3361 (N-H), 2487 (br) (O-H), 1594, 1489, 1461, 1249, 1162, 1108, 909, 
864, 835, 709; 
1H δ/ppm (500 MHz, DMSO-d6) 5.32 (2H, s, br, NH2), 6.84-6.86 (2H, 
m, Ar-H), 7.05-7.06 (1H, m, Ar-H), 7.41-7.42 (2H, m, Ar-H), 7.86 (1H, d, Ar-H, J = 
2.5 Hz), 7.96 (1H, d, Ar-H, J = 1.9 Hz), 9.57 (1H, s, OH); 
13C δ/ppm (125 MHz, 
DMSO-d6) 115.8, 116.9, 127.7, 128.6, 134.6, 134.8, 135.6, 144.7, 157.3; LC-MS 
(ESI+) m/z = 187.2 [M+H]
+
;  HRMS calcd. for C11H11ON2 [M+H]
+
 187.0866, found 
187.0865; HRMS calcd. for C11H9ON2 [M-H]
-
 185.0720, found 185.0721; LC-MS (m/z) 
187.2 [M+H] 
 
4-(4-Aminopyridin-2-yl)phenol (127c) 
 
 
 
 
General Procedure B: Using 4-hydroxybenzeneboronic acid (97 mg, 0.70 mmol) and 
aminopyridine 126c (100 mg, 0.58 mmol), irradiation for 2.5 h and chromatography 
(silica, 2-25% MeOH, EtOAc) afforded 127c as a dark brown solid (45.6 mg, 42%); Rf 
= 0.20 (silica, 20% MeOH, EtOAc); m.p. 250 
o
C (decomposed); UV λmax (EtOH/nm) 
250.0; IR νmax/cm
-1
 3478 (N-H), 3380 (N-H), 3208 (C-H), 2965 (C-H), 2487 (br) (O-H), 
1600, 1556, 1482, 1429, 1282, 1250, 1127, 1001, 950, 842, 816, 724, 659; 
1H δ/ppm 
(500 MHz, DMSO-d6) 5.98 (2H, s, br, NH2), 6.38 (1H, dd, Ar-H, J = 2.0 and 5.6 Hz), 
6.80-6.82 (2H, m, Ar-H), 6.88 (1H, d, Ar-H, J = 1.8 Hz), 7.74-7.76 (2H, m, Ar-H), 8.02 
(1H, d, Ar-H, J = 5.6 Hz), 9.60 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 103.8, 
107.1, 115.1, 127.4, 130.5, 149.1, 155.0, 156.2, 157.9; LC-MS (ESI+) m/z = 187.1 
[M+H]
+
; HRMS calcd. for C11H11ON2 [M+H]
+
 187.0866, found 187.0865; HRMS 
calcd. for C11H9ON2 [M-H]
-
 185.0720, found 185.0721 
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3-((4-Fluorobenzyl)amino)-5-(4-hydroxyphenyl)pyridine-1-oxide (128d) 
 
 
 
 
General procedure B: Using bromopyridine 133 (19 mg, 0.06 mmol) and 4-
hydroxybenzeneboronic acid (13.2 mg, 0.10 mmol), chromatography (silica, 70-80% 
EtOAc, DCM) yielded 128d as a brown gum (11 mg, 67%); Rf = 0.39 (silica, 10% 
MeOH, DCM); m.p. 116 
oC (decomposed); UV λmax (EtOH/nm) 345.0 and 261.5; IR 
νmax/cm
-1
 3336 (N-H), 3061 (br) (O-H), 2922 (C-H), 1581, 1507, 1224 (C-O), 1154 (N-
O), 1091, 816; 
1H δ/ppm (500 MHz, DMSO-d6) 4.33(2H, d, CH2, J = 5.8 Hz), 6.79-6.86 
(4H, m, Ar-H), 7.16-7.19 (2H, m, Ar-H), 7.39-7.43 (4H, m, Ar-H), 7.50 (1H, m, Ar-H), 
7.70 (1H, m, NH), 9.75 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 45.1, 107.4, 
115.1, 115.3, 115.8, 121.7, 124.7, 126.2, 127.9, 129.18, 129.24, 135.0, 138.4, 146.7, 
158.2, 160.3, 162.2; LC-MS (ESI+) m/z = 311.3 [M+H]
+
; HRMS calcd. for 
C18H14O2N2F [M-H]
- 
309.1045, found 309.1048; Analytical HPLC: 97.1%  
 
4-Fluoro-N-(2-(4-hydroxyphenyl)pyridine-4-yl)benzamide (131) 
 
 
 
 
General procedure B: Using aryl bromide 130 (280 mg, 0.95 mmol) and 4-
hydroxybenzeneboronic acid (270 mg, 1.96 mmol), chromatography (silica, 40-70% 
EtOAc, hexane) yielded a beige solid (163 mg). The solid was dissolved in methanol (5 
mL) and distilled water (2 mL), mixed with sodium methoxide (705 mg, 13.1 mmol) 
and stirred in air at room temperature. After 48 h, the reaction was partitioned with 2 M 
NaOH (20 mL) and diethyl ether (20 mL). The aqueous layer was extracted with 
diethylether (20 mL) and filtered, neutralised with 1 M HCl (30 mL) and extracted with 
EtOAc (3 × 10 mL). The organic layer was washed with brine (10 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give 131 as a beige solid (110 mg, 38%); Rf = 0.15 
(silica, 50% EtOAc, hexane); m.p. 258-260 
oC; UV λmax (EtOH/nm) 265.5; IR νmax/cm
-1
 
3349 (N-H), 2480 (br) (O-H), 1692 (C=O), 1588, 1497, 1447, 1384, 1319, 1272, 1238, 
1212, 1157, 1089, 1010, 839, 809, 760, 654; 
1H δ/ppm (500 MHz, DMSO-d6) 6.88-6.90 
(2H, m, Ar-H), 7.40-7.45 (2H, m, Ar-H), 7.69 (1H, dd, Ar-H, J = 1.9 and 5.5 Hz), 7.85-
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7.87 (2H, m, Ar-H), 8.07-8.11 (2H, m, Ar-H), 8.21 (1H, d, Ar-H, J = 1.7 Hz), 8.51 (1H, 
d, Ar-H, J = 5.5 Hz), 9.75 (1H, s, OH), 10.60 (1H, s, NH); 
13C δ/ppm (125 MHz, 
DMSO-d6) 109.1, 111.9, 115.4, 115.5, 115.6, 127.7, 129.8, 130.6, 130.68, 130.71, 
146.7, 150.1, 157.0, 158.5, 163.4, 165.3; LC-MS (ESI+) m/z = 309.3 [M+H]
+
; 
Analytical HPLC: 98.9%  
 
2’-(4-Chlorophenoxy)-3’-nitro-[1,1’-biphenyl]-4-ol (136a) 
 
 
 
 
 
General Procedure B: Using 4-hydroxybenzeneboronic acid (66.2 mg, 0.48 mmol) and 
aryl bromide 135a (130 mg, 0.40 mmol), chromatography (silica, 1% EtOAc, DCM) 
afforded 136a as a dark brown solid (101 mg, 74%); Rf = 0.42 (silica, 1% EtOAc, 
DCM); m.p. 125-130 
oC; UV λmax (EtOH/nm) 263.0; IR νmax/cm
-1
 3228 (O-H), 1593, 
1515, 1483, 1345, 1230, 1195, 1090, 1008, 887, 813, 794, 756; 
1H δ/ppm (500 MHz, 
DMSO-d6) 6.68-6.74 (4H, m, Ar-H), 7.21-7.24 (2H, m, Ar-H), 7.29-7.32 (2H, m, Ar-
H), 7.60 (1H, t, Ar-H, J = 8.0 Hz), 7.81 (1H, dd, Ar-H, J = 1.6 and 7.8 Hz), 8.03 (1H, 
dd, Ar-H, J = 1.6 and 8.2 Hz), 9.63 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 
115.3, 116.8, 123.8, 125.4, 126.1, 126.7, 129.3, 130.1, 135.8, 137.3, 142.8, 144.2, 
155.7, 157.5; LC-MS (ESI+) m/z = 340.2 [M-H]
- 
 
2-(4-Chlorophenoxy)-3-nitro-1,1’-biphenyl (136b) 
 
 
 
 
 
General Procedure B: Using benzeneboronic acid (196 mg, 1.61 mmol) and aryl 
bromide 135a (440 mg, 1.34 mmol), chromatography (silica, 0-5% EtOAc, petrol) 
afforded 136b as a yellow oil (382 mg, 79%); Rf = 0.33 (silica, 10% EtOAc, petrol); UV 
λmax (EtOH/nm) 225.5; IR νmax/cm
-1
 3069 (C-H), 1583, 1529 (N=O asym. stretch), 
1483, 1352 (N=O sym. stretch), 1237 (C-O), 1091, 827, 761, 699; 
1H δ/ppm (500 MHz, 
CDCl3) 6.57-6.60 (2H, m, Ar-H), 7.04-7.07 (2H, m, Ar-H), 7.27-7.33 (3H, m, Ar-H), 
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7.37-7.40 (2H, m, Ar-H), 7.45 (1H, t, Ar-H, J = 8.0 Hz), 7.68 (1H, dd, Ar-H, J = 1.7 and 
7.8 Hz), 7.92 (1H, dd, Ar-H, J = 1.6 and 8.1 Hz); 
13C δ/ppm (125 MHz, CDCl3) 116.69, 
116.74, 124.5, 125.8, 127.4, 128.37, 128.44, 129.0, 129.3, 129.7, 135.3, 135.9, 138.7, 
144.5, 144.7, 155.9; LC-MS (ESI+) m/z = mass not observe 
 
2’-((4-Chlorobenzyl)oxy)-3’-nitro-[1,1’-biphenyl]-4-ol (136c) 
 
 
 
 
 
 
General Procedure B: Using 4-hydroxybenzeneboronic acid (149 mg, 1.08 mmol) and 
aryl bromide 135b (310 mg, 0.90 mmol), chromatography (silica, 10-20% EtOAc, 
petrol) afforded 136c as a yellow/brown solid (290 mg, 86%); Rf = 0.19 (silica, 20% 
EtOAc, petrol); m.p. 129-131 
oC; UV λmax (EtOH/nm) 262.0; IR νmax/cm
-1
 3263 (O-H), 
1600, 1512 (N=O asym. stretch), 1349 (N=O sym. stretch), 1230 (C-O), 1082, 966, 836, 
803; 
1H δ/ppm (500 MHz, DMSO-d6) 4.56 (2H, s, CH2), 6.87-6.90 (2H, m, Ar-H), 7.11-
7.13 (2H, m, Ar-H), 7.37-7.39 (2H, m, Ar-H), 7.42 (1H, t, Ar-H, J = 7.9 Hz), 7.43-7.45 
(2H, m, Ar-H), 7.67 (1H, dd, Ar-H, J = 1.7 and 7.8 Hz), 7.83 (1H, dd, Ar-H, J = 1.6 and 
8.0 Hz); 
13C δ/ppm (125 MHz, DMSO-d6) 74.1, 115.5, 122.9, 125.1, 126.3, 128.3, 
129.9, 130.1, 132.9, 134.7, 134.9, 137.1, 145.3, 147.4, 157.6; LC-MS (ESI+) m/z = 
354.1 [M-H]
-
; HRMS calcd. for C19H13O4N
35
Cl [M-H]
-
 354.0539, found 354.0530 
 
2-(4-Chlorophenoxy)-4’-fluoro-3-nitro-1,1’-biphenyl (136f) 
 
 
 
 
 
General procedure B: Using aryl bromide 135a (700 mg, 2.13 mmol) and 4-
fluorobenzeneboronic acid (448 mg, 3.20 mmol), chromatography (silica, 10% Et2O, 
petrol) yielded 136f as a dark yellow oil (627 mg, 86%); Rf = 0.31 (silica, 20% Et2O, 
petrol); UV λmax (EtOH/nm) 226.2; IR νmax/cm
-1
 3077 (C-H), 1604, 1532, 1510, 1483, 
1448, 1403, 1351, 1235 (C-O), 1195, 1160, 1091, 1010, 887, 813, 754; 
1H δ/ppm (500 
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MHz, CDCl3) 6.56-6.59 (2H, m, Ar-H), 6.98-7.03 (2H, m, Ar-H), 7.06-7.09 (2H, m, Ar-
H), 7.35-7.39 (2H, m, Ar-H), 7.46 (1H, t, Ar-H, J = 8.0 Hz), 7.66 (1H, dd, Ar-H, J = 1.7 
and 7.8 Hz), 7.93 (1H, dd, Ar-H, J = 1.7 and 8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 
115.5, 115.7, 116.6, 124.7, 125.9, 127.6, 129.4, 130.7, 130.8, 131.27, 131.30, 135.7, 
137.6, 144.5, 144.6, 155.8, 161.7, 163.7; LC-MS (ESI+) m/z = mass not observed 
 
2’-Fluoro-2-methyl-3’-nitro-[1,1’-biphenyl]-4-ol (144a) 
 
 
 
 
General procedure B: Using boronic ester 142 (230 mg, 0.86 mmol) and 4-bromo-3-
methylboronic acid (322 mg, 1.72 mmol), chromatography (silica, 5-15% EtOAc, 
petrol) yielded 144a as a dark brown solid (183 mg, 79%); Rf = 0.28 (silica, 20% 
EtOAc, petrol); m.p. 127-129 
oC; UV λmax (EtOH/nm) 252.8; IR νmax/cm
-1
 3261 (O-H), 
3093 (C-H), 2924 (C-H), 2858 (C-H), 1613, 1581, 1532, 1504, 1466, 1447, 1344 (C-O), 
1294, 1234, 1162, 1124, 1083, 951, 880, 806, 734; 
1H δ/ppm (500 MHz, CDCl3) 2.16 
(3H, s, ArCH3), 4.89 (1H, s, br, OH), 6.74 (1H, dd, Ar-H, J = 2.5 and 8.1 Hz), 6.80 (1H, 
d, Ar-H, J = 2.4 Hz), 7.07 (1H, d, Ar-H, J = 8.4 Hz), 7.30-7.33 (1H, m, Ar-H), 7.50-
7.53 (1H, m, Ar-H), 8.00-8.03 (1H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 113.0, 
117.1, 123.87, 123.92, 124.8, 124.86, 125.90, 131.4, 132.1, 132.3, 137.2, 137.3, 138.2, 
138.4, 151.6, 153.7, 156.0; 
19F δ/ppm (470 MHz, CDCl3) -119.8; LC-MS (ESI+) m/z = 
246.2 [M-H]
-
; HRMS calcd. for C13H9O3NF [M-H]
- 
246.0572, found 246.0571 
 
2-Chloro-2’-fluoro-3’-nitro-[1,1’-biphenyl]-4-ol (144b) 
 
 
 
 
General procedure B: Using boronic ester 142 (230 mg, 0.86 mmol) and 4-bromo-3-
chloroboronic acid (357 mg, 1.72 mmol), chromatography (silica, 10-25% EtOAc, 
petrol) yielded 144b as a light brown solid (192 mg, 76%); Rf = 0.50 (silica, 40% 
EtOAc, petrol); m.p. 120-123 
oC; UV λmax (EtOH/nm) 249.4; IR νmax/cm
-1
 3442 (O-H), 
3098 (C-H), 1605, 1586, 1525, 1499, 1421, 1346 (C-O), 1300, 1269, 1243, 1213, 1078, 
1029, 909, 879, 863, 809, 739, 692; 
1H δ/ppm (500 MHz, CDCl3) 5.63 (1H, s, br, OH), 
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6.85 (1H, dd, Ar-H, J = 2.6 and 8.4 Hz), 7.04 (1H, d, Ar-H, J = 2.5 Hz), 7.19 (1H, d, 
Ar-H, 8.5 Hz), 7.31-7.35 (1H, m, Ar-H), 7.57-7.60 (1H, m, Ar-H), 8.04-8.07 (1H, m, 
Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 114.3, 114.4, 116.3, 116.8, 116.9, 123.7, 123.8, 
124.7, 125.5, 129.9, 130.0, 132.3, 134.2, 137.4, 151.8, 153.9, 157.0; 
19F δ/ppm (470 
MHz, CDCl3) -119.0; LC-MS (ESI+) m/z = 266.2 [M-H]
-
; HRMS calcd. for 
C12H6O3N
35
ClF [M-H]
- 
266.0026, found 266.0025 
 
N-(4’-Fluoro-2-methyl-[1,1’-biphenyl]-3-yl)-4-methoxybenzamide (148a) 
 
 
 
 
General procedure B: Using aryl bromide 147a (650 mg, 2.03 mmol) and 4-
fluorobenzeneboronic acid (511 mg, 3.65 mmol), chromatography (silica, 20-50% 
EtOAc, petrol) yielded 148a as a brown solid (590 mg, 87%); Rf = 0.32 (silica, 30% 
EtOAc, petrol); m.p. 158-160 
oC; UV λmax (EtOH/nm) 253.4; IR νmax/cm
-1
 3200 (N-H), 
3006 (C-H), 2848 (C-H), 1638 (C=O), 1605, 1577, 1529, 1495, 1450, 1299, 1242 (C-
O), 1179, 1030, 935, 905, 851, 803, 766, 665; 
1H δ/ppm (500 MHz, CDCl3) 2.19 (3H, s, 
ArCH3), 3.88 (3H, s, OCH3), 6.98-7.01 (2H, m, Ar-H), 7.08-7.13 (3H, m, Ar-H), 7.25-
7.31 (3H, m, Ar-H), 7.65 (1H, s, br, NH), 7.86-7.90 (3H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 15.2, 55.5, 114.1, 115.0, 115.2, 122.9, 126.2, 127.08, 127.12, 127.6, 
129.0, 130.86, 130.93, 136.3, 137.66, 137.69, 142.1, 161.1, 162.6, 163.0, 165.3; LC-MS 
(ESI+) m/z = 336.4 [M+H]
+
; HRMS calcd. for C21H17O2NF [M-H]
- 
334.1249, found 
334.1246; Analytical HPLC: 100.0%  
 
N-(4’-Fluoro-2-methyl-[1,1’-biphenyl]-3-yl)-4-hydroxybenzamide (148b) 
 
 
 
 
General procedure B: Using aryl bromide 147b (500 mg, 1.63 mmol) and 4-
fluorobenzeneboronic acid (410 mg, 2.93 mmol), chromatography (silica, 30-45% 
EtOAc, petrol) yielded 148b as a brown solid (486 mg, 93%); Rf = 0.23 (silica, 30% 
EtOAc, petrol); m.p. 104-106 
oC; UV λmax (EtOH/nm) 256.2; IR νmax/cm
-1
 3198 (O-H), 
1641 (C=O), 1605, 1497, 1440, 1375, 1280, 1220 (C-O), 1171, 1108, 1039, 996, 931, 
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838, 785, 765, 727; 
1H δ/ppm (500 MHz, CDCl3) 2.19 (3H, s, ArCH3), 5.67 (1H, s, br, 
OH), 6.92-6.94 (2H, m, Ar-H), 7.09-7.13 (3H, m, Ar-H), 7.25-7.31 (3H, m, Ar-H), 7.64 
(1H, s, br, NH), 7.81-7.86 (3H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 15.2, 115.0, 
115.2, 115.7, 123.1, 126.3, 127.1, 127.3, 127.8, 129.2, 130.86, 130.92, 136.1, 142.2, 
159.1; LC-MS (ESI+) m/z = 322.4 [M+H]
+
; HRMS calcd. for C20H15O2NF [M-H]
- 
320.1092, found 320.1092; Analytical HPLC: 97.0%  
 
2-Fluoro-4’-methoxy-3-nitro-1,1’-biphenyl (216) 
 
 
 
General Procedure B: Using aryl bromide 139 (200 mg, 0.91 mmol) and 4-
methoxybenzeneboronic acid (277 mg, 1.82 mmol), chromatography (silica, 0-40% 
DCM, petrol) afforded 216 as a white solid (197 mg, 88%); Rf = 0.34 (silica, 40% 
DCM, petrol); m.p. 106-108 
o
C; UV λmax (EtOH/nm) 257.0; IR νmax/cm
-1
 3086 (C-H), 
2972 (C-H), 2935 (C-H), 2840 (C-H), 1605, 1583, 1510, 1454, 1344, 1297, 1251 (C-O), 
1178, 1115, 1022, 882, 837, 799, 733; 
1
H δ/ppm (500 MHz, MeOH-d4) 3.86 (3H, s, 
OCH3), 7.06 (2H, d, 4-MeOPh C3-H and C5-H, J = 8.8 Hz), 7.42 (1H, t, 2-FPh C5-H, J = 
7.9 Hz), 7.51 (2H, dd, 4-MeOPh C2-H and C6-H, J = 1.7 and 8.8 Hz), 7.76-7.80 (1H, m, 
Ar-H), 7.97-8.00 (1H, m, Ar-H); 
13
C δ/ppm (125 MHz, MeOH-d4) 54.4, 113.9, 123.89, 
123.91, 124.2, 124.3, 125.8, 130.0, 130.1, 131.6, 131.7, 135.51, 135.54, 151.0, 153.0, 
160.2; 
19
F δ/ppm (470 MHz, MeOH-d4) -127.5; LC-MS (ESI+) m/z = 248.2 [M+H]
+
; 
HRMS calcd. for C13H11O3NF [M+H]
+ 
248.0717, found 248.0716 
 
6-(4-Chlorophenoxy)-4’-hydroxy-5-nitro-[1,1’-biphenyl]-3-carboxylic acid (224) 
 
 
 
 
 
General Procedure B: Using aryl bromide 223 (110 mg, 0.30 mmol) and 4-
hydroxybenzeneboronic acid (83 mg, 0.60 mmol), chromatography (C18, 50-70% 
MeOH + 0.1% (v/v) HCO2H, H2O) afforded 224 as a yellow solid (64 mg, 56%); Rf = 
0.18 (silica, 10% MeOH, DCM); m.p. 201-203 
oC; UV λmax (EtOH/nm) 225.2; IR 
νmax/cm
-1
 3294 (phenol O-H), 3071 (C-H), 2650 (carboxyl O-H), 1695 (C=O), 1609, 
323 
 
1536, 1482, 1420, 1347, 1304, 1232 (C-O), 1189, 1090, 1009, 927, 820, 736, 667; 
1
H 
δ/ppm (500 MHz, DMSO-d6) 6.74 (2H, d, 4-HOPh C2-H and C6-H, J = 8.7 Hz), 6.78 
(2H, d, 4-ClPh C3-H and C5-H, J = 9.1 Hz), 7.24 (2H, d, 4-ClPh C2-H and C6-H, J = 9.1 
Hz), 7.33 (2H, d, 4-HOPh C3-H and C5-H, J = 8.7 Hz), 8.21 (1H, dd, Ar-H, J = 2.1 Hz), 
8.46 (1H, dd, Ar-H, J = 2.2 Hz), 9.70 (1H, s, br, ArOH), 13.74 (1H, s, br, CO2H); 
13
C 
δ/ppm (125 MHz, DMSO-d6) 115.4, 117.1, 124.6, 124.8, 126.5, 129.4, 130.2, 135.8, 
137.7, 144.1, 146.2, 155.3, 157.7, 165.1; LC-MS (ESI+) m/z = 384.2 [M-H]
-
; HRMS 
calcd. for C19H11O6N
35
Cl [M-H]
-
384.0280, found 384.0272 
 
Methyl 6-(4-chlorophenoxy)-4’-hydroxy-5-nitro-[1,1’-biphenyl]-3-carboxylate 
(228) 
 
 
 
 
 
General Procedure B: Using aryl bromide 227 (492 mg, 1.27 mmol) and 4-
hydroxybenzeneboronic acid (350 mg, 2.54 mmol), chromatography (silica, 0-20% 
EtOAc, petrol followed by 45-80% DCM, petrol) afforded 228 as a yellow solid (255 
mg, 50%); Rf = 0.23 (silica, 30% EtOAc, petrol); m.p. 76-78 
o
C; UV λmax (EtOH/nm) 
226.2; IR νmax/cm
-1
 3389 (phenol O-H), 3085 (C-H), 2953 (C-H), 1723 (C=O), 1610, 
1537, 1483, 1433, 1352, 1312, 1235 (C-O), 1193, 1114, 1075, 1009, 981, 913, 821, 762, 
695; 
1
H δ/ppm (500 MHz, CDCl3) 3.99 (3H, s, CO2CH3), 4.84 (1H, s, br, ArOH), 6.60 
(2H, d, Ar-H, J = 9.0 Hz), 6.79 (2H, d, Ar-H, J = 8.7 Hz), 7.09 (2H, d, Ar-H, J = 9.0 
Hz), 7.32 (2H, d, Ar-H, J = 8.7 Hz), 8.32 (1H, d, Ar-H, J = 2.1 Hz), 8.51 (1H, d, Ar-H, 
J = 2.1 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 52.9, 115.6, 116.8, 125.2, 127.1, 127.8, 
128.0, 129.5, 130.5, 136.3, 138.4, 144.5, 147.9, 155.4, 156.0, 164.6; LC-MS (ESI+) m/z 
= 400.3 [M+H]
+
 and 398.2 [M-H]
-
; HRMS calcd. for C20H13O6N
35
Cl [M-H]
- 
398.0437, 
found 398.0426 
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2-(6-(4-Chlorophenoxy)-4’-hydroxy-5-nitro-[1,1’-biphenyl]-3-yl)acetonitrile (241) 
 
 
 
 
 
General Procedure B: Using aryl bromide 234 (595 mg, 1.62 mmol) and 4-
hydroxybenzeneboronic acid (446 mg, 3.24 mmol) and irradiating at 120 
o
C for 22 min, 
chromatography (silica, 0-10% EtOAc, DCM) afforded 241 as a yellow solid (374 mg, 
61%); Rf = 0.21 (silica, 40% EtOAc, petrol); m.p. 159-161 
o
C; UV λmax (EtOH/nm) 
270.0; IR νmax/cm
-1
 3367 (O-H), 3069 (C-H), 2924 (C-H), 2250 (C≡N), 1610, 1588, 
1535, 1515, 1482, 1412, 1346, 1266, 1235 (C-O), 1196, 1174, 1090, 1042, 1009, 936, 
822, 744; 
1
H δ/ppm (500 MHz, CDCl3) 3.88 (2H, s, ArCH2), 4.87 (1H, s, br, ArOH), 
6.59 (2H, d, Ar-H, J = 9.0 Hz), 6.78 (2H, d, Ar-H, J = 8.7 Hz), 7.08 (2H, d, Ar-H, J = 
9.0 Hz), 7.29 (2H, d, Ar-H, J = 8.7 Hz), 7.64 (1H, d, Ar-H, J = 2.2 Hz), 7.85 (1H, d, Ar-
H, J = 2.2 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 23.1, 115.6, 116.4, 116.7, 123.4, 127.0, 
127.8, 128.0, 129.4, 130.4, 134.8, 139.4, 144.4, 144.7, 155.6, 156.0; LC-MS (ESI+) m/z 
= 379.1 [M-H]
-
; HRMS calcd. for C20H12O4N2
35
Cl [M-H]
- 
379.0491, found 379.0483  
 
Methyl 6-(4-chlorophenoxy)-4’-methoxy-5-nitro-[1,1’-biphenyl]-3-carboxylate 
(245) 
 
 
 
 
 
General Procedure B: Using aryl bromide 227 (250 mg, 0.65 mmol) and 4-
methxybenzeneboronic acid (198 mg, 1.30 mmol) and irradiating at 120 
o
C for 19 min, 
chromatography (silica, 0-20% Et2O, petrol) afforded 245 as a yellow oil (160 mg, 
60%); Rf = 0.26 (silica, 30% Et2O, petrol); UV λmax (EtOH/nm) 225.8; IR νmax/cm
-1
 
3237 (C-H), 3086 (C-H), 2954 (C-H), 2839 (C-H), 1724 (C=O), 1609, 1538, 1513, 
1483, 1464, 1434, 1356, 1306, 1230 (C-O), 1197, 1112, 1091, 1029, 1009, 983, 910, 
824, 799, 762, 733, 694; 
1
H δ/ppm (500 MHz, CDCl3) 3.79 (3H, s, ArOCH3), 3.99 (3H, 
s, CO2CH3), 6.60 (2H, d, 4-ClPh C3-H and C5-H, J = 9.0 Hz), 6.85 (2H, d, 4-MeOPh 
C2-H and C6-H, J = 8.8 Hz), 7.08 (2H, d, 4-ClPh C2-H and C6-H, J = 9.0 Hz), 7.36 (2H, 
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d, 4-MeOPh C3-H and C5-H, J = 8.8 Hz), 8.33 (1H, d, Ar-H, 2.1 Hz), 8.50 (1H, d, Ar-H, 
J = 2.1 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 52.9, 55.3, 114.1, 116.8, 125.2, 126.8, 127.8, 
128.0, 129.5, 130.2, 136.3, 138.5, 144.4, 147.9, 155.4, 159.9, 164.6; LC-MS (ESI+) m/z 
= 414.3 [M+H]
+
; HRMS calcd. for C21H17O6N
35
Cl [M+H]
+ 
414.0739, found 414.0741 
 
4-Fluoro-N-(4-(1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)thiazol-2-
yl)benzamide (274) 
 
 
 
 
 
 
General Procedure B: Using boronic ester 273 (230 mg, 0.70 mmol) and 
bromothiazole 268 (142 mg, 0.47 mmol) and irradiating for 40 min, chromatography 
(silica, 10-60% EtOAc, petrol) afforded 274 as a brown solid (155 mg, 78%); Rf = 0.25 
(silica, 10% EtOAc, petrol); m.p. 215-217 
oC; UV λmax (EtOH/nm) 245.4 and 222.8; IR 
νmax/cm
-1
 3333 (N-H), 3088 (C-H), 2927 (C-H), 2857 (C-H), 1668 (C=O), 1600, 1532, 
1511, 1483, 1446, 1420, 1372, 1341, 1315, 1272, 1226, 1208, 1164, 1079, 1040, 994, 
911, 891, 848, 791, 752, 716, 684; 
1H δ/ppm (500 MHz, DMSO-d6) 1.61 (2H, m, Alk-
H), 1.98-2.07 (2H, m, Alk-H), 2.37-2.47 (2H, m, Alk-H), 3.74-3.79 (1H, m, Alk-H), 
3.91-3.94 (1H, m, Alk-H), 5.87-5.89 (1H, m, Alk-H), 7.40-7.43 (2H, m, Ar-H), 7.69 
(1H, s, thiazole C5-H), 7.80 (1H, d, Ar-H, J = 8.8 Hz), 8.04 (1H, dd, Ar-H, J = 1.2 and 
8.8 Hz), 8.20 (1H, s, Ar-H), 8.22-8.25 (2H, m, Ar-H), 8.35 (1H, s, Ar-H), 12.82 (1H, s, 
NH); 
13C δ/ppm (125 MHz, DMSO-d6) 22.2, 24.8, 29.0, 66.6, 84.1, 107.5, 110.6, 115.6, 
115.7, 117.7, 124.5, 125.0, 128.0, 128.6, 131.1, 134.1, 139.0, 139.3, 150.9, 158.4, 
164.2, 185.5; 
19F δ/ppm (470 MHz, DMSO-d6) -107.0; LC-MS (ESI+) m/z = 423.4 
[M+H]
+
 and 421.3 [M-H]
-
; HRMS calcd. for C22H20O2N4FS [M+H]
+ 
423.1286, found 
423.1285; Analytical HPLC: 94.9% 
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3’-((4-Fluorobenzyl)amino)-[1,1’-biphenyl]-3-ol (118b) 
 
 
 
 
General Procedure C: Using aniline 117b (97 mg, 0.52 mmol) and 4-
fluorobenzaldehyde (67 µL, 77 mg, 0.62 mmol), chromatography (silica, 20% EtOAc, 
hexane) afforded 118b as a light brown solid (130 mg, 85%); Rf = 0.43 (silica, 30% 
EtOAc, hexane); m.p. 106-109 
oC; UV λmax (EtOH/nm) 239.0; IR νmax/cm
-1
 3323 (N-H), 
3048 (C-H), 2856 (br) (O-H), 1602, 1574, 1508, 1483, 1456, 1416, 1349, 1315, 1226, 
1189, 1157, 1072, 1046, 1014, 933, 875, 836, 777, 695; 
1H δ/ppm (500 MHz, CDCl3) 
4.35 (2H, s, CH2), 4.68 (1H, s, OH), 4.79 (1H, s, br, NH), 6.61-6.63 (1H, m, Ar-H), 
6.78-6.81 (1H, m, Ar-H), 6.82-6.83 (1H, m, Ar-H), 6.93-6.94 (1H, m, Ar-H), 7.00-7.07 
(3H, m, Ar-H), 7.10-7.12 (1H, m, Ar-H), 7.23 (1H, t, Ar-H, J = 7.9 Hz), 7.28 (1H, t, Ar-
H, J = 7.9 Hz), 7.33-7.37 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 47.9, 111.9, 
112.4, 114.1, 115.4, 115.6, 117.2, 119.8, 128.8, 129.1, 129.2, 129.7, 129.9, 134.7, 
142.0, 143.4, 147.9, 155.7, 161.2, 163.1; LC-MS (ESI+) m/z = 294.3 [M+H]
+
; HRMS 
calcd. for C19H17ONF [M+H]
+
 294.1289, found 294.1294; HRMS calcd. for C19H15ONF 
[M-H]
-
 292.1143, found 292.1136; Analytical HPLC: 99.1%  
 
3’-((4-Fluorobenzyl)amino)-[1,1’-biphenyl]-3,4-diol (118c) 
 
 
 
 
General Procedure C: Using aniline 117c (60 mg, 0.30 mmol) and 4-
fluorobenzaldehyde (39 µL, 45 mg, 0.36 mmol), chromatography (silica, 10-50% 
EtOAc, hexane) afforded 118c as a dark brown oil (56.6 mg, 61%); Rf = 0.44 (silica, 
50% EtOAc, hexane); UV λmax (EtOH/nm) 252.5 and 214.5; IR νmax/cm
-1
 3414 (N-H), 
3047 (C-H), 2948 (C-H), 2846 (br) (O-H), 1601, 1507, 1439, 1261, 1218, 1113, 1043, 
814, 773, 697; 
1H δ/ppm (500 MHz, CDCl3) 4.34 (2H, s, CH2), 5.15 (3H, s, br, OH and 
NH), 6.57-6.59 (1H, m, Ar-H), 6.77-6.78 (1H, m, Ar-H), 6.88-6.90 (2H, m, Ar-H), 
6.98-7.06 (4H, m, Ar-H), 7.21 (1H, t, Ar-H, J = 7.8 Hz), 7.34-7.36 (2H, m, Ar-H); 
13
C 
δ/ppm (125 MHz, CDCl3) 47.8, 111.5, 111.7, 114.3, 115.4, 115.6, 116.8, 119.9, 129.1, 
129.6, 134.9, 135.1, 141.9, 143.1, 143.6, 148.0, 161.1, 163.1; LC-MS (ESI+) m/z = 
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310.3 [M+H]
+
; HRMS calcd. for C19H17O2NF [M+H]
+
 310.1238, found 310.1241; 
HRMS calcd. for C19H15O2NF [M-H]
-
 308.1092, found 308.1084; Analytical HPLC: 
97.5%  
 
1,1,1-Trifluoro-N-(3’-((4-fluorobenzyl)amino)-[1,1’-biphenyl]-4-
yl)methanesulfonamide (118d) 
 
 
 
 
 
General Procedure C: Using aniline 117d (89 mg, 0.28 mmol) and 4-
fluorobenzaldehyde (36 µL, 42 mg, 0.34 mmol), chromatography (silica, 25% EtOAc, 
hexane) afforded 118d as a light brown solid (105.2 mg, 90%); Rf = 0.41 (silica, 30% 
EtOAc, hexane); m.p. 106-109 
oC; UV λmax (EtOH/nm) 251.5; IR νmax/cm
-1
 3459 
(amino N-H), 3265 (sulfonamido N-H), 3049 (C-H), 1606, 1507, 1449, 1416, 1364, 
1331 (S=O asym. stretch), 1216, 1188, 1137 (S=O sym. stretch), 1014, 990, 819, 772, 
728, 684; 
1H δ/ppm (500 MHz, CDCl3) 4.36 (2H, s, CH2), 4.67 (1H, s, NH), 6.64-6.66 
(1H, m, Ar-H), 6.79-6.80 (1H, m, Ar-H), 6.91-6.93 (1H, m, Ar-H), 7.02-7.07 (2H, m, 
Ar-H), 7.25 (2H, t, Ar-H, J = 7.8 Hz), 7.29-7.32 (2H, m, Ar-H), 7.34-7.37 (2H, m, Ar-
H), 7.52-7.55 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 48.1, 115.5, 115.7, 121.1, 
124.0, 128.3, 129.3, 129.9, 132.7, 140.9, 161.2; LC-MS (ESI+) m/z = 425.3 [M+H]
+
; 
HRMS calcd. for C20H17O2N2F4S [M+H]
+
 425.0941, found 425.0943; HRMS calcd. for 
C20H15O2N2F4S [M-H]
-
 423.0796, found 423.0782; Analytical HPLC: 95.6%  
 
1,1,1-Trifluoro-N-(4’-((4-fluorobenzyl)amino)-[1,1’-biphenyl]-4-
yl)methanesulfonamide (118e) 
 
 
 
 
 
General Procedure C: Using aniline 117e (103 mg, 0.33 mmol) and 4-
fluorobenzaldehyde (43 µL, 50 mg, 0.40 mmol), chromatography (silica, 25% EtOAc, 
hexane) afforded 118e as a light brown solid (75.6 mg, 54%); Rf = 0.45 (silica, 30% 
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EtOAc, hexane); m.p. 144-146 
oC; UV λmax (EtOH/nm) 298.5; IR νmax/cm
-1
 3403 
(amino N-H), 3277 (sulfonamido N-H), 3033 (C-H), 2841 (C-H), 1615, 1501, 1467, 
1413, 1364, 1330 (S=O asym. stretch), 1198, 1137 (S=O sym. stretch), 936, 821, 769; 
1H δ/ppm (500 MHz, CDCl3) 4.19 (1H, s, br, NH), 4.35 (2H, s, CH2), 6.67-6.70 (3H, m, 
Ar-H and sulfonamido NH), 7.03-7.07 (2H, m, Ar-H), 7.27-7.30 (2H, m, Ar-H), 7.33-
7.36 (2H, m, Ar-H), 7.39-7.42 (2H, m, Ar-H), 7.52-7.54 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 47.5, 113.2, 115.5, 115.6, 124.5, 127.3, 127.9, 128.9, 129.0, 131.4, 140.9, 
147.7; LC-MS (ESI+) m/z = 425.3 [M+H]
+
; HRMS calcd. for C20H17O2N2F4S [M+H]
+
 
425.0941, found 425.0944; HRMS calcd. for C20H15O2N2F4S [M-H]
-
 423.0796, found 
423.0795; Analytical HPLC: 98.2%  
 
N-(4-Fluorobenzyl)-[1,1’-biphenyl]-3-amine (118l) 
 
 
 
 
 
General Procedure C: Using aniline 117g (100 mg, 0.59 mmol) and 4-
fluorobenzaldehyde (76.1 µL, 88.1 mg, 0.71 mmol), chromatography (silica, 0-5% 
EtOAc, petrol) afforded 118l as a yellow oil (148 mg, 91%); Rf = 0.24 (silica, 5% 
EtOAc, petrol); UV λmax (EtOH/nm) 316.5 and 241.0; IR νmax/cm
-1
 3419 (N-H), 3032 
(C-H), 1599, 1509, 1486, 1328, 1223, 1155, 756, 699; 
1H δ/ppm (500 MHz, CDCl3) 
4.20 (1H, s, br, NH), 4.36 (2H, s, CH2), 6.62 (1H, dd, Ar-H, J = 2.2 and 8.0 Hz), 6.84-
6.85 (1H, m, Ar-H), 6.96-6.98 (1H, m, Ar-H), 7.03-7.06 (2H, m, Ar-H), 7.25 (1H, t, Ar-
H, J = 7.8 Hz), 7.31-7.35 (1H, m, Ar-H), 7.35-7.38 (2H, m, Ar-H), 7.40-7.43 (2H, m, 
Ar-H), 7.54-7.55 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 47.9, 112.0, 112.2, 
115.4, 115.6, 117.3, 127.17, 127.24, 128.7, 129.16, 129.21, 129.7, 134.8, 141.6, 142.5, 
147.9, 161.2, 163.1; LC-MS (ESI+) m/z = 278.3 [M+H]
+
; HRMS calcd. for C19H17NF 
[M+H]
+
 278.1340, found 278.1345; Analytical HPLC: 99.9%  
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N-(4-Fluorobenzyl)-3-(pyridin-4-yl)aniline (118m) 
 
 
 
 
General Procedure C: Using aniline 117i (100 mg, 0.59 mmol) and 4-
fluorobenzaldehyde (76.1 µL, 88.1 mg, 0.71 mmol), trituration with EtOAc (5 × 2 mL) 
afforded 118m as a pale yellow solid (86 mg, 52%); Rf = 0.28 (silica, 50% EtOAc, 
petrol); m.p. 160-162 
oC; UV λmax (EtOH/nm) 340.5 and 248.0; IR νmax/cm
-1
 3228 (N-
H), 3037 (C-H), 1594, 1551, 1507, 1405, 1217, 823, 775, 694; 
1H δ/ppm (500 MHz, 
CDCl3) 4.20 (1H, s, br, NH), 4.37 (2H, d, CH2, J = 3.7 Hz), 6.69 (1H, dd, Ar-H, J = 2.3 
and 8.1 Hz), 6.85 (1H, m, Ar-H), 6.98-6.99 (1H, m, Ar-H), 7.03-7.07 (2H, m, Ar-H), 
7.29 (1H, t, Ar-H, J = 7.8 Hz), 7.35-7.37 (2H, m, Ar-H), 7.44-7.45 (2H, m, Ar-H), 8.63 
(2H, s, br, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 47.6, 111.2, 113.7, 115.5, 115.7, 116.5, 
121.9, 129.0, 129.1, 130.1, 134.6, 134.7, 139.1, 148.5, 149.4, 149.5, 161.2, 163.1; LC-
MS (ESI+) m/z = 279.3 [M+H]
+
; Analytical HPLC: 98.0%  
 
N-(4-Fluorobenzyl)-3-(pyridin-3-yl)aniline (118o) 
 
 
 
 
General Procedure C: Using aniline 117h (100 mg, 0.59 mmol) and 4-
fluorobenzaldehyde (76.1 µL, 88.1 mg, 0.71 mmol), chromatography (silica, 30-40% 
EtOAc, petrol) afforded 118o as a white solid (144 mg, 86%); Rf = 0.40 (silica, 50% 
EtOAc, petrol); m.p. 81-84 
oC; UV λmax (EtOH/nm) 324.5 and 241.0; IR νmax/cm
-1
 3280 
(N-H), 3042 (C-H), 1599, 1507, 1477, 1426, 1336, 1223, 1154, 1018, 831, 766, 707; 
1
H 
δ/ppm (500 MHz, CDCl3) 4.20 (1H, s, br, NH), 4.37 (2H, s, CH2), 6.66 (1H, dd, Ar-H, J 
= 0.7 and 8.1 Hz), 6.80 (1H, m, Ar-H), 6.92-6.94 (1H, m, Ar-H), 7.02-7.07 (2H, m, Ar-
H), 7.28 (1H, t, Ar-H, J = 7.9 Hz), 7.32-7.37 (3H, m, Ar-H), 7.81-7.83 (1H, m, Ar-H), 
8.57 (1H, dd, Ar-H, J = 1.5 and 4.8 Hz), 8.80 (1H, d, Ar-H, J = 1.9 Hz); 
13C δ/ppm (125 
MHz, CDCl3) 47.6, 111.4, 112.7, 115.5, 115.7, 116.7, 123.6, 129.0, 129.1, 130.1, 
134.72, 134.74, 134.8, 137.3, 138.8, 147.88, 147.90, 148.5, 161.2, 163.1; LC-MS 
(ESI+) m/z = 279.3 [M+H]
+
; HRMS calcd. for C18H16N2F [M+H]
+
 279.1292, found 
279.1297; Analytical HPLC: 98.3%  
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N-(4-Fluorobenzyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (123) 
 
 
 
 
General Procedure C: Using aniline 122 (50 mg, 0.23 mmol) and 4-
fluorobenzaldehyde (30 µL, 34.8 mg, 0.28 mmol), chromatography (silica, 0-30% 
EtOAc, hexane) afforded 123 as a white solid (52.4 mg, 70%); Rf = 0.72 (silica, 30% 
EtOAc, hexane); m.p. 68-72 
oC; UV λmax (EtOH/nm) 318.0 and 254.0; IR νmax/cm
-1
 
3362 (N-H), 2983 (C-H), 2855 (C-H), 1605, 1578, 1508, 1468, 1362, 1318, 1240, 1220, 
1141, 1089, 965, 908, 852, 827, 789, 764, 706, 677; 
1H δ/ppm (500 MHz, CDCl3) 1.33 
(12H, s, (CH3)4), 4.32 (2H, s, CH2), 6.69-6.72 (1H, m, Ar-H), 6.99-7.04 (2H, m, Ar-H), 
7.13 (1H, m, Ar-H), 7.19 (2H, d, Ar-H, J = 4.7 Hz), 7.31-7.34 (2H, m, Ar-H); 
13
C 
δ/ppm (125 MHz, CDCl3) 24.9, 47.8, 83.7, 115.3, 115.5, 115.7, 119.5, 124.5, 128.8, 
129.2, 161.1, 163.1; LC-MS (ESI+) m/z = 328.3 [M+H]
+
; HRMS calcd. for 
C19H24O2N
10
BF [M+H]
+
 328.1879, found 328.1886 
 
4-(2-((4-Fluorobenzyl)amino)pyridin-4-yl)phenol (128a) 
 
 
 
 
General Procedure C: Using aniline 127a (80 mg, 0.43 mmol) and 4-
fluorobenzaldehyde (246 µL, 285 mg, 2.30 mmol), chromatography (silica, 30% 
EtOAc, DCM followed by 0-3% MeOH, DCM) afforded 128a as a white solid (15.5 
mg, 12%); Rf = 0.40 (silica, 50% EtOAc, DCM); m.p. 68 
oC (decomposed); UV λmax 
(EtOH/nm) 253.0; IR νmax/cm
-1
 3421 (N-H), 3027 (C-H), 2575 (br) (O-H), 1604, 1553, 
1506, 1467, 1220, 1175, 1103, 996, 879, 809; 
1H δ/ppm (500 MHz, DMSO-d6) 4.50 
(2H, d, CH2, J = 6.1 Hz), 6.68-6.69 (1H, m, NH), 6.74 (1H, dd, Ar-H, J = 5.4 and 1.6 
Hz), 6.84-6.87 (2H, m, Ar-H), 7.03 (1H, t, Ar-H, J = 6.1 Hz), 7.11-7.16 (2H, m, Ar-H), 
7.37-7.40 (2H, m, Ar-H), 7.47-7.49 (2H, m, Ar-H), 7.96 (1H, d, Ar-H, J = 5.4 Hz), 9.71 
(1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 43.5, 104.1, 109.7, 114.7, 114.9, 115.7, 
127.6, 128.8, 129.0, 129.1, 136.9, 147.7, 148.0, 158.2, 159.2, 161.9; LC-MS (ESI+) m/z 
= 295.3 [M+H]
+
; HRMS calcd. for C18H16ON2F [M+H]
+
 295.1241, found 295.1243; 
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HRMS calcd. for C18H14ON2F [M-H]
-
 293.1096, found 293.1086; Analytical HPLC: 
97.5%  
 
4-(5-((4-Fluorobenzyl)amino)pyridin-3-yl)phenol (128b) 
 
 
 
 
General Procedure C: Using aniline 127b (70 mg, 0.38 mmol) and 4-
fluorobenzaldehyde (167 µL, 193 mg, 1.56 mmol), chromatography (silica, 50% 
EtOAc, DCM) afforded 128b as a white solid (67.6 mg, 61%); Rf = 0.19 (silica, 50% 
EtOAc, DCM); m.p. 73 
oC (decomposed); UV λmax (EtOH/nm) 325.0 and 257.5; IR 
νmax/cm
-1
 3350 (N-H), 3030 (C-H), 2582 (br) (O-H), 1591, 1507, 1464, 1431, 1333, 
1223, 1155, 1106, 1014, 828, 707; 
1H δ/ppm (500 MHz, DMSO-d6) 4.36 (2H, d, CH2, J 
= 6.0 Hz), 6.54 (1H, t, NH, J = 6.1 Hz), 6.82-6.85 (2H, m, Ar-H), 7.03 (1H, t, Ar-H, J = 
2.3 Hz), 7.14-7.19 (2H, m, Ar-H), 7.39-7.44 (4H, m, Ar-H), 7.90 (1H, d, Ar-H, J = 2.6 
Hz), 7.97 (1H, d, Ar-H, J = 1.90 Hz), 9.59 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-
d6) 45.2, 115.0, 115.1, 115.7, 127.8, 128.5, 129.1, 129.2, 133.8, 134.9, 135.6, 135.8, 
144.4, 157.4, 160.2; LC-MS (ESI+) m/z = 295.3 [M+H]
+
; HRMS calcd. for C18H16ON2F 
[M+H]
+
 295.1241, found 295.1246; HRMS calcd. for C18H14ON2F [M-H]
-
 293.1096, 
found 293.1087; Analytical HPLC: 98.4%  
 
5-Bromo-N-(4-fluorobenzyl)pyridin-3-amine (132) 
 
 
 
 
General Procedure C: Using pyridine 126b (400 mg, 2.31 mmol) and 4-
fluorobenzaldehyde (743 µL, 860 mg, 6.93 mmol) at 50 
o
C, chromatography (silica, 0-
7% EtOAc, DCM) eluted 132 as a beige solid (533 mg, 82%); Rf = 0.25 (silica, 10% 
EtOAc, DCM); m.p. 92-94 
oC; UV λmax (EtOH/nm) 319.5 and 258.0; IR νmax/cm
-1
 3256 
(N-H), 3052 (C-H), 1579, 1507, 1447, 1412, 1335, 1224, 1156, 1085, 1004, 829, 778, 
690; 
1H δ/ppm (500 MHz, DMSO-d6) 4.31 (2H, d, CH2, J = 6.1 Hz), 6.82-6.85 (1H, m, 
NH), 7.09-7.10 (1H, m, Ar-H), 7.15-7.20 (2H, m, Ar-H), 7.38-7.42 (2H, m, Ar-H), 7.81 
(1H, d, Ar-H, J = 2.0 Hz), 7.97 (1H, d, Ar-H, J = 2.5 Hz); 
13C δ/ppm (125 MHz, 
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DMSO-d6) 44.9, 115.1, 115.2, 119.4, 120.4, 129.18, 129.24, 134.2, 135.03, 135.05, 
136.7, 145.8, 160.3, 162.2; LC-MS (ESI+) m/z = 281.2 and 283.2 [M+H]
+
; HRMS 
calcd. for C12H11N2
79
BrF [M+H]
+
 281.0084, found 281.0086; Analytical HPLC: 97.6%  
 
2’-(4-Chlorophenoxy)-3’-((4-fluorobenzyl)amino)-[1,1’-biphenyl]-4-ol (138a) 
 
 
 
 
 
General Procedure C: Using aniline 137a (50 mg, 0.16 mmol) and 4-
fluorobenzaldehyde (42 µL, 47.2 mg, 0.38 mmol), chromatography (silica, 80% DCM, 
hexane) afforded 138a as a white solid (22.5 mg, 34%); Rf = 0.33 (silica, 80% DCM, 
hexane); m.p. 126-129 
oC; UV λmax (EtOH/nm) 246.0 and 232.0; IR νmax/cm
-1
 3426 (N-
H), 3235 (br) (O-H), 1603, 1509, 1484, 1413, 1333, 1278, 1215, 1126, 1097, 1009, 869, 
830, 782, 747; 
1H δ/ppm (500 MHz, DMSO-d6) 4.31 (2H, d, CH2, J = 6.1 Hz), 5.89-
5.92 (1H, m, NH), 6.54 (1H, d, Ar-H, J = 8.1 Hz), 6.58 (1H, d, Ar-H, J = 7.7 Hz), 6.65-
6.68 (4H, m, Ar-H), 7.03 (1H, t, Ar-H, J = 8.0 Hz), 7.11 (1H, t, Ar-H, J = 8.9 Hz), 7.20-
7.23 (4H, m, Ar-H), 7.30 (2H, dd, Ar-H, J = 5.6 and 8.3 Hz), 9.38 (1H, s, OH); 
13
C 
δ/ppm (125 MHz, DMSO-d6) 45.1, 110.4, 114.8, 114.9, 115.0, 116.7, 117.3, 124.9, 
126.2, 128.0, 128.6, 128.7, 128.9, 129.7, 134.6, 136.2, 137.0, 141.3, 155.9, 156.5, 
160.0; LC-MS (ESI+) m/z = 420.3 [M+H]
+
; HRMS calcd. for C25H20O2NClF [M+H]
+
 
420.1161, found 420.1171; HRMS calcd. for C25H18O2N
35
ClF [M-H]
-
 418.1016, found 
418.1005; Analytical HPLC: 98.2%  
 
2-(4-Chlorophenoxy)-N-(4-fluorobenzyl)-[1,1’-biphenyl]-3-amine (138b) 
 
 
 
 
 
General Procedure C: Using aniline 137b (150 mg, 0.51 mmol) and 4-
fluorobenzaldehyde (164 µL, 190 mg, 1.53 mmol) at 70 
o
C, chromatography (silica, 10-
30% DCM, petrol) eluted 138b as a yellow oil (23 mg, 11%); Rf = 0.72 (silica, 20% 
EtOAc, petrol); m.p. 103-105 
oC; UV λmax (EtOH/nm) 259.5; IR νmax/cm
-1
 3444 (N-H), 
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2920 (C-H), 2850 (C-H), 1602, 1507, 1482, 1335, 1214 (C-O), 1090, 1008, 810, 756, 
699; 
1H δ/ppm (500 MHz, DMSO-d6) 4.33 (2H, d, CH2, J = 6.1 Hz), 5.99-6.01 (1H, m, 
NH), 6.60-6.63 (2H, m, Ar-H), 6.66-6.68 (2H, m, Ar-H), 7.06-7.13 (3H, m, Ar-H), 
7.20-7.23 (3H, m, Ar-H), 7.27-7.32 (4H, m, Ar-H), 7.38-7.39 (2H, m, Ar-H); 
13C δ/ppm 
(125 MHz, DMSO-d6) 45.1, 111.1, 114.9, 115.0, 116.7, 117.5, 125.0, 126.4, 127.1, 
128.0, 128.6, 128.7, 129.0, 134.7, 136.2, 137.1, 137.5, 141.3, 155.9, 160.0, 162.0; LC-
MS (ESI+) m/z = 404.3 [M+H]
+
; HRMS calcd. for C25H20ON
35
ClF [M+H]
+
 404.1212, 
found 404.1212; Analytical HPLC: 94.3%  
 
2’-((4-Chlorobenzyl)oxy)-3’-((4-fluorobenzyl)amino)-[1,1’-biphenyl]-4-ol (138h) 
 
 
 
 
 
 
General Procedure C: Using aniline 137c (100 mg, 0.31 mmol) and 4-
fluorobenzaldehyde (101 µL, 116 mg, 0.93 mmol) at 70 
o
C, chromatography (silica, 10-
30% Et2O, petrol) eluted 138h as a yellow oil (35 mg, 26%); Rf = 0.27 (silica, 30% 
Et2O, petrol); UV λmax (EtOH/nm) 246.0; IR νmax/cm
-1
 3411 (br) (O-H and N-H), 3033 
(C-H), 2927 (C-H), 2860 (C-H), 1598, 1509, 1469, 1336, 1218 (C-O), 1172, 1084, 972, 
810, 781, 743; 
1H δ/ppm (500 MHz, DMSO-d6) 4.33 (2H, d, HN-CH2, J = 6.0 Hz), 4.43 
(2H, s, O-CH2), 5.80 (1H, t, NH, J = 5.9 Hz), 6.40-6.41 (1H, m, Ar-H), 6.49-6.50 (1H, 
m, Ar-H), 6.80-6.81 (2H, m, Ar-H), 6.86-6.89 (1H, m, Ar-H), 7.12-7.15 (2H, m, Ar-H), 
7.21-7.23 (2H, m, Ar-H), 7.34-7.36 (6H, m, Ar-H); 
13C δ/ppm (125 MHz, DMSO-d6) 
45.2, 71.8, 109.7, 114.9, 115.0, 117.4, 124.7, 128.0, 128.67, 128.74, 128.9, 129.8, 
130.0, 132.3, 134.0, 136.1, 136.4, 141.6, 141.9, 156.5, 160.0, 162.0; LC-MS (ESI+) m/z 
= 434.4 [M+H]
+
; HRMS calcd. for C26H20O2N
35
ClF [M-H]
-
 432.1172, found 432.1161; 
Analytical HPLC: 97.1%  
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2-(4-Chlorophenoxy)-4’-fluoro-N-(4-methoxybenzyl)-[1,1’-biphenyl]-3-amine 
(138q) 
 
 
 
 
 
General procedure E: Using aniline 137f (40 mg, 0.13 mmol) and 4-anisaldehyde (20 
µL, 21.8 mg, 0.16 mmol), chromatography (silica, 2-10% Et2O, petrol) eluted 138q as a 
yellow oil (23.8 mg, 42%); Rf = 0.21 (silica, 10% EtOAc, petrol); UV λmax (EtOH/nm) 
230.6; IR νmax/cm
-1
 3434 (N-H), 3064 (C-H), 3002 (C-H), 2932 (C-H), 2836 (C-H), 
1604, 1576, 1512, 1483, 1423, 1400, 1337, 1284, 1246, 1216 (C-O), 1174, 1159, 1129, 
1089, 1034, 1009, 824, 778, 744; 
1H δ/ppm (500 MHz, CDCl3) 3.79 (3H, s, OCH3), 
4.29 (2H, d, CH2, J = 4.9 Hz), 4.43 (1H, s, br, NH), 6.60-6.63 (2H, m, Ar-H), 6.70-6.73 
(2H, m, Ar-H), 6.82-6.85 (2H, m, Ar-H), 6.91-6.96 (2H, m, Ar-H), 7.04-7.08 (2H, m, 
Ar-H), 7.12-7.16 (3H, m, Ar-H), 7.34-7.38 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, 
CDCl3) 47.2, 55.3, 111.3, 114.0, 114.8, 115.0, 116.4, 118.7, 126.4, 126.6, 128.4, 129.3, 
130.5, 130.6, 131.0, 137.8, 141.6, 155.9, 157.8, 158.8; 
19F δ/ppm (470 MHz, CDCl3) -
115.3; LC-MS (ESI+) m/z = 434.1 [M+H]
+
; HRMS calcd. for C26H22O2N
35
ClF [M+H]
+ 
434.1318, found 434.1317; Analytical HPLC: 99.4%  
 
2’-(4-Chlorophenoxy)-2-methyl-3’-nitro-[1,1’-biphenyl]-4-ol (136d) 
 
 
 
 
 
General procedure F: Using aryl fluoride 144a (164 mg, 0.66 mmol) and 4-
chlorophenol (509 mg, 3.96 mmol), chromatography (silica, 0-10% EtOAc, petrol) 
eluted 136d as a yellow oil (194 mg, 83%); Rf = 0.24 (silica, 20% EtOAc, petrol); UV 
λmax (EtOH/nm) 256.4; IR νmax/cm
-1
 3466 (O-H), 2925 (C-H), 1607, 1585, 1531, 1484, 
1438, 1351, 1292, 1235 (C-O), 1197, 1162, 1090, 1045, 1010, 951, 885, 863, 818, 794, 
755; 
1H δ/ppm (500 MHz, CDCl3) 2.07 (3H, s, CH3), 4.74 (1H, s, br, OH), 6.49-6.53 
(3H, m, Ar-H), 6.60-6.61 (1H, m, Ar-H), 6.84 (1H, d, Ar-H, J = 8.3 Hz), 7.01-7.04 (2H, 
m, Ar-H), 7.41 (1H, t, Ar-H, J = 7.8 Hz), 7.50 (1H, dd, Ar-H, J = 1.7 and 7.7 Hz), 7.93 
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(1H, dd, Ar-H), 1.7 and 8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 20.0, 112.5, 112.6, 
116.6, 116.7, 117.1, 124.3, 125.4, 127.5, 129.0, 131.1, 136.7, 137.9, 138.3, 144.4, 
145.7, 155.4, 155.5, 156.0; LC-MS (ESI+) m/z = 354.2 [M-H]
-
; HRMS calcd. for 
C19H13O4N
35
Cl [M-H]
- 
354.0539, found 354.0540; Analytical HPLC: 97.7%  
 
2-Chloro-2’-(4-chlorophenoxy)-3’-nitro-[1,1’-biphenyl]-4-ol (136e) 
 
 
 
 
 
General procedure F: Using aryl fluoride 144b (152 mg, 0.57 mmol) and 4-
chlorophenol (440 mg, 3.42 mmol), chromatography (silica, 0-10% EtOAc, petrol) 
eluted 136e as a yellow oil (198 mg, 82%); Rf = 0.24 (silica, 20% EtOAc, petrol); UV 
λmax (EtOH/nm) 250.6; IR νmax/cm
-1
 3411 (O-H), 3088 (C-H), 1605, 1531, 1504, 1484, 
1445, 1350, 1279, 1236 (C-O), 1196, 1163, 1089, 1030, 910, 883, 863, 821, 793, 755; 
1H δ/ppm (500 MHz, CDCl3) 5.02 (1H, s, OH), 6.56-6.60 (2H, m, Ar-H), 6.65 (1H, dd, 
Ar-H, J = 2.5 and 8.4 Hz), 6.83 (1H, d, Ar-H, J = 2.5 Hz), 7.04-7.07 (3H, m, Ar-H), 
7.42 (1H, t, Ar-H, J = 8.0 Hz), 7.59 (1H, dd, Ar-H, J = 1.7 and 7.7 Hz), 7.96 (1H, dd, 
Ar-H, J = 1.7 and 8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 113.9, 114.0, 116.5, 116.6, 
117.0, 125.0, 125.1, 126.3, 127.6, 129.2, 132.2, 133.8, 135.7, 137.2, 144.3, 145.7, 
155.9, 156.2; LC-MS (ESI+) m/z = 374.2 [M-H]
-
; HRMS calcd. for C18H10O4N
35
Cl2 
[M-H]
- 
373.9992, found 373.9992; Analytical HPLC: 97.4%  
 
2-(4-Chlorophenoxy)-1-ethynyl-3-nitrobenzene (165) 
 
 
 
 
General procedure F: Using aryl fluoride 164 (1.83 g, 5.68 mmol) and 4-chlorophenol 
(1.46 g, 11.4 mmol), the crude material was dissolved in THF (5 mL) and mixed with 
TBAF (1 M in THF, 5.68 mL, 5.68 mmol) at room temperature for 30 min, then 
concentrated to a low volume in vacuo. Chromatography (silica, 10-30% Et2O, petrol) 
eluted 165 as a yellow solid (1.47 g, 94%); Rf = 0.24 (silica, 30% DCM, petrol); m.p. 
68-70 
oC; UV λmax (EtOH/nm) 227.0; IR νmax/cm
-1
 3287 (alkyne C-H), 3081 (C-H), 
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2873 (C-H), 1885 (C≡C), 1588, 1526, 1487, 1445, 1354, 1283, 1237 (C-O), 1196, 1170, 
1093, 1011, 874, 828, 799, 750, 670; 
1H δ/ppm (500 MHz, CDCl3) 3.20 (1H, s, CCH), 
6.81 (2H, d, 4-ClPh C3-H and C5-H, J = 9.1 Hz), 7.26 (2H, d, 4-ClPh C2-H and C6-H, J 
= 8.9 Hz), 7.36 (1H, t, 3- NO2Ar C5-H, J = 8.1 Hz), 7.78 (1H, dd, Ar-H, J = 1.6 and 7.8 
Hz), 7.95 (1H, dd, Ar-H, 1.6 and 8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 85.5, 117.1, 
120.4, 125.5, 125.9, 128.0, 129.5, 138.7, 144.1, 149.1, 156.2; LC-MS (ESI+) m/z = 
mass not observed 
 
3-Bromo-4-(4-chlorophenoxy)-5-nitrobenzoic acid (223) 
 
 
 
 
 
General procedure F: Using aryl fluoride 222 (970 mg, 3.67 mmol) and 4-
chlorophenol (944 mg, 7.34 mmol), chromatography (C18, 50-80% MeOH, H2O) eluted 
223 as a white solid (1.15 g, 84%); Rf = 0.42 (C18, 70% MeOH, H2O); m.p. 219-221 
oC;  UV λmax (EtOH/nm) 226.0; IR νmax/cm
-1
 3085 (C-H), 2959 (C-H), 2814 (C-H), 
2654 (O-H), 1687 (C=O), 1609, 1585, 1536, 1481, 1414, 1352, 1280 (C-O), 1192, 
1159, 1085, 1007, 905, 823, 753, 723, 675; 
1H δ/ppm (500 MHz, DMSO-d6) 6.99 (2H, 
d, 4-ClPh C3-H and C5-H, J = 9.0 Hz), 7.43 (2H, d, 4-ClPh C2-H and C6-H, J = 9.0 Hz), 
8.53 (1H, dd, Ar-H, J = 2.0 Hz), 8.56 (1H, dd, Ar-H, J = 2.0 Hz), 14.00 (1H, s, br, 
CO2H); 
13C δ/ppm (125 MHz, DMSO-d6) 117.1, 119.4, 126.1, 127.2, 129.8, 130.2, 
138.8, 144.1, 146.9, 155.1, 164.1; LC-MS (ESI+) m/z = 371.0 and 373.3 [M+H]
+
 and 
370.1 and 372.1 [M-H]
-
; HRMS calcd. for C13H6O5N
79
Br
35
Cl [M-H]
- 
369.9123, found 
369.9110 
 
2-(4-Chlorophenoxy)-4’-methoxy-3-nitro-1,1’-biphenyl (251) 
 
 
 
 
General procedure F: Using aryl fluoride 216 (190 mg, 0.77 mmol) and 4-
chlorophenol (149 mg, 1.16 mmol), chromatography (silica, 0-40% DCM, petrol) eluted 
251 as a green oil (264 mg, 96%); Rf = 0.25 (silica, 40% DCM, petrol); UV λmax 
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(EtOH/nm) 261.6; IR νmax/cm
-1
 3072 (C-H), 2932 (C-H), 2836 (C-H), 1607, 1521, 1512, 
1482, 1442, 1348, 1233 (C-O), 1177, 1089, 1027, 886, 823, 803, 751; 
1H δ/ppm (500 
MHz, CDCl3) 3.79 (3H, s, OCH3), 6.60 (2H, d, 4-ClPh C3-H and C5-H, J = 9.1 Hz), 
6.84 (2H, d, 4-MeOPh C2-H and C6-H, J = 8.8 Hz), 7.07 (2H, d, 4-ClPh C2-H and C6-H, 
J = 9.0 Hz), 7.36 (2H, d, 4-MeOPh C3-H and C5-H, J = 8.8 Hz), 7.43 (1H, t, 3-NO2Ar 
C5-H, J = 8.0 Hz), 7.66 (1H, dd, Ar-H, J = 1.6 and 7.7 Hz), 7.88 (1H, dd, Ar-H, J = 1.6 
and 8.1 Hz); 
13C δ/ppm (125 MHz, CDCl3) 55.2, 113.9, 116.6, 124.1, 125.8, 127.4, 
127.6, 129.3, 130.2, 135.7, 138.3, 144.4, 144.5, 155.9, 159.6; LC-MS (ESI+) m/z = 
mass not observed; HRMS calcd. for C19H15O4N
35
Cl [M+H]
+ 
356.0684, found 356.0677
 
 
2-(4-Chlorophenoxy)-[1,1’-biphenyl]-3-amine (137b) 
 
 
 
 
 
General Procedure G: Using 136b (374 mg, 1.15 mmol), chromatography (silica, 0-
10% EtOAc, petrol) eluted 137b as a yellow solid (309 mg, 96%); Rf = 0.40 (silica, 
20% EtOAc, petrol); m.p. 98-101 
oC; UV λmax (EtOH/nm) 229.0; IR νmax/cm
-1
 3484 and 
3388 (N-H), 3057 (C-H), 2925 (C-H), 1616, 1467, 1434, 1219 (C-O), 1086, 822, 756, 
697; 
1H δ/ppm (500 MHz, DMSO-d6) 4.99 (2H, s, NH), 6.63 (1H, dd, Ar-H, J = 1.5 and 
7.6 Hz), 6.64-6.68 (2H, m, Ar-H), 6.84 (1H, dd, Ar-H, J = 1.6 and 8.0 Hz), 7.08 (1H, t, 
Ar-H, J = 7.8 Hz), 7.17-7.23 (3H, m, Ar-H), 7.27-7.30 (2H, m, Ar-H), 7.38-7.40 (2H, 
m, Ar-H); 
13C δ/ppm (125 MHz, DMSO-d6) 115.2, 116.6, 117.7, 124.8, 126.3, 127.0, 
128.0, 128.5, 129.0, 135.1, 136.6, 141.8, 155.9; LC-MS (ESI+) m/z = 296.3 [M+H]
+
; 
HRMS calcd. for C18H15ON
35
Cl [M+H]
+
 296.0837, found 296.0843; Analytical HPLC: 
96.9%  
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3’-Amino-2’-((4-chlorobenzyl)oxy)-[1,1’-biphenyl]-4-ol (137c) 
 
 
 
 
 
 
General Procedure G: Using 136c (250 mg, 0.70 mmol), chromatography (silica, 0-
20% EtOAc, petrol) eluted 137c as a brown solid (208 mg, 92%); Rf = 0.17 (silica, 20% 
EtOAc, petrol); m.p. 160-163 
oC; UV λmax (EtOH/nm) 208.0; IR νmax/cm
-1
 3386 (N-H), 
3268 (br) (O-H and N-H), 1591, 1516, 1467, 1246 (C-O), 1204, 989, 874, 831, 804, 
746; 
1H δ/ppm (500 MHz, DMSO-d6) 4.40 (2H, s, CH2), 4.92 (2H, s, br, NH2), 6.53 
(1H, m, Ar-H), 6.71 (1H, m, Ar-H), 6.78-6.80 (2H, m, Ar-H), 6.88-6.89 (1H, m, Ar-H), 
7.20-7.22 (2H, m, Ar-H), 7.34 (4H, m, Ar-H), 9.45 (1H, s, OH); 
13C δ/ppm (125 MHz, 
DMSO-d6) 71.5, 115.0, 115.2, 115.3, 117.8, 124.5, 127.8, 128.0, 128.4, 129.5, 129.8, 
135.1, 135.3, 156.0; LC-MS (ESI+) m/z = 326.3 [M+H]
+
; HRMS calcd. for 
C19H17O2NCl [M+H]
+
 326.0942, found 326.0944; HRMS calcd. for C19H15O2N
35
Cl [M-
H]
-
 324.0797, found 324.0788 
 
3’-Amino-2’-(4-chlorophenoxy)-2-methyl-[1,1’-biphenyl]-4-ol (137d) 
 
 
 
 
 
General Procedure G: Using 136d (191 mg, 0.54 mmol), chromatography (silica, 0-
20% EtOAc, petrol) eluted 137d as a yellow oil (131 mg, 75%); Rf = 0.26 (silica, 20% 
EtOAc, petrol); UV λmax (EtOH/nm) 228.6; IR νmax/cm
-1
 3384 and 3323 (N-H), 3196 
(br) (O-H), 3028 (C-H), 2919 (C-H), 1610, 1583, 1508, 1483, 1467, 1281, 1217 (C-O), 
1161, 1087, 1008, 953, 859, 823, 785, 735; 
1H δ/ppm (500 MHz, DMSO-d6) 2.02 (3H, 
s, CH3), 4.93 (2H, s, br, NH2), 6.40 (2H, ddd, Ar-H, J = 2.5, 8.2 and 12.9 Hz), 6.52 (1H, 
d, Ar-H, J = 2.4 Hz), 6.55-6.58 (2H, m, Ar-H), 6.77 (1H, d, Ar-H, J = 8.3 Hz), 6.80 
(1H, dd, Ar-H, J = 1.5 and 8.0 Hz), 7.01 (1H, t, Ar-H, J = 7.9 Hz), 7.13-7.16 (2H, m, 
Ar-H), 9.15 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 19.9, 112.0, 114.5, 116.1, 
116.6, 118.6, 124.6, 125.7, 128.2, 128.8, 130.5, 135.3, 136.6, 137.7, 141.5, 156.1, 
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156.2; LC-MS (ESI+) m/z = 326.3 [M+H]
+
 and 324.2 [M-H]
-
; HRMS calcd. for 
C19H15O2N
35
Cl [M-H]
-
324.0797, found 324.0794; Analytical HPLC: 99.0 % 
 
3’-Amino-2-chloro-2’-(4-chlorophenoxy)-[1,1’-biphenyl]-4-ol (137e) 
 
 
 
 
 
General Procedure G: Using 136e (199 mg, 0.53 mmol), chromatography (silica, 0-
20% EtOAc, petrol) eluted 137e as a yellow oil (149 mg, 81%); Rf = 0.23 (silica, 20% 
EtOAc, petrol); UV λmax (EtOH/nm) 280.6 and 228.8; IR νmax/cm
-1
 3384 and 3323 (N-
H), 3066 (br) (O-H), 2971 (C-H), 2919 (C-H), 1609, 1583, 1507, 1483, 1466, 1278, 
1215 (C-O), 1161, 1088, 1035, 1008, 953, 919, 859, 823, 784, 748; 
1H δ/ppm (500 
MHz, DMSO-d6) 4.98 (1H, s, br, NH2), 6.45 (1H, dd, Ar-H, J = 1.4 and 7.5 Hz), 6.57-
6.62 (3H, m, Ar-H), 6.75 (1H, d, Ar-H, J = 2.4 Hz), J = 6.83 (1H, dd, Ar-H, J = 1.5 and 
8.0 Hz), 6.95 (1H, d, Ar-H, J = 8.4 Hz), 7.02 (1H, t, Ar-H, J = 7.8 Hz), 7.15-7.18 (2H, 
m, Ar-H), 9.78 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 113.8, 115.2, 115.5, 
116.7, 118.6, 124.8, 125.5, 126.9, 128.8, 132.0, 132.4, 133.0, 137.7, 141.5, 156.1, 
157.2; LC-MS (ESI+) m/z = 346.2 [M+H]
+
 and 344.1 [M-H]
-
; HRMS calcd. for 
C18H12O2N
35
Cl2 [M-H]
- 
344.0251, found 344.0252 Analytical HPLC: 98.6 % 
 
2-(4-Chlorophenoxy)-4’-fluoro-[1,1’-biphenyl]-3-amine (137f) 
 
 
 
 
 
General Procedure G: Using 136f (617 mg, 1.79 mmol), chromatography (silica, 10-
20% Et2O, petrol) eluted 137f as a dark orange solid (440 mg, 78%); Rf = 0.40 (silica, 
20% Et2O, petrol); m.p. 87-91 
oC;  UV λmax (EtOH/nm) 229.2; IR νmax/cm
-1
 3485 and 
3389 (N-H), 3070 (C-H), 1617, 1511, 1468, 1402, 1335, 1278, 1217 (C-O), 1157, 1085, 
1007, 905, 867, 815, 778, 746, 659; 
1H δ/ppm (500 MHz, CDCl3) 4.59 (2H, s, br, NH2), 
6.60-6.66 (2H, m, Ar-H), 6.84-6.88 (2H, m, Ar-H) 6.93-6.97 (2H, m, Ar-H), 7.06-7.09 
(2H, m, Ar-H), 7.13-7.16 (1H, m, Ar-H), 7.35-7.38 (2H, m, Ar-H); 
13C δ/ppm (125 
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MHz, CDCl3) 114.9, 115.1, 116.3, 126.4, 126.7, 129.4, 130.5, 130.6, 135.2, 144.9, 
155.7, 161.2; LC-MS (ESI+) m/z = 314.3 [M+H]
+
; HRMS calcd. for C18H14ON
35
ClF 
[M+H]
+ 
314.0742, found 314.0747 
 
N
1
-(2-(4-Chlorophenoxy)-4’-fluoro-[1,1’-biphenyl]-3-yl)benzene-1,4-diamine (138t) 
 
 
 
 
 
General Procedure G: Using 138s (280 mg, 0.64 mmol), heating at 50 
o
C for 48 h, 
chromatography (silica, 0-30% EtOAc, petrol) eluted 138t as a dark red solid (162 mg, 
63%); Rf = 0.20 (silica, 90% DCM, petrol); m.p. 146-150 
oC;  UV λmax (EtOH/nm) 
261.0; IR νmax/cm
-1
 3731 (secondary N-H), 3427 and 3347 (primary N-H), 2926 (C-H), 
1592, 1488, 1464, 1399, 1300, 1259, 1217 (C-O), 1160, 1097, 1062, 824; 
1H δ/ppm 
(500 MHz, CDCl3) 5.55 (2H, s, br, NH2), 5.83 (1H, s, NH), 6.79-6.81 (2H, m, Ar-H), 
6.83-6.85 (2H, m, Ar-H), 6.95-7.00 (3H, m, Ar-H), 7.05-7.08 (1H, m, Ar-H), 7.08-7.13 
(2H, m, Ar-H), 7.15-7.17 (2H, m, Ar-H), 7.20-7.21 (1H, m, Ar-H), 7.53-7.57 (2H, m, 
Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 115.1, 115.3, 118.2, 118.5, 121.2, 124.9, 126.7, 
127.4, 128.1, 128.6, 129.3, 130.86, 130.92, 133.6, 146.3, 149.2; 
19F δ/ppm (470 MHz, 
CDCl3) -115.1; LC-MS (ESI+) m/z = 405.4 [M+H]
+
 and 403.3 [M-H]
-
; HRMS calcd. 
for C24H19ON2
35
ClF [M+H]
+ 
405.1164, found 405.1165; Analytical HPLC: 98.7 % 
 
N-(5-Bromothiazol-2-yl)-4-fluorobenzamide (267) 
 
 
 
 
General Procedure H: Using thiazole hydrobromide 266 (500 mg, 1.92 mmol) and 4-
fluorobenzoyl chloride (272 µL, 365 mg, 2.30 mmol), chromatography (silica, 10-30% 
THF, petrol) eluted 267 as a brown solid (511 mg, 88%); Rf = 0.29 (silica, 20% EtOAc, 
petrol); m.p. 224 
oC (decomposed); UV λmax (EtOH/nm) 293.8 and 230.0; IR νmax/cm
-1
 
3647 (N-H), 3141 (C-H), 3080 (C-H), 2953 (C-H), 2916 (C-H), 2874 (C-H), 1667 
(C=O), 1602, 1550, 1509, 1448, 1307, 1291, 1222, 1150, 1114, 1094, 994, 900, 847, 
815, 753, 695; 
1H δ/ppm (500 MHz, DMSO-d6) 7.39-7.42 (2H, m, Ar-H), 7.67 (1H, s, 
341 
 
thiazole C4-H), 8.16-8.19 (2H, m, Ar-H), 12.95 (1H, s, NH); 
13C δ/ppm (125 MHz, 
DMSO-d6) 102.2, 115.6, 115.8, 124.9, 128.0, 131.1, 131.2, 138.8, 163.8, 165.8, 189.0; 
LC-MS (ESI+) m/z = 301.2 and 303.1 [M+H]
+
 and 299.0 and 301.1 [M-H]
-
; HRMS 
calcd. for C10H7ON2
79
BrFS [M+H]
+ 
300.9441, found 300.9444 and calcd. for 
C10H5ON2BrFS [M-H]
- 
298.9295, found 298.9294 
 
N-(4-((2-(4-Chlorophenoxy)-4’-fluoro-[1,1’-biphenyl]-3-yl)amino)phenyl)-1,1,1-
trifluoromethanesulfonamide (138p) 
 
 
 
 
 
General procedure I: Using aniline 138t (40 mg, 0.10 mmol) and 
trifluoromethanesulfonic anhydride (16.6 µL, 27.9 mg, 0.10 mmol) with no base at 0 
o
C, 
chromatography (silica, 0-30% EtOAc, petrol) eluted 138p as a dark red oil (18.8 mg, 
35%); Rf = 0.23 (silica, 20% EtOAc, petrol); UV λmax (EtOH/nm) 288.4 and 231.4; IR 
νmax/cm
-1
 3409 (N-H), 3280 (N-H), 2962 (C-H), 2925 (C-H), 1604, 1576, 1513, 1484, 
1422, 1368, 1334, 1278, 1206 (C-O), 1139, 1089, 1009, 949, 825, 781, 751; 
1H δ/ppm 
(500 MHz, CDCl3) 5.93 (1H, s, br, NH), 6.58 (1H, s, br, NH), 6.59-6.62 (2H, m, Ar-H), 
6.95-7.00 (3H, m, Ar-H), 7.03-7.07 (4H, m, Ar-H), 7.17-7.19 (2H, m, Ar-H), 7.24 (1H, 
t, Ar-H, J = 7.8 Hz), 7.36-7.40 (3H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 109.4, 
115.1, 115.2, 116.3, 116.6, 119.0, 123.3, 126.2, 126.9, 127.0, 129.5, 130.5, 130.6, 
133.1, 135.6, 142.3, 152.1, 155.7; 
19F δ/ppm (470 MHz, CDCl3) -75.1 and -114.7; LC-
MS (ESI+) m/z = 537.3 [M+H]
+
 and 535.2 [M-H]
-
; HRMS calcd. for 
C25H16O3N2
35
ClF4S [M-H]
- 
535.0512, found 535.0504; Analytical HPLC: 96.3% 
 
Methyl 4-(trifluoromethylsulfonamido)benzoate (153) 
 
 
 
 
General procedure I: Using methyl aniline 152 (500 mg, 3.31 mmol) and 
trifluoromethanesulfonic anhydride (1.22 mL, 2.05 g, 7.28 mmol), chromatography 
(silica, 5-10% Et2O, DCM) eluted 153 as a light brown solid (682 mg, 74%); Rf = 0.17 
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(silica, 5% Et2O, DCM); m.p. 149-151 
oC; UV λmax (EtOH/nm) 250.4; IR νmax/cm
-1
 
3151 (N-H), 3069 (C-H), 2957 (C-H), 2854 (C-H), 1688 (C=O), 1608, 1513, 1421, 
1380, 1300 (S=O asym. stretch), 1183 (C-O), 1137 (S=O sym. stretch), 1020, 944, 855, 
766, 695; 
1H δ/ppm (500 MHz, CDCl3) 3.93 (3H, s, CO2CH3), 6.94 (1H, s, br, NH), 
7.32-7.34 (2H, m, Ar-H), 8.06-8.08 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 52.4, 
121.4, 128.8 131.3, 135.5, 166.0; 
19F δ/ppm (470 MHz, CDCl3) -75.5; LC-MS (ESI+) 
m/z = 282.2 [M-H]
-
; HRMS calcd. for C9H7O4NF3S [M-H]
- 
282.0053, found 282.0046; 
Analytical HPLC: 97.5%  
 
N-(4-Acetylphenyl)-1,1,1-trifluoromethanesulfonamide (263) 
 
 
 
 
General procedure I: Using aniline 262 (500 mg, 3.70 mmol) and 
trifluoromethanesulfonic anhydride (1.37 mL, 2.30 g, 8.14 mmol), washing the reaction 
mixture with 1 M HCl (50 mL) and distilled water (8 × 10 mL), brine (10 mL), drying 
(MgSO4), filtering and concentration in vacuo afforded 263 as a brown solid (887 mg, 
90%); Rf = 0.21 (silica, 20% EtOAc, petrol); m.p. 114-118 
oC; UV λmax (EtOH/nm) 
260.0; IR νmax/cm
-1
 3146 (N-H), 3065 (C-H), 2948 (C-H), 2856 (C-H), 1666 (C=O), 
1601, 1513, 1485, 1414, 1376 (S=O asym. stretch), 1275, 1181, 1136 (S=O sym. 
stretch), 1017, 941, 841, 670; 
1H δ/ppm (500 MHz, CDCl3) 2.61 (3H, s, CH3), 7.35-7.38 
(2H, m, Ar-H), 7.98-8.01 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 26.6, 121.5, 
130.1, 135.4, 138.4, 196.6; 
19F δ/ppm (470 MHz, CDCl3) -75.5; LC-MS (ESI+) m/z = 
268.3 [M+H]
+
 and 266.2 [M-H]
-
; HRMS calcd. for C9H7O3NF3S [M-H]
- 
266.0104, 
found 266.0101 
 
4’-Fluoro-N-(4-methoxybenzyl)-2-methyl-[1,1’-biphenyl]-3-amine (149a) 
 
 
 
 
General Procedure J: Using benzamide 148a (150 mg, 0.45 mmol), chromatography 
(silica, 90% EtOAc, petrol followed by C18, 80-90% MeOH + 0.1% (v/v) HCO2H, 
H2O) eluted 149a as a brown solid (81 mg, 56%); Rf = 0.26 (C18, 90% MeOH, H2O); 
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m.p. 87-89 
oC; UV λmax (EtOH/nm) 228.6; IR νmax/cm
-1
 3421 (N-H), 2985 (C-H), 2933 
(C-H), 2845 (C-H), 1582, 1510, 1463, 1420, 1322, 1281, 1251 (C-O), 1211, 1185, 1154, 
1110, 1088, 1067, 1037, 992, 887, 828, 782, 722, 669; 
1H δ/ppm (500 MHz, CDCl3) 
2.02 (3H, s, ArCH3), 3.82 (3H, s, OCH3), 3.90 (1H, s, br, NH), 4.34 (2H, s, CH2), 6.66 
(2H, dd, Ar-H, J = 7.9 and 15.4 Hz), 6.90-6.92 (2H, m, Ar-H), 7.06-7.10 (2H, m, Ar-H), 
7.15 (1H, t, Ar-H, J = 7.9 Hz), 7.23-7.28 (2H, m, Ar-H), 7.33-7.35 (2H, m, Ar-H); 
13
C 
δ/ppm (125 MHz, CDCl3) 14.3, 48.1, 55.3, 109.1, 114.1, 114.7, 114.9, 119.2, 119.4, 
126.4, 128.9, 130.88, 130.94, 138.6, 141.6, 159.0, 160.9, 162.8; LC-MS (ESI+) m/z = 
mass not observed 
 
N-(4-Fluorobenzyl)-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)thiazol-2-
amine (276) 
 
 
 
 
 
 
General Procedure J: Using benzamide 274 (266 mg, 0.63 mmol), and lithium 
aluminium hydride (1 M in THF, 5.0 mL, 5.0 mmol) at 60 
o
C for 24 h, chromatography 
(silica, 0-30% EtOAc, petrol followed by 0-10% EtOAc, DCM) eluted 276 as a yellow 
oil (131 mg, 51%); Rf = 0.25 (silica, 30% EtOAc, petrol); 
1H δ/ppm (500 MHz, CDCl3) 
1.64-1.69 (1H, m, Alk-H), 1.72-1.82 (2H, m, Alk-H), 2.08-2.11 (1H, m, Alk-H), 2.15-
2.18 (1H, m, Alk-H), 2.54-2.62 (1H, m, Alk-H), 3.73-3.78 (1H, m, CH2-O), 4.03-4.05 
(1H, m, CH2-O), 4.53 (2H, d, NHCH2Ar, J = 5.3 Hz), 5.52 (1H, s, br, NH), 5.72 (1H, 
dd, NCHO, J = 2.7 and 9.4 Hz), 6.69 (1H, s, thiazole C5-H), 7.06 (2H, t, 4-FPh C2-H 
and C6-H, J = 8.8 Hz), 7.36-7.43 (2H, m, 4-FPh C3-H and C5-H), 7.57 (1H, d, indazole 
C7-H, J = 8.8 Hz), 7.83 (1H, dd, indazole C6-H, J = 1.5 and 8.8 Hz), 8.03 (1H, s, 
indazole C3-H), 8.20 (1H, m, indazole C4-H); 
13C δ/ppm (125 MHz, CDCl3) 22.6, 25.1, 
29.5, 49.2, 67.5, 85.4, 99.9, 110.2, 115.6, 115.8, 118.6, 125.1, 125.2, 127.7, 127.9, 
128.8, 129.4, 129.5, 134.6, 139.2; 
19F δ/ppm (470 MHz, CDCl3) -114.4; LC-MS (ESI+) 
m/z = 409.3 [M+H]
+
 and 407.3 [M-H]
-
; Analytical HPLC: 93.8% 
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2-(4-Chlorophenoxy)-N-(4-fluorophenyl)-[1,1’-biphenyl]-3-amine (138d) 
 
 
 
 
 
General Procedure K: Using aniline 137b (150 mg, 0.51 mmol) and 1-bromo-4-
fluorobenzene (112 µL, 179 mg, 1.02 mmol), chromatography (silica, 0-10% DCM, 
petrol) eluted 138d as a white solid (113 mg, 56%); Rf = 0.25 (silica, 20% DCM, 
petrol); m.p. 123-126 
oC; UV λmax (EtOH/nm) 279.5 and 231.5; IR νmax/cm
-1
 3408 (N-
H), 3064 (C-H), 1594, 1510, 1484, 1428, 1213 (C-O), 1087, 820, 756, 698; 
1H δ/ppm 
(500 MHz, DMSO-d6) 6.60-6.64 (2H, m, Ar-H), 6.98 (1H, dd, Ar-H, J = 2.1 and 7.0 
Hz), 7.02-7.08 (4H, m, Ar-H), 7.13-7.17 (2H, m, Ar-H), 7.22-7.28 (3H, m, Ar-H), 7.32-
7.35 (2H, m, Ar-H), 7.43-7.44 (2H, m, Ar-H), 7.67 (1H, s, NH); 
13C δ/ppm (125 MHz, 
DMSO-d6) 115.3, 115.5, 116.7, 117.0, 119.96, 120.02, 122.0, 125.0, 126.3, 127.3, 
128.1, 128.7, 128.9, 135.8, 137.2, 137.7, 139.2, 140.3, 156.0; LC-MS (ESI+) m/z = 
390.3 [M+H]
+
; Analytical HPLC: 98.5%  
 
2’-(4-Chlorophenoxy)-3’-(phenylamino)-[1,1’-biphenyl]-4-ol (138e) 
 
 
 
 
 
General Procedure K: Using aniline 137a (50 mg, 0.16 mmol) and bromobenzene 
(51.2 µL, 75.4 mg, 0.48 mmol), chromatography (silica, 5-20% EtOAc, petrol) eluted 
138e as a brown solid (49.3 mg, 79%); Rf = 0.29 (silica, 20% EtOAc, petrol); m.p. 105-
108 
oC;  UV λmax (EtOH/nm) 277.4 and 230.8; IR νmax/cm
-1
 3517 (N-H), 3388 (br) (O-
H), 3036 (C-H), 2926 (C-H), 1594, 1519, 1483, 1470, 1399, 1332, 1265, 1216 (C-O), 
1172, 1086, 1007, 921, 868, 819, 779, 746, 713, 690; 
1H δ/ppm (500 MHz, CDCl3) 4.60 
(1H, s, NH), 5.90 (1H, s, OH), 6.65-6.68 (2H, m, Ar-H), 6.72-6.75 (2H, m, Ar-H), 6.91 
(1H, dd, Ar-H, J = 1.5 and 7.6 Hz), 6.96-6.99 (1H, m, Ar-H), 7.04-7.07 (2H, m, Ar-H), 
7.08-7.10 (2H, m, Ar-H), 7.18 (1H, t, Ar-H, J = 7.9 Hz), 7.26-7.29 (2H, m, Ar-H), 7.30-
7.35 (3H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 114.7, 115.0, 116.3, 119.6, 121.9, 
122.1, 126.0, 126.7, 129.3, 130.3, 135.8, 137.6, 139.7, 141.9, 154.9, 155.9; LC-MS 
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(ESI+) m/z = 386.3 [M+H]
+
; HRMS calcd. for C24H17O2N
35
Cl [M-H]
- 
386.0953, found 
386.0952; Analytical HPLC: 98.2%  
 
2’-(4-Chlorophenoxy)-3’-((4-chlorophenyl)amino)-[1,1’-biphenyl]-4-ol (138f) 
 
 
 
 
 
General Procedure K: Using aniline 137a (30 mg, 0.10 mmol) and 1-bromo-4-
chlorobenzene (55.1 mg, 0.29 mmol), chromatography (silica, 5-20% EtOAc, petrol) 
eluted 138f as a brown solid (38 mg, 94%); Rf = 0.28 (silica, 20% EtOAc, petrol); m.p. 
65-68 
oC;  UV λmax (EtOH/nm) 280.6; IR νmax/cm
-1
 3533 (N-H), 3408 (br) (O-H), 3032 
(C-H), 2927 (C-H), 1594, 1519, 1429, 1420, 1384, 1332, 1263, 1215 (C-O), 1173, 1088, 
1008, 921, 867, 822, 781, 750; 
1H δ/ppm (500 MHz, CDCl3) 4.62 (1H, s, NH), 5.85 
(1H, s, OH), 6.62-6.66 (2H, m, Ar-H), 6.72-6.75 (2H, m, Ar-H), 6.94 (1H, dd, Ar-H, J = 
1.6 and 7.6 Hz), 6.99-7.02 (2H, m, Ar-H), 7.04-7.07 (2H, m, Ar-H), 7.19 (1H, t, Ar-H, J 
= 7.8 Hz), 7.20-7.23 (2H, m, Ar-H), 7.26 (1H, dd, Ar-H, J = 1.5 and 8.1 Hz), 7.29-7.32 
(2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 115.08, 115.13, 116.3, 126.0, 126.77, 
126.80, 129.3, 129.4, 129.9, 130.3, 135.9, 137.1, 140.0, 140.6, 154.9, 155.9; LC-MS 
(ESI+) m/z = 422.4 [M+H]
+
; HRMS calcd. for C24H16O2N
35
Cl2 [M-H]
- 
420.0564, found 
420.0562; Analytical HPLC: 98.0%  
 
2’-((4-Chlorobenzyl)oxy)-3’-((4-fluorophenyl)amino)-[1,1’-biphenyl]-4-ol (138g) 
 
 
 
 
 
 
General Procedure K: Using aniline 137c (100 mg, 0.31 mmol) and 1-bromo-4-
fluorobenzene (68 µL, 109 mg, 0.62 mmol), chromatography (silica, 10-15% EtOAc, 
petrol) eluted 138g as a brown gum (90 mg, 69%); Rf = 0.34 (silica, 20% EtOAc, 
petrol); UV λmax (EtOH/nm) 267.5; IR νmax/cm
-1
 3403 (br) (O-H and N-H), 3038 (C-H), 
2926 (C-H), 1597, 1506, 1469, 1334, 1211 (C-O), 1090, 968, 834, 783; 
1H δ/ppm (500 
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MHz, DMSO-d6) 4.47 (2H, s, CH2), 6.81-6.83 (3H, m, Ar-H), 7.03-7.08 (8H, m, Ar-H), 
7.23-7.25 (2H, m, Ar-H), 7.35-7.37 (2H, m, Ar-H), 7.52 (1H, s, NH), 9.50 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 72.2, 115.0, 115.3, 115.4, 119.2, 119.3, 124.6, 127.8, 
129.9, 130.0, 132.3, 135.5, 135.8, 137.5, 145.3; LC-MS (ESI+) m/z = 420.3 [M+H]
+
; 
HRMS calcd. for C25H20O2NClF [M+H]
+
 420.1161, found 420.1164; HRMS calcd. for 
C25H18O2N
35
ClF [M-H]
-
 418.1016, found 418.1006; Analytical HPLC: 93.3%  
 
2’-(4-Chlorophenoxy)-3’-((4-fluoro-2-methylphenyl)amino)-[1,1’-biphenyl]-4-ol 
(138i) 
 
 
 
 
 
General Procedure K: Using aniline 137a (50 mg, 0.16 mmol) and 2-bromo-5-
fluorotoluene (60.7 µL, 90.7 mg, 0.48 mmol), chromatography (silica, 5-20% EtOAc, 
petrol) eluted 138i as a dark brown oil (67 mg, 100%); Rf = 0.31 (silica, 20% EtOAc, 
petrol); UV λmax (EtOH/nm) 263.6 and 232.2; IR νmax/cm
-1
 3400 (br) (N-H and O-H), 
2977 (C-H), 1602, 1519, 1483, 1375, 1333, 1265, 1213 (C-O), 1173, 1088, 1043, 1008, 
956, 913 868, 824, 780, 748; 
1H δ/ppm (500 MHz, CDCl3) 2.09 (3H, s, ArCH3), 4.62 
(1H, s, NH), 5.47 (1H, s, OH), 6.69-6.72 (3H, m, Ar-H), 6.73-6.76 (2H, m, Ar-H), 6.84 
(1H, dd, Ar-H, J = 1.5 and 7.7 Hz), 6.87 (1H, td, Ar-H, J = 3.0, 8.4 and 16.7 Hz), 6.92 
(1H, dd, Ar-H, J = 2.9 and 9.2 Hz), 7.07-7.10 (2H, m, Ar-H), 7.11 (1H, t, Ar-H, J = 7.8 
Hz), 7.15 (1H, dd, Ar-H, J = 5.3 and 8.6 Hz), 7.32-7.35 (2H, m, Ar-H); 
13C δ/ppm (125 
MHz, CDCl3) 18.0, 113.1, 113.3, 113.5, 115.0, 116.3, 117.4, 117.5, 120.6, 125.17, 
125.24, 126.1, 129.4, 130.1, 130.3, 135.6, 138.5, 139.2, 154.8, 155.9; LC-MS (ESI+) 
m/z = 420.4 [M+H]
+
; HRMS calcd. for C25H18O2N
35
ClF [M-H]
- 
418.1016, found 
418.1012; Analytical HPLC: 99.1%  
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3’-((2-Chloro-4-fluorophenyl)amino)-2’-(4-chlorophenoxy)-[1,1’-biphenyl]-4-ol 
(138j) 
 
 
 
 
 
General Procedure K: Using aniline 137a (50 mg, 0.16 mmol) and 1-bromo-2-chloro-
4-fluorobenzene (101 mg, 0.48 mmol), chromatography (silica, 5-20% EtOAc, petrol) 
eluted 138j as a brown oil (70 mg, 100%); Rf = 0.32 (silica, 20% EtOAc, petrol); UV 
λmax (EtOH/nm) 272.4 and 232.0; IR νmax/cm
-1
 3407 (br) (N-H and O-H), 3068 (C-H), 
2928 (C-H), 1605, 1520, 1481, 1419, 1333, 1256, 1214 (C-O), 1184, 1090, 1041, 1008, 
930, 893, 859, 823, 779, 749; 
1H δ/ppm (500 MHz, CDCl3) 4.68 (1H, s, NH), 6.00 (1H, 
s, OH), 6.64-6.67 (2H, m, Ar-H), 6.73-6.77 (2H, m, Ar-H), 6.90-6.94 (1H, m, Ar-H), 
7.00 (1H, dd, Ar-H, J = 1.8 and 7.5 Hz), 7.05-7.08 (2H, m, Ar-H), 7.11 (1H, dd, Ar-H, J 
= 2.9 and 8.3 Hz), 7.15-7.22 (2H, m, Ar-H), 7.29 (1H, dd, Ar-H, J = 5.3 and 9.1 Hz), 
7.32-7.34 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 114.3, 114.5, 115.1, 115.8, 
116.4, 116.9, 117.1, 119.7, 119.8, 123.1, 126.0, 129.4, 130.3, 136.2, 136.5, 154.9, 
155.9; LC-MS (ESI+) m/z = 440.4 [M+H]
+
; HRMS calcd. for C24H15O2N
35
Cl2F [M-H]
- 
438.0469, found 438.0469; Analytical HPLC: 99.2%  
 
2’-(4-Chlorophenoxy)-3’-((4-fluorophenyl)amino)-2-methyl-[1,1’-biphenyl]-4-ol 
(138k) 
 
 
 
 
 
General Procedure K: Using aniline 137d (50 mg, 0.15 mmol) and 1-bromo-4-
fluorobenzene (50.0 µL, 79 mg, 0.45 mmol), chromatography (silica, 0-15% EtOAc, 
petrol) eluted 138k as a yellow oil (49.8 mg, 80%); Rf = 0.24 (silica, 20% EtOAc, 
petrol); UV λmax (EtOH/nm) 278.8; IR νmax/cm
-1
 3534 (N-H), 3410 (br) (O-H), 3029 (C-
H), 2924 (C-H), 1607, 1576, 1507, 1483, 1434, 1387, 1333, 1290, 1211 (C-O), 1159, 
1091, 1043, 1009, 954, 913, 864, 823, 783, 750; 
1H δ/ppm (500 MHz, CDCl3) 2.11 (3H, 
s, ArCH3), 4.53 (1H, s, br, OH), 6.50 (1H, dd, Ar-H, J = 2.7 and 8.2 Hz), 6.54-6.58 (2H, 
348 
 
m, Ar-H), 6.60 (1H, d, Ar-H, J = 2.6 Hz), 6.72 (1H, dd, Ar-H, J = 1.7 and 7.4 Hz), 6.87 
(1H, d, Ar-H, 8.2 Hz), 6.98-7.04 (4H, m, Ar-H), 7.08-7.11 (2H, m, Ar-H), 7.13-7.14 
(1H, m, Ar-H), 7.18 (1H, dd, Ar-H, J = 1.7 and 8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 
20.1, 112.1, 113.7, 115.9, 116.1, 116.3, 116.7, 122.3, 122.36, 122.41, 125.6, 126.8, 
129.1, 131.1, 135.7, 137.9, 138.1, 140.5, 156.2; 
19F δ/ppm (470 MHz, CDCl3) -120.5; 
LC-MS (ESI+) m/z = 420.4 [M+H]
+
 and 418.3 [M-H]
-
; HRMS calcd. for 
C25H18O2N
35
ClF [M-H]
- 
418.1016, found 418.1014; Analytical HPLC: 99.6%  
 
2-Chloro-2’-(4-chlorophenoxy)-3’-((4-fluorophenyl)amino)-[1,1’-biphenyl]-4-ol 
(138l) 
 
 
 
 
 
General Procedure K: Using aniline 137e (50 mg, 0.14 mmol) and 1-bromo-4-
fluorobenzene (46.0 µL, 74 mg, 0.42 mmol), chromatography (silica, 0-15% EtOAc, 
petrol) eluted 138l as a yellow oil (51.5 mg, 84%); Rf = 0.35 (silica, 20% EtOAc, 
petrol); UV λmax (EtOH/nm) 279.4; IR νmax/cm
-1
 3535 (N-H), 3405 (br) (O-H), 3041 (C-
H), 2934 (C-H), 1608, 1577, 1507, 1483, 1439, 1388, 1335, 1275, 1211 (C-O), 1160, 
1091, 1039, 1009, 930, 894, 824, 782, 748; 
1H δ/ppm (500 MHz, CDCl3) 4.95 (1H, s, 
br, OH), 6.60 (1H, dd, Ar-H, J = 2.6 and 8.4 Hz), 6.61-6.64 (2H, m, Ar-H), 6.80 (1H, 
dd, Ar-H, J = 1.6 and 7.5 Hz), 6.83 (1H, d, Ar-H, J = 2.5 Hz), 6.97-7.07 (5H, m, Ar-H), 
7.07-7.12 (2H, m, Ar-H), 7.15 (1H, t, Ar-H, J = 7.6 Hz), 7.21 (1H, dd, Ar-H, J = 1.6 and 
8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 113.6, 114.4, 115.9, 116.1, 116.3, 116.6, 122.4, 
122.50, 122.53, 125.5, 126.9, 128.6, 129.2, 132.2, 133.3, 133.8, 137.6, 138.2, 140.3, 
155.4, 156.0; 
19F δ/ppm (470 MHz, CDCl3) -120.4; LC-MS (ESI+) m/z = 440.3 [M+H]
+
 
and 438.2 [M-H]
-
; HRMS calcd. for C24H15O2N
35
Cl2F [M-H]
- 
438.0469, found 
438.0472; Analytical HPLC: 98.8%  
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2-(4-Chlorophenoxy)-4’-fluoro-N-(4-methoxyphenyl)-[1,1’-biphenyl]-3-amine 
(138r) 
 
 
 
 
 
General Procedure K: Using aniline 137f (50 mg, 0.16 mmol) and 4-bromoanisole 
(60.1 µL, 89.8 mg, 0.48 mmol), chromatography (silica, 5% Et2O, petrol) eluted 138r as 
an off-white solid (24.8 mg, 37%); Rf = 0.41 (silica, 10% Et2O, petrol); m.p. 76-79 
o
C; 
UV λmax (EtOH/nm) 279.8 and 230.2; IR νmax/cm
-1
 3405 (N-H), 2956 (C-H), 2926 (C-
H), 1603, 1514, 1483, 1439, 1389, 1335, 1276, 1217 (C-O), 1161, 1089, 1040, 923, 
867, 826, 781, 749, 721; 
1H δ/ppm (500 MHz, CDCl3) 3.80 (3H, s, OCH3), 5.74 (1H, s, 
br, NH), 6.66-6.69 (2H, m, Ar-H), 6.80 (1H, dd, Ar-H, J = 1.6 and 7.5 Hz), 6.85-6.88 
(2H, m, Ar-H), 6.94-6.98 (2H, m, Ar-H), 7.06-7.09 (5H, m, Ar-H), 7.13 (1H, t, Ar-H, J 
= 8.0 Hz), 7.37-7.41 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, CDCl3) 55.6, 113.4, 114.7, 
114.9, 115.1, 116.3, 120.5, 124.1, 126.2, 126.8, 129.4, 130.5, 130.6, 133.6, 134.3, 
135.0, 138.5, 139.7, 155.8, 156.1; LC-MS (ESI+) m/z = 420.4 [M+H]
+
; HRMS calcd. 
for C25H20O2N
35
ClF [M+H]
+ 
420.1161, found 420.1160; Analytical HPLC: 99.0%  
 
2-(4-Chlorophenoxy)-N-(4-fluorophenyl)-3-((triisopropylsilyl)ethynyl)aniline (178) 
 
 
 
General Procedure K: Using aniline 177 (30 mg, 0.075 mmol), 1-bromo-4-
fluorobenzene (41.2 µL, 66 mg, 0.38 mmol) and NaO
t
Bu (18 mg, 0.19 mmol) 
chromatography (silica, 0-10% DCM, petrol) eluted 178 as a colourless gum (25 mg, 
70%); Rf = 0.29 (silica, 10% DCM, petrol); UV λmax (EtOH/nm) 264.2 and 253.0; IR 
νmax/cm
-1
 3419 (N-H), 2941 (C-H), 2862 (C-H), 2154 (C≡C), 1595, 1509, 1468, 1387, 
1330, 1279, 1212 (C-O), 1158, 1091, 1002, 919, 879, 824, 769, 739; 
1H δ/ppm (500 
MHz, CDCl3) 0.96 (21H, s, Si(CH(CH3)2)3), 5.81 (1H, s, br, NH), 6.83-6.84 (2H, m, Ar-
H), 6.97-7.07 (6H, m, Ar-H), 7.11-7.12 (1H, m, Ar-H), 7.19-7.21 (2H, m, Ar-H); 
13
C 
δ/ppm (125 MHz, CDCl3) 11.1, 18.5, 97.1, 101.6, 114.8, 116.0, 116.2, 116.4, 118.6, 
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123.0, 123.1, 124.4, 125.7, 127.1, 129.4, 137.2, 137.3, 138.5, 142.6, 156.1, 158.0, 
159.9; 
19F δ/ppm (470 MHz, CDCl3) -119.8; LC-MS (ESI+) m/z = 492.5 and 494.5 [M-
H]
-
; HRMS calcd. for C29H34ON
35
ClFSi [M+H]
+ 
494.2077, found 494.2067; Analytical 
HPLC: 93.8% 
 
Methyl-6-(4-chlorophenoxy)-5-((4-fluorophenyl)amino)-4’-hydroxy-[1,1’-
biphenyl]-3-carboxylate (230) 
 
 
 
 
 
 
General Procedure K: Using aniline 229 (40 mg, 0.11 mmol) and 1-bromo-4-
fluorobenzene (72 µL, 113 mg, 0.65 mmol), chromatography (silica, 0-20% EtOAc, 
petrol) eluted 230 as a white solid (35 mg, 70%); Rf = 0.36 (silica, 30% EtOAc, petrol); 
m.p. 216-218 
oC; UV λmax (EtOH/nm) 277.0 and 228.2; IR νmax/cm
-1
 3422 (br) (N-H 
and O-H), 2957 (C-H), 1699 (C=O), 1610, 1499, 1436, 1359, 1211 (C-O), 1096, 1009, 
937, 886, 824, 770, 734; 
1H δ/ppm (500 MHz, CDCl3) 3.89 (3H, s, OCH3), 4.74 (1H, s, 
br, NH), 5.87 (1H, s, br, OH), 6.64-6.67 (2H, m, Ar-H), 6.74-6.76 (2H, m, Ar-H), 7.00-
7.05 (2H, m, Ar-H), 7.06-7.11 (4H, m, Ar-H), 7.31-7.33 (2H, m, Ar-H), 7.58 (1H, d, 
Ar-H, J = 2.0 Hz), 7.76 (1H, d, Ar-H, J = 2.0 Hz); 
13C δ/ppm (125 MHz, CDCl3) 52.3, 
114.1, 115.2, 116.2, 116.4, 122.8, 123.1, 123.2, 127.2, 127.9, 129.1, 129.5, 130.3, 
135.7, 136.4, 136.9, 138.8, 142.5, 155.2, 155.3, 158.2, 166.7; 
19F δ/ppm (470 MHz, 
CDCl3) -119.3; LC-MS (ESI+) m/z = 464.4 [M+H]
+
 and 462.3 [M-H]
-
; HRMS calcd. 
for C26H18O4N
35
ClF [M-H]
- 
462.0914, found 462.0903; Analytical HPLC: 97.3%  
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Methyl-6-(4-chlorophenoxy)-5-((4-fluorophenyl)amino)-4’-methoxy-[1,1’-
biphenyl]-3-carboxylate (247) 
 
 
 
 
 
 
General Procedure K: Using aniline 246 (480 mg, 1.25 mmol) and 1-bromo-4-
fluorobenzene (824 µL, 1.31 g, 7.50 mmol), chromatography (silica, 0-10% EtOAc, 
petrol) eluted 247 as a beige solid (454 mg, 76%); Rf = 0.17 (silica, 10% EtOAc, 
petrol); m.p. 152-155 
o
C; UV λmax (EtOH/nm) 275.0; IR νmax/cm
-1
 3417 (N-H), 3073 (C-
H), 2953 (C-H), 2842 (C-H), 1720 (C=O), 1606, 1504, 1433, 1358, 1290, 1212 (C-O), 
1090, 1010, 942, 820, 768; 
1
H δ/ppm (500 MHz, CDCl3) 3.78 (3H, s, OCH3), 3.89 (3H, 
s, CO2CH3), 5.87 (1H, s, NH), 6.67 (2H, d, 4-ClPh C3-H and C5-H, J = 9.0 Hz), 6.82 
(2H, d, 4-MeOPh, C2-H and C6-H, J = 8.8 Hz), 7.01-7.05 (2H, m, Ar-H), 7.06-7.10 (4H, 
m, 4-ClPh C2-H and C6-H and Ar-H), 7.37 (2H, d, 4-MeOPh, C3-H and C5-H, J = 8.8 
Hz), 7.60 (1H, d, Ar-H, J = 2.0 Hz), 7.76 (1H, d, Ar-H, J = 2.0 Hz); 
13
C δ/ppm (125 
MHz, CDCl3) 52.3, 55.2, 113.7, 114.1, 116.2, 116.4, 122.9, 123.1, 123.2, 127.2, 128.0, 
128.9, 129.3, 129.5, 130.1, 130.3, 135.8, 136.97, 136.99, 138.8, 142.5, 155.3, 159.2, 
166.7; 
19
F δ/ppm (470 MHz, CDCl3) -119.4; LC-MS (ESI+) m/z = 478.3 [M+H]
+
; 
HRMS calcd. for C27H22O4N
35
ClF [M+H]
+ 
478.1216, found 478.1209 
 
Methyl 3-(2-(4-chlorophenoxy)-3-nitrophenyl)propiolate (168) 
 
 
 
 
General Procedure O: Using acetylene 165 (600 mg, 2.22 mmol), diisopropylamine 
(404 µL, 292 mg, 2.89 mmol), n-butyllithium (2.5 M in hexanes, 1.16 mL, 2.89 mmol) 
and methyl chloroformate (343 µL, 420 mg, 4.44 mmol) and transferring the 
i
Pr2NH/n-
BuLi, as a solution in THF (1.16 mL, 1 M) to a solution of 165 in THF (12.4 mL) at -78 
o
C, chromatography (silica, 0-40% Et2O, petrol) eluted 168 as a dark yellow solid (596 
mg, 81%); Rf = 0.30 (silica, 20% EtOAc, petrol); m.p. 94-97 
oC; UV λmax (EtOH/nm) 
225.8; IR νmax/cm
-1
 3086 (C-H), 2955 (C-H), 2223 (C≡C), 1712 (C=O), 1588, 1533, 
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1484, 1445, 1351, 1301, 1220, 1195, 1090, 1010, 931, 879, 854, 829, 796, 746, 664; 
1
H 
δ/ppm (500 MHz, CDCl3) 3.76 (3H, s, CO2CH3), 6.85 (2H, d, 4-ClPh C3-H and C5-H, J 
= 9.1 Hz), 7.27 (2H, d, 4-ClPh C2-H and C6-H, J = 8.9 Hz), 7.40 (1H, t, 3-NO2Ar C5-H, 
J = 8.0 Hz), 7.84 (1H, dd, Ar-H, J = 1.7 and 7.8 Hz), 8.03 (1H, dd, Ar-H, J = 1.7 and 
8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 53.0, 78.7, 87.1, 117.6, 117.8, 125.5, 127.6, 
128.6, 129.7, 139.2, 144.0, 150.2, 153.3, 156.1; LC-MS (ESI+) m/z = mass not 
observed; HRMS calcd. for C16H11O5N
35
Cl [M+H]
+ 
332.0320, found 332.0317 
 
Methyl 3-(2-(4-Chlorophenoxy)-3-((4-
fluorophenyl)(methoxycarbonyl)amino)phenyl)propiolate (179) 
 
 
 
 
 
General Procedure O: Using aniline 167 (20 mg, 0.06 mmol), diisopropylamine (9.1 
µL, 6.6 mg, 0.07 mmol), n-butyllithium (2.5 M in hexanes, 26 µL, 0.07 mmol) and 
methyl chloroformate (5.3 µL, 6.5 mg, 0.07 mmol) and transferring the 
i
Pr2NH/n-BuLi, 
as a solution in THF (0.5 mL, 0.1 M) to a solution of 167 in THF (1.4 mL) at -78 
o
C, 
chromatography (silica, 0-80% DCM, petrol) eluted 179 as a brown gum (15 mg, 56%); 
Rf = 0.32 (silica, 40% DCM, petrol); UV λmax (EtOH/nm) 227.4; IR νmax/cm
-1
 2953 (C-
H), 2225 (C≡C), 1707 (C=O), 1588, 1505, 1437, 1292, 1211 (C-O), 1087, 1045, 956, 
866, 824, 745; 
1H δ/ppm (500 MHz, CDCl3) 3.60 (3H, s, OCH3), 3.71 (3H, s, OCH3), 
6.71-6.73 (2H, m, Ar-H), 6.92-6.97 (2H, m, Ar-H), 7.07-7.10 (2H, m, Ar-H), 7.18-7.21 
(2H, m, Ar-H), 7.28 (1H, t, Ar-H, J = 7.9 Hz), 7.53 (1H, d, Ar-H, J = 7.7 Hz), 7.57 (1H, 
dd, Ar-H, J = 1.5 and 7.8 Hz); 
13C δ/ppm (125 MHz, CDCl3) 52.8, 53.4, 80.5, 86.1, 
115.5, 115.7, 115.9, 117.4, 125.7, 127.8, 129.3, 133.4, 134.3, 136.1, 137.2, 153.1, 
153.7, 154.8, 155.9; 
19F δ/ppm (470 MHz, CDCl3) -115.3; LC-MS (ESI+) m/z = mass 
not observed; HRMS mass not observed; Analytical HPLC: 98.8% 
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Methyl 3-(3-((tert-butoxycarbonyl)(4-fluorophenyl)amino)-2-(4-
chlorophenoxy)phenyl)propiolate (182) 
 
 
 
 
General Procedure O: Using aniline 181 (130 mg, 0.30 mmol), diisopropylamine (51 
µL, 36.4 mg, 0.36 mmol), n-butyllithium (2.5 M in hexanes, 144 µL, 0.36 mmol) and 
methyl chloroformate (70 µL, 85 mg, 0.90 mmol), chromatography (silica, 0-20% Et2O, 
petrol) eluted 182 as a yellow oil (98 mg, 67%); Rf = 0.23 (silica, 20% Et2O, petrol); 
UV λmax (EtOH/nm) 224.2; IR νmax/cm
-1
 2976 (C-H), 2227 (C≡C), 1707 (C=O), 1588, 
1506, 1484, 1452, 1314, 1291, 1212 (C-O), 1152, 1087, 1010, 978, 901, 871, 827, 747, 
703; 
1H δ/ppm (500 MHz, CDCl3) 1.34 (9H, s, C(CH3)3), 3.71 (3H, s, CO2CH3), 6.71 
(2H, d, 4-ClPh, C3-H and C5-H, J = 8.7 Hz), 6.92 (2H, t, 4-FPh C3-H and C5-H, J = 8.1 
Hz), 6.99-7.00 (2H, m, 4-FPh C2-H and C6-H), 7.20 (2H, d, 4-ClPh C2-H and C6-H, J = 
8.9 Hz), 7.29 (1H, t, C5-H, J = 7.8 Hz), 7.53-7.56 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, 
CDCl3) 28.0, 52.8, 80.8, 82.0, 85.6, 115.2, 115.4, 116.1, 117.3, 125.6, 127.6, 129.2, 
133.80, 133.82, 136.5, 153.1, 153.8, 155.9; 
19F δ/ppm (470 MHz, CDCl3) -116.3; LC-
MS (ESI+) m/z = mass not observed; HRMS mass not observed 
 
5-(2-(4-Chlorophenoxy)-3-nitrophenyl)isoxazol-3-ol (169) 
 
 
 
 
 
General Procedure P: Using propiolate ester 168 (100 mg, 0.30 mmol) and 
hydroxylamine hydrochloride (21 mg, 0.30 mmol) in 3 M NaOH (0.1 mL, 0.30 mmol) 
and ethanol (3 mL), chromatography (silica, 20-80% EtOAc, petrol) eluted 169 as a 
brown solid (28 mg, 28%); Rf = 0.24 (silica, 50% EtOAc, petrol); m.p. 204-207 
o
C; UV 
λmax (EtOH/nm) 253.2 and 223.0; IR νmax/cm
-1
 2997 (C-H), 2776 (C-H), 2626 (br) (O-
H), 1619, 1578, 1535, 1483, 1449, 1335, 1290, 1237, 1185, 1088, 1009, 951, 879, 828, 
790, 745, 689; 
1
H δ/ppm (500 MHz, DMSO-d6) 6.30 (1H, s, isoxazole C4-H), 6.91-6.94 
(2H, m, 4-ClPh, C3-H and C5-H), 7.37-7.40 (2H, m, 4-ClPh C2-H and C6-H), 7.74 (1H, 
t, Ar-H, J = 8.3 Hz), 8.27 (1H, dd, Ar-H, 1.6 and 8.2 Hz), 8.31 (1H, dd, Ar-H, J = 1.6 
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and 7.9 Hz), 11.52 (1H, s, OH); 
13
C δ/ppm (125 MHz, DMSO-d6) 96.8, 116.6, 123.8, 
127.0, 127.4, 127.6, 129.9, 132.8, 142.5, 143.9, 155.3, 162.4, 170.8; LC-MS (ESI+) m/z 
= 333.3 [M+H]
+
 and 331.2 [M-H]
-
; HRMS calcd. for C15H8O5N2
35
Cl [M-H]
- 
331.0127, 
found 331.0117; Analytical HPLC: 94.6% 
 
5-(2-(4-Chlorophenoxy)-3-((4-fluorophenyl)amino)phenyl)isoxazol-3-ol (183a) 
 
 
 
 
 
General Procedure P: Using propiolate ester 182 (50 mg, 0.10 mmol) and 
hydroxylamine hydrochloride (21 mg, 0.30 mmol) in 3 M NaOH (0.3 mL, 0.90 mmol) 
and methanol (1 mL), semi-preparative HPLC (5-100% MeCN, H2O + 0.1% (v/v) 
HCO2H) eluted 183a as a white powder (21.7 mg, 56%); Rf = 0.25 (silica, 5% MeOH, 
DCM); m.p. 217-219 
oC; UV λmax (EtOH/nm) 270.0 and 226.6; IR νmax/cm
-1
 3425 (N-
H), 2923 (C-H), 2848 (C-H), 2773 (C-H), 2628 (br) (O-H), 1594, 1512, 1482, 1445, 
1338, 1278, 1202 (C-O), 1158, 1087, 1007, 961, 864, 824, 780, 744; 
1H δ/ppm (500 
MHz, DMSO-d6) 6.14 (1H, s, isoxazole C4-H), 6.79-6.82 (2H, m, Ar-H), 7.00-7.03 (2H, 
m, Ar-H), 7.05-7.09 (2H, m, Ar-H), 7.29-7.34 (4H, m, Ar-H), 7.39-7.43 (1H, m, Ar-H), 
7.76 (1H, s, br, NH), 11.30 (1H, s, br, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 95.2, 
115.4, 115.6, 116.4, 118.1, 119.2, 120.6, 120.7, 122.2, 125.8, 126.8, 129.4, 138.4, 
138.6, 139.3, 155.0, 158.0, 164.5, 170.7; 
19F δ/ppm (470 MHz, DMSO-d6) -122.3; LC-
MS (ESI+) m/z = 397.3 [M+H]
+
 and 395.3 [M-H]
-
; HRMS calcd. for C21H13O3N2
35
ClF 
[M-H]
- 
395.0604, found 395.0593; Analytical HPLC: 99.6% 
 
N-(2-(4-Chlorophenoxy)-4’-fluoro-[1,1’-biphenyl]-3-yl)-4-hydroxybenzamide 
(151a) 
 
 
 
 
 
General procedure Q: Using aniline 137f (40 mg, 0.13 mmol) and ethyl 4-
hydroxybenzoate (26 mg, 0.16 mmol), chromatography (silica, 15-80% EtOAc, petrol) 
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eluted 151a as a white solid (51 mg, 91%); Rf = 0.22 (silica, 30% EtOAc, petrol); m.p. 
87 
oC (decomposed); UV λmax (EtOH/nm) 229.8; IR νmax/cm
-1
 3417 (N-H), 3280 (br) 
(O-H), 3076 (C-H), 3023 (C-H), 1650 (C=O), 1607, 1534, 1505, 1483, 1427, 1397, 
1273, 1244, 1217 (C-O), 1160, 1091, 1009, 868, 826, 786, 753, 659; 
1H δ/ppm (500 
MHz, DMSO-d6) 6.66-6.69 (2H, m, Ar-H), 6.73-6.75 (2H, m, Ar-H), 7.16-7.22 (4H, m, 
Ar-H), 7.35 (1H, dd, Ar-H, J = 1.7 and 7.7 Hz), 7.42 (1H, t, Ar-H, J = 7.9 Hz), 7.47-
7.50 (2H, m, Ar-H), 7.52-7.54 (2H, m, Ar-H), 7.79 (1H, dd, Ar-H, J = 1.7 and 7.9 Hz), 
9.54 (1H, s, NH), 10.05 (1H, s, OH); 
13C δ/ppm (125 MHz, DMSO-d6) 114.7, 115.1, 
115.2, 116.7, 124.6, 125.5, 125.8, 126.4, 127.4, 129.2, 129.5, 130.7, 130.8, 132.0, 
133.1, 134.3, 144.1, 155.9, 160.5, 164.9; 
19F δ/ppm (470 MHz, DMSO-d6) -114.7; LC-
MS (ESI+) m/z = 434.1 [M+H]
+
 and 432.1 [M-H]
-
; HRMS calcd. for C25H16O3N
35
ClF 
[M-H]
- 
432.0808, found 432.0807; Analytical HPLC: 97.8%  
 
N-(2-(4-Chlorophenoxy)-4’-fluoro-[1,1’-biphenyl]-3-yl)-4-
(trifluoromethylsulfonamido)benzamide (151b) 
 
 
 
 
 
General procedure Q: Using aniline 137f (50 mg, 0.16 mmol) and ester 153 (45.3 mg, 
0.16 mmol), chromatography (silica, 0-70% EtOAc, petrol) eluted 151b as an off-white 
solid (19 mg, 21%); Rf = 0.21 (silica, 50% EtOAc, petrol); m.p. 163-166 
oC; UV λmax 
(EtOH/nm) 230.8; IR νmax/cm
-1
 3428 (sulfonamido N-H), 3081 (amido N-H), 3038 (C-
H), 2921 (C-H), 2829 (C-H), 1662 (C=O), 1607, 1535, 1508, 1473, 1431, 1376, 1330 
(S=O asym. stretch), 1275, 1211 (C-O), 1192 (C-O), 1135 (S=O sym. stretch), 1090, 
1017, 951, 828, 784, 751, 698; 
1H δ/ppm (500 MHz, CDCl3) 6.64-6.66 (2H, m, Ar-H), 
6.96-7.00 (3H, m, Ar-H), 7.09-7.11 (2H, m, Ar-H), 7.20 (1H, dd, Ar-H, J = 1.4 and 7.7 
Hz), 7.30-7.32 (2H, m, Ar-H), 7.35-7.41 (3H, m, Ar-H), 7.65-7.67 (2H, m, Ar-H), 8.20 
(1H, s, br, amido NH), 8.56-8.57 (1H, m, sulfonamido NH); 
13C δ/ppm (125 MHz, 
CDCl3) 115.2, 115.4, 116.4, 120.7, 122.2, 126.5, 126.6, 127.7, 128.6, 129.8, 130.56, 
130.63, 131.9, 133.1, 134.6, 137.3, 140.6, 155.4, 164.1; LC-MS (ESI+) m/z = 563.2 [M-
H]
-
; HRMS calcd. for C26H16O4N2
35
ClF4S [M-H]
- 
563.0461, found 563.0450; Analytical 
HPLC: 99.4%  
 
356 
 
N-(2-(4-Chlorophenoxy)-4’-fluoro-[1,1’-biphenyl]-3-yl)-4-methoxybenzamide 
(151c) 
 
 
 
 
 
General procedure Q: Using aniline 137f (100 mg, 0.32 mmol) and methyl 4-
methoxybenzoate (53.2 mg, 0.32 mmol), chromatography (silica, 0-20% EtOAc, petrol) 
eluted 151c as a white solid (117.4 mg, 82%); Rf = 0.34 (silica, 20% EtOAc, petrol); 
m.p. 120-123 
oC; UV λmax (EtOH/nm) 230.6; IR νmax/cm
-1
 3289 (N-H), 2933 (C-H), 
2839 (C-H), 1648, 1606, 1531, 1504, 1482, 1430, 1395, 1316, 1293, 1251, 1221 (C-O), 
1175, 1092, 1031, 894, 827, 779, 749; 
1H δ/ppm (500 MHz, CDCl3) 3.84 (3H, s, 
OCH3), 6.64-6.67 (2H, m, Ar-H), 6.88-6.91 (2H, m, Ar-H), 6.95-7.00 (2H, m, Ar-H), 
7.08-7.11 (2H, m, Ar-H), 7.16 (1H, dd, Ar-H, J = 1.6 and 7.7 Hz), 7.35-7.39 (3H, m, 
Ar-H), 7.59-7.62 (2H, m, Ar-H), 8.18 (1H, s, br, NH), 8.61 (1H, dd, Ar-H, J = 1.6 and 
8.3 Hz); 
13C δ/ppm (125 MHz, CDCl3) 55.5, 114.1, 115.1, 115.3, 116.4, 120.5, 125.8, 
126.6, 126.8, 127.6, 128.8, 129.7, 130.58, 130.64, 132.5, 132.9, 134.5, 140.3, 155.5, 
161.3, 162.6, 163.3, 164.9; LC-MS (ESI+) m/z = 448.4 [M+H]
+
; HRMS calcd. for 
C26H20O3N
35
ClF [M+H]
+ 
448.1110, found 448.1105 Analytical HPLC: 97.3%  
 
1,1,1-Trifluoro-N-(4-(2-((4-fluorophenyl)amino)thiazol-4-
yl)phenyl)methanesulfonamide (44s) 
 
 
 
 
 
General procedure S: Using phenacyl bromide 264 (120 mg, 0.35 mmol) and thiourea 
261 (49.4 mg, 0.29 mmol), preparative HPLC (C18, 15%  H2O + 0.1% (v/v) HCO2H, 
MeCN) eluted 44s as a white solid (44.6 mg, 37%); Rf = 0.25 (silica, 30% EtOAc, 
petrol); m.p. 198-201 
oC; UV λmax (EtOH/nm) 281.8; IR νmax/cm
-1
 3330 (amino N-H), 
3121 (C-H), 3018 (C-H), 2653 (br) (sulfonamido N-H), 1611, 1551, 1501, 1430, 1411, 
1370, 1329, 1211, 1186, 1141, 1064, 964, 833, 807, 745, 721, 671; 
1H δ/ppm (500 
MHz, DMSO-d6) 7.17-7.21 (2H, m, Ar-H), 7.31-7.32 (2H, m, Ar-H), 7.34 (1H, s, 
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thiazole C5-H), 7.74-7.77 (2H, m, Ar-H), 7.94-7.96 (2H, m, Ar-H), 10.31 (1H, s, amino 
NH), 11.96 (1H, s, br, sulfonamido NH); 
13C δ/ppm (125 MHz, DMSO-d6) 103.3, 
115.4, 115.6, 118.3, 118.4, 123.0, 126.7, 137.7, 149.0, 155.9, 157.8, 163.2; 
19F δ/ppm 
(470 MHz, DMSO-d6) -75.3, -121.9; LC-MS (ESI+) m/z = 418.3 [M+H]
+
 and 416.2 [M-
H]
-
; HRMS calcd. for C16H10O2N3F4S2 [M-H]
- 
416.0156, found 416.0147; Analytical 
HPLC: 98.7%  
 
1,1,1-Trifluoro-N-(4-(2-((4-fluorobenzyl)amino)thiazol-4-
yl)phenyl)methanesulfonamide (44j)  
 
 
 
 
General procedure S: Using phenacyl bromide 264 (4:1 mixture with 265, 337 mg, 
0.78 mmol) and thiourea 279 (116 mg, 0.63 mmol), chromatography (silica, 0-30% 
EtOAc, petrol) eluted 44j as a yellow solid (168 mg, 62%); Rf = 0.29 (silica, 30% 
EtOAc, petrol); m.p. 181-183 
oC; UV λmax (EtOH/nm) 295.2 and 248.8; IR νmax/cm
-1
 
3386 (amino N-H), 3281 (sulfonamido N-H), 3115 (C-H), 2919 (C-H), 1561, 1510, 
1442, 1408, 1359, 1289, 1192, 1137, 1047, 958, 821, 753, 688; 
1H δ/ppm (500 MHz, 
DMSO-d6) 4.49 (2H, d, CH2, J = 5.5 Hz), 7.07 (1H, s, thiazole C5-H), 7.16-7.19 (2H, m, 
Ar-H), 7.25-7.27 (2H, m, Ar-H), 7.43-7.45 (2H, m, Ar-H), 7.83-7.85 (2H, m, Ar-H), 
8.21 (1H, t, amino NH, J = 4.9 Hz), 11.90 (1H, s, sulfonamido NH); 
13C δ/ppm (125 
MHz, DMSO-d6) 47.5, 102.2, 115.4, 115.6, 123.5, 127.1, 130.0, 130.1, 133.6, 134.5, 
135.9, 149.3, 160.8, 162.8, 168.7; 
19F δ/ppm (470 MHz, DMSO-d6) -75.5, -115.9; LC-
MS (ESI+) m/z = 432.2 [M+H]
+
 and 430.2 [M-H]
-
; HRMS calcd. for C17H12O2N3F4S 
[M-H]
- 
430.0313, found 430.0301; Analytical HPLC 99.1%  
 
2-(2-Methoxy-6-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (204) 
 
 
 
 
General procedure V: Using aryl bromide 189 (2.40 g, 10.3 mmol) and B2(pin)2 (5.78 
g, 22.8 mmol) at 90 
o
C for 20 h, chromatography (silica, 0-20%, Et2O, petrol), afforded 
204 as a brown solid (2.76 g, 78%); Rf = 0.17 (silica, 20% Et2O, petrol); m.p. 94-97 
o
C; 
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UV λmax (EtOH/nm) 332.2, 271.4 and 233.0; IR νmax/cm
-1
 3288 (C-H), 3083 (C-H), 
2979 (C-H), 2939 (C-H), 1620, 1528, 1478, 1349, 1303, 1261, 1182, 1142, 1102, 1054, 
962, 908, 856, 827, 796, 738, 658; 
1H δ/ppm (500 MHz, CDCl3) 1.44 (12H, s, (CH3)4), 
3.86 (3H, s, OCH3), 7.13 (1H, d, C3-H, J = 8.2 Hz), 7.46 (1H, t, C4-H, J = 8.2 Hz), 7.79 
(1H, dd, C5-H, J = 0.6 and 8.2 Hz); 
13C δ/ppm (125 MHz, CDCl3) 24.7, 56.3, 84.6, 
115.2, 115.8, 131.1, 151.3, 163.0; LC-MS (ESI+) m/z = mass not observed; HRMS 
calcd. for C13H19O5N
10
B [M+H]
+ 
279.1387, found 279.1389 
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (272) 
 
 
 
 
General procedure V: Using indazole 271 (100 mg, 0.51 mmol) in DMF (5.7 mL) at 
90 
o
C for 15 h, chromatography (silica, 0-20%, EtOAc, petrol), afforded 272 as a white 
solid (75 mg, 61%); Rf = 0.25 (silica, 30% EtOAc, petrol); m.p. 166-168 
oC; UV λmax 
(EtOH/nm) 222.4; IR νmax/cm
-1
 3332 (N-H), 2978 (C-H), 2941 (C-H), 1616, 1536, 
1511, 1473, 1447, 1363, 1339, 1309, 1271, 1139, 1077, 948, 857, 819, 748, 667; 
1
H 
δ/ppm (500 MHz, CDCl3) 1.37 (12H, s, (CH3)4), 7.56 (1H, d, C6-H, J = 8.5 Hz), 7.87 
(1H, d, C7-H, J = 8.5 Hz), 8.16 (1H, s, C4-H), 8.33 (1H, s, C3-H) - NH proton was not 
observed; 
13C δ/ppm (125 MHz, CDCl3) 24.9, 83.9, 109.2, 123.0, 129.3, 132.9, 135.1, 
141.5; LC-MS (ESI+) m/z = 245.3 [M+H]
+
 and 243.2 [M-H]
-
; HRMS calcd. for 
C13H16O2N2
10
B [M-H]
- 
243.1310, found 243.1311 
 
N-(4-(1H-indazol-5-yl)thiazol-2-yl)-4-fluorobenzamide (275) 
 
 
 
 
Poor solubility meant a suitable 
13
C and 
19
F NMR could not be obtained for this 
compound. 
General procedure X: Using indazole 274 (140 mg, 0.33 mg) at 55 
o
C for 24 h, 
trituration with ice-cooled DCM (5 × 10 mL) isolated 275 as a light brown solid (54 mg, 
45%); Rf = 0.20 (silica, 20% EtOAc, petrol); m.p. > 400 
oC; UV λmax (EtOH/nm) 242.6 
and 220.2; IR νmax/cm
-1
 3197 (br) indazolo and amino N-H), 2978 (C-H), 2921 (C-H), 
1681 (C=O), 1605, 1564, 1512, 1453, 1343, 1312, 1295, 1236, 1159, 1056, 1004, 949, 
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834, 702; 
1H δ/ppm (500 MHz, DMSO-d6) 5.61 (1H, s, br, thiazole C5-H), 7.04 (1H, s, 
br, Ar-H), 7.16 (2H, s, br, Ar-H), 7.50 (1H, s, br, Ar-H), 7.94 (1H, s, br, Ar-H), 8.07 
(1H, s, br, Ar-H), 8.20 (2H, s, br, Ar-H), 8.30 (1H, s, br, Ar-H), 13.10 (1H, s, br, NH); 
LC-MS (ESI+) m/z = 339.3 [M+H]
+
 and 337.2 [M-H]
-
; HRMS mass not observed; 
Analytical HPLC 94.2% 
 
 
3-(2-(4-Chlorophenoxy)-3-((4-fluorophenyl)amino)phenyl)propiolic acid (187) 
 
 
 
 
 
General Procedure A’: Using carbamate 186 (100 mg, 0.21 mmol) and TFA (322 µL) 
in DCM (2.1 mL), partitioning with diethyl ether and saturated aqueous NaHCO3 
afforded 187 as a brown solid (74 mg, 93%); Rf = 0.40 (silica, 15% MeOH, DCM); m.p. 
149-151 
oC; UV λmax (EtOH/nm) 271.4 and 227.0; IR νmax/cm
-1
 3428 (N-H), 2923 (C-
H), 2822 (br) (O-H), 2217 (C≡C), 1669 (C=O), 1593, 1513, 1473, 1441, 1407, 1337, 
1285, 1204 (C-O), 1162, 1088, 825, 779, 742; 
1H δ/ppm (500 MHz, DMSO-d6) 6.78-
6.81 (2H, m, Ar-H), 7.02-7.09 (4H, m, Ar-H), 7.13 (1H, dd, Ar-H, J = 1.3 and 7.6 Hz), 
7.21 (1H, t, Ar-H, J = 7.9 Hz), 7.31-7.33 (3H, m, Ar-H), 7.84 (1H, s, NH) - CO2H peak 
not observed); 
13C δ/ppm (125 MHz, DMSO-d6) 78.4, 87.3, 115.4, 115.6, 117.1, 119.3, 
120.8, 120.9, 124.8, 125.8, 126.5, 129.2, 138.1, 138.39, 138.41, 144.6, 154.3, 156.1, 
156.2, 158.1; 
19F δ/ppm (470 MHz, DMSO-d6) -122.1; LC-MS (ESI+) m/z = mass not 
observed; HRMS calcd. for C21H12O3N
35
ClF [M-H]
- 
380.0495, found 380.0483; 
Analytical HPLC: 93.5% 
 
Methyl 3-(2-(4-chlorophenoxy)-3-((4-fluorophenyl)amino)phenyl)propiolate (188) 
 
 
 
 
 
General Procedure A’: Using carbamate 182 (49 mg, 0.10 mmol) and TFA (155 µL) 
in DCM (1.0 mL), partitioning with diethyl ether and saturated aqueous NaHCO3 
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afforded 188 as a brown oil (33 mg, 85%); Rf = 0.43 (silica, 10% EtOAc, petrol); UV 
λmax (EtOH/nm) 272.2 and 224.8; IR νmax/cm
-1
 3383 (N-H), 2952 (C-H), 2220 (C≡C), 
1704 (C=O), 1594, 1507, 1482, 1434, 1391, 1337, 1283, 1205 (C-O), 1088, 1040, 1009, 
961, 824, 778, 743; 
1H δ/ppm (500 MHz, CDCl3) 3.74 (3H, s, CO2CH3), 5.88 (1H, s, 
NH), 6.86-6.89 (2H, m, Ar-H), 6.99-7.03 (2H, m, Ar-H), 7.04-7.10 (4H, m, Ar-H), 7.22 
(1H, dd, Ar-H, J = 2.1 and 8.0 Hz), 7.24-7.26 (2H, m, Ar-H); 
13C δ/ppm (125 MHz, 
CDCl3) 52.7, 81.7, 85.1, 114.7, 116.1, 116.3, 116.9, 117.0, 123.38, 123.44, 124.7, 
126.0, 127.8, 129.7, 136.7, 138.8, 144.2, 154.0, 156.0, 158.2, 160.2; 
19F δ/ppm (470 
MHz, CDCl3) -119.0; LC-MS (ESI+) m/z = 396.3 [M+H]
+
 and 394.2 [M-H]
-
; HRMS 
calcd. for C22H16O3N
35
ClF [M+H]
+ 
396.0797, found 396.0800; Analytical HPLC: 
94.9% 
 
6-(4-Chlorophenoxy)-5-((4-fluorophenyl)amino)-4’-hydroxy-[1,1’-biphenyl]-3-
carboxylic acid (226) 
 
 
 
 
 
 
General Procedure B’: Using  ester 230 (30 mg, 0.07 mmol) and lithium hydroxide 
monohydrate (55 mg, 1.30 mmol) in 50% THF, H2O (2.8 mL), chromatography (silica, 
0-5%, MeOH, DCM), afforded 226 as a light red solid (22.5 mg, 78%); Rf = 0.30 (silica, 
5% MeOH, DCM); m.p. 245-248 
o
C; UV λmax (EtOH/nm) 276.6 and 228.0; IR νmax/cm
-1
 
3564 (N-H), 3420 (phenol O-H), 2919 (C-H), 2850 (C-H), 2607 (br) (carboxyl O-H), 
1682 (C=O), 1581, 1510, 1413, 1353, 1260, 1214 (C-O), 1186, 1088, 1008, 943, 890, 
823, 773; 
1
H δ/ppm (500 MHz, DMSO-d6) 6.66-6.68 (2H, m, Ar-H), 6.72-6.73 (2H, m, 
Ar-H), 7.06-7.13 (4H, m, Ar-H), 7.17-7.19 (2H, m, Ar-H), 7.28-7.29 (2H, m, Ar-H), 
7.45 (1H, d, Ar-H, J = 1.8 Hz), 7.68 (1H, d, Ar-H, J = 1.7 Hz), 7.80 (1H, s, NH), 9.54 
(1H, s, br,  ArOH), 13.00 (1H, s, br, CO2H); 
13
C δ/ppm (125 MHz, DMSO-d6) 115.1, 
115.5, 115.7, 115.8, 116.8, 121.16, 121.23, 122.4, 125.3, 127.0, 129.0, 129.8, 135.7, 
138.3, 138.6, 143.2, 155.4, 156.3, 157.0, 167.0; 
19
F δ/ppm (470 MHz, DMSO-d6) -
121.9; LC-MS (ESI+) m/z = 450.4 [M+H]
+
 and 448.3 [M-H]
-
; HRMS calcd. for 
C25H16O4N
35
ClF [M-H]
- 
448.0757, found 448.0749; Analytical HPLC: 97.0% 
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2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3-carboxylic 
acid (220c) 
 
 
 
 
 
 
General Procedure B’: Using ester 283a (239 mg, 0.51 mmol) and NaOH (518 mg, 
13.0 mmol) in 75% MeOH, H2O (4.3 mL) at 90 
o
C for 4 h, chromatography (silica, 10-
40%, EtOAc, petrol), afforded 220c as a white solid (182 mg, 81%); Rf = 0.39 (silica, 
50% EtOAc, petrol); m.p. 186-187 
o
C; UV λmax (EtOH/nm) 221.4; IR νmax/cm
-1
 3044 
(C-H), 2938 (C-H), 2851 (C-H), 2582 (br) (O-H), 1670 (C=O), 1654, 1560, 1526, 1490, 
1458, 1429, 1255, 1234 (C-O), 1152, 1089, 1074, 1015, 938, 835, 774; 
1
H δ/ppm (500 
MHz, DMSO-d6) 4.25 (2H, s, CH2), 6.76 (1H, s, pyrrole C4-H), 6.79-6.81 (2H, m, Ar-
H), 7.04-7.12 (6H, m, Ar-H), 7.20-7.21 (2H, m, Ar-H), 7.41-7.43 (2H, m, Ar-H), 12.20 
(1H, s, br, CO2H); 
13
C δ/ppm (125 MHz, DMSO-d6) 29.8, 110.3, 114.0, 115.1, 115.3, 
128.0, 129.2, 129.5, 130.1, 130.2, 130.5, 132.9, 133.2, 135.9, 137.7, 138.4, 160.1,  
162.1, 165.8; 
19
F δ/ppm (470 MHz, DMSO-d6) -114.9; LC-MS (ESI+) m/z = 440.2, 
442.2, 444.2 [M+H]
+
 and 438.2, 440.2, 442.1 [M-H]
-
; HRMS calcd. for 
C24H15O2N
35
Cl2F [M-H]
- 
438.0469, found 438.0462; Analytical HPLC: 96.9% 
 
5-(4-Chlorobenzyl)-1-(4-chlorophenyl)-2-(4-fluorophenyl)-1H-pyrrole-3-carboxylic 
acid (220g) 
 
 
 
 
 
General Procedure B’: Using ester 283b (149 mg, 0.32 mmol) and NaOH (390 mg, 
9.75 mmol) in 75% MeOH, H2O (3.2 mL) at 90 
o
C for 4 h, chromatography (silica, 10-
40%, EtOAc, petrol), afforded 220g as a white solid (124 mg, 88%); Rf = 0.29 (silica, 
40% EtOAc, petrol); m.p. 229-231 
oC; UV λmax (EtOH/nm) 223.0; IR νmax/cm
-1
 2919 
(C-H), 2849 (C-H), 2587 (br) (O-H), 1653 (C=O), 1594, 1527, 1490, 1338, 1259, 1221 
(C-O), 1161, 1091, 1013, 987, 842, 797, 739; 
1H δ/ppm (500 MHz, DMSO-d6) 3.74 
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(2H, s, ArCH2), 6.32 (1H, s, pyrrole C4-H), 7.01-7.04 (4H, m, Ar-H), 7.10-7.12 (2H, m, 
Ar-H), 7.17-7.20 (2H, m, Ar-H), 7.28-7.29 (2H, m, Ar-H), 7.35-7.37 (2H, m, Ar-H), 
11.74 (1H, s, br, CO2H); 
13C δ/ppm (125 MHz, DMSO-d6) 32.2, 110.3, 114.1, 114.6, 
114.8, 128.2, 128.3, 128.6, 129.4, 130.9, 131.1, 131.3, 133.3, 133.5, 133.6, 133.7, 
136.3, 137.5, 138.0, 160.9, 162.9, 165.6; 
19F δ/ppm (470 MHz, DMSO-d6) -114.1; LC-
MS (ESI+) m/z = 440.3 [M+H]
+
 and 438.2 [M-H]
-
; HRMS calcd. for C24H15O2N
35
Cl2F 
[M-H]
- 
438.0469, found 438.0462; Analytical HPLC: 97.5% 
 
(3-Bromo-4-(4-chlorophenoxy)-5-nitrophenyl)methanol (232) 
 
 
 
 
 
General Procedure D’: Using ester 227 (1.92 g, 4.97 mmol) and DIBAL-H (1 M in 
hexanes, 10.9 mL, 10.9 mmol), the reaction was quenched at 0 
o
C with distilled water 
(0.44 mL), 15% NaOH (0.44 mL) and more distilled water (1.09 mL), filtered through 
celite and worked up with EtOAc. Chromatography (silica, 50-100%, DCM, petrol), 
afforded 232 as a yellow solid (1.13 g, 64%); Rf = 0.22 (silica, 100% DCM); m.p. 85-87 
o
C; UV λmax (EtOH/nm) 222.2; IR νmax/cm
-1
 3339 (O-H), 3075 (C-H), 2927 (C-H), 2868 
(C-H), 1531, 1482, 1341, 1251 (C-O), 1189, 1087, 1058, 1009, 945, 865, 821, 729; 
1
H 
δ/ppm (500 MHz, CDCl3) 1.97 (1H, t, OH, J = 5.6 Hz), 4.82 (2H, d, ArCH2, J = 5.6 
Hz), 6.77 (2H, d, 4-ClPh C3-H and C5-H, J = 9.0 Hz), 7.27 (2H, d, 4-ClPh C2-H and C6-
H, J = 9.0 Hz), 7.93-7.94 (2H, m, 3-BrPh C2-H and C6-H); 
13
C δ/ppm (125 MHz, 
CDCl3) 63.0, 116.7, 120.2, 122.6, 128.2, 129.7, 136.1, 140.3, 144.0, 144.7, 155.5; LC-
MS (ESI+) m/z = 358.2 [M+H]
+
; HRMS calcd. for C13H10O4N
79
Br
35
Cl [M+H]
+ 
357.9476, found 357.9480 
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Tert-butyl (2-(4-chlorophenoxy)-5-(hydroxymethyl)-4’-methoxy-[1,1’-biphenyl]-3-
yl)(4-fluorophenyl)carbamate (249) 
 
 
 
 
 
 
General Procedure D’: Using ester 248 (180 mg, 0.31 mmol) and DIBAL-H (1 M in 
hexanes, 0.69 mL, 0.69 mmol), the reaction was quenched at 0 
o
C with distilled water 
(12 µL), 15% NaOH (12 µL) and more distilled water (31 µL), filtered through celite 
and worked up with EtOAc. Chromatography (silica, 0-10%, EtOAc, DCM), afforded 
249 as a colourless solid (124 mg, 73%); Rf = 0.29 (silica, 100% DCM); m.p. 99-101 
o
C;  UV λmax (EtOH/nm) 233.8; IR νmax/cm
-1
 3421 (O-H), 2978 (C-H), 2933 (C-H), 
2906 (C-H), 2874 (C-H), 2837 (C-H), 1708 (C=O), 1608, 1506, 1484, 1460, 1436, 
1368, 1320, 1228 (C-O), 1158, 1146, 1089, 1042, 1008, 827, 764, 727; 
1
H δ/ppm (500 
MHz, CDCl3) 1.35 (9H, s, CO2C(CH3)3), 1.83 (1H, t, OH, J = 5.8 Hz), 3.75 (3H, s, 
OCH3), 4.78 (2H, d, CH2OH, J = 5.9 Hz), 6.56 (2H, d, 4-ClPh C3-H and C5-H, J = 8.8 
Hz), 6.79 (2H, d, 4-MeOPh C2-H and C6-H, J = 8.8 Hz), 6.88-6.91 (2H, m, 4-FPh C3-H 
and C5-H, J = 8.4 Hz), 6.96-6.97 (2H, m, 4-FPh, C2-H and C6-H), 7.07 (2H, d, 4-ClPh 
C2-H and C6-H, J = 9.1 Hz), 7.30 (2H, d, 4-MeOPh C3-H and C5-H, J = 8.8 Hz), 7.38 
(1H, d, Ar-H, J = 2.1 Hz), 7.41 (1H, s, br, Ar-H); 
13
C δ/ppm (125 MHz, CDCl3) 28.1, 
55.2, 64.5, 81.5, 113.7, 114.9, 115.1, 116.7, 126.5, 127.5, 128.0, 128.3, 129.0, 129.1, 
130.0, 136.9, 137.9, 138.5, 146.4, 153.3, 156.0, 159.15, 159.20, 171.2; 
19
F δ/ppm (470 
MHz, CDCl3) -117.0; LC-MS (ESI+) m/z = mass not observed; HRMS mass not 
observed 
 
(6-(4-Chlorophenoxy)-4’-methoxy-5-nitro-[1,1’-biphenyl]-3-yl)methanol (250) 
 
 
 
 
 
General Procedure D’: Using ester 245 (540 mg, 1.30 mmol) and DIBAL-H (1 M in 
hexanes, 2.86 mL, 2.86 mmol), the reaction was quenched at 0 
o
C with distilled water 
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(52 µL), 15% NaOH (52 µL) and more distilled water (0.13 mL), filtered through celite 
and worked up with EtOAc. Chromatography (silica, 0-10%, EtOAc, DCM), afforded 
250 as a yellow oil (321 mg, 64%); Rf = 0.14 (silica, 100% DCM); UV λmax (EtOH/nm) 
260.6; IR νmax/cm
-1
 3417 (O-H), 3268 (C-H), 3067 (C-H), 1506, 1483, 1305, 1241, 1215 
(C-O), 1152, 1082, 1023, 823, 765, 736, 701; 
1
H δ/ppm (500 MHz, CDCl3) 1.94 (1H, t, 
OH, J = 5.7 Hz), 3.78 (3H, s, OCH3), 4.84 (2H, d, CH2OH, J = 5.7 Hz), 6.60 (2H, d, 4-
ClPh C3-H and C5-H, J = 9.0 Hz), 6.84 (2H, d, 4-MeOPh C2-H and C6-H, J = 8.8 Hz), 
7.07 (2H, d, 4-ClPh C2-H and C6-H, J = 9.1 Hz), 7.35 (2H, d, 4-MeOPh C3-H and C5-H, 
J = 8.8 Hz), 7.66 (1H, d, Ar-H, 2.2 Hz), 7.90 (1H, d, Ar-H, J = 2.1 Hz); 
13
C δ/ppm (125 
MHz, CDCl3) 55.3, 63.7, 113.9, 116.6, 122.0, 127.4, 127.6, 129.3, 130.2, 133.6, 138.3, 
139.0, 143.6, 144.4, 155.9, 159.7; LC-MS (ESI+) m/z = 386.3 [M+H]
+
; HRMS calcd. 
for C20H17O5N
35
Cl [M+H]
+ 
386.0790, found 386.0795 
 
Ethyl 2-(4-chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3-
carboxylate (283a) 
 
 
 
 
 
 
General Procedure E’: Using 1,4-diketone 282a (400 mg, 1.07 mmol) and 4-
chloroaniline (682 mg, 5.35 mmol), chromatography (silica, 0-20% Et2O, petrol) 
afforded 283a as a yellow solid (252 mg, 50%); Rf = 0.39 (silica, 20% Et2O, petrol); 
m.p. 115-117 
o
C; UV λmax (EtOH/nm) 223.4; IR νmax/cm
-1
 3050 (C-H), 2972 (C-H), 
1693 (C=O), 1565, 1526, 1489, 1420, 1376, 1222 (C-O), 1158, 1067, 1013, 960, 833; 
1
H δ/ppm (500 MHz, CDCl3) 1.33 (3H, t, CO2CH2CH3, J = 7.1 Hz), 4.23 (2H, s, 
ArCH2), 4.32 (2H, q, CO2CH2CH3, J = 7.1 Hz), 6.79-6.83 (4H, m, Ar-H), 6.86 (2H, t, 
Ar-H, J = 8.6 Hz), 6.97-7.00 (2H, m, Ar-H), 7.13 (2H, d, Ar-H, J = 8.3 Hz), 7.24-7.26 
(3H, m, Ar-H); 
13
C δ/ppm (125 MHz, CDCl3) 14.5, 30.8, 59.9, 110.4, 114.2, 115.2, 
115.4, 128.4, 129.3, 129.4, 129.97, 130.03, 130.1, 131.8, 133.8, 134.6, 136.0, 137.4, 
138.8, 165.1; 
19
F δ/ppm (470 MHz, CDCl3) -114.6; LC-MS (ESI+) m/z = 468.3 
[M+H]
+
; HRMS calcd. for C26H21O2N
35
Cl2F [M+H]
+ 
468.0928, found 468.0924 
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3-Bromo-6-chloro-1-(4-methoxybenzyl)-1H-indole (210) 
 
 
 
 
General Procedure I’: Using indole 206 (480 mg, 1.77 mmol) and NBS (377 mg, 2.12 
mmol) at -78 
o
C for 1 h, chromatography (silica, 10-20%, DCM, petrol), afforded 210 
as a brown solid (598 mg, 84%); Rf = 0.25 (silica, 20% DCM, petrol); m.p. 53-55 
o
C; 
UV λmax (EtOH/nm) 284.0 and 230.6; IR νmax/cm
-1
 3114 (C-H), 3000 (C-H), 2929 (C-
H), 2834 (C-H), 1609, 1510, 1459, 1321, 1244 (C-O), 1173, 1111, 1030, 947, 798, 761; 
1
H δ/ppm (500 MHz, CDCl3) 3.79 (3H, s, OCH3), 5.16 (2H, s, NCH2Ar), 6.86 (2H, d, 4-
ClPh C3-H and C5-H, J = 8.7 Hz), 7.08 (2H, d, 4-ClPh C2-H and C6-H, J = 8.2 Hz), 7.09 
(1H, s, indole C2-H), 7.15 (1H, dd, indole C5-H, J = 1.8 and 8.5 Hz), 7.30 (1H, d, indole 
C7-H, J = 1.5 Hz), 7.47 (1H, d, indole C4-H, J = 8.5 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 
50.0, 55.3, 90.3, 109.9, 114.4, 120.5, 121.1, 126.2, 127.6, 128.1, 128.5, 129.0, 136.1, 
159.5; LC-MS (ESI+) m/z = mass not observed; HRMS mass not observed 
 
Tert-butyl 3-bromo-6-chloro-1H-indole-1-carboxylate (213) 
 
 
 
 
General Procedure I’: Using indole 212 (731 mg, 2.90 mmol) and NBS (570 mg, 3.20 
mmol)  in DMF (6.7 mL) at 60 
o
C for 1 h, chromatography (silica, 0-10%, DCM, 
petrol), afforded 213 as a white solid (827 mg, 86%); Rf = 0.49 (silica, 10% DCM, 
petrol); m.p. 124-126 
o
C; UV λmax (EtOH/nm) 271.8 and 231.4; IR νmax/cm
-1
 3149 (C-
H), 2987 (C-H), 2938 (C-H), 1732 (C=O), 1605, 1572, 1540, 1450, 1430, 1366, 1320, 
1281, 1243, 1210, 1152, 1085, 953, 842, 805, 761, 729; 
1
H δ/ppm (500 MHz, CDCl3) 
1.67 (9H, s, C(CH3)3), 7.29 (1H, dd, C5-H, J = 1.8 and 8.4 Hz), 7.44 (1H, d, C4-H, 8.4 
Hz), 7.61 (1H, s, C2-H), 8.21 (1H, s, br, C7-H); 
13
C δ/ppm (125 MHz, CDCl3) 28.1, 
84.9, 97.6, 115.5, 120.4, 123.9, 125.3, 128.0, 131.6, 134.9, 148.5; LC-MS (ESI+) m/z = 
mass not observed; HRMS mass not observed 
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((2-(4-Chlorophenoxy)-3-nitrophenyl)ethynyl)triisopropylsilane (176) 
 
 
 
General Procedure J’: Using aryl bromide 135a (100 mg, 0.30 mmol) and TIPS-
acetylene (0.1 mL, 82 mg, 0.45 mmol), chromatography (silica, 10-20%, DCM, petrol), 
afforded 176 as a yellow oil (109 mg, 84%); Rf = 0.22 (silica, 20% DCM, petrol); UV 
λmax (EtOH/nm) 249.8 and 226.0; IR νmax/cm
-1
 2942 (C-H), 2864 (C-H), 2150 (C≡C), 
1533, 1484, 1462, 1352, 1240 (C-O), 1197, 1091, 1010, 942, 879, 822, 807, 749, 675; 
1
H δ/ppm (500 MHz, CDCl3) 0.95 (21H, s, Si((CH(CH3)2)3), 6.75-6.79 (2H, m, Ar-H), 
7.20-7.23 (2H, m, Ar-H), 7.33 (1H, t, C5-H, J = 7.8 Hz), 7.76 (1H, dd, C6-H, J = 1.6 and 
7.8 Hz), 7.90(1H, dd, C4-H, J = 1.6 and 8.2 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 11.0, 
18.4, 99.2, 101.2, 116.7, 121.7, 125.1, 125.4, 127.7, 129.4, 138.6, 144.3, 148.3, 156.2; 
LC-MS (ESI+) m/z = mass not observed; HRMS calcd. for C23H29O3N
35
ClSi [M+H]
+ 
430.1600, found 430.1595 
 
3-Bromo-2-(4-chlorophenoxy)aniline (171) 
 
 
 
 
General Procedure K’: Using 135a (1.40 g, 4.26 mmol) and SnCl2.2H2O (5.77 g, 25.6 
mmol), filtration through celite, work-up with EtOAc and distilled water and 
concentration in vacuo isolated 171 as a brown solid (1.26 g, 93%); Rf = 0.43 (silica, 
20% EtOAc, petrol); m.p. 62-64 
o
C; UV λmax (EtOH/nm) 286.6; IR νmax/cm
-1
 3485 and 
3392 (N-H), 3185 (C-H), 3081 (C-H), 1609, 1586, 1473, 1315, 1223 (C-O), 1201, 1161, 
1093, 1039, 1009, 888, 860, 828, 772, 737; 
1
H δ/ppm (500 MHz, CDCl3) 4.14 (2H, s, 
br, NH2), 6.78 (1H, dd, Ar-H, J = 1.4 and 8.0 Hz), 6.82 (2H, d, 4-ClPh C3-H and C5-H, 
J = 9.0 Hz), 6.95 (1H, t, 3-BrPh C5-H, J = 8.0 Hz), 7.02 (1H, dd, Ar-H, J = 1.3 and 8.0 
Hz), 7.24 (2H, d, 4-ClPh C2-H and C6-H, J = 9.0 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 
116.2, 116.3, 117.8, 123.7, 127.3, 127.4, 129.7, 138.7, 140.0, 155.2; LC-MS (ESI+) m/z 
= 298.2, 300.2 and 302.2 [M+H]
+
; HRMS mass not observed 
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2-(4-Chlorophenoxy)-3-((triisopropylsilyl)ethynyl)aniline (177) 
 
 
 
General Procedure K’: Using 176 (970 mg, 2.26 mmol) and SnCl2.2H2O (3.06 g, 13.6 
mmol), filtration through celite, work-up with EtOAc and distilled water and 
concentration in vacuo isolated 177 as a yellow oil (897 mg, 99.5%); Rf = 0.35 (silica, 
30% DCM, petrol); UV λmax (EtOH/nm) 265.2 and 230.4; IR νmax/cm
-1
 3481 and 3389 
(N-H), 2941 (C-H), 2863 (C-H), 2152 (C≡C), 1613, 1464, 1320, 1220 (C-O), 1161, 
1090, 1059, 989, 880, 824, 756, 726, 656; 
1
H δ/ppm (500 MHz, CDCl3) 0.94-0.95 (21H, 
m, Si((CH(CH3)2)3), 4.56 (2H, s, br, NH2), 6.80 (2H, d, 4-ClPh C3-H and C5-H, J = 9.0 
Hz), 6.84 (1H, dd, Ar-H, J = 2.0 and 7.5 Hz), 6.97-7.03 (2H, m, Ar-H), 7.18 (2H, d, 4-
ClPh C2-H and C6-H, J = 9.0 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 11.1, 18.4, 96.8, 101.7, 
116.4, 117.3, 118.6, 123.1, 124.5, 125.8, 126.8, 129.3, 142.2, 156.0; LC-MS (ESI+) m/z 
= 400.5 and 402.5 [M+H]
+
; HRMS calcd. for C23H31ON
35
ClSi [M+H]
+ 
400.1858, found 
400.1858 
 
5-Amino-6-(4-chlorophenoxy)-4’-hydroxy-[1,1’-biphenyl]-3-carboxylic acid (225) 
 
 
 
 
 
General Procedure K’: Using 224 (60 mg, 0.16 mmol) and SnCl2.2H2O (211 mg, 0.94 
mmol), filtration through celite, work-up with EtOAc and 0.5 M HCl, H2O and 
concentration in vacuo isolated 225 as a brown solid (46 mg, 84%); Rf = 0.26 (silica, 
10% MeOH, DCM); m.p. 235-237 
o
C; UV λmax (EtOH/nm) 246.8 and 228.2; IR 
νmax/cm
-1
 3351 and 3282 (N-H), 3067 (phenol O-H), 3058 (C-H), 2631 (carboxyl O-H), 
1700 (C=O), 1596, 1519, 1481, 1401, 1333, 1260, 1205 (C-O), 1171, 1089, 1008, 928, 
873, 824, 812, 678; 
1
H δ/ppm (500 MHz, DMSO-d6) 5.23 (2H, s, br, NH2), 6.67 (2H, d, 
4-ClPh C3-H and C5-H, J = 9.0 Hz), 6.68 (2H, d, 4-HOPh C2-H and C6-H, J = 8.5 Hz), 
7.16 (1H, d, Ar-H, J = 2.1 Hz), 7.20 (2H, d, 4-ClPh, C2-H and C6-H, J = 8.9 Hz), 7.24 
(2H, d, 4-HOPh, C3-H and C5-H, J = 8.5 Hz), 7.40 (1H, d, Ar-H, J = 2.1 Hz), 9.46 (1H, 
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s, ArOH), 12.73 (1H, s, br, CO2H); 
13
C δ/ppm (125 MHz, DMSO-d6) 115.0, 115.1, 
116.7, 118.6, 125.1, 127.5, 128.4, 129.1, 129.7, 135.0, 139.8, 142.0, 155.3, 156.7, 
167.3; LC-MS (ESI+) m/z = 356.3 [M+H]
+
 and 354.2 [M-H]
-
; HRMS calcd. for 
C19H13O4N
35
Cl [M-H]
- 
354.0539, found 354.0533 
 
Methyl 5-amino-6-(4-chlorophenoxy)-4’-hydroxy-[1,1’-biphenyl]-3-carboxylate 
(229) 
 
 
 
 
 
General Procedure K’: Using 228 (249 mg, 0.62 mmol) and SnCl2.2H2O (844 mg, 
3.74 mmol), filtration through celite, work-up with EtOAc and distilled water and 
concentration in vacuo isolated 229 as a brown solid (217 mg, 94%); Rf = 0.36 (silica, 
40% EtOAc, petrol); m.p. 175-177 
o
C; UV λmax (EtOH/nm) 328.4, 251.0 and 227.4; IR 
νmax/cm
-1
 3472 (N-H), 3382 (N-H and phenol O-H), 3027 (C-H), 2951 (C-H), 1681 
(C=O), 1612, 1519, 1481, 1439, 1361, 1256, 1212 (C-O), 1163, 1092, 1006, 930, 882, 
819, 772; 
1
H δ/ppm (500 MHz, CDCl3) 3.91 (3H, s, CO2CH3), 3.97 (2H, s, br, NH2), 
4.80 (1H, s, br, ArOH), 6.65 (2H, d, Ar-H, J = 9.1 Hz), 6.74(2H, d, Ar-H, J = 8.7 Hz), 
7.09 (2H, d, Ar-H, J = 9.0 Hz), 7.30 (2H, d, Ar-H, J = 8.6 Hz), 7.48 (1H, d, Ar-H, J = 
2.0 Hz), 7.51 (1H, d, Ar-H, J = 2.0 Hz); 
13
C δ/ppm (125 MHz, CDCl3) 52.2, 115.1, 
116.1, 116.3, 121.9, 127.0, 128.0, 129.3, 129.5, 130.3, 135.7, 140.3, 141.6, 155.1, 
155.2, 166.8; LC-MS (ESI+) m/z = 370.3 [M+H]
+
 and 368.2 [M-H]
-
; HRMS calcd. for 
C20H15O4N
35
Cl [M-H]
- 
368.0695, found 368.0682 
 
2-(5-Amino-6-(4-chlorophenoxy)-4’-hydroxy-[1,1’-biphenyl]-3-yl)acetonitrile (242) 
 
 
 
 
 
General Procedure K’: Using 241 (63 mg, 0.17 mmol) and SnCl2.2H2O (325 mg, 1.44 
mmol), filtration through celite, work-up with EtOAc and distilled water and 
chromatography (0-70% Et2O, petrol) isolated 242 as a yellow solid (38.8 mg, 67%); Rf 
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= 0.34 (silica, 40% EtOAc, petrol); m.p. 50-52 
o
C; UV λmax (EtOH/nm) 232.6; IR 
νmax/cm
-1
 3446 and 3368 (N-H), 3201 (br) (O-H), 3032 (C-H), 2956 (C-H), 2924 (C-H), 
2855 (C-H), 2254 (C≡N), 1611, 1588, 1478, 1444, 1424, 1355, 1260, 1214 (C-O), 1159, 
1089, 1006, 926, 822; 
1
H δ/ppm (500 MHz, DMSO-d6) 3.96 (2H, s, ArCH2), 5.14 (2H, 
s, NH2), 6.53 (1H, s, br, Ar-H), 6.66-6.68 (4H, m, 4-ClPh C3-H, C5-H and 4-HOPh C2-H 
and C6-H), 6.76 (1H, s, br, Ar-H), 7.18-7.23 (4H, m, 4-ClPh C2-H, C6-H and 4-HOPh 
C3-H and C5-H), 9.43 (1H, s, ArOH); 
13
C δ/ppm (125 MHz, DMSO-d6) 22.6, 114.0, 
115.5, 117.1, 117.4, 119.9, 125.4, 128.2, 129.3, 129.5, 130.1, 135.8, 136.4, 142.7, 
156.3, 157.2; LC-MS (ESI+) m/z = 351.1 [M+H]
+
 and 349.2 [M-H]
-
; HRMS calcd. for 
C20H14O2N2
35
Cl [M-H]
- 
349.0749, found 349.0743; Analytical HPLC: 96.2% 
 
tert-Butyl 6-chloro-1H-indole-1-carboxylate (212) 
 
 
 
General Procedure L’: Using indole 199 (200 mg, 1.32 mmol), Boc2O (607 µL, 576 
mg, 2.64 mmol) and DMAP (322 mg, 2.64 mmol) at room temperature for 1 h, 
chromatography (silica, 0-10%, DCM, petrol), afforded 212 as a colourless solid (306 
mg, 95%); Rf = 0.18 (silica, 10% DCM, petrol); m.p. 97-100 
o
C; UV λmax (EtOH/nm) 
258.4 and 228.8; IR νmax/cm
-1
 2978 (C-H), 1732 (C=O), 1606, 1528, 1434, 1371, 1333, 
1247, 1204, 1150, 1120, 1092, 1021, 896, 851, 809, 760, 718; 
1
H δ/ppm (500 MHz, 
CDCl3) 1.67 (9H, s, C(CH3)3), 6.54 (1H, d, C3-H, J = 3.5 Hz), 7.20 (1H, dd, C5-H, J = 
1.9 and 8.3 Hz), 7.46 (1H, d, C4-H, J = 8.3 Hz), 7.57 (1H, dd, C2-H, J = 3.3 Hz), 8.19 
(1H, s, br, C7-H); 
13
C δ/ppm (125 MHz, CDCl3) 28.2, 84.2, 107.0, 115.5, 121.6, 123.2, 
126.4, 129.0, 130.2, 135.6, 149.4; LC-MS (ESI+) m/z = mass not observed; HRMS 
mass not observed 
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Methyl 5-((tert-butoxycarbonyl)(4-fluorophenyl)amino)-6-(4-chlorophenoxy)-4’-
methoxy-[1,1’-biphenyl]-3-carboxylate (248) 
 
 
 
 
 
 
General Procedure L’: Using aniline 247 (200 mg, 0.42 mmol), Boc2O (183 mg, 0.84 
mmol) and DMAP (10.3 mg, 0.084 mmol) at 60 
o
C for 2 h, chromatography (silica, 50-
80%, DCM, petrol), afforded 248 as a yellow solid (202 mg, 93%); Rf = 0.20 (silica, 
80% DCM, petrol); m.p. 92-95 
o
C; UV λmax (EtOH/nm) 256.8 and 227.0; IR νmax/cm
-1
 
3071 (C-H), 2953 (C-H), 2839 (C-H), 1713 (C=O), 1609, 1507, 1485, 1458, 1434, 
1349, 1320, 1293, 1217 (C-O), 1159, 1091, 1056, 1033, 1007, 827, 798, 766 ; 
1
H δ/ppm 
(500 MHz, CDCl3) 1.36 (9H, s, C(CH3)3), 3.76 (3H, s, ArOCH3), 3.96 (3H, s, CO2CH3), 
6.55 (2H, d, 4-ClPh C3-H and C5-H, J = 8.8 Hz), 6.80 (2H, d, 4-MeOPh C2-H and C6-H, 
J = 8.8 Hz), 6.89-6.93 (2H, m, 4-FPh C3-H and C5-H, J = 8.4 Hz), 6.96-6.99 (2H, m, 4-
FPh, C2-H and C6-H), 7.07 (2H, d, 4-ClPh C2-H and C6-H, J = 9.0 Hz), 7.31 (2H, d, 4-
MeOPh C3-H and C5-H, J = 8.8 Hz), 8.07 (1H, s, br, Ar-H), 8.08 (1H, d, Ar-H, J = 2.2 
Hz); 
13
C δ/ppm (125 MHz, CDCl3) 28.1, 52.5, 55.2, 81.8, 113.8, 115.1, 115.3, 116.8, 
127.0, 127.5, 127.7, 128.3, 129.1, 130.1, 131.0, 131.2, 136.5, 137.1, 137.5, 151.0, 
153.1, 155.5, 159.3, 159.4, 161.3, 165.9; 
19
F δ/ppm (470 MHz, CDCl3) -116.7; LC-MS 
(ESI+) m/z = mass not observed; HRMS mass not observed 
 
Ethyl 5-(4-chlorophenyl)-2-(4-fluorobenzoyl)-4-oxopentanoate (282b) 
 
 
 
 
General Procedure S’: Using ethyl 3-(4-fluorophenyl)-3-oxopropanoate (201 µL, 235 
mg, 1.12 mmol), α-bromoketone 286 (233 mg, 0.94 mmol) and sodium hydride (60% in 
mineral oil, 56 mg, 1.40 mmol), chromatography (silica, 10-20%, EtOAc, petrol), 
afforded 282b as a yellow oil (165 mg, 47%); Rf = 0.38 (silica, 20% EtOAc, petrol); UV 
λmax (EtOH/nm) 247.8; IR νmax/cm
-1
 3071 (C-H), 2982 (C-H), 2908 (C-H), 1719 (C=O), 
1681 (C=O), 1595 (C=O), 1491, 1408, 1329, 1232 (C-O), 1156, 1090, 1014, 956, 846, 
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811; 
1
H δ/ppm (500 MHz, CDCl3) 1.14 (3H, t, CO2CH2CH3, J = 7.2 Hz), 3.14 (1H, dd, 
CH2COCH2Ar, J = 5.8 and 18.3 Hz), 3.28 (1H, dd, CH2COCH2Ar, J = 8.0 and 18.3 
Hz), 3.77 (2H, d, ArCH2, J = 1.5 Hz), 4.11 (2H, q, CO2CH2CH3, J = 7.2 Hz), 4.83 (1H, 
dd, COCHCO2Et, J = 5.08 and 8.0 Hz), 7.12-7.16 (4H, m, Ar-H), 7.29-7.30 (2H, m, Ar-
H), 8.02-8.05 (2H, m, Ar-H); 
13
C δ/ppm (125 MHz, CDCl3) 13.9, 41.0, 48.8, 48.9, 61.9, 
115.8, 115.9, 128.9, 130.9, 131.6, 131.7, 131.9, 132.37, 132.40, 133.2, 165.1, 167.1, 
168.8, 192.8, 204.8; 
19
F δ/ppm (470 MHz, CDCl3) -104.0; LC-MS (ESI+) m/z = 375.1 
[M-H]
-
; HRMS calcd. for C20H19O4
35
ClF [M+H]
+ 
377.0950, found 377.0952 
 
2-(6-(4-Chlorophenoxy)-4’-methoxy-5-nitro-[1,1’-biphenyl]-3-yl)acetonitrile (250a) 
 
 
 
 
 
General Procedures T’ and V’: Using alcohol 250 (327 mg, 0.85 mmol) and 
methanesulfonic anhydride (223 mg, 1.28 mmol), the crude mesylate was dissolved in 
acetonitrile (3.4 mL) and mixed with TMS-cyanide (160 µL, 127 mg, 1.28 mmol) and 
TBAF (1 M in THF, 1.28 mL, 1.28 mmol). Chromatography (silica, 10-30%, EtOAc, 
petrol), afforded 250a as a yellow oil (69 mg, 21%); Rf = 0.25 (silica, 30% EtOAc, 
petrol); UV λmax (EtOH/nm) 263.0; IR νmax/cm
-1
 3069 (C-H), 2932 (C-H), 2837 (C-H), 
2254 (C≡N), 1607, 1535, 1513, 1483, 1408, 1348, 1297, 1236 (C-O), 1179, 1090, 1027, 
825, 793, 736; 
1
H δ/ppm (500 MHz, CDCl3) 3.79 (3H, s, OCH3), 3.88 (2H, s, CH2CN), 
6.58 (2H, d, 4-ClPh C3-H and C5-H, J = 8.8 Hz), 6.84 (2H, d, 4-MeOPh C2-H and C6-H, 
J = 8.6 Hz), 7.08 (2H, d, 4-ClPh C2-H and C6-H, J = 8.8 Hz), 7.34 (2H, d, 4-MeOPh C3-
H and C5-H, J = 8.6 Hz), 7.65 (1H, s, Ar-H), 7.84 (1H, s, Ar-H); 
13
C δ/ppm (125 MHz, 
CDCl3) 23.1, 55.3, 114.1, 116.4, 116.6, 123.3, 126.8, 127.7, 128.0, 129.4, 130.2, 134.8, 
139.5, 144.4, 144.7, 155.6, 160.0; LC-MS (ESI+) m/z = 393.1 [M-H]
-
; HRMS calcd. for 
C21H15O4N2
35
Cl [M+H]
+ 
394.0715, found 394.0715 
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